学术周报 · IF≥10
肿瘤领域文献阅读汇编
2026年第42周 (2026-10-17) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Cancer letters | 39 | IF 11.8 |
| Cancer research | 22 | IF 22.6 |
| Cancer cell | 21 | IF 56.1 |
| Neuro-oncology | 13 | IF 13.1 |
| Science advances | 9 | IF 13.9 |
| Cell host & microbe | 8 | IF 23.2 |
| Biosensors & bioelectronics | 8 | IF 11.8 |
| Blood | 7 | IF 23.9 |
| MedComm | 7 | IF 14.1 |
| Molecular biomedicine | 6 | IF 13.0 |
1血液肿瘤 (103篇)
临床研究 (28篇)
RAS mutations are recurrent in acute myeloid leukemia (AML); yet, their genomic and clinical landscape remain poorly characterized. We analyzed centralized molecular profiling data in 8,553 patients with newly diagnosed AML. Of these, 1,775 (21%) harbored RAS mutations: NRAS in 1,103 (13%), KRAS in 445 (5%), and both in 227 (3%). RAS mutations primarily clustered in P-loop hotspots (G12/G13, 70%), with NRAS showing higher Q61 mutation prevalence (24% vs. 9%) and KRAS showing additional K117/A146 hotspots. Multiple RAS mutations occurred in 23% of patients. Convergent evolution of RAS signaling mutations emerged as a key feature of RASmut AML. RTK/RAS pathway mutations were non-uniformly enriched: PTPN11, KIT and FLT3-TKD mutations were positively associated, CBL mutations showed no association, and FLT3-ITD mutations were negatively associated. The prognostic impact of RAS mutations was dependent on the genomic background and treatment. In multivariate analyses in intensively treated patients, NRAS mutations showed opposing associations with overall survival (OS): adverse in patients with AML, myelodysplasia-related (HR=1.32, p=0.036) and favorable in those with NPM1 (HR=0.61, p=0.036) or FLT3-ITD (HR=0.63, p=0.048) mutations, among others. KRAS mutations predicted inferior OS (HR=1.41; p=0.003). In patients treated with non-intensive, venetoclax-based regimens, RAS mutations were associated with markedly inferior OS in patients with NPM1 (HR=2.98, p=0.007) or IDH1/2 mutations (HR=4.06, p<0.001). These data inform risk stratification and development of RAS-targeting strategies in AML.
中文摘要:RAS突变在急性髓系白血病(AML)中反复出现,其基因组和临床特征仍缺乏充分描述。我们分析了8,553例初诊AML患者的集中分子谱数据。其中1,775例(21%)携带RAS突变:NRAS 1,103例(13%)、KRAS 445例(5%)、两者同时存在227例(3%)。RAS突变主要集中于P环热点(G12/G13,70%),NRAS的Q61突变发生率更高(24%对9%),KRAS还存在K117/A146热点。23%的患者存在多个RAS突变。RAS信号突变的趋同进化是RAS突变型AML的关键特征。RTK/RAS通路突变呈非均匀富集:PTPN11、KIT和FLT3-TKD突变呈正相关,CBL突变无关联,FLT3-ITD突变呈负相关。RAS突变的预后影响取决于基因组背景和治疗。在接受强化治疗患者的多变量分析中,NRAS突变与总生存(OS)呈相反关联:在AML伴骨髓增生异常相关改变患者中为不利关联(HR=1.32,p=0.036),在NPM1突变(HR=0.61,p=0.036)或FLT3-ITD突变(HR=0.63,p=0.048)等患者中为有利关联。KRAS突变预示OS较差(HR=1.41;p=0.003)。在接受非强化、基于维奈克拉方案治疗的患者中,RAS突变与NPM1突变(HR=2.98,p=0.007)或IDH1/2突变(HR=4.06,p<0.001)患者的OS显著较差相关。这些数据有助于AML的风险分层和RAS靶向策略开发。
Contrast enhancement is generally considered an adverse prognostic feature in adult glioma. However, its significance in newly diagnosed grade 2 IDH-mutant glioma remains uncertain, with important implications for use of the mutant IDH inhibitor vorasidenib. We evaluated survival outcomes associated with preoperative enhancement in this population. We retrospectively evaluated consecutive patients with grade 2 IDH-mutant glioma treated at two institutions between 2010 and 2021. Preoperative MRIs were assessed for intratumoral enhancement by two independent readers with third-reader adjudication. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier analysis, univariate and multivariable Cox regression. Among 325 evaluable patients, median age was 37 years, 47% had 1p/19q-codeletion, and 35% had gross-total resection. Median follow-up was 10.5 years. Preoperative enhancement was observed in 53 (16%) patients, most commonly nonmeasurable (72%) or ill-defined (62%); most (87%) had no residual postoperative enhancement. Preoperative enhancement was not associated with OS or PFS in either univariate analyses (OS HR 1.16 [0.67-2.01], p = 0.591; PFS HR 1.25 [0.88-1.80], p = 0.216) or multivariable analyses adjusting for established prognostic factors (OS HR 0.86 [0.46-1.61], p = 0.633; PFS HR 1.29 [0.86-1.92], p = 0.219). Enhancement characteristics (measurable size, well-defined morphology) were not associated with OS. In grade 2 IDH-mutant glioma, preoperative enhancement was not associated with OS or PFS. These findings suggest that preoperative enhancement does not identify a higher-risk subgroup in this population, and that its presence alone should not preclude consideration of vorasidenib in eligible patients.
中文摘要:在成人胶质瘤中,对比增强通常被视为不良预后特征,但其在新诊断的2级IDH突变型胶质瘤中的意义仍不确定,而这关系到突变型IDH抑制剂vorasidenib的使用。本研究评估该人群中术前强化与生存结局的关系。回顾性纳入2010年至2021年在两家机构连续治疗的2级IDH突变型胶质瘤患者,术前MRI由两名独立阅片者评估瘤内强化,分歧由第三名阅片者裁定。采用Kaplan-Meier分析、单因素与多因素Cox回归评估总生存(OS)和无进展生存(PFS)。325例可评估患者的中位年龄为37岁,47%存在1p/19q共缺失,35%实现大体全切除,中位随访10.5年。53例(16%)存在术前强化,多为不可测量(72%)或边界不清(62%);87%术后无残留强化。术前强化与OS或PFS均无关联:单因素分析OS HR 1.16(0.67-2.01),p=0.591,PFS HR 1.25(0.88-1.80),p=0.216;校正已知预后因素的多因素分析OS HR 0.86(0.46-1.61),p=0.633,PFS HR 1.29(0.86-1.92),p=0.219。强化特征(可测量大小、形态清晰)与OS亦无关联。在2级IDH突变型胶质瘤中,术前强化与OS或PFS无关联。这些结果提示术前强化并未界定出该人群中的高危亚组,仅凭存在强化不应排除符合条件的患者使用vorasidenib。
Plasma cell-free DNA (cfDNA) whole-genome methylation sequencing enables simultaneous characterization of DNA methylation and fragmentomic features for cancer detection. However, it remains unclear whether methylation library preparation faithfully preserves fragmentomic signals, how methylation and fragmentation are biologically coupled, and how these two modalities can be systematically integrated. We systematically evaluated the preservation of cfDNA fragmentomic features in whole-genome bisulfite sequencing (WGBS) and enzymatic methyl sequencing (EM-seq) relative to conventional whole-genome sequencing (WGS). We next investigated the biological relationship between methylation and fragmentation and delineated methylation haplotype blocks (MHBs) directly from plasma cfDNA as biologically interpretable units for organizing multimodal cfDNA signals. Guided by these findings, we developed multimodal diagnostic models integrating complementary methylation and fragmentomic features. Canonical cfDNA fragmentomic patterns were partially preserved across methylation sequencing protocols, although the degree of preservation varied among individual features. DNA methylation levels were associated with characteristic fragment length and end-motif patterns. Plasma-derived MHBs exhibited tissue-associated regulatory features and distinct patterns of chromatin accessibility, repeat enrichment, and methylation heterogeneity, providing biologically interpretable units for integrated cfDNA analysis. Within these regions, methylation and fragmentomic signals exhibited coordinated yet complementary patterns. Leveraging this framework, we developed Fragmentomics And Methylation Ensemble (FAME), an interpretable multimodal model integrating MHB-centered methylation and fragmentomic features for cancer detection and tissue-of-origin prediction, and further extended it with complementary genome-wide methylation and fragmentomic features to generate a genome-wide-augmented FAME model (FAME-GW). Across cross-validation, independent validation, and comparisons with THEMIS (THorough Epigenetic Marker Integration Solution), SPOT-MAS (screening for the presence of tumor by methylation and size), and DELFI (DNA evaluation of fragments for early interception), FAME-based models achieved robust diagnostic performance, with FAME providing a compact and interpretable representation and FAME-GW delivering the strongest overall predictive performance. Our study demonstrates that cfDNA whole-genome methylation sequencing partially preserves informative fragmentomic signals and establishes plasma-derived MHBs as biologically interpretable units for organizing and integrating complementary methylation and fragmentomic information. This framework provides insight into the coupling of epigenetic and fragmentomic information and an effective strategy for interpretable cfDNA-based cancer diagnosis.
中文摘要:血浆游离DNA(cfDNA)全基因组甲基化测序能够同时刻画DNA甲基化与片段组学特征,用于癌症检测。然而,甲基化文库制备是否忠实保留片段组学信号、甲基化与片段化在生物学上如何耦合,以及两类模态如何系统整合,仍不清楚。我们系统评估了全基因组亚硫酸氢盐测序(WGBS)和酶法甲基化测序(EM-seq)相对于传统全基因组测序(WGS)对cfDNA片段组学特征的保留情况。随后考察甲基化与片段化之间的生物学关系,并直接从血浆cfDNA中界定甲基化单倍型区块(MHB),作为组织多模态cfDNA信号的生物学可解释单元。基于这些发现,我们构建了整合互补甲基化与片段组学特征的多模态诊断模型。经典cfDNA片段组学模式在甲基化测序方案中部分保留,但各特征的保留程度存在差异。DNA甲基化水平与特征性片段长度和末端基序模式相关。血浆来源MHB呈现组织相关调控特征,以及染色质可及性、重复序列富集和甲基化异质性的不同模式,为整合cfDNA分析提供生物学可解释单元。在这些区域内,甲基化与片段组学信号呈现协调而互补的模式。利用该框架,我们开发了Fragmentomics And Methylation Ensemble(FAME),一种可解释多模态模型,整合以MHB为中心的甲基化与片段组学特征,用于癌症检测和组织来源预测,并进一步加入互补的全基因组甲基化与片段组学特征,生成全基因组增强FAME模型(FAME-GW)。在交叉验证、独立验证以及与THEMIS、SPOT-MAS和DELFI比较中,基于FAME的模型取得稳健诊断性能,FAME提供紧凑且可解释的表征,FAME-GW总体预测性能最强。这些结果说明,cfDNA全基因组甲基化测序部分保留有信息量的片段组学信号,并确立血浆来源MHB作为组织和整合互补甲基化与片段组学信息的生物学可解释单元。该框架为理解表观遗传与片段组学信息的耦合提供洞见,并为可解释的cfDNA癌症诊断提供有效策略。
Large B-cell lymphoma (LBCL) encompasses a biologically and clinically heterogeneous group of aggressive B-cell lymphomas, and outcomes remain poor in high-risk and relapsed/refractory settings. Beyond conventional anti-CD20 monoclonal antibodies, the Fc-modified anti-CD19 antibody tafasitamab, the CD79b-directed antibody-drug conjugate polatuzumab vedotin, and CD20×CD3 bispecific antibodies are expanding treatment options across disease stages and patient populations. At the 2026 ASCO Annual Meeting, the phase 3 frontMIND trial provided randomized evidence for tafasitamab plus lenalidomide and R-CHOP in newly diagnosed high-risk disease, while OLYMPIA-3 further explored CD20×CD3 bispecific antibody intensification in the same setting. In older or treatment-unfit patients, early-phase nonrandomized studies of epcoritamab plus R-mini-CVP and mosunetuzumab monotherapy suggested the feasibility of chemotherapy-attenuated and chemotherapy-free approaches. In relapsed/refractory LBCL, SUNMO established a progression-free survival advantage for mosunetuzumab plus polatuzumab vedotin in autologous stem-cell transplantation (ASCT)-ineligible disease, whereas EPCORE NHL-2 supported epcoritamab-based salvage therapy in transplant-eligible patients. Collectively, these findings broaden the role of antibody-based regimens from frontline intensification and reduced-intensity treatment to nontransplant and transplant-directed salvage. Longer follow-up and randomized comparisons are needed to establish response durability, refine patient selection, and define optimal treatment sequencing.
中文摘要:大B细胞淋巴瘤(LBCL)包括一组生物学和临床异质性强的侵袭性B细胞淋巴瘤,在高危和复发/难治情况下结局仍差。除常规抗CD20单克隆抗体外,Fc修饰的抗CD19抗体tafasitamab、靶向CD79b的抗体偶联药物polatuzumab vedotin以及CD20×CD3双特异性抗体正在不同疾病阶段和患者人群中拓展治疗选择。在2026年ASCO年会上,3期frontMIND试验为新诊断高危疾病中tafasitamab联合来那度胺和R-CHOP提供了随机证据,OLYMPIA-3进一步探索了同一背景下CD20×CD3双特异性抗体强化治疗。在老年或不适合治疗的患者中,epcoritamab联合R-mini-CVP和mosunetuzumab单药治疗的早期非随机研究提示,化疗减量和无化疗方案具有可行性。在复发/难治LBCL中,SUNMO确立了mosunetuzumab联合polatuzumab vedotin在不适合自体干细胞移植(ASCT)疾病中的无进展生存优势,而EPCORE NHL-2支持适合移植患者中基于epcoritamab的挽救治疗。这些发现将基于抗体的方案作用从一线强化和减低强度治疗拓展至非移植和移植导向的挽救治疗。仍需更长时间随访和随机比较来确定缓解持久性、细化患者选择并界定最佳治疗顺序。
In 2026, three high-throughput sequencing platforms approached the widely publicised sub-$100 30× human genome. Behind these figures, which reflect consumable prices rather than total cost of ownership, the more consequential shift is the end of single-vendor dominance: these systems make comprehensive genomic profiling and multi-omic liquid biopsy feasible in small batches.
中文摘要:2026年,三款高通量测序平台已接近广泛宣传的100美元以下30×人类基因组目标。这些数字反映的是耗材价格,而非总拥有成本;更具影响的转变是单一供应商主导格局的结束:这些系统使小批量开展全面基因组分析和多组学液体活检成为可行。
Gene expression profiling (GEP) reliably predicts metastatic uveal melanoma risk and is used to manage uveal melanoma (UM) in patients with this diagnosis. Efforts to refine molecular prognostication continue. To determine if confirmatory cytopathology findings influence the prognostic accuracy of a commercially available GEP/Preferentially Expressed Antigen in Melanoma (PRAME) assay. The Collaborative Ocular Oncology Group 2 study, a prospective cohort study, was conducted from 2017 to 2020 with follow-up recorded at 6-month intervals. This was a multicenter study that included patients with choroidal and/or ciliary body melanoma and results from a 15-GEP and PRAME RNA expression (15-GEP/PRAME) assay. Patients with iris tumors or less than 6 months' follow-up were excluded. Study data were analyzed from April 2025 to July 2026. 15-GEP/PRAME, cytopathology, and next-generation sequencing (NGS). Metastatic uveal melanoma rates in patients who had 15-GEP/PRAME and confirmatory cytopathology (CCP) results confirming or suspicious for UM (GEP+CCP) were compared with those who had 15-GEP/PRAME and no cytopathology performed, or unknown or nondiagnostic cytopathology results (GEP only). UM-associated variants identified by NGS were also evaluated. Of 1537 patients (mean [SD] age, 62.0 [13.4] years; 787 male [51.2%]), 727 (47.3%) had CCP results, and 810 (52.7%) had nondiagnostic cytopathology results or no cytopathology performed. Class 2/PRAME+ tumors were more common (136 of 727 [18.7%]) in the GEP+CCP group than in the GEP-only group (72 of 810 [8.9%]; 9.8% difference; 95% CI, 6.4-13.3; P <.001), whereas class 1/PRAME- tumors were less common (330 of 727 [45.4%] vs 495 of 810 [61.1%]; 15.7% difference; 95% CI, 10.8-20.6; P <.001). In patients with GEP+CCP, 22.7% (n = 165) developed metastasis vs 15.4% (n = 125) in patients with GEP only (7.3% difference, 95% CI, 3.3-11.2; P < .001). Adjusting for 15-GEP/PRAME status, there were no differences in metastasis rates between CCP groups. Of 1327 patients with successful NGS, 94.1% (605 of 643) in the GEP+CCP group and 71.9% (492 of 684) in the GEP-only group had a UM-associated variant (22.2% difference, 95% CI, 18.3-26.0; P < .001). Results of this cohort study reveal that no differences in metastasis outcomes were observed between patients with and without CCP within any GEP/PRAME categories. UM-associated variants were found less frequently in the GEP-only group than in the GEP+CCP group. In this cohort, 15-GEP/PRAME classification without CCP retained prognostic validity, supporting its clinical consideration in guiding metastatic surveillance in cases in which cytopathology is unavailable.
中文摘要:基因表达谱(GEP)可可靠预测葡萄膜黑色素瘤转移风险,并用于确诊患者的疾病管理。分子预后评估仍在持续优化。本研究要明确经细胞病理学确认的结果是否影响商业化GEP/黑色素瘤优先表达抗原(PRAME)检测的预后准确性。协作性眼肿瘤组2研究为前瞻性队列研究,2017至2020年开展,每6个月记录随访。这项多中心研究纳入脉络膜和/或睫状体黑色素瘤患者,且有15-GEP与PRAME RNA表达(15-GEP/PRAME)检测结果。排除虹膜肿瘤或随访不足6个月者。研究数据于2025年4月至2026年7月分析。检测包括15-GEP/PRAME、细胞病理学和二代测序(NGS)。比较有15-GEP/PRAME且有支持或可疑葡萄膜黑色素瘤的确认性细胞病理学(CCP)结果者(GEP+CCP)与有15-GEP/PRAME但未做细胞病理学、结果未知或不可诊断者(仅GEP)的转移性葡萄膜黑色素瘤发生率。还评估NGS识别的葡萄膜黑色素瘤相关变异。1537例患者(平均[SD]年龄62.0[13.4]岁;787例男性[51.2%])中,727例(47.3%)有CCP结果,810例(52.7%)细胞病理学结果不可诊断或未做细胞病理学。GEP+CCP组中2类/PRAME+肿瘤更常见(727例中136例[18.7%]),仅GEP组为810例中72例[8.9%];差异9.8%,95% CI 6.4-13.3,P<0.001;1类/PRAME-肿瘤则较少见(727例中330例[45.4%] vs 810例中495例[61.1%];差异15.7%,95% CI 10.8-20.6,P<0.001)。GEP+CCP组22.7%(n=165)发生转移,仅GEP组15.4%(n=125)发生转移(差异7.3%,95% CI 3.3-11.2,P<0.001)。校正15-GEP/PRAME状态后,CCP组间转移率无差异。1327例NGS成功患者中,GEP+CCP组94.1%(643例中605例)和仅GEP组71.9%(684例中492例)存在葡萄膜黑色素瘤相关变异(差异22.2%,95% CI 18.3-26.0,P<0.001)。该队列研究结果提示,在任何GEP/PRAME类别内,有与无CCP的患者转移结局未见差异。仅GEP组葡萄膜黑色素瘤相关变异检出率低于GEP+CCP组。该队列中,无CCP的15-GEP/PRAME分类仍保留预后有效性,支持在细胞病理学不可获得时将其用于指导转移监测的临床考虑。
Rocbrutinib (; LP-168) is a fourth generation Bruton's tyrosine kinase (BTK) inhibitor with both covalent and non-covalent modes of binding, which allow it to inhibit both wildtype as well as mutant variants of BTK. It is being developed by Lupeng Pharmaceuticals primarily as a treatment for patients with B-cell malignancies. Rocbrutinib received its first approval in June 2026 in China for use in adult patients with mantle cell lymphoma (MCL) that is relapsed or refractory to BTK inhibitors, and who have received ≥ 2 systemic therapies (including BTK inhibitors). This article summarizes the milestones in the development of rocbrutinib leading to its first approval in this indication.
中文摘要:Rocbrutinib(LP-168)是第四代布鲁顿酪氨酸激酶(BTK)抑制剂,兼具共价与非共价两种结合模式,因而能够抑制野生型BTK以及其突变变体。该药由麓鹏制药(Lupeng Pharmaceuticals)开发,主要方向为B细胞恶性肿瘤患者的治疗。2026年6月,Rocbrutinib在中国获得首次批准,用于对BTK抑制剂复发或难治、且已接受至少2种系统治疗(包括BTK抑制剂)的成人套细胞淋巴瘤(MCL)患者。本文梳理了Rocbrutinib在该适应症上获得首次批准之前的研发里程碑。
The impact of chimeric antigen receptor (CAR) T-cell expansion and persistence on clinical outcomes and treatment-related morbidity in patients with relapsed/refractory (R/R) multiple myeloma (MM) remains undefined, partly due to limited availability of standardized CAR T-cell quantification assays. We evaluated CAR T-cell kinetics and their association with efficacy and toxicity in patients with R/R MM treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel). Using a uniform flow cytometry-based platform (N = 90; cilta-cel, n = 54; ide-cel, n = 36), we observed greater CAR T-cell expansion with cilta-cel than with ide-cel (median, 106 vs 49 cells per μL). Peak CAR T-cell expansion was associated with clinical response in the ide-cel cohort but not in the cilta-cel cohort, in which rapid and excessive expansion was associated with an increased risk of delayed neurotoxicities (DNTs), a complication with potential long-term functional consequences (median peak, 1009 vs 96 cells per μL). To identify clinically accessible biomarkers of CAR T-cell expansion, we analyzed absolute lymphocyte count (ALC) as a surrogate biomarker in a multicenter cohort (N = 532; cilta-cel, n = 256; ide-cel, n = 276). Higher peak ALC was significantly associated with the development of DNTs, particularly parkinsonism after cilta-cel. A peak ALC ≥3 × 10³/μL, or ≥2.5 × 10³/μL following an increase of twofold or more, predicted elevated DNT risk (sensitivity, 81%; specificity, 59%). Together, these findings delineate distinct expansion-toxicity relationships in cilta-cel and ide-cel therapy, establish ALC as a practical, uniformly available surrogate for CAR T-cell expansion, and define quantitative thresholds that may enable early recognition of patients at risk of DNT, informing preemptive strategies to mitigate morbidity after cilta-cel.
中文摘要:复发/难治性多发性骨髓瘤(R/R MM)患者中,嵌合抗原受体(CAR)T细胞扩增与持续性对临床结局及治疗相关疾病负担的影响仍未明确,部分原因在于标准化CAR T细胞定量检测方法可及性有限。我们评估了接受idecabtagene vicleucel(ide-cel)或ciltacabtagene autoleucel(cilta-cel)治疗的R/R MM患者的CAR T细胞动力学及其与疗效和毒性的关联。采用统一的流式细胞术平台(N=90;cilta-cel,n=54;ide-cel,n=36),观察到cilta-cel的CAR T细胞扩增高于ide-cel(中位数,106 vs 49个细胞/μL)。峰值CAR T细胞扩增在ide-cel队列中与临床反应相关,但在cilta-cel队列中未见此关联;在cilta-cel队列中,快速且过度的扩增与延迟性神经毒性(DNTs)风险增加相关,该并发症可能带来长期功能后果(峰值中位数,1009 vs 96个细胞/μL)。为识别临床可及的CAR T细胞扩增生物标志物,我们在多中心队列(N=532;cilta-cel,n=256;ide-cel,n=276)中分析绝对淋巴细胞计数(ALC)作为替代生物标志物。较高的峰值ALC与DNTs发生显著相关,尤其是cilta-cel后出现的帕金森综合征。峰值ALC≥3×10³/μL,或在升高两倍及以上后≥2.5×10³/μL,可预测DNT风险升高(敏感性81%;特异性59%)。这些结果刻画了cilta-cel与ide-cel治疗中不同的扩增-毒性关系,确立ALC作为实用且普遍可得的CAR T细胞扩增替代指标,并定义可能有助于早期识别DNT风险患者的定量阈值,为减轻cilta-cel后疾病负担的预防性策略提供信息。
Treatment options for patients with immunoglobulin light chain (AL) amyloidosis and advanced cardiac involvement remain limited. The prospective phase 2 European Myeloma Network 22 trial included patients with previously untreated AL amyloidosis, measurable hematologic disease, and Mayo2004/European cardiac stage IIIB disease to receive daratumumab monotherapy at the standard dose and schedule for up to 2 years (28-day cycles); patients with inadequate response after 3 cycles could additionally receive weekly bortezomib and dexamethasone. The primary end point was 6-month overall survival (OS) rate. Of 40 patients enrolled, 10 (25.0%) received additional treatment with bortezomib and dexamethasone. The 6-month OS rate was 65% (95% confidence interval, 48.2-77.6), and median OS was 10.4 months. The best hematologic response rate (partial response or better) up to 6 months was 75% (very good partial response or better, 47.5%; complete response, 12.5%), with the median time to first and best hematologic response being 1 week and 2.3 months, respectively. Cardiac response rate at 6 months was 30%. Common serious adverse events were cardiac failure (25%), sudden cardiac death (10%), and acute kidney injury (7.5%). The patients' quality of life remained stable throughout the trial treatment and observation. In patients with high-risk, advanced (stage IIIB) AL amyloidosis, daratumumab monotherapy was feasible and well tolerated, achieving rapid hematologic responses and associated with prolonged survival relative to historical cohorts. Cardiac response rates at 6 months were significant, considering advanced cardiac disease. These findings support daratumumab as the backbone of anticlonal therapy in advanced cardiac AL amyloidosis. This trial was registered at www.clinicaltrials.gov as #NCT04131309.
中文摘要:免疫球蛋白轻链(AL)淀粉样变性且伴晚期心脏受累患者的治疗选择仍有限。前瞻性2期欧洲骨髓瘤网络22试验纳入既往未治疗、可测量血液学疾病且为Mayo2004/欧洲心脏分期IIIB期的AL淀粉样变性患者,接受标准剂量和方案的达雷妥尤单抗单药治疗,最长2年(28天周期);3个周期后反应不足者可额外接受每周硼替佐米和地塞米松。主要终点为6个月总生存(OS)率。40例入组患者中,10例(25.0%)接受了硼替佐米和地塞米松的额外治疗。6个月OS率为65%(95%置信区间48.2-77.6),中位OS为10.4个月。至6个月的最佳血液学缓解率(部分缓解或更好)为75%(非常好的部分缓解或更好47.5%;完全缓解12.5%),首次和最佳血液学缓解的中位时间分别为1周和2.3个月。6个月时心脏缓解率为30%。常见严重不良事件为心力衰竭(25%)、心源性猝死(10%)和急性肾损伤(7.5%)。患者在试验治疗和观察期间生活质量保持稳定。在高危晚期(IIIB期)AL淀粉样变性患者中,达雷妥尤单抗单药治疗可行且耐受良好,能获得快速血液学缓解,并相较历史队列与生存延长相关。考虑心脏疾病晚期,6个月时心脏缓解率具有意义。这些结果支持达雷妥尤单抗作为晚期心脏AL淀粉样变性抗克隆治疗的骨干药物。该试验在www.clinicaltrials.gov注册,编号NCT04131309。
Combining inhibition of poly(ADP-ribose) polymerase and androgen receptor (AR) pathway has demonstrated clinical activity in men with metastatic prostate cancer, although the extent of benefit in tumors lacking homologous recombination repair (HRR) gene alterations remains uncertain. We conducted a randomized phase 2 trial evaluating talazoparib plus enzalutamide versus enzalutamide alone in men with high-volume metastatic hormone-naive prostate cancer (mHNPC). Fifty-four patients starting androgen deprivation therapy received two cycles of enzalutamide lead-in before 1:2 randomization to enzalutamide (n = 17) or enzalutamide plus talazoparib (n = 37). The primary endpoint was met, with a 73% prostate-specific antigen (PSA) <0.2 ng ml-1 response rate at 12 months in the combination arm (95% confidence interval (CI) = 56-86%), exceeding the prespecified efficacy threshold (P < 0.001); the PSA <0.2 rate in the control arm was 64.7% (95% CI = 38-86%, P = 0.54 for exploratory comparison between arms). Grade ≥3 adverse events occurred in 68% patients receiving the combination versus 35% with enzalutamide alone, predominantly anemia (41%). Two fatal therapy-emergent myeloid neoplasms occurred in the enzalutamide plus talazoparib arm in patients with underlying genomic susceptibility. Analyses of paired tumor biopsies acquired at baseline and during enzalutamide lead-in phase demonstrated marked tumor transcriptional reprogramming after AR inhibition, including suppression of proliferation-associated and HRR-related gene expression programs, but without functional impairment of homologous recombination activity. Overall, talazoparib plus enzalutamide demonstrated clinical activity in patients with high-volume mHNPC but did not establish clear additional clinical benefit over enzalutamide alone in this biomarker-unselected population, while being associated with increased toxicity. ClinicalTrials.gov identifier: NCT04332744 .
中文摘要:抑制聚腺苷二磷酸核糖聚合酶与雄激素受体(AR)通路联用在转移性前列腺癌男性患者中已显示临床活性,但缺乏同源重组修复(HRR)基因改变的肿瘤能否获益仍不确定。我们开展了一项随机2期试验,在高瘤负荷转移性激素初治前列腺癌(mHNPC)男性患者中评估talazoparib联合恩扎卢胺对比恩扎卢胺单药。54例开始雄激素剥夺治疗的患者先接受两周期恩扎卢胺导入,随后按1:2随机分配至恩扎卢胺组(n=17)或恩扎卢胺联合talazoparib组(n=37)。主要终点达到,联合组12个月前列腺特异性抗原(PSA)<0.2 ng/ml应答率为73%(95%置信区间(CI)=56–86%),超过预设疗效阈值(P<0.001);对照组PSA<0.2率为64.7%(95%CI=38–86%,组间探索性比较P=0.54)。联合组≥3级不良事件发生率为68%,恩扎卢胺单药组为35%,主要为贫血(41%)。恩扎卢胺联合talazoparib组中,存在潜在基因组易感的患者发生两例致命性治疗相关髓系肿瘤。基线及恩扎卢胺导入期采集的配对肿瘤活检分析显示,AR抑制后肿瘤转录程序发生显著重编程,包括增殖相关及HRR相关基因表达程序受抑制,但同源重组活性未出现功能受损。总体而言,talazoparib联合恩扎卢胺在高瘤负荷mHNPC患者中显示临床活性,但在未按生物标志物选择的人群中未确立优于恩扎卢胺单药的明确额外临床获益,同时毒性增加。ClinicalTrials.gov注册号:NCT04332744。
Adipose tissue has a central role in systemic energy balance and the pathogenesis of obesity and its sequelae1,2. In contrast to white adipose tissue, brown adipose tissue (BAT) uses energy to produce heat3. Detectable BAT in humans is associated with decreased prevalence of cardiometabolic diseases4. However, the complete spectrum of health conditions associated with BAT remains unknown, and high-throughput methods to quantify BAT activity in humans are lacking5,6. Here we leveraged big data and artificial intelligence to systematically define the clinical impact of BAT in a cohort of 101,243 patients from a large cancer centre. Our unbiased analyses revealed that, across all diagnoses, cardiovascular and psychiatric diseases were less prevalent in people with BAT. Using a machine learning approach, we semi-automatically quantified BAT activity in approximately 8,700 patients and demonstrated that higher BAT activity, especially in the axillary depot, is associated with lower odds of cardiometabolic diseases and healthier white fat distribution. People with BAT also exhibited more favourable glycaemic parameters, lipid profiles, inflammatory markers and echocardiographic indices. Analysis of medication usage demonstrated that angiotensin receptor blocker use was positively associated with BAT presence. As proof of concept, we showed that the angiotensin receptor blocker losartan increased brown adipocyte activity and whole-body energy expenditure. Altogether, our studies harnessing artificial intelligence and big data identify new clinical phenotypes linked to BAT and serve as a platform for drug repurposing to activate this tissue in humans.
中文摘要:脂肪组织在全身能量平衡以及肥胖及其并发症的发生中起核心作用。与白色脂肪组织不同,棕色脂肪组织(BAT)利用能量产热。人体内可检测到BAT与心血管代谢疾病患病率降低相关。但BAT相关的完整健康状态谱仍不清楚,也缺乏在人群中高通量量化BAT活性的方法。研究利用大数据和人工智能,在一家大型癌症中心的101,243例患者队列中系统界定BAT的临床影响。无偏分析显示,在所有诊断中,有BAT的人群心血管疾病和精神疾病患病率较低。采用机器学习方法对约8,700例患者的BAT活性进行半自动量化,发现较高的BAT活性,尤其是腋窝脂肪库的活性,与较低的心血管代谢疾病风险及更健康的白色脂肪分布相关。有BAT的人还表现出更有利的血糖参数、血脂谱、炎症标志物和超声心动图指标。药物使用分析显示,血管紧张素受体阻滞剂的使用与BAT存在呈正相关。作为概念验证,研究显示血管紧张素受体阻滞剂氯沙坦可增加棕色脂肪细胞活性和全身能量消耗。这些利用人工智能和大数据的研究识别出与BAT相关的新临床表型,并为通过药物重定位在人体内激活该组织提供了平台。
To determine long-term visual and ocular outcomes in a large cohort of patients with choroidal melanoma treated using palladium-103 (103Pd) plaque brachytherapy. This is a retrospective cohort study. 170 patients with a minimum of 10 years of continuous follow-up at The New York Eye Cancer Center following 103Pd plaque brachytherapy treatment for choroidal melanoma. The study includes collected data consisting of patient demographic characteristics, tumor features, such as size, location, and AJCC clinical T-category (cT), visual outcomes, variables related to post-treatment retinopathy management, and long-term ocular comorbidities. The primary endpoints were tumor control, ocular conservation, and visual acuity. Secondary endpoints included long-term radiation-related complications, additional ocular interventions, and associated comorbidities. Statistical analyses were performed using the Kaplan-Meier survival method, t-tests, Wilcoxon rank-sum tests, chi-square tests, and linear regression plots. Among 170 patients with a minimum 10-year follow-up there was 100% local tumor control. One eye (0.6%) was enucleated due to neovascular glaucoma and patient choice. Kaplan-Meier analysis demonstrated visual acuity retention rates of 92.7% at 12 years, 87.0% at 15 years, and 63.7% at 20 years defined as vision of 20/200 or better. Radiation retinopathy was managed with anti-vascular endothelial growth factor (anti-VEGF) therapy, intravitreal corticosteroids, and laser treatment. Tumors located closer to the fovea were associated with increased foveal radiation doses and poorer visual acuity outcomes. Treatment of juxtapapillary and circumpapillary tumors was associated with the highest rates of vision loss. This study is the largest and longest follow-up analysis of 103Pd plaque brachytherapy for choroidal melanoma. It provides new long-term information on tumor control, ocular morbidity, and visual outcomes that are valuable for patient counseling and therapeutic decision-making.
中文摘要:确定一大组接受钯-103(103Pd)敷贴近距离放疗的脉络膜黑色素瘤患者的长期视力与眼部结局。这是一项回顾性队列研究,纳入170例在纽约眼癌中心接受103Pd敷贴近距离放疗后连续随访至少10年的脉络膜黑色素瘤患者。研究收集的数据包括患者人口学特征、肿瘤特征(如大小、位置和AJCC临床T分期cT)、视力结局、治疗后视网膜病变处理相关变量以及长期眼部合并症。主要终点为肿瘤控制、保眼和视力;次要终点包括长期放射相关并发症、额外眼部干预及相关合并症。统计分析采用Kaplan-Meier生存法、t检验、Wilcoxon秩和检验、卡方检验和线性回归图。在170例随访至少10年的患者中,局部肿瘤控制率为100%。1只眼(0.6%)因新生血管性青光眼并结合患者意愿行眼球摘除。Kaplan-Meier分析显示,以视力20/200或更好为定义,视力保留率在12年为92.7%,15年为87.0%,20年为63.7%。放射性视网膜病变通过抗血管内皮生长因子(anti-VEGF)治疗、玻璃体内糖皮质激素和激光治疗进行管理。更靠近黄斑中心凹的肿瘤与更高的中心凹放射剂量和更差的视力结局相关。毗邻视盘和环绕视盘肿瘤的治疗与最高视力丧失率相关。该研究是103Pd敷贴近距离放疗治疗脉络膜黑色素瘤样本量最大、随访时间最长的分析,提供了关于肿瘤控制、眼部疾病负担和视力结局的新长期信息,对患者咨询和治疗决策具有价值。
Although chimeric antigen receptor T-cell (CAR-T) therapy has substantially improved outcomes in diffuse large B-cell lymphoma (DLBCL), disease relapse remains a major clinical challenge. Because treatment-associated immune remodeling evolves dynamically over time, complementary biomarkers capable of longitudinally monitoring immune-cell state changes are needed to evaluate therapeutic response and relapse following CAR-T therapy. In this study, we developed a label-free, high-throughput image cytometry platform for longitudinal, multiparametric profiling of peripheral blood mononuclear cells (PBMCs) collected from a cohort of 17 DLBCL patients undergoing CAR-T therapy. Using bright-field single-cell imaging, we quantified four representative biophysical parameters, including cell size, eccentricity, refractive index, and mean pixel intensity, from PBMC populations at base and post-treatment time points. These parameters were analyzed at both population and patient levels to characterize treatment-associated remodeling trajectories and biophysical heterogeneity. Static comparisons revealed population-level biophysical differences between the 10 relapsed (R) and 7 nonrelapsed (NR) patients. Longitudinal and patient-level analyses, performed by tracking serial PBMC samples collected from the same patients across treatment time points, demonstrated that treatment outcome was associated with coordinated remodeling trajectories in NR patients and greater patient-specific heterogeneity in R patients. Patient-level effect size and heterogeneity analyses further demonstrated that relapse was associated with altered remodeling dynamics that were not apparent from population-averaged measurements alone. These findings demonstrate that longitudinal biophysical profiling of PBMCs enables quantitative monitoring of treatment-associated immune remodeling and provides a complementary biomarker for assessing therapeutic response following CAR-T therapy.
中文摘要:嵌合抗原受体T细胞(CAR-T)治疗已明显改善弥漫大B细胞淋巴瘤(DLBCL)的结局,但疾病复发仍是主要临床难题。治疗相关免疫重塑随时间动态演变,需要能够纵向监测免疫细胞状态变化的补充性生物标志物,以评估CAR-T治疗后的治疗反应和复发。本研究建立无标记、高通量图像细胞术平台,对接受CAR-T治疗的17例DLBCL患者队列外周血单个核细胞(PBMC)进行纵向、多参数分析。利用明场单细胞成像,在基线和治疗后时间点定量PBMC群体的4项代表性生物物理参数,包括细胞大小、偏心率、折射率和平均像素强度。这些参数在群体和患者层面分析,用于刻画治疗相关重塑轨迹和生物物理异质性。静态比较显示10例复发(R)和7例未复发(NR)患者之间存在群体层面的生物物理差异。通过追踪同一患者跨治疗时间点采集的连续PBMC样本进行纵向和患者层面分析,显示治疗结局与NR患者协调的重塑轨迹相关,而R患者具有更大的患者特异性异质性。患者层面的效应量和异质性分析进一步显示,复发与重塑动态改变相关,这些改变仅靠群体平均测量无法显现。这些发现表明,PBMC纵向生物物理分析可定量监测治疗相关免疫重塑,并为评估CAR-T治疗后的治疗反应提供补充性生物标志物。
Hypomethylating agents (HMAs) combined with Venetoclax have reshaped the therapeutic landscape of acute myeloid leukemia (AML), yet the biological determinants of response remain unclear. We integrated clinical and genomic profiling in 132 newly diagnosed or relapsed/refractory AML patients treated with HMA-Venetoclax and performed single-cell RNA sequencing and T cell receptor (TCR) profiling in 10 newly diagnosed cases to define cellular and immune correlates of response. Response rates and survival aligned with published data. DNA Sequencing confirmed the favorable impact of IDH2 and the poor prognosis of TP53 mutations. scRNA-seq and TCR analysis showed that responders exhibited expansion of cytotoxic CD8+ T cells, increased TCR clonal diversity, and activation of antigen-presentation pathways. Nonresponders displayed baseline inflammatory signaling, impaired myeloid maturation, and a suppressive microenvironment enriched in IDO1+ dendritic cells. Resistant AMLs showed stem-like dedifferentiation and sustained EMT. LAG-3 expression marked dysfunctional T cell states and emerged as a potential biomarker and therapeutic target.
中文摘要:低甲基化药物(HMA)联合Venetoclax改变了急性髓系白血病(AML)的治疗格局,但决定疗效的生物学因素仍不清楚。研究整合132例新诊断或复发/难治AML患者的临床与基因组分析,并对10例新诊断病例进行单细胞RNA测序和T细胞受体(TCR)谱分析,以界定疗效相关的细胞与免疫特征。缓解率和生存与已发表数据一致。DNA测序证实IDH2突变的有益影响及TP53突变的不良预后。scRNA-seq与TCR分析显示,缓解者出现细胞毒性CD8+ T细胞扩增、TCR克隆多样性增加和抗原呈递通路激活。未缓解者基线存在炎症信号、髓系成熟受损以及富含IDO1+树突状细胞的抑制性微环境。耐药AML表现为干样去分化和持续的EMT。LAG-3表达标记功能障碍T细胞状态,并成为潜在的生物标志物和治疗靶点。
Different metastatic sites in advanced melanoma show distinct responses to immune checkpoint inhibitors (ICIs). In patients treated with ICI, liver metastases are associated with reduced responses, while lung metastases are associated with improved responses. Metabolic reprogramming, including enhanced glycolysis and hypoxia-associated signaling, is a hallmark of tumor progression. Increased hypoxia-inducible factor 1 (HIF1α) expression has been associated with poorer prognosis and reduced response to ICI across several solid malignancies. We characterized and compared metabolic and hypoxic profiles across melanoma metastatic sites to provide insight into organ-specific responses to ICI. We described metabolic and hypoxic profiles in tumor samples from 182 melanoma patients across metastatic sites, including liver (n=24), lung (n=35), brain (n=41), lymph node (n=25), and subcutaneous tissue (n=57). Multiplex immunohistochemistry staining (n=92; CD3, SOX10, CAIX, HIF1α, GLUT1) and transcriptomic analysis of bulk RNA sequencing (n=158), were performed to compare cell densities and gene expression across these sites. Liver metastases showed upregulation of glycolytic and metabolic pathways compared with other sites, though 97% of pathways were also characteristic of normal liver tissue; SLC2A1 (GLUT1), however, was selectively elevated in liver metastases relative to normal liver, consistent with tumor-specific metabolic reprogramming overlayed on the hepatic niche. Liver, lung, and brain metastases exhibited higher proportions of GLUT1+CD3+ T cells compared with lymph node and subcutaneous metastases. In both liver and lung, GLUT1+ tumor regions had lower T cell infiltration than GLUT1- regions. Lung metastases had the highest HIF1α expression, while liver showed reduced expression of CAIX compared with other sites. These results demonstrate that the metabolic features of melanoma metastases and their accompanying immune cells differ across anatomical sites, possibly reflecting both the intrinsic biology of the host organ as well as tumor-specific metabolic reprogramming. This variability may contribute to organ-specific differences in response to ICI. They highlight the potential for therapies targeting metabolic pathways to overcome liver-mediated ICI resistance.
中文摘要:晚期黑色素瘤的不同转移部位对免疫检查点抑制剂(ICI)表现出不同反应。在接受ICI治疗的患者中,肝转移与反应较差相关,肺转移与反应较好相关。代谢重编程包括糖酵解增强和缺氧相关信号增强,是肿瘤进展的标志。HIF1α表达升高与多种实体瘤预后较差及ICI反应降低相关。为理解器官特异性ICI反应,研究比较了黑色素瘤不同转移部位的代谢和缺氧特征。对182例黑色素瘤患者不同转移部位的肿瘤样本进行代谢和缺氧特征分析,包括肝(n=24)、肺(n=35)、脑(n=41)、淋巴结(n=25)和皮下组织(n=57)。采用多重免疫组化染色(n=92;CD3、SOX10、CAIX、HIF1α、GLUT1)和bulk RNA测序转录组分析(n=158)比较各部位细胞密度和基因表达。肝转移灶较其他部位显示糖酵解和代谢通路上调,但97%的通路也见于正常肝组织的特征;SLC2A1(GLUT1)在肝转移灶中相对正常肝组织选择性升高,符合肿瘤特异性代谢重编程叠加于肝脏微环境的情况。肝、肺和脑转移灶中GLUT1+CD3+ T细胞比例高于淋巴结和皮下转移灶。在肝和肺中,GLUT1+肿瘤区域的T细胞浸润低于GLUT1-区域。肺转移灶HIF1α表达最高,肝转移灶CAIX表达低于其他部位。这些结果说明黑色素瘤转移灶及其伴随免疫细胞的代谢特征因解剖部位而异,可能反映宿主器官固有生物学和肿瘤特异性代谢重编程,这种差异可能促成ICI反应的器官特异性差异。结果提示靶向代谢通路的治疗有潜力克服肝转移介导的ICI耐药。
Conventional chimeric antigen receptor (CAR)-T manufacturing requires prolonged ex vivo activation and expansion, which may compromise T cell fitness and promote inflammatory differentiation. Here, we developed PrimeCAR, a 2-day manufacturing strategy combining low-intensity anti-CD3 priming with IL-7 and IL-21. Compared with conventionally manufactured CAR-T cells, PrimeCAR products exhibited a distinct transcriptional state characterized by preserved stemness-associated programs and a PrimeCAR-enriched primed naive T cell (Tn)-like state. Following antigen stimulation, PrimeCAR cells preferentially engaged proliferative programs while limiting exhaustion-associated regulators and inflammatory mediators. Functionally, PrimeCAR cells demonstrated enhanced expansion, persistence, and durable antitumor activity in xenograft models. In investigator-initiated phase I studies of relapsed or refractory B cell acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma, PrimeCAR showed encouraging clinical activity with a favorable safety profile. Together, these findings demonstrate that rapid manufacturing with controlled early T cell priming selectively restrains inflammatory programming while preserving CAR-T cell fitness, providing a practical strategy for improving CAR-T manufacturing and therapeutic performance.
中文摘要:常规嵌合抗原受体(CAR)-T细胞制备需要长时间的体外激活与扩增,这可能损害T细胞适应性并促发炎症性分化。为此,我们建立了PrimeCAR,一种为期2天的制备策略,将低强度抗CD3预激活与IL-7、IL-21联合使用。与常规制备的CAR-T细胞相比,PrimeCAR产品呈现独特的转录状态,其特征是干性相关程序得以保留,并富集一种预激活的类初始T细胞(Tn)状态。抗原刺激后,PrimeCAR细胞优先进入增殖相关程序,同时限制耗竭相关调控因子与炎症介质的表达。功能上,PrimeCAR细胞在异种移植模型中表现出更强的扩增、存续和持久的抗肿瘤活性。在研究者发起的针对复发或难治性B细胞急性淋巴细胞白血病与B细胞非霍奇金淋巴瘤的I期研究中,PrimeCAR显示出令人鼓舞的临床活性与良好的安全性。上述结果提示,受控的早期T细胞预激活结合快速制备能选择性抑制炎症程序,同时保留CAR-T细胞适应性,为改进CAR-T制备与治疗性能提供了可行策略。
Artificial intelligence (AI) is increasingly being applied across neuro-oncology domains to analyze complex, high-dimensional, multimodal data. Despite major advances in the biological understanding and classification of CNS tumors, clinical outcomes for many of them remain poor, reflecting intra- and inter-tumor heterogeneity and limitations of conventional reductionist approaches. AI offers a paradigm shift to capture this heterogeneity and provide quantitative, reproducible diagnostic, predictive, and prognostic insights. This article describes a joint effort across the Response Assessment in Neuro-Oncology (RANO) working groups to provide an overarching review of the AI use across six key domains of neuro-oncology: neuroimaging, neuropathology, laboratory medicine, neurosurgery, drug discovery, and clinical trials. Applications closest to clinical use include imaging segmentation and quantification, AI-assisted image reconstruction, DNA methylation-based classification, and workflow optimization. Radiogenomics, WSI-based molecular prediction, AI-guided surgical targeting, liquid biopsy interpretation, AI-guided drug discovery, digital twins, and in silico trials remain promising but require stronger prospective validation. Key challenges include limited availability of large diverse datasets, variability in data acquisition and reference standards, and limited external validation. This review provides a unifying framework for understanding the role of AI across neuro-oncology and highlights key considerations for its responsible implementation, emphasizing standardization, reproducibility, multi-institutional validation, and human oversight.
中文摘要:人工智能(AI)正日益应用于神经肿瘤学各领域,用于分析复杂、高维多模态数据。尽管中枢神经系统肿瘤的生物学认识与分类取得重大进展,许多患者的临床结局仍然不佳,反映出肿瘤内与肿瘤间异质性以及传统还原论方法的局限。AI提供了捕捉这种异质性的范式转变,并可提供定量、可重复的诊断、预测和预后见解。RANO各工作组联合开展的工作对AI在神经肿瘤学六个关键领域——神经影像、神经病理、检验医学、神经外科、药物发现和临床试验——的应用进行总体综述。最接近临床使用的应用包括影像分割与定量、AI辅助图像重建、基于DNA甲基化的分类和工作流程优化。放射基因组学、基于全切片图像(WSI)的分子预测、AI引导的手术靶向、液体活检解读、AI引导的药物发现、数字孪生和计算机模拟试验仍有前景,但需要更强的前瞻性验证。主要挑战包括大型多样数据集可及性有限、数据采集与参考标准存在差异以及外部验证不足。该综述为理解AI在神经肿瘤学中的作用提供统一框架,并强调负责任实施的关键考虑,着重标准化、可重复性、多机构验证和人工监督。
Platinum compounds preferably create intrastrand G-G adducts to halt replication in cancer cells. When successfully bypassed, resulting somatic variants end up in the genome. Unexpectedly, current double-base substitution signatures associated with platinum lack a GG component, and we hypothesized that deletion was missing from the possible solutions to circumvent a double-base lesion. We investigated a large pan-cancer metastatic cohort and generated platinum specific de novo double-base substitution and deletion (DBSD) signatures. One of the oxaliplatin associated DBSD signatures had GG deletion as dominant characteristic and also included new and known substitutions associated with platinum. Unforeseen among the additional results, DBSD signatures with deletion of TT as singular characteristic were strongly associated with microsatellite instability in multiple cohorts and provisionally in liquid biopsies. This study showed that DBSD signatures increase our understanding and cataloging of the effects caused by platinum and, in general, may aid in the discovery of new biological insights.
中文摘要:铂类化合物倾向于形成链内 G-G 加合物,从而阻断癌细胞复制。当这种损伤被成功绕过时,产生的体细胞变异会留在基因组中。与铂类相关的现有双碱基替换特征意外地缺乏 GG 组分,我们据此推测,缺失可能是规避双碱基损伤的解决方案中被遗漏的一类。我们研究了一个大型泛癌转移队列,生成了铂类特异的从头双碱基替换与缺失(DBSD)特征。其中一个与奥沙利铂相关的 DBSD 特征以 GG 缺失为主要特征,同时包含与铂类相关的新型和已知替换。在其他结果中,以 TT 缺失为单一特征的 DBSD 特征在多个队列中与微卫星不稳定强相关,并在液体活检中初步显示相关性。这项研究表明,DBSD 特征加深了我们对铂类所致效应的理解与归类,总体上可能有助于发现新的生物学认识。
Obesity, particularly visceral adiposity, is a key driver of cardiovascular mortality (CVM), yet conventional measures such as body mass index (BMI) inadequately capture fat distribution. The Body Roundness Index (BRI) is a novel anthropometric measure integrating waist circumference and height to better reflect body shape and visceral fat. This study examined the association between BRI and CVM in U.S. adults and across sociodemographic subgroups. We analysed data from 31 351 adults (median age 43 yrs, 50% females) aged ≥20 years in NHANES 1999-2018, excluding those with prior cardiovascular disease or cancer. BRI was computed using a validated equation and categorized into quintiles (Q3 as reference). The primary outcome was CVM; secondary outcomes included all-cause, heart disease, and cerebrovascular mortality. Weighted Cox proportional hazards and restricted cubic spline (RCS) models evaluated associations after adjustment for demographic, behavioural, and clinical factors. Subgroup and sensitivity analyses tested consistency and effect modification. During a median follow-up of 10.1 years (IQR: 5.3-14.9 years), 883 cardiovascular deaths occurred. In fully adjusted models, participants in the highest BRI quintile had a 54% higher risk of CVM (HR, 1.54; 95% CI, 1.13-2.08; P = 0.006) vs. Q3. This risk remained high even among those with normal BMI. RCS analysis indicated a modest U-shaped association. Stronger effects were observed among middle-aged adults (45-64 years) and those with higher educational attainment. Higher BRI is independently associated with increased cardiovascular mortality, particularly among middle aged adults and those with normal BMI, underscoring its potential as a practical, noninvasive tool for cardiovascular risk stratification. Incorporating BRI into clinical and public health assessment may improve identification of individuals at elevated risk.
中文摘要:肥胖,尤其是内脏脂肪堆积,是心血管死亡(CVM)的重要驱动因素,但体重指数(BMI)等传统指标不能充分反映脂肪分布。身体圆度指数(BRI)是一种新型人体测量指标,整合腰围与身高,以更好地反映体型和内脏脂肪。本研究考察美国成年人中BRI与CVM的关联,并分析不同社会人口学子组中的差异。我们分析NHANES 1999—2018中31 351名≥20岁成年人(中位年龄43岁,女性50%)的数据,排除既往心血管疾病或癌症者。BRI采用经验证的公式计算,并按五分位数分组(Q3为参照)。主要结局为CVM;次要结局包括全因死亡、心脏病死亡和脑血管病死亡。在校正人口学、行为与临床因素后,采用加权Cox比例风险模型和限制性立方样条(RCS)模型评估关联。亚组分析和敏感性分析检验结果一致性与效应修饰。中位随访10.1年(IQR:5.3—14.9年)期间,发生883例心血管死亡。完全校正模型中,BRI最高五分位者CVM风险较Q3高54%(HR,1.54;95% CI,1.13—2.08;P = 0.006)。BMI正常者中该风险仍升高。RCS分析提示轻度U形关联。中年成年人(45—64岁)和受教育程度较高者中效应更强。较高的BRI独立关联心血管死亡增加,在中年成年人和BMI正常者中尤为明显,提示其作为实用、无创心血管风险分层工具的潜力。将BRI纳入临床和公共卫生评估,可能改善对高风险个体的识别。
Cancer cachexia is a wasting syndrome with outsized impact on morbidity and mortality, yet its drivers and systemic consequences remain poorly defined. In this study, we repurposed longitudinal clinicogenomic data from 52,236 patients with cancer profiled by MSK-IMPACT (2010-2024) at Memorial Sloan Kettering Cancer Center to define episode-resolved trajectories of consensus-defined cachectic weight loss and linked these events to outcomes, serology and tumor genotypes. Cachectic episodes clustered near periods of disease progression and were associated with inferior outcomes in nearly all cancer types. Across diverse malignancies, cachectic weight loss episodes exhibited a consistent serologic signature characterized by lower albumin and hemoglobin and higher levels of liver enzymes. Numerous somatic tumor genotypes, including TP53 mutation across several diseases, were also associated with more frequent onset of cachectic episodes. Motivated by these observations, we developed a multivariate model to predict impending risk of cachectic weight loss in patients with lung, colorectal and prostate cancer, validated in an independent, external cohort from Dana-Farber Cancer Institute (n = 5,785). Routine clinicogenomic data are, therefore, a scalable resource for discovery in cancer cachexia.
中文摘要:癌症恶病质是一种消耗性综合征,对发病率和死亡率影响巨大,但其驱动因素和全身性后果仍不清楚。对纪念斯隆-凯特琳癌症中心2010至2024年经MSK-IMPACT检测的52,236例癌症患者的纵向临床基因组数据加以再利用,定义符合共识标准的恶病质性体重下降的按发作解析轨迹,并将这些事件与结局、血清学指标和肿瘤基因型关联。恶病质发作聚集在疾病进展期附近,并与几乎所有癌种的较差结局相关。在多种恶性肿瘤中,恶病质性体重下降发作呈现一致的血清学特征,表现为白蛋白和血红蛋白较低、肝酶水平较高。多种肿瘤体细胞基因型也与恶病质发作更频繁发生相关,包括跨若干疾病的TP53突变。基于这些观察,建立多变量模型,用于预测肺癌、结直肠癌和前列腺癌患者即将发生的恶病质性体重下降风险,并在丹娜-法伯癌症研究所一个独立外部队列(n=5,785)中验证。常规临床基因组数据因此可作为癌症恶病质研究的可扩展资源。
Multiple Lugol-voiding lesions (LVLs) confer a high risk of metachronous multiple esophageal squamous cell carcinomas (ESCCs) after endoscopic submucosal dissection (ESD); however, risk heterogeneity within this high-risk group remains unclear. Precise stratification could help optimize the surveillance intensity and reduce the burden of Lugol chromoendoscopy. We aimed to identify risk factors for metachronous multiple ESCCs among patients with multiple LVLs and to explore practical risk stratification. This single-center retrospective exploratory cohort study included patients who underwent initial ESD for superficial ESCC between 2014 and 2022 and had grade C LVLs, defined as ≥10 LVLs per endoscopic field of view. Grade C LVLs were subclassified by LVL counts as subgrade α (10-20), β (21-30), and γ (≥31). Among 331 patients (median follow-up 57 months), 163 (49.2%) developed metachronous multiple ESCCs; the 5-year cumulative incidence was 55.2% (95%CI 48.8-61.7). In multivariable analysis, positive flushing response (hazard ratio [HR] 1.59, 95%CI 1.10-2.31) and subgrade γ (HR 5.34 vs. α, 95%CI 2.36-12.1) were independently associated with increased risk. Subgrade γ showed higher 5-year incidence than subgrade α/β among both flushing-positive (71.4% vs. 27.2%; P < 0.001) and flushing-negative (57.5% vs. 16.9%; P = 0.004) patients. No confirmed ESCC-related deaths occurred during follow-up. Within grade C LVLs, subgrade γ and flushing positivity were associated with an increased risk of metachronous multiple ESCCs. Combining LVL subclassification and flushing status may provide clinically relevant risk stratification and may help inform risk-adapted surveillance after ESD.
中文摘要:多发性卢戈液不染区(LVLs)使内镜黏膜下剥离术(ESD)后发生异时性多发性食管鳞状细胞癌(ESCCs)的风险升高,但这一高危人群内部的风险异质性仍不清楚。精确分层有助于优化监测强度并减轻卢戈染色内镜负担。研究旨在识别多发性LVLs患者发生异时性多发性ESCCs的危险因素,并探索实用的风险分层。这项单中心回顾性探索性队列研究纳入2014年至2022年因浅表性ESCC接受初次ESD且存在C级LVLs的患者,C级LVLs定义为每个内镜视野≥10个LVLs。C级LVLs按LVL数量分为亚级α(10-20个)、β(21-30个)和γ(≥31个)。331例患者(中位随访57个月)中,163例(49.2%)发生异时性多发性ESCCs,5年累积发生率为55.2%(95%CI 48.8-61.7)。多变量分析中,flushing反应阳性(风险比[HR] 1.59,95%CI 1.10-2.31)和亚级γ(相比α的HR 5.34,95%CI 2.36-12.1)与风险升高独立相关。在flushing反应阳性患者(71.4% vs. 27.2%;P < 0.001)和flushing反应阴性患者(57.5% vs. 16.9%;P = 0.004)中,亚级γ的5年发生率均高于亚级α/β。随访期间未发生确认的ESCC相关死亡。在C级LVLs中,亚级γ和flushing反应阳性与异时性多发性ESCCs风险升高相关。结合LVL亚分级与flushing状态可能提供具有临床相关性的风险分层,并有助于指导ESD后风险适配的监测。
With seven products approved by the US Food and Drug Administration (FDA) for 15 indications and more than 2,600 active clinical trials, chimeric antigen receptor (CAR) T cell therapy is firmly established as an effective therapeutic modality for cancer treatment, and promising early data demonstrate its potential in autoimmune diseases. Key challenges facing the field include extending efficacy to solid tumors and reducing the cost and complexity of manufacturing to improve patient access. In this review, we summarize the clinical lessons learned from the now substantial experience with commercial CAR T cells and clinical trials and discuss three waves shaping next-generation development: multi-engineered and logic-gated CAR T cells, rational combination strategies, and in vivo CAR T cell generation. By integrating clinical experience with emerging strategies, we highlight where CAR T cell therapy has succeeded, where current approaches remain insufficient, and how next-generation cell therapies may be designed to overcome these barriers.
中文摘要:已有七款产品获美国食品药品监督管理局(FDA)批准用于15项适应证,2600多项临床试验正在进行,嵌合抗原受体(CAR)T细胞疗法已成为治疗癌症的有效手段,早期数据也显示其在自身免疫性疾病中的潜力。该领域面临的关键挑战包括将疗效拓展至实体瘤,以及降低生产成本与复杂性以改善患者可及性。本综述总结从商业CAR T细胞和临床试验累积经验中获得的临床教训,并讨论塑造下一代开发的三个方向:多工程化与逻辑门控CAR T细胞、合理联合策略、体内生成CAR T细胞。将临床经验与新兴策略结合,可明确CAR T细胞疗法已取得成功之处、当前方法仍不足的环节,以及下一代细胞疗法如何设计以克服这些障碍。
Central nervous system (CNS) tumors pose a major global health challenge, particularly in low- and middle-income countries (LMICs), where outcomes remain disproportionately poor. The global CONCORD-3 study (Lancet Oncology) highlighted stark disparities in five-year survival (2010-2014): from ∼15% in Thailand to 46% in Japan among adults, and from ∼ 80% in Denmark to < 40% in Brazil among children. Limited access to specialized pathology and molecular diagnostics in LMICs results in diagnostic uncertainty and restricted treatment options. DNA methylation-based tumor classification, has revolutionized CNS tumor diagnosis and got incorporated into the 2021 world health organization (WHO) CNS5 classification. However, its accessibility, feasibility, and performance in LMICs remain insufficiently explored. Importantly, several ethnic groups common in LMICs are underrepresented in current reference datasets. To address this, the Molecular Neuro-Pathology (MNP) Outreach Consortium was launched in Heidelberg, partnering with 11 countries-including nine LMICs from Asia, Africa, and South America. Early insights from Brazil, Jordan and Argentina, show methylation profiling changing diagnosis in up to 25% cases. Gains are greatest in pediatric and adolescents and young adults (AYA) populations. In addition, it reduced the designation of not otherwise specified (NOS) from 51.3% to 8.8% across 476 CNS tumours in Brazil.
中文摘要:中枢神经系统(CNS)肿瘤构成重大全球健康挑战,尤其在低收入和中等收入国家(LMICs),其结局仍然格外差。全球CONCORD-3研究(Lancet Oncology)显示2010—2014年五年生存率存在明显差距:成人从泰国约15%到日本46%,儿童从丹麦约80%到巴西低于40%。LMICs获取专科病理和分子诊断的机会有限,导致诊断不确定并限制治疗选择。基于DNA甲基化的肿瘤分类已彻底改变CNS肿瘤诊断,并被纳入2021年世界卫生组织(WHO)CNS5分类。然而,其在LMICs的可及性、可行性和性能仍研究不足。LMICs常见的若干族群在当前参考数据集中代表性不足。为此,分子神经病理(MNP)外展联盟在海德堡启动,与11个国家合作,包括亚洲、非洲和南美洲的九个LMICs。来自巴西、约旦和阿根廷的早期观察显示,甲基化谱分析使多达25%病例的诊断发生改变,获益在儿童和青少年及年轻成人(AYA)人群中最大。在巴西476例CNS肿瘤中,该分析还将未另作说明(NOS)的分类从51.3%降至8.8%。
Comparative data evaluating the predictive performance of various obesity and metabolic indices for multiple noncommunicable diseases (NCDs) remain limited. We used the data sourced from the Health Evaluation and risk Reduction through nationwide Teamwork cohort (ChinaHEART), a national population-based study that enrolled 4,258,033 Chinese adults and followed them for more than 20 million person-years between November 2014 and December 2023. Fifteen obesity and metabolic indices were categorized into three groups: (1) body shape-related indices, including body mass index (BMI), body roundness index (BRI), waist-to-height ratio (WHtR), a body shape index (ABSI), weight-adjusted waist index (WWI), and conicity index (CI); (2) visceral fat-related indices, including lipid accumulation product (LAP) and Chinese visceral adiposity index (CVAI); and (3) metabolic function-related indices, including triglyceride-glucose index (TyG), TyG-BMI, TyG-BRI, TyG-WHtR, TyG-ABSI, TyG-WWI, and TyG-CI. The study outcomes comprised composite events of death or first hospitalization attributable to each of cardiovascular diseases (CVD), diabetes mellitus (DM), cancers, and chronic obstructive pulmonary disease (COPD) individually. Composite obesity and metabolic indices reflecting visceral adiposity accumulation and insulin resistance, respectively exhibited enhanced predictive accuracy for cardiovascular and diabetic risk, whereas their performance for cancer and COPD was comparatively limited. These findings support the paradigm that weight management strategies should be guided by risk assessments rather than relying solely on body weight or body shape. Furthermore, the development of diverse definitions for obesity measurement and management tailored to different population subgroups is warranted.
中文摘要:比较评估各种肥胖和代谢指标对多种非传染性疾病预测性能的数据仍有限。研究使用中国HEART队列数据,该全国性人群研究纳入4,258,033名中国成人,2014年11月至2023年12月随访超过2000万人年。15项肥胖和代谢指标分为三组:体形相关指标,包括体重指数、身体圆度指数、腰高比、身体形状指数、体重调整腰围指数和锥度指数;内脏脂肪相关指标,包括脂质蓄积产物和中国内脏脂肪指数;代谢功能相关指标,包括甘油三酯-葡萄糖指数、TyG-BMI、TyG-BRI、TyG-WHtR、TyG-ABSI、TyG-WWI和TyG-CI。研究结局为心血管疾病、糖尿病、癌症和慢性阻塞性肺疾病各自归因的死亡或首次住院复合事件。分别反映内脏脂肪蓄积和胰岛素抵抗的复合肥胖与代谢指标,对心血管和糖尿病风险显示出更高的预测准确性,而对癌症和慢性阻塞性肺疾病的预测表现相对有限。这些发现支持体重管理策略应以风险评估为指导,而非仅依赖体重或体形。针对不同人群亚组制定多样化的肥胖测量与管理定义具有必要性。
Sequential chemoradiotherapy remains a standard treatment option for patients with isocitrate dehydrogenase (IDH)-mutant gliomas. The results of the phase III INDIGO trial have led to the recent regulatory approval of vorasidenib, a brain-penetrant IDH1 and IDH2 inhibitor, indicated for patients with IDH1- or IDH2-mutant WHO grade 2 astrocytoma or oligodendroglioma after biopsy or resection. While IDH inhibitors represent a significant advancement for patients with IDH-mutant glioma, there is substantial controversy regarding which patients are most likely to derive benefit from IDH inhibition and how this strategy can be optimally integrated into clinical practice. Specifically, whether IDH inhibitors should be used prior to, in conjunction with or potentially in lieu of radiation-based treatment strategies are fundamental questions for the neuro-oncology community. Additionally, whether IDH inhibitors can be extrapolated to higher-grade disease settings or utilized in higher-risk patient populations remains unknown. These open questions provide an opportunity for the field of radiation oncology to develop pragmatic biomarker-based approaches to guide patient selection, to monitor treatment response and to identify optimal treatment strategy and timing/sequencing of treatment. Several candidate biomarkers have emerged for IDH-mutant glioma with unique potential to be rationally integrated into radiation oncology workflows to personalize care.
中文摘要:序贯放化疗仍是IDH突变型胶质瘤患者的标准治疗选择之一。III期INDIGO试验结果促成vorasidenib近期获批;这是一种可透过血脑屏障的IDH1和IDH2抑制剂,适用于活检或切除后WHO 2级IDH1或IDH2突变型星形细胞瘤或少突胶质细胞瘤患者。IDH抑制剂为IDH突变型胶质瘤患者带来重要进展,但哪些患者最可能从IDH抑制中获益、该策略如何最佳整合进临床实践仍存在明显争议。具体而言,IDH抑制剂应在放疗策略之前、与放疗联合,还是可能替代放疗策略,是神经肿瘤学界需要回答的基本问题。IDH抑制剂能否外推至更高级别疾病场景,或用于更高风险患者人群,仍不清楚。这些开放问题为放射肿瘤学领域提供了机会,可发展基于生物标志物的务实方法,用于指导患者选择、监测治疗反应,并确定最佳治疗策略及治疗时机/顺序。IDH突变型胶质瘤已出现若干候选生物标志物,具有被合理整合进放射肿瘤学工作流程以实现个体化治疗的独特潜力。
Although most human papillomavirus (HPV) infections are transient, a small fraction persist and eventually progress to invasive cancer. Predicting the outcome of an HPV infection remains a major unresolved challenge. Despite decades of intensive research, no single viral, host, or molecular biomarker has demonstrated sufficient accuracy to reliably identify HPV infections and associated preneoplastic lesions at increased risk of persistence or progression. We argue that this limitation reflects the dynamic and multifactorial nature of HPV-associated carcinogenesis rather than a lack of candidate biomarkers. Recent advances in high-throughput molecular analysis, artificial intelligence, and integrative risk modeling provide new opportunities to capture this complexity. Such approaches may ultimately improve clinical decision-making and reduce reliance on prolonged surveillance as a surrogate for accurate prediction.
中文摘要:多数人乳头瘤病毒(HPV)感染为一过性,但少部分会持续存在并最终进展为浸润性癌。预测HPV感染的结局仍是尚未解决的重要难题。尽管经过数十年深入研究,尚无任何单一的病毒、宿主或分子生物标志物能够足够准确可靠地识别持续存在或进展风险升高的HPV感染及相关癌前病变。我们认为,这一局限反映的是HPV相关癌变过程的动态性和多因素性,而非候选生物标志物不足。高通量分子分析、人工智能与整合风险建模的近期进展,为捕捉这种复杂性提供了新机会。这些方法最终可能改善临床决策,并减少对长期监测作为准确预测替代手段的依赖。
As molecular profiling improves, treatment responses are increasingly observed in smaller, biomarker-defined subgroups, highlighting the need for novel clinical trial designs and endpoints. We review principles for the selection and assessment of biomarkers, a crucial component of biomarker-enriched protocols, and illustrate common pitfalls in biomarker ascertainment through recent examples. We summarize current response assessment criteria and their integration into single-arm trials with surrogate endpoints based on response rate, which have supported recent accelerated regulatory approvals in biomarker-selected populations. We describe how window-of-opportunity trials can help validate CNS penetration and target engagement early, and define master protocol designs: basket, umbrella, and adaptive platform trials. Finally, we evaluate external control arms and their current role in neuro-oncology research. Throughout, we provide guidance on the use of novel designs and endpoints while preserving scientific rigor.
中文摘要:随着分子谱分析不断改善,治疗反应越来越多地出现在由生物标志物定义的较小子群中,凸显了对新型临床试验设计和终点的需求。我们回顾生物标志物选择和评估的原则,这是生物标志物富集方案的关键组成部分,并通过近期实例说明生物标志物确定过程中的常见陷阱。我们总结当前疗效评估标准及其在以缓解率为替代终点的单臂试验中的整合,这类试验支持了近期在生物标志物筛选人群中获得的加速监管批准。我们描述机会窗试验如何早期帮助验证中枢神经系统穿透和靶点结合,并界定主方案设计:篮式试验、伞式试验和适应性平台试验。最后,我们评估外部对照臂及其当前在神经肿瘤学研究中的作用。全文就使用新型设计和终点同时保持科学严谨性提供指导。
Meningiomas represent the most common intracranial tumors, overall. While a majority of tumors can be considered indolent, a subset of patients will experience repeated recurrences despite surgical and radiotherapeutic interventions. For these patients, there are only a limited number of promising systemic therapy options available. Effective drug development for meningiomas has been limited by variability in trial design, the clinical trial endpoints being used across studies, heterogeneous tumor biology and patient selection in clinical trials, and inconsistent radiological response assessment criteria. However, over the past years, tremendous progress has been made in understanding the biological and molecular underpinnings of meningiomas. Guidance on clinical trial endpoints and response assessment criteria has also improved clinical trial design and it is widely recognized that patient participation in a clinical trial remains the best way to evaluate novel therapy options and move drug development forward. In this review, we discuss factors of optimal clinical trial design for meningioma clinical trials and review and discuss the evidence supporting the use of various contemporary biomarker-guided and systemic therapy options for patients with meningioma.
中文摘要:脑膜瘤总体上是最常见的颅内肿瘤。多数肿瘤可视为惰性,但一部分患者即使接受手术和放疗仍会反复复发。对这些患者,有前景的系统治疗选择数量有限。脑膜瘤有效药物开发受限于试验设计差异、各研究采用的临床试验终点不同、肿瘤生物学和临床试验患者选择的异质性,以及影像学缓解评估标准不一致。过去几年,对脑膜瘤生物学和分子基础的理解取得了巨大进展。关于临床试验终点和缓解评估标准的指导也改善了临床试验设计,人们广泛认识到,患者参与临床试验仍是评估新治疗选择并推动药物开发的最佳方式。讨论脑膜瘤临床试验优化设计的因素,并回顾和讨论支持采用各类当代生物标志物指导策略和系统治疗策略治疗脑膜瘤患者的证据。
基础研究 (75篇)
Attenuated oncolytic bacteria represent a promising targeted delivery platform for cancer therapy; however, the lack of non-invasive biomarkers to monitor their persistent intra-tumoral colonization severely limits clinical translation, efficacy assessment, and safety monitoring. Here, we identify the sustained elevation of peripheral blood CXCL1 as a dynamic, non-invasive biomarker for the persistent colonization of attenuated Salmonella in solid tumors. Across four orthotopic preclinical models (including lung, breast, and bladder cancers, as well as melanoma), effective bacterial colonization specifically drove prolonged systemic CXCL1 elevation. Focusing specifically on the melanoma model, rapid bacterial eradication via intratumoral antibiotics restored CXCL1 to baseline. Furthermore, comparisons with a colonization-deficient mutant strain confirmed that CXCL1 elevation strictly depends on intra-tumoral, rather than systemic, bacterial burden. Mechanistically, single-cell RNA sequencing (scRNA-seq) revealed that tumor-colonizing bacteria profoundly reshape the tumor microenvironment by directly activating and recruiting neutrophils, monocytes, and cancer-associated fibroblasts (CAFs), which act as the primary cellular sources of CXCL1 production and systemic leakage. These findings highlight peripheral blood CXCL1 as a robust and actionable biomarker for real-time monitoring of oncolytic bacterial colonization, providing crucial guidance for dosing optimization and biosafety evaluation in clinical applications.
中文摘要:减毒溶瘤细菌是肿瘤治疗中颇具前景的靶向递送平台,但缺乏可在无创条件下监测其在瘤内持续定植的标志物,这严重制约了临床转化、疗效评估与安全性监测。本研究报告外周血CXCL1持续升高可作为减毒沙门氏菌在实体瘤内持续定植的动态无创标志物。在四种原位临床前模型(包括肺癌、乳腺癌、膀胱癌和黑色素瘤)中,有效的细菌定植特异性地驱动循环CXCL1长时间升高。以黑色素瘤模型为重点,经瘤内抗生素快速清除细菌后,CXCL1回落至基线水平。与定植缺陷突变株的比较证实,CXCL1升高严格依赖瘤内细菌负荷而非全身细菌负荷。单细胞RNA测序显示,定植于肿瘤的细菌直接激活并招募中性粒细胞、单核细胞和肿瘤相关成纤维细胞(CAF),显著重塑肿瘤微环境,这些细胞是CXCL1产生并进入循环的主要来源。外周血CXCL1可作为实时监测溶瘤细菌定植的稳健且可操作的标志物,为临床应用中给药方案优化和生物安全性评价提供关键依据。
Resistance to next-generation androgen receptor antagonists represents a major clinical challenge in prostate cancer (PCa), underscoring the need to define its underlying mechanisms. Here, through an integrated analysis of multiple cohorts, we identify PABPC1 as an RNA-binding protein upregulated in therapy-resistant tumors, whose expression correlates with adverse clinicopathological features. Elevated PABPC1 confers enzalutamide (Enz) resistance by suppressing tumor-cell ferroptosis and CD8+ T-cell cytotoxicity. Mechanistically, PABPC1 promotes the cytoplasmic colocalization of EIF4A1 with ATF4 mRNA and enhances EIF4A1-associated translation of ATF4 mRNA. Subsequently, ATF4 binds the BCAT1 promoter and transcriptionally upregulates BCAT1, thereby promoting branched-chain amino acid (BCAA) metabolic remodeling and ferroptosis resistance, with leucine emerging as a major functional contributor to both ferroptosis regulation and CD8+ T-cell effector responses. In preclinical models, ixazomib restores ferroptotic vulnerability, reinvigorates T-cell activity, and synergizes with Enz, without overt histopathological abnormalities in major organs. These results identify the PABPC1-ATF4-BCAT1 axis as a key regulatory pathway linking RNA regulation with metabolic and immune reprogramming to facilitate treatment resistance in PCa.
中文摘要:对下一代雄激素受体拮抗剂耐药是前列腺癌临床治疗的主要难题,明确其机制十分必要。通过对多个队列的整合分析,发现PABPC1是一种在治疗耐药肿瘤中上调的RNA结合蛋白,其表达与不良临床病理特征相关。PABPC1升高通过抑制肿瘤细胞铁死亡和CD8+ T细胞细胞毒性导致恩杂鲁胺耐药。机制上,PABPC1促进EIF4A1与ATF4 mRNA在细胞质中的共定位,并增强EIF4A1相关的ATF4 mRNA翻译。随后ATF4结合BCAT1启动子并转录上调BCAT1,推动支链氨基酸代谢重塑和铁死亡抵抗,亮氨酸成为铁死亡调控与CD8+ T细胞效应应答的主要功能贡献者。在临床前模型中,伊沙佐米恢复铁死亡易感性、重新激活T细胞活性,并与恩杂鲁胺协同,主要器官未见明显组织病理学异常。这些结果确定PABPC1-ATF4-BCAT1轴是连接RNA调控与代谢、免疫重编程以促进前列腺癌治疗耐药的关键调控通路。
Chromosomal aberrations, including aneuploidies and structural rearrangements, are key drivers of cancer and numerous genetic disorders. Experimental modeling of these alterations is essential for understanding their role in disease initiation and progression. Historically, chromosome engineering relied on methods that lacked precision and could generate off-target genomic damage. Recent advances in genome editing have enabled the precise generation of defined chromosomal abnormalities in human cells. This review summarizes current approaches for modeling numerical and structural chromosomal aberrations, including CRISPR-based chromosome elimination, KaryoCreate, prime editing, programmable recombinases, and RNA-guided bridge recombinases. We also discuss strategies for generating complex chromosomal rearrangements, their applications in studying genome instability, and their limitations. Together, these technologies provide powerful tools to investigate the earliest genomic events underlying cancer and genetic diseases.
中文摘要:染色体异常包括非整倍体和结构重排,是癌症和众多遗传性疾病的关键驱动因素。对这些变异进行实验建模,对于理解其在疾病发生和进展中的作用至关重要。历史上,染色体工程所依赖的方法缺乏精确性,并可能产生脱靶基因组损伤。基因组编辑的最新进展使得在人细胞中精确生成明确的染色体异常成为可能。本综述总结了当前对数目异常和结构异常进行建模的方法,包括基于CRISPR的染色体消除、KaryoCreate、先导编辑、可编程重组酶以及RNA引导的桥重组酶。我们还讨论了生成复杂染色体结构重排的策略、它们在研究基因组不稳定性中的应用及其局限性。这些技术共同为探究癌症和遗传性疾病的最早期基因组事件提供了有力工具。
Cancer is not biologically confined to the tumor bed. Cachexia, fatigue, metabolic dysfunction, circadian disruption, and immune dysfunction reflect disturbances that local models alone cannot fully explain. The brain is well positioned to participate in these processes because it continuously samples circulating signals and coordinates endocrine and autonomic responses. Yet the afferent side of this communication has received less attention than its downstream consequences. Here, we synthesize evidence showing that cytokines, hormones, metabolites, and cargo carried by extracellular vesicles can engage central sensory interfaces and integrative regions, particularly circumventricular organs and hypothalamic and brainstem circuits. We use the term Endocriception to describe afferent humoral sensing and early central decoding of circulating biochemical signals, and focus here on how tumor- and host-associated changes engage this process in cancer. Central neuroendocrine governance refers to the subsequent integration of this information and the generation of autonomic and endocrine outputs. Persistent inflammation, stress, circadian disruption, and impaired feedback may gradually reconfigure this regulatory system. The resulting changes can affect systemic immunity, metabolism, behavior, and host tolerance of cancer. Evidence is strongest for a limited number of pathways, whereas many proposed links remain incomplete or dependent on tumor type and experimental context. We therefore present central neuroendocrine governance as a working framework for organizing current evidence and guiding mechanistic studies, biomarker development, and interventions aimed at restoring host physiology.
中文摘要:癌症在生物学上并不局限于瘤床。恶病质、疲乏、代谢功能障碍、昼夜节律紊乱和免疫功能障碍反映的紊乱,仅靠局部模型无法充分解释。大脑适合参与这些过程,因为它持续采样循环信号并协调内分泌与自主神经反应。然而,这一通信的传入侧受到的关注少于其下游后果。综合现有证据表明,细胞因子、激素、代谢物以及细胞外囊泡携带的货物可作用于中枢感觉界面和整合区域,尤其是室周器官以及下丘脑和脑干回路。我们用Endocriception一词描述传入性体液感知以及对循环生化信号的早期中枢解码,并在此聚焦肿瘤和宿主相关变化如何在癌症中作用于这一过程。中枢神经内分泌治理指随后对这些信息的整合以及自主神经和内分泌输出的产生。持续炎症、应激、昼夜节律紊乱和反馈受损可能逐步重塑这一调节系统。由此产生的变化可影响全身免疫、代谢、行为以及宿主对癌症的耐受。证据仅在少数通路上最强,许多提出的联系仍不完整,或取决于肿瘤类型和实验背景。因此,我们将中枢神经内分泌治理作为一个工作框架,用于组织现有证据并指导机制研究、生物标志物开发以及旨在恢复宿主生理的干预。
Serine incorporator 3 (SERINC3) is a multi-transmembrane protein involved in membrane lipid biosynthesis but its role in oral squamous cell carcinoma (OSCC) is undefined. Combining clinical specimens with public transcriptomic datasets, we found that SERINC3 was upregulated in OSCC tissues and that high expression was associated with poorer overall survival. Functionally, SERINC3 depletion impaired OSCC cell proliferation, migration, and invasion, whereas SERINC3 overexpression enhanced these phenotypes. In vivo, Serinc3 deletion suppressed 4NQO-induced oral tumorigenesis, and SERINC3 knockdown reduced tumor growth in both subcutaneous and patient-derived xenograft models. Mechanistically, SERINC3 sustained c-MET expression, and knockdown of either SERINC3 or MET increased JNK phosphorylation and PGC-1α levels; JNK inhibition with JNK-IN-8 partially reversed the phenotypic effects of SERINC3 depletion, while pharmacological PGC-1α activation with ZLN005 suppressed migration and invasion in vitro and xenograft growth in vivo. Single-cell RNA sequencing and metabolic assays further linked SERINC3 to mitochondrial metabolic reprogramming. Together, these findings identify SERINC3 as a candidate driver of OSCC progression acting through c-MET/JNK/PGC-1α-associated signaling and mitochondrial metabolic regulation, and suggest it as a potential therapeutic target. The precise causal relationships within this signaling axis warrant further investigation.
中文摘要:丝氨酸整合因子3(SERINC3)是一种参与膜脂生物合成的多次跨膜蛋白,但其在口腔鳞状细胞癌(OSCC)中的作用尚不明确。结合临床标本与公共转录组数据集,我们发现SERINC3在OSCC组织中上调,高表达与较差的总生存相关。功能上,敲低SERINC3削弱OSCC细胞增殖、迁移和侵袭,而过表达SERINC3增强这些表型。体内,Serinc3缺失抑制4NQO诱导的口腔肿瘤发生,SERINC3敲低在皮下和患者来源异种移植模型中均减少肿瘤生长。机制上,SERINC3维持c-MET表达,敲低SERINC3或MET均增加JNK磷酸化与PGC-1α水平;JNK-IN-8抑制JNK可部分逆转SERINC3缺失的表型效应,而ZLN005药理学激活PGC-1α在体外抑制迁移和侵袭、在体内抑制移植瘤生长。单细胞RNA测序和代谢实验进一步将SERINC3与线粒体代谢重编程联系起来。这些发现将SERINC3识别为OSCC进展的候选驱动因子,其通过c-MET/JNK/PGC-1α相关信号和线粒体代谢调控发挥作用,并提示其作为潜在治疗靶点。该信号轴内确切的因果关系仍需进一步研究。
An urgent requirement in chimeric antigen receptor (CAR) immune cell therapy [e.g., CAR-natural killer (NK) cells] for solid tumors is to engineer the cells for precise tumor targeting. Meanwhile, medical microrobots can be navigated toward specific target sites using external magnetic fields. Here, by bridging these approaches, we turn CAR-NK cells into magnetic biohybrid microrobots (CAR-NK microrobots) that achieve controllable long-distance targeted navigation at therapeutic doses (∼106 cells) in both murine and nonhuman primate animal models in vivo. CAR-NK microrobots are developed through genetic engineering with CAR structures and loading with magnetic nanoparticles for field-based navigation. Different magnetic field inputs reconfigure their swarms between vortex and ribbon modes, allowing dense aggregation for targeted navigation and further broad dispersion for large-area coverage. Using programmable magnetic fields, in vivo CAR-NK microrobot-based therapy is demonstrated for metastatic leptomeningeal carcinomatosis in brain's cerebrospinal fluid space. After intrathecal injection, the microrobots are magnetically guided long distance through the spinal canal toward the brain in vortex mode and subsequently spread over the target site in ribbon mode, as visualized by real-time angiographic imaging in a nonhuman primate model, providing a proof-of-feasibility demonstration in a nonhuman primate anatomical setting.
中文摘要:嵌合抗原受体(CAR)免疫细胞疗法(如CAR-自然杀伤(NK)细胞)用于实体瘤时,一项迫切需求是对细胞进行工程化改造,使其能精准靶向肿瘤。医学微机器人则可借助外部磁场被导航至特定靶点。把这两条路线衔接起来,本研究将CAR-NK细胞转化为磁性生物杂合微机器人(CAR-NK微机器人),在小鼠与非人灵长类动物体内模型中,于治疗剂量(约10^6个细胞)下实现可控的长距离靶向导航。CAR-NK微机器人通过基因工程引入CAR结构,并负载磁性纳米颗粒以支持基于磁场的导航。不同的磁场输入可在涡旋模式与带状模式之间重构其集群,涡旋模式形成密集聚集以完成靶向导航,带状模式则进一步大范围分散覆盖。借助可编程磁场,在脑脊液空间内的转移性软脑膜癌病中展示了基于CAR-NK微机器人的体内治疗。鞘内注射后,微机器人以涡旋模式沿椎管长距离磁导向脑部,随后以带状模式在靶部位铺展,非人灵长类模型中的实时血管造影成像对此进行了可视化,从而在非人灵长类的解剖环境中给出了可行性验证。
Oncogenic gene fusions are key drivers of cancer, yet most remain undruggable by current therapies. Here, we establish CRISPR-PspCas13b as a personalizable platform for systematic silencing of various fusion transcripts. We reveal that recognition and cleavage of the breakpoint sequence by PspCas13b disrupt the fusion transcript, resulting in efficient protein depletion. PspCas13b cleavage produces aberrant, translation-incompetent target RNA species, a subset of which harbors internal deletions proximal to the cleavage site. We demonstrate that targeting the BCR::ABL1 breakpoint sequence efficiently degrades both wild-type and drug-resistant BCR::ABL1 mutants, which are the primary drivers of tyrosine kinase inhibitor resistance and relapse in chronic myeloid leukemia. Molecular profiling revealed that PspCas13b impairs BCR::ABL1 tyrosine phosphokinase activity and triggers extensive transcriptomic and proteomic remodeling, leading to erythroid differentiation and apoptosis in drug-resistant cells. Beyond BCR::ABL1, personalized design of PspCas13b effectively silences other undruggable oncogenic fusions. Collectively, this study establishes a molecular framework for precise targeting of undruggable or drug-resistant oncogenic transcripts.
中文摘要:致癌性基因融合是癌症的关键驱动因素,但现有疗法大多无法靶向这些融合。我们建立CRISPR-PspCas13b作为可个性化定制的平台,用于系统性沉默多种融合转录本。研究发现,PspCas13b识别并切割断点序列会破坏融合转录本,导致蛋白高效耗竭。PspCas13b切割产生异常的、无翻译能力的靶RNA种类,其中一部分在切割位点附近带有内部缺失。靶向BCR::ABL1断点序列可高效降解野生型及耐药性BCR::ABL1突变体,而这些突变体是慢性髓性白血病中酪氨酸激酶抑制剂耐药和复发的主要驱动因素。分子谱分析显示,PspCas13b削弱BCR::ABL1酪氨酸磷酸激酶活性,并引发广泛的转录组和蛋白质组重塑,导致耐药细胞红系分化和凋亡。除BCR::ABL1外,个性化设计的PspCas13b还能有效沉默其他难以成药的致癌融合。这些结果建立了精准靶向难以成药或耐药的致癌转录本的分子框架。
Macrophages play a key role in cardiac injury and repair after myocardial infarction (MI). Salt-inducible kinase 2 (SIK2), a member of the adenosine monophosphate-activated protein kinase family, is notably up-regulated in monocytes/macrophages of patients with MI and animal models. In this study, we investigated the role of SIK2 in macrophage-mediated inflammation and efferocytosis following MI. Macrophage-specific SIK2 deletion reduces infarct size and improves healing post-MI. Furthermore, SIK2-knockout macrophages decrease proinflammatory factor expression and enhance efferocytosis, thereby increasing repair factors expression. SIK2 associates with tumor necrosis factor receptor-associated factor 2 (TRAF2), promoting its phosphorylation and K63 polyubiquitylation, which exacerbates inflammation and hinders efferocytosis via the P38 and nuclear factor κB pathways. In contrast, the SIK2T175A mutation exhibits no effect. Macrophage-specific SIK2 overexpression worsens cardiac changes after MI, whereas P38 inhibition reduces this effect. In addition, pharmacological inactivation of SIK2 substantially enhances cardiac repair after MI in mice. These findings highlight the crucial role of macrophage SIK2 in the regulation of inflammation and efferocytosis via TRAF2 polyubiquitination in MI, thereby presenting potential therapeutic targets.
中文摘要:巨噬细胞在心肌梗死后心脏损伤与修复中起关键作用。盐诱导激酶2(SIK2)属于AMP活化蛋白激酶家族,在心肌梗死患者及动物模型的单核细胞/巨噬细胞中明显上调。本研究探讨SIK2在心肌梗死后巨噬细胞介导的炎症与胞葬作用中的角色。巨噬细胞特异性敲除SIK2可缩小梗死面积并改善梗死后愈合。SIK2敲除巨噬细胞降低促炎因子表达并增强胞葬作用,从而提高修复因子表达。SIK2与肿瘤坏死因子受体相关因子2(TRAF2)结合,促进其磷酸化及K63多聚泛素化,经P38与核因子κB通路加重炎症并阻碍胞葬作用。SIK2 T175A突变则无此作用。巨噬细胞特异性过表达SIK2会加重心肌梗死后的心脏改变,而抑制P38可减轻该效应。药物性失活SIK2可显著促进小鼠心肌梗死后的心脏修复。这些发现表明,巨噬细胞SIK2通过TRAF2多聚泛素化调控心肌梗死中的炎症与胞葬作用,并提示潜在治疗靶点。
T cell exhaustion is often viewed as a terminal state marked by irreversible loss of function during chronic infection and cancer. However, the rapid recovery of antitumor activity in clinical responders after PD-1 blockade suggests that some exhausted T cells retain hidden functional potential. To explain this paradox, we present a theoretical framework that separates latent effector capacity from active effector function. Latent effector capacity represents a history-dependent state reflecting preserved epigenetic accessibility and regulatory readiness, distinct from ongoing gene expression. In this model, PD-1 signaling acts as a reversible mask that suppresses effector function without eliminating the underlying effector capacity. The framework explains preserved chromatin accessibility, rapid reinvigoration after checkpoint blockade, and variable therapeutic responses. By incorporating nonlinear maintenance and erosion of latent effector capacity, the model predicts a bistable system with a point of no return beyond which exhaustion becomes irreversible. These principles may guide development of mechanistically informed biomarkers and artificial intelligence models predicting response to PD-1 therapy.
中文摘要:T细胞耗竭常被视为慢性感染和癌症中功能不可逆丧失的终末状态。然而,PD-1阻断后临床应答者抗肿瘤活性快速恢复,提示部分耗竭T细胞仍保留隐藏的功能潜能。为解释这一矛盾,我们提出一个理论框架,将潜在效应能力与活跃效应功能区分开。潜在效应能力是一种依赖历史的状态,反映被保留的表观遗传可及性和调控准备度,不同于正在进行的基因表达。在该模型中,PD-1信号作为可逆面具抑制效应功能,却不消除 underlying effector capacity。该框架解释了染色质可及性得以保留、检查点阻断后快速再激活以及治疗反应差异。通过纳入潜在效应能力的非线性维持与侵蚀,模型预测出一个双稳态系统,并存在一旦越过耗竭便不可逆的不可返回点。这些原理可能指导开发机制信息生物标志物和预测PD-1治疗反应的人工智能模型。
Diffuse gliomas are frequently associated with epilepsy, particularly in low-grade variants. Seizures are key events to be considered in glioma management, including during surgery. Optimizing resection of epileptic areas may affect not only postoperative epilepsy but also glioma prognosis in the context of interactions between glioma growth and neuronal activities. As for glioma tissue resection, surgery of epileptic networks requires a deeper understanding of their organization and reliable biomarkers. We investigated the spatiotemporal dynamics of the transition from interictal to ictal-like events (ILEs) using ex vivo human peritumoral tissue from glioma patients. Slices were recorded with multi-electrode arrays during the transition from the spontaneous interictal state to pharmacologically induced seizures considering the dynamics of slow versus fast oscillatory neuronal activities. Transition to seizure was characterized by the emergence of preictal discharges (PIDs), allowing subdivision of the preictal phase into build-up, steady-state, and trigger periods. PIDs progressively increased in amplitude, duration, and slope with significant changes during the trigger phase. Concurrently, high-frequency activity (180-550 Hz) and high-frequency oscillations (HFOs) increased across the transition period, particularly during the trigger phase. In addition to such preictal recruitment, the reinforcement of HFOs was accompanied by a spatial organization in additive microdomains, peaking at seizure onset and encompassing slow field potential dynamics. In the periglioma human cortex, seizures arise from progressively recruited neuronal assemblies sculpted together with HFOs, providing new insights into the microphysiological processes of glioma-related ictogenesis and requiring consideration of the preictal fast and focal neuronal activity.
中文摘要:弥漫性胶质瘤常与癫痫相关,低级别亚型尤为明显。癫痫发作是胶质瘤管理中需重点考虑的事件,包括术中。优化致痫区切除可能不仅影响术后癫痫,在胶质瘤生长与神经元活动相互作用的背景下也可能影响胶质瘤预后。与胶质瘤组织切除类似,致痫网络手术需要更深入理解其组织和可靠生物标志物。我们使用胶质瘤患者的离体人瘤周组织,研究发作间期向癫痫样事件(ILEs)转变的时空动态。切片在多电极阵列记录下,从自发发作间期状态向药理学诱导的癫痫发作转变,考虑慢速与快速振荡神经元活动的动态。向癫痫发作的转变以癫痫前放电(PIDs)出现为特征,使发作前期可细分为累积期、稳态期和触发期。PIDs的波幅、持续时间和斜率逐步增加,在触发期发生显著变化。同时,高频活动(180-550 Hz)和高频振荡(HFOs)在整个转变期增加,触发期尤为明显。除这种发作前募集外,HFOs增强伴随空间组织成叠加微域,在癫痫发作起始时达到峰值,并涵盖慢场电位动态。在胶质瘤周围人皮层中,癫痫发作源于逐步募集的神经元组装,这些组装与HFOs共同塑造,为胶质瘤相关致痫发生的微生理过程提供新见解,并需要考虑发作前快速和局灶性神经元活动。
Chimeric antigen receptor T-cell (CAR-T) therapy targeting the C-type lectin-like molecule-1 (CLL1) antigen has emerged as a promising therapeutic approach for acute myeloid leukemia (AML). However, its clinical translation is hindered by on-target, off-tumor toxicity, particularly severe neutropenia caused by CLL1 expression on normal neutrophils. To address this limitation, we constructed a synthetic Notch (SynNotch) dual-antigen AND-gated CAR-T system targeting CD123 and CLL1 to improve tumor specificity and reduce off-tumor toxicity. CD123 and CLL1 expression was first assessed in AML cell lines and primary AML blasts by flow cytometry. The in vitro cytotoxicity, serial killing activity, cytokine secretion, exhaustion-associated protein markers, and transcriptomic profiles of engineered CAR-T cells were then evaluated, and therapeutic efficacy and safety were further examined in AML xenograft models. SynNotch CD123 and CLL1 CAR-T cells showed stronger cytotoxic activity against AML blasts while exhibiting reduced activity toward normal neutrophils. In addition, these cells displayed lower expression of exhaustion-associated genes and markers, together with increased expression of genes related to naive/memory differentiation. In vivo, this CAR-T variant showed improved expansion, longer persistence, and stronger anti-leukemic activity, together with less severe neutropenia. Increased cytokine production in vitro indicated stronger T-cell activation but also suggested the need for careful evaluation of potential cytokine-related toxicity. These findings indicate that SynNotch dual-antigen-gated CAR-T cells may provide a more specific and potentially safer therapeutic strategy for relapsed/refractory AML.
中文摘要:靶向C型凝集素样分子-1(CLL1)抗原的嵌合抗原受体T细胞(CAR-T)疗法已成为急性髓系白血病(AML)有前景的治疗方向,但临床转化受靶向非肿瘤毒性限制,尤其是CLL1在正常中性粒细胞上表达所导致的严重中性粒细胞减少。为解决这一限制,构建了同时靶向CD123和CLL1的合成Notch(SynNotch)双抗原AND门控CAR-T系统,以提高肿瘤特异性并降低脱靶毒性。先用流式细胞术评估AML细胞系和原代AML原始细胞中CD123与CLL1的表达,随后检测工程化CAR-T细胞的体外细胞毒性、连续杀伤活性、细胞因子分泌、耗竭相关蛋白标志物和转录组特征,并在AML异种移植模型中进一步考察疗效与安全性。SynNotch CD123和CLL1 CAR-T细胞对AML原始细胞表现出更强的细胞毒活性,对正常中性粒细胞的活性则降低。这些细胞中耗竭相关基因和标志物表达较低,与naive/memory分化相关的基因表达升高。体内实验中,该CAR-T变体扩增改善、持久性延长、抗白血病活性更强,同时中性粒细胞减少程度较轻。体外细胞因子产生增加提示T细胞激活更强,也提示需要仔细评估潜在的细胞因子相关毒性。这些发现提示,SynNotch双抗原门控CAR-T细胞可能为复发/难治性AML提供更具特异性和潜在更安全的治疗策略。
We develope an enzyme-activatable platform (NO2-RGD-Gd) for the integrated urinary biomarker detection, highcontrast fluorescence-magnetic resonance (MR) dualmodal imaging, and real-time image-guided surgical navigation within a single molecule. The advantages, including the favorable tumor-targeting affinity (RGD peptide), high renal clearance efficiency, and tumor-specific fluorescence activation, are achieved by rationally engineering the molecular architecture. Benefiting from these characteristics, the NO2-RGD-Gd effectively bridges the boundary between diagnosis and therapy, achieving outstanding combinatorial performance in in vivo applications. It allows early and precise diagnosis through urinary biomarkers, provides anatomical-pathological and molecular imaging information of tumor lesions via fluorescence-MR dual-modal imaging, and delineates tumor boundaries for accurate surgical navigation relying on tumor-targeted activatable fluorescence imaging signals. Furthermore, all these processes can be realized simply via intravenous injection, offering a more efficient and feasible strategy for integrated diagnostic and therapeutic applications.
中文摘要:我们开发了一种酶可激活平台(NO2-RGD-Gd),在单一分子内整合尿液生物标志物检测、高对比度荧光-磁共振(MR)双模态成像和实时图像引导手术导航。通过合理设计分子结构,实现了良好的肿瘤靶向亲和力(RGD肽)、高肾清除效率及肿瘤特异性荧光激活等优势。得益于这些特性,NO2-RGD-Gd有效连接诊断与治疗,在体内应用中表现出优异的综合性能。它可通过尿液生物标志物实现早期精准诊断,借助荧光-MR双模态成像提供肿瘤病变的解剖-病理与分子成像信息,并依靠肿瘤靶向可激活荧光成像信号勾勒肿瘤边界以进行准确手术导航。上述过程均可仅通过静脉注射实现,为诊疗一体化应用提供了更高效、可行的策略。
Understanding how stromal and immune cells regulate tumor mechanics is essential for deciphering cancer progression and therapy resistance. This study presents a microparticle-based traction force microscopy strategy for in situ quantification of compressive forces within 3D tumor spheroids. Multicellular spheroids composed of tumor cells (T), fibroblasts (F), and macrophages (M) were generated to mimic the tumor microenvironment and to understand the contribution of fibroblast-macrophage crosstalk in tumor mechanobiology. Tri-culture spheroids exhibited the highest proliferative capacity compared to mono- and bi-cultured tumor spheroids. Gene expression profiling indicated strong fibroblast activation, extracellular matrix remodeling, and M2-like macrophage polarization, highlighting a pro-tumoral phenotype. Incorporation of deformable hydrogel microparticles allowed direct mapping of local compressive and indirect quantification of anisotropic stresses. This mapping revealed fibroblasts are the principal source of force generation with the spheroids. Notably, macrophages amplified bulk and anisotropic stresses over two-fold through paracrine activation of fibroblasts. Spatial mapping showed pressure gradients from the core to the periphery, while temporal analyses demonstrated a progressive increase in mechanical stresses with spheroid growth. Together, these findings reveal a surprising governing of intratumoral mechanics by macrophage-fibroblast interactions and demonstrate the potential of microparticle-based 3D force mapping within complex tumor environments.
中文摘要:理解基质细胞和免疫细胞如何调控肿瘤力学,对解析癌症进展与治疗耐药十分关键。本研究提出一种基于微颗粒的牵引力显微策略,用于原位量化三维肿瘤球体内的压缩力。研究构建了由肿瘤细胞(T)、成纤维细胞(F)和巨噬细胞(M)组成的多细胞球体,以模拟肿瘤微环境,并理解成纤维细胞与巨噬细胞交互在肿瘤力学生物学中的作用。与单培养和双培养肿瘤球体相比,三培养球体表现出最高的增殖能力。基因表达谱显示成纤维细胞强激活、细胞外基质重塑以及M2样巨噬细胞极化,提示促肿瘤表型。引入可变形水凝胶微颗粒后,可直接映射局部压缩力,并间接量化各向异性应力。该映射显示成纤维细胞是球体内力产生的主要来源。巨噬细胞通过旁分泌激活成纤维细胞,使整体应力和各向异性应力增强两倍以上。空间映射显示从核心到外周存在压力梯度,时间分析显示机械应力随球体生长逐步增加。这些发现揭示了巨噬细胞与成纤维细胞相互作用对瘤内力学的意外主导作用,并展示了基于微颗粒的三维力映射在复杂肿瘤环境中的应用潜力。
Transposable elements (TEs) constitute nearly half of the human genome and have crucial roles in regulatory networks and clinical utility in cancers. However, the expression profiles at a single-element resolution remain unexplored. By integrating multiomics data from ∼10,000 samples and 1000 cancer cell lines, we established an expression atlas of 95,512 individual TEs across 980 subfamilies. Transcription factors and RNA binding proteins that are broadly associated with expressed TEs were involved in cancer-related signaling pathways (e.g., MYC activity). We identified 264,252 TEs as putative cis-regulatory elements associated with oncogenic pathways such as inflammatory response. We analyzed alterations in TE expression in tumors and their associations with clinical relevance and responses to more than 1000 anticancer drugs. Last, we developed the Atlas of Transposon Expression in Cancer (ATEC), a TE data portal enabling users to explore TE expression patterns, putative regulatory networks, and clinical significance. Overall, this study established a comprehensive resource for TEs across cancer types.
中文摘要:转座元件(TEs)约占人类基因组的一半,在癌症调控网络和临床应用中具有重要作用。单元件分辨率下的表达谱仍未被系统描绘。整合约10,000份样本和1000个癌细胞系的多组学数据,建立了覆盖980个亚家族的95,512个独立TE的表达图谱。与表达TE广泛相关的转录因子和RNA结合蛋白参与癌症相关信号通路(如MYC活性)。研究将264,252个TE鉴定为推定的顺式调控元件,这些元件与炎症反应等致癌通路相关。分析了肿瘤中TE表达改变及其与临床相关性、对1000多种抗癌药物反应的关联。开发了癌症转座子表达图谱ATEC,该TE数据门户可供用户探索TE表达模式、推定调控网络和临床意义。这项工作建立了跨癌种的TE综合资源。
Understanding the functional consequences of genetic variants, particularly those classified as variants of uncertain significance (VUS), is a major challenge in genomics. While variant effects at protein level are well recognized, roles in post-transcriptional regulation are increasingly appreciated. Here, we introduce cPRIME (prime editing with cDNA readout), a scalable method for assessing variant effects at RNA level. cPRIME employs prime editing to insert genetic variants into endogenous genomic loci, followed by the quantification of changes in variant frequencies at RNA (cDNA) and genomic DNA (gDNA) level. We demonstrate its effectiveness across diverse karyotypes and genomic loci and reveal that synonymous marker edits - frequently used in prime editing screens - can themselves alter RNA processing and thereby confound the interpretation of variant effects. Taken together, cPRIME provides a platform for studying the post-transcriptional consequences of genetic variants in their genomic context and establishes a framework for the functional interpretation of RNA-altering variants in cancer and other diseases.
中文摘要:理解遗传变异的功能后果,尤其是被归类为意义未明变异(VUS)的变异,是基因组学中的一大挑战。蛋白质水平的变异效应已被广泛认识,转录后调控中的作用也日益受到重视。我们提出 cPRIME(结合 cDNA 读出的先导编辑),一种用于评估 RNA 水平变异效应的可扩展方法。cPRIME 利用先导编辑将遗传变异插入内源基因组位点,随后定量 RNA(cDNA)和基因组 DNA(gDNA)水平上变异频率的变化。我们在不同核型和基因组位点中展示了其有效性,并发现同义标记编辑(常用于先导编辑筛选)本身可改变 RNA 加工,从而干扰对变异效应的解读。cPRIME 提供了一个在基因组背景下研究遗传变异转录后后果的平台,并为癌症及其他疾病中改变 RNA 的变异的功能解读建立了框架。
Premortem exposure of calreticulin (CALR) on stressed cancer cells is a cardinal damage-associated molecular pattern that licenses anticancer immunity, yet its immunological sufficiency has remained difficult to define because it normally coincides with cellular stress and cell death. Here, we engineered a chemical-genetic system enabling the conditional, biotin-driven translocation of a membrane-anchored CALR chimera from the endoplasmic reticulum to the plasma membrane, thereby uncoupling CALR exposure from cytotoxicity and other hallmarks of immunogenic cell death. This reductionist approach revealed that isolated CALR surface presentation is sufficient to promote CD91/LRP1-dependent engulfment of tumor cells by conventional dendritic cells, particularly cDC1 and cDC2, leading to enhanced dendritic cell activation, cytotoxic lymphocyte responses, and immunological memory. Across multiple syngeneic tumor models, enforced CALR exposure exerted modest standalone antitumor activity but robustly sensitized poorly immunogenic cancers to cisplatin and PD-1 blockade, culminating in T cell-dependent tumor eradication and durable protective immunity. Remarkably, concurrent inhibition of the CD47-SIRPα axis facilitated complete tumor eradication in all treated animals, highlighting the functional cooperation between eat-me and don't-eat-me signals in orchestrating antigen presentation and adaptive immune priming. These findings further suggest that maximizing the therapeutic activity of CD47 blockade may require concomitant reinforcement of pro-phagocytic signals such as CALR exposure, providing a conceptual framework for the rational design of next-generation combination immunotherapies. Collectively, these findings establish surface-exposed CALR as a cell-autonomous immunogenic signal with instructive activity for dendritic cell-mediated cross-priming and provide a tractable platform to mechanistically deconvolute immunogenic stress responses, with immediate implications for the rational design of combinatorial chemo- and immunotherapeutic regimens in preclinical and potentially clinical oncology.
中文摘要:应激癌细胞在死亡前暴露钙网蛋白(CALR)是一种关键的损伤相关分子模式,能够赋予抗癌免疫许可,但其免疫学充分性一直难以界定,因为该暴露通常与细胞应激和细胞死亡同时发生。我们构建了一种化学遗传学系统,使膜锚定的CALR嵌合体能够在生物素驱动下从内质网条件性转位至质膜,从而将CALR暴露与细胞毒性及免疫原性细胞死亡的其他标志解耦。这一还原论方法显示,单独的CALR表面呈递足以促进常规树突状细胞,尤其是cDC1和cDC2,通过CD91/LRP1依赖方式吞噬肿瘤细胞,并增强树突状细胞活化、细胞毒性淋巴细胞反应和免疫记忆。在多种同基因肿瘤模型中,强制CALR暴露的单药抗肿瘤活性有限,但可稳健地使免疫原性较差的癌症对顺铂和PD-1阻断敏感,最终实现T细胞依赖性肿瘤清除和持久保护性免疫。同时抑制CD47-SIRPα轴可使所有治疗动物实现肿瘤完全清除,凸显「吃我」与「别吃我」信号在协调抗原呈递和适应性免疫启动中的功能协同。这些结果进一步提示,最大化CD47阻断的治疗活性可能需要同时增强CALR暴露等促吞噬信号,为合理设计下一代联合免疫治疗提供概念框架。这些发现共同确立表面暴露的CALR是一种细胞自主的免疫原性信号,对树突状细胞介导的交叉致敏具有指导活性,并提供一个可操作平台以机制性地解析免疫原性应激反应,对临床前乃至潜在临床肿瘤学中化疗与免疫治疗联合方案的合理设计具有直接意义。
Ferroptosis is implicated as a vulnerability in multiple cancers, yet approaches for effectively inducing ferroptosis in vivo are limited. Bypassing conventional strategies targeting the antiferroptotic glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1) proteins, we designed metabolic initiators of lipid peroxidation (MILPOs) and developed the compounds WMK-1/2, which contain tetraoxane radical-generating and mitochondria-targeting groups, as de novo ferroptosis inducers. WMK-1 localizes primarily to mitochondria, induces local lipid peroxidation, and impairs oxidative phosphorylation. WMK-1 induces a "mito-ferroptosis" sub-pathway that skips GPX4 inhibition as a prerequisite, can be rescued by lipophilic radical-trapping antioxidants, yet is minimally sensitive to acyl-coenzyme A synthetase long-chain family member 4 (ACSL4) perturbation and long-chain polyunsaturated fatty acid (PUFA) supplementation, and evades retinol-mediated protection. Instead, WMK-1-induced cell death requires labile Fe2+ and can be selectively suppressed by ɑ-lipoic acid, an endogenous, mitochondria-resident antioxidant. WMK-1/2 are bioavailable and exhibit significant efficacy in tumor suppression by eliciting ferroptosis in multiple cancer models and augmenting the antitumor effects of immune-checkpoint blockers. Our work provides a protein-targeting-independent metabolic ferroptosis induction strategy for potential cancer therapy.
中文摘要:铁死亡被视为多种癌症的脆弱点,但在体内有效诱导铁死亡的方法仍有限。研究绕开靶向抗铁死亡的谷胱甘肽过氧化物酶4(GPX4)和铁死亡抑制蛋白1(FSP1)的常规策略,设计脂质过氧化代谢启动剂(MILPOs),并开发含四氧烷自由基生成基团和线粒体靶向基团的化合物WMK-1/2,作为从头诱导铁死亡的化合物。WMK-1主要定位于线粒体,诱导线粒体局部脂质过氧化并损害氧化磷酸化。WMK-1诱导一种「mito-ferroptosis」亚通路,不以抑制GPX4为前提,可被亲脂性自由基捕获抗氧化剂挽救,但对酰基辅酶A合成酶长链家族成员4(ACSL4)扰动和长链多不饱和脂肪酸(PUFA)补充的敏感性很低,并可逃避视黄醇介导的保护。WMK-1诱导的细胞死亡需要不稳定Fe2+,可被内源性线粒体驻留抗氧化剂α-硫辛酸选择性抑制。WMK-1/2具有生物利用度,在多种癌症模型中通过诱发铁死亡并增强免疫检查点阻断剂的抗肿瘤效应,表现出显著的抑瘤效果。该工作为潜在癌症治疗提供了一种不依赖蛋白靶向的代谢性铁死亡诱导策略。
Nicotinamide adenine dinucleotide (NAD) occupies a privileged position at the intersection of cellular bioenergetics, redox homeostasis, and signal transduction. Beyond its canonical role in ATP synthesis, NAD serves as an obligate cofactor for enzymes including poly(ADP-ribose) polymerases (PARPs), sirtuins, and CD38, thereby regulating DNA repair, epigenetic remodeling, and inflammatory signaling. Thus, NAD metabolism supports the preservation of cellular homeostasis against oncogenic insults. Malignant transformation, however, imposes substantial biosynthetic and genotoxic stress, often driving metabolic adaptations that amplify NAD production via nicotinamide phosphoribosyltransferase (NAMPT). This endows cancer cells with enhanced proliferative capacity, stress tolerance, and immunoevasive features. Importantly, the dependence of malignant cells on sustained NAD availability constitutes a therapeutically exploitable vulnerability. Accordingly, NAMPT inhibitors, PARP inhibitors, and strategies targeting NAD-consuming ectoenzymes have shown preclinical and, in select settings, clinical efficacy. Here, we critically review the rewiring of NAD metabolism in cancer, associated therapeutic opportunities, and barriers to their clinical exploitation.
中文摘要:烟酰胺腺嘌呤二核苷酸(NAD)处于细胞生物能量学、氧化还原稳态与信号转导的交汇点,具有特殊地位。除在ATP合成中的经典作用外,NAD还是聚(ADP-核糖)聚合酶(PARPs)、sirtuins和CD38等酶的必需辅因子,由此调控DNA修复、表观遗传重塑和炎症信号。因而,NAD代谢有助于细胞在致癌性损伤下维持稳态。然而,恶性转化带来显著的生物合成与基因毒性应激,常驱动代谢适应,通过烟酰胺磷酸核糖转移酶(NAMPT)增强NAD生成。这使癌细胞获得更强的增殖能力、应激耐受和免疫逃逸特征。恶性细胞对持续NAD供应的依赖构成可治疗利用的脆弱点。据此,NAMPT抑制剂、PARP抑制剂以及靶向消耗NAD的胞外酶的策略已在临床前显示疗效,并在特定情形下显示临床疗效。本综述批判性梳理癌症中NAD代谢的重编程、相关治疗机会及其临床利用的障碍。
Met1-linked ubiquitin chains (Met1-Ub), synthesized by the linear ubiquitin chain assembly complex (LUBAC) and disassembled by the deubiquitinase OTULIN, regulate inflammatory signaling and cell death. OTULIN activity prevents tumor necrosis factor (TNF)-driven autoinflammatory pathology and embryonic lethality, but the role of the direct OTULIN-LUBAC interaction remains unclear. Here, we show that mice harboring a point mutation in the OTULIN peptide:N-glycanase/UBA- or UBX-containing proteins (PUB)-interacting motif (OTULINY56A), which disrupts LUBAC binding, are viable without spontaneous pathology but are highly sensitive to TNF-induced toxicity and TNF-mediated immunopathology during Listeria monocytogenes infection. Mechanistically, the OTULIN-LUBAC interaction prevents Met1-linked autoubiquitination, thereby limiting LUBAC activity and Met1-Ub conjugation on non-LUBAC substrates. Disrupting the OTULIN-LUBAC interaction increased Met1-Ub accumulation at the TNF receptor signaling complex, which stabilized the signaling complex, increased nuclear factor-kappa B (NF-κB) signaling, and, unlike loss of OTULIN or its activity, protected from TNF-induced apoptosis. Collectively, we identify the OTULIN-LUBAC interaction as a critical brake restricting LUBAC function and Met1-Ub-dependent signaling.
中文摘要:Met1连接的泛素链(Met1-Ub)由线性泛素链组装复合物(LUBAC)合成,并由去泛素化酶OTULIN解聚,调控炎症信号和细胞死亡。OTULIN活性可防止肿瘤坏死因子(TNF)驱动的自身炎症性病理和胚胎致死,但OTULIN与LUBAC直接相互作用的作用仍不清楚。本研究发现,携带OTULIN肽:N-聚糖酶/UBA或UBX蛋白(PUB)相互作用基序点突变(OTULINY56A)的小鼠无法结合LUBAC,能够存活且无自发病理,但对TNF诱导的毒性以及单核细胞增生李斯特菌感染期间TNF介导的免疫病理高度敏感。机制上,OTULIN-LUBAC相互作用防止Met1连接的自身泛素化,从而限制LUBAC活性及非LUBAC底物上的Met1-Ub结合。破坏OTULIN-LUBAC相互作用增加TNF受体信号复合物处Met1-Ub积累,稳定该信号复合物,增强核因子κB(NF-κB)信号,并且与OTULIN缺失或活性丧失不同,可防止TNF诱导的凋亡。这些结果共同确定OTULIN-LUBAC相互作用是限制LUBAC功能和Met1-Ub依赖信号的关键刹车。
The increasing prevalence of type 2 diabetes mellitus (T2DM) represents a significant public health challenge with serious implications for cancer incidence and treatment. Currently affecting over 400 million individuals worldwide, T2DM is characterized by chronic hyperglycemia and insulin resistance, which contribute to a pro-tumorigenic environment. This review seeks to elucidate the complex relationship between diabetes medications and cancer treatment, emphasizing how various agents, including metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones (TZDs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors, interact with critical signaling pathways involved in cancer progression. Evidence suggests that these medications can modulate oncogenic pathways such as AMPK/mTOR, insulin/IGF signaling, and Nuclear factor kappa B (NF-κB), leading to either inhibition or stimulation of tumor growth and survival depending on the drug class and biological context. For instance, metformin activates AMPK, inhibiting mTOR and promoting apoptosis, while TZDs exert anti-inflammatory effects that may reduce obesity-related cancer risks. Conversely, some DPP-4 inhibitors have been associated with pro-tumorigenic effects under certain conditions. Given the intricate interplay among diabetes, obesity, and cancer, understanding the effects of antidiabetic therapies on tumor biology is crucial for refining treatment strategies. This review consolidates current findings on the cellular and molecular impacts of major T2DM drug classes on cancer, highlighting their potential benefits and limitations. In conclusion, the findings presented in this analysis are intended to enhance treatment strategies and shape future research initiatives aimed at effectively addressing the complexities of managing patients who are concurrently affected by diabetes and cancer.
中文摘要:2型糖尿病(T2DM)患病率不断上升,已成为重要的公共卫生挑战,并对癌症发生和治疗产生严重影响。目前全球有超过4亿人受累,T2DM以慢性高血糖和胰岛素抵抗为特征,这两者共同促成促肿瘤环境。该综述试图阐明糖尿病药物与癌症治疗之间的复杂关系,重点讨论二甲双胍、磺脲类、二肽基肽酶-4(DPP-4)抑制剂、胰高血糖素样肽-1(GLP-1)受体激动剂、噻唑烷二酮类(TZDs)和钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂等药物如何与癌症进展相关的关键信号通路相互作用。证据提示,这些药物可调节AMPK/mTOR、胰岛素/IGF信号和核因子κB(NF-κB)等致癌通路,依据药物类别和生物学背景不同,或抑制或促进肿瘤生长与存活。例如,二甲双胍激活AMPK,抑制mTOR并促进凋亡,而TZDs发挥抗炎作用,可能降低肥胖相关癌症风险。相反,某些DPP-4抑制剂在特定条件下与促肿瘤效应相关。鉴于糖尿病、肥胖和癌症之间错综复杂的相互作用,理解抗糖尿病治疗对肿瘤生物学的影响对于优化治疗策略至关重要。该综述汇总了主要T2DM药物类别对癌症的细胞和分子影响的最新发现,强调其潜在获益和局限。这些分析结果旨在改进治疗策略并塑造未来研究方向,以有效应对同时患有糖尿病和癌症患者的复杂管理问题。
Developing advanced instrumentation systems for the automated, precise isolation of target circulating tumor cells (CTCs) from blood, followed by molecular marker analysis, stands as a pivotal trend in the field of liquid biopsy. However, current isolation technologies typically rely on subsequent centrifugation steps to enrich CTC samples for downstream assays, such as single-cell western blotting (scWB), creating challenges for developing integrated systems. Here, we present an integrated viscoelastic microfluidic system (IVEM) that leverages viscoelastic fluids to automatically separate and concentrate CTCs. The IVEM includes a CTC separation module (CSM) for high-purity isolation and a CTC concentration module (CCM) to remove excess cell suspension. To clarify the working mechanism, particle migration behavior is systematically analyzed through theoretical modeling and numerical simulations and validated by polystyrene (PS) particle experiments. The performance of the IVEM is evaluated through separation experiments using blood samples spiked with MCF-7 cells. The processing throughput, purity, recovery rate, and concentration factor of MCF-7 cells reach 1.82 mL·h-1, 82.13 ± 2.87, 81.30 ± 4.72, and 4.26 ± 0.92%, respectively. The IVEM enables label-free, continuous on-chip enrichment of separated CTCs without additional off-chip processing. This integration facilitates future incorporation of other functional modules, such as high performance single-cell capture, into liquid biopsy systems, thereby further enhancing the clinical applicability of technologies such as scWB.
中文摘要:构建可自动、精准分离血液中目标循环肿瘤细胞(CTC)并进行分子标志物分析的先进仪器系统,是液体活检领域的重要趋势。现有分离技术通常依赖后续离心步骤富集CTC样本以供下游检测,例如单细胞蛋白质印迹(scWB),这给集成化系统开发带来挑战。研究提出一种集成粘弹性微流控系统(IVEM),利用粘弹性流体自动分离并浓缩CTC。IVEM包含用于高纯度分离的CTC分离模块(CSM)和用于去除多余细胞悬液的CTC浓缩模块(CCM)。为阐明工作机制,通过理论建模与数值模拟系统分析颗粒迁移行为,并用聚苯乙烯(PS)颗粒实验验证。采用加标MCF-7细胞的血液样本进行分离实验,评估IVEM性能。MCF-7细胞的处理通量、纯度、回收率和浓缩倍数分别达到1.82 mL·h-1、82.13 ± 2.87、81.30 ± 4.72和4.26 ± 0.92%。IVEM无需额外的芯片外处理,即可对分离后的CTC进行无标记、连续片上浓缩。这种集成便于未来将其他功能模块(如高性能单细胞捕获)整合到液体活检系统中,从而进一步提升scWB等技术的临床适用性。
Polysaccharide-based physical hydrogels are promising drug-delivery platforms due to their biocompatibility, tunable mechanical properties, and reversible crosslinking. However, bulk hydrogels may require in situ gelation for administration, while controlled release of nanoparticles larger than the hydrogel mesh remains challenging. This study aimed to develop an injectable konjac glucomannan (KGM)-kappa carrageenan (KCAR) microgels platform, based on a previously established bulk hydrogel system, for the sustained delivery of doxorubicin (Dox)-loaded liposomes and protein-containing biomimetic nanoparticles termed Tumorosomes (Tumoro). Microgels were fabricated using a mild-temperature water-in-oil batch-emulsion method compatible with protein-containing nanoparticles. Incorporation of liposomes or Tumoro did not significantly affect microgel size or rheological properties. All formulations exhibited solid-like behavior at low strain, shear-thinning, and rapid structural recovery after high strain, supporting injectability. The reversible KGM-KCAR network enabled complete nanoparticle release within 48 h under physiological conditions. Empty microgels did not reduce 4 T1 cell viability, whereas Dox-loaded nanoparticles released from the microgels retained cytotoxic activity. Tumoro-loaded microgels produced a greater reduction in cell viability than dispersed Tumoro after 24 h, consistent with sustained release and enhanced Tumoro-cell association. These findings establish KGM-KCAR microgels as a preformed injectable platform with potential for localized and sustained delivery of protein-containing biomimetic nanoparticles in cancer therapy.
中文摘要:多糖基物理水凝胶因生物相容性、可调机械性能和可逆交联而成为有前景的药物递送平台。但块状水凝胶在给药时可能需要原位凝胶化,尺寸大于水凝胶网孔的纳米颗粒实现控释仍具挑战。本研究旨在开发可注射魔芋葡甘聚糖(KGM)-κ-卡拉胶(KCAR)微凝胶平台,基于既往建立的块状水凝胶体系,用于持续递送载多柔比星(Dox)脂质体和含蛋白仿生纳米颗粒Tumorosomes(Tumoro)。微凝胶采用温和温度的水包油批式乳化法制备,与含蛋白纳米颗粒相容。掺入脂质体或Tumoro未显著影响微凝胶尺寸或流变学性质。所有制剂在低应变下表现为类固体行为,具剪切变稀特征,并在高应变后快速结构恢复,支持其可注射性。可逆KGM-KCAR网络使纳米颗粒在生理条件下48小时内完全释放。空白微凝胶未降低4T1细胞活力,而微凝胶释放的载Dox纳米颗粒保留细胞毒活性。载Tumoro微凝胶在24小时后较分散Tumoro引起更大细胞活力下降,这与持续释放及Tumoro与细胞结合增强一致。这些结果确立KGM-KCAR微凝胶作为一种预成型可注射平台,在癌症治疗中具有局部持续递送含蛋白仿生纳米颗粒的潜力。
Conventional crustacean-derived chitin is constrained by allergen risk, corrosive processing and variable purity. Fungal chitin-glucan complex (CGC) offers a structurally distinct alternative because chitin microfibrils are covalently integrated with β-glucan domains, creating a bicomponent network that links extraction quality to modification potential and biological presentation. This review evaluates fungal CGC across source selection, green extraction, multiscale modification and biomedical translation. Four extraction strategies, deep eutectic solvents, enzymatic methods, ionic liquids and physical field-assisted techniques, are compared using five structural quality indicators: degree of acetylation, weight-average molecular weight, crystallinity index, glucan content and deproteinization efficiency. These parameters define the substrate available for nanoarchitecture formation, chemical derivatization and stimuli-responsive crosslinking, and guide application matching in wound management, tissue engineering, drug delivery, cancer immunomodulation and microbiota-related immune regulation. We further propose the CGC Translational Quality Index (CTQI) as a conceptual decision framework linking extraction sustainability, modification readiness, biomedical evidence, biosafety, regulatory preparedness and manufacturing feasibility. Finally, we outline priorities for standardizing source-to-function material profiles, validating CTQI across laboratories and resolving structure-function mechanisms required for reproducible biomedical translation.
中文摘要:传统甲壳类来源几丁质受过敏原风险、腐蚀性加工和纯度波动限制。真菌几丁质-葡聚糖复合物(CGC)提供了结构上不同的替代方案,因为几丁质微纤丝与β-葡聚糖结构域共价整合,形成双组分网络,将提取质量与修饰潜力及生物呈现联系起来。综述从来源选择、绿色提取、多尺度修饰和生物医学转化方面评估真菌CGC。深共熔溶剂、酶法、离子液体和物理场辅助技术四类提取策略通过五项结构质量指标进行比较:乙酰化度、重均分子量、结晶度指数、葡聚糖含量和脱蛋白效率。这些参数界定了可用于纳米结构形成、化学衍生化和刺激响应交联的底物,并指导在创面管理、组织工程、药物递送、癌症免疫调节和微生物群相关免疫调节中的应用匹配。文章进一步提出CGC转化质量指数(CTQI)作为概念性决策框架,将提取可持续性、修饰就绪度、生物医学证据、生物安全性、监管准备度和制造可行性联系起来。文末概述标准化来源到功能材料谱、跨实验室验证CTQI以及解析可重复生物医学转化所需结构-功能机制的优先事项。
The human transcriptome contains millions of A-to-I editing sites arising from an unclear number of poorly characterized dsRNAs. Editing sites reveal the presence of dsRNA, but this method is limited by transcription levels, read depth, and ADAR expression and cannot identify unedited dsRNA. To address these limitations, we developed dsRNAscan. Applying dsRNAscan to the human genome predicted 5 million dsRNAs, mostly in repetitive and intergenic regions. Machine learning models trained on A-to-I editing and RNA structure-probing data identified ∼2.4 million high-confidence predictions, which were enriched at dsRNA-binding protein binding sites. Additionally, we predicted hundreds of dsRNAs conserved across vertebrates and observed thousands of editing-enriched regions suspected to arise from intermolecular dsRNAs formed with sense-antisense transcripts. Quantifying expression of intramolecular and intermolecular dsRNAs accessible to cytoplasmic immune sensors revealed that their ratio correlated with ADAR dependency across cancer cell lines. The human dsRNAome is available as a resource at https://dsrna.chpc.utah.edu/.
中文摘要:人类转录组包含数百万个A-to-I编辑位点,这些位点来源的双链RNA数量不清且特征不明。编辑位点可提示dsRNA存在,但该方法受转录水平、测序深度和ADAR表达限制,且无法识别未编辑的dsRNA。为克服这些限制,我们开发了dsRNAscan。将dsRNAscan应用于人类基因组,预测出500万个dsRNA,主要位于重复区和基因间区。基于A-to-I编辑和RNA结构探测数据训练的机器学习模型识别出约240万个高置信度预测,这些预测在dsRNA结合蛋白结合位点富集。此外,我们预测出数百个在脊椎动物中保守的dsRNA,并观察到数千个编辑富集区域,推测其源于与正义-反义转录本形成的分子间dsRNA。定量细胞质免疫传感器可接近的分子内和分子间dsRNA表达后发现,其比例与不同癌细胞系中的ADAR依赖性相关。人类dsRNAome可作为资源在https://dsrna.chpc.utah.edu/获取。
Despite major progress with chimeric antigen receptor T-cell therapy, multiple myeloma (MM) remains largely incurable and most patients relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)-based targeting of intracellular antigens derived from immunoglobulin heavy chain constant domains. Using HLA class-I peptidomics, we identified 9 immunoglobulin G (IgG)- or IgA-derived peptides presented by common HLA alleles (HLA-A∗01:01, HLA-A∗02:01, HLA-A∗03:01, and HLA-B∗07:02). High-avidity T-cell clones recognizing 4 of these epitopes were isolated from HLA-mismatched healthy donors. The transfer of these immunoglobulin-specific TCRs into donor T cells conferred potent and selective recognition of IgG- or IgA-expressing MM cell lines, sparing antigen-negative cells. Safety profiling confirmed strict HLA-restricted specificity without cross-reactivity toward other HLA alleles, non-B-lineage tumor cell lines, or healthy tissues, except for the depletion of isotype-matched B cells. Immunoglobulin-TCR T cells efficiently lysed patient-derived MM cells ex vivo and eradicated established IgA- or IgG-expressing MM tumors in murine xenograft models. Mechanistic studies revealed that dendritic cells could cross-present immunoglobulin peptides at high serum concentrations, potentially enhancing T-cell activation in vivo. Importantly, subtype-specific depletion of B cells implies that immunoglobulin-TCR T-cell therapy could partly preserve humoral immunity, reducing the need for antibody replacement compared with pan-B-cell depletion strategies. Collectively, these findings establish immunoglobulin heavy chain constant domains as promising targets for TCR-based cellular immunotherapy in MM and potentially other immunoglobulin-producing malignancies or autoantibody-mediated autoimmune diseases.
中文摘要:尽管嵌合抗原受体T细胞治疗取得重大进展,多发性骨髓瘤(MM)仍大多不可治愈,且多数患者会复发。为拓宽治疗选择并克服抗原逃逸,研究探索了以T细胞受体(TCR)靶向免疫球蛋白重链恒定区来源的胞内抗原。利用HLA I类肽组学,鉴定出9条由常见HLA等位基因(HLA-A*01:01、HLA-A*02:01、HLA-A*03:01和HLA-B*07:02)呈递的IgG或IgA来源肽。从HLA不匹配的健康供者中分离出可识别其中4个表位的高亲和力T细胞克隆。将这些免疫球蛋白特异性TCR转入供者T细胞后,可对表达IgG或IgA的MM细胞系产生强效且选择性的识别,而不损伤抗原阴性细胞。安全性分析证实其具有严格的HLA限制性,对其他HLA等位基因、非B系肿瘤细胞系或健康组织无交叉反应,例外是同型匹配B细胞会被清除。免疫球蛋白-TCR T细胞可在体外有效裂解患者来源的MM细胞,并在小鼠异种移植模型中清除已建立的表达IgA或IgG的MM肿瘤。机制研究显示,树突状细胞在高血清浓度下可交叉呈递免疫球蛋白肽,可能在体内增强T细胞活化。亚型特异性B细胞清除提示,免疫球蛋白-TCR T细胞治疗可部分保留体液免疫,与泛B细胞清除策略相比可减少抗体替代需求。这些发现确立免疫球蛋白重链恒定区作为MM以及潜在其他产生免疫球蛋白的恶性肿瘤或自身抗体介导自身免疫病的TCR细胞免疫治疗靶点。
Intratumor transcriptional heterogeneity (ITTH), defined as the coexistence of diverse cell states within a single tumor, complicates cancer treatment and contributes to variable therapeutic responses. Although single-cell RNA sequencing (scRNA-seq) can resolve this complexity, its cost and technical demands limit large-scale use. Bulk RNA-seq provides a scalable alternative but requires computational methods to deconvolve bulk transcriptomes into distinct cell states. Existing supervised approaches rely on accurate reference data, which are lacking for many cancer types, whereas unsupervised methods are not tailored to capture heterogeneity within the malignant compartment. To address these limitations, we developed CDState, an unsupervised deconvolution method based on nonnegative matrix factorization with a sum-to-one constraint and a cosine similarity-based optimization, which infers malignant cell states using bulk RNA-seq data. CDState demonstrated robustness using pseudobulk scRNA-seq datasets from five cancer types, outperforming existing unsupervised methods in estimating both state-specific gene expression and cell proportions. Applied to 33 cancer types from The Cancer Genome Atlas, CDState revealed recurrent gene programs, including epithelial-mesenchymal transition, MYC targets, and oxidative phosphorylation, as major contributors to malignant ITTH. The malignant state proportions were linked to clinical features, including patient survival and therapeutic response. Finally, mutations and copy-number alterations in genes such as TP53, KRAS, PIK3CA, SOX2, and SATB1 were identified as potential genetic drivers of malignant cell ITTH across cancer types. This study demonstrates the utility of CDState for characterization of malignant cell states from bulk RNA-seq data, establishing a framework for investigating malignant cell ITTH in large-scale cancer atlases. CDState leverages bulk RNA sequencing to resolve malignant states, revealing recurrent patterns of tumor heterogeneity that may help interpret outcomes and guide future biomarker development.
中文摘要:肿瘤内转录异质性(ITTH)指同一肿瘤内多种细胞状态共存,使治疗复杂化并导致疗效差异。单细胞RNA测序(scRNA-seq)可解析这种复杂性,但成本和技术要求限制其大规模应用。批量RNA测序(bulk RNA-seq)提供了可扩展的替代方案,但需要计算方法将批量转录组解卷积为不同细胞状态。现有监督方法依赖准确参考数据,而许多癌种缺乏此类数据;无监督方法未针对恶性细胞区室内的异质性进行捕捉。为解决这些限制,我们开发了CDState,一种基于非负矩阵分解的无监督解卷积方法,采用和为一约束与基于余弦相似度的优化,利用bulk RNA-seq数据推断恶性细胞状态。CDState在五种癌种的伪批量scRNA-seq数据集上表现出稳健性,在估计状态特异性基因表达和细胞比例方面优于现有无监督方法。将其应用于癌症基因组图谱(TCGA)的33个癌种,CDState揭示了反复出现的基因程序,包括上皮-间质转化、MYC靶基因和氧化磷酸化,它们是恶性ITTH的主要贡献因素。恶性状态比例与临床特征相关,包括患者生存和治疗反应。TP53、KRAS、PIK3CA、SOX2和SATB1等基因的突变和拷贝数改变被识别为跨癌种恶性细胞ITTH的潜在遗传驱动因素。该研究展示了CDState利用bulk RNA-seq数据表征恶性细胞状态的效用,为在大规模癌症图谱中研究恶性细胞ITTH建立了框架。CDState利用批量RNA测序解析恶性状态,揭示肿瘤异质性的反复模式,可能有助于解释结局并指导未来生物标志物开发。
ETV6-rearranged acute lymphoblastic leukemia (ALL) is associated with poor prognosis in adults. Previously, a super-enhancer (SE) located within the ETV6 intragenic region (ETV6-SE) was identified in a rare fusion gene, ETV6::ACSL6; however, further work is needed to determine whether ETV6-SE is broadly present in ALL and how ETV6 rearrangements affect the SE function. In this study, we demonstrated that ETV6 functions as a regulatory element via ETV6-SE in ALL, with CDKN1B as a key target. CRISPR interference and knockout experiments revealed the core enhancer region within ETV6-SE responsible for CDKN1B regulation. ETV6 rearrangements disrupted ETV6-SE and impaired long-range chromatin interaction with the CDKN1B locus, leading to its downregulation that in turn activated the NF-κB pathway and increased expression of antiapoptotic proteins BCL-2/BCL-XL. In patient-derived xenograft models, pharmacologic inhibition of BCL-2/BCL-XL using venetoclax or navitoclax showed additive effects when combined with dexamethasone. Collectively, these findings establish the ETV6-SE-CDKN1B regulatory axis as a mechanism contributing to treatment resistance in ETV6-rearranged ALL. ETV6 comprises a super-enhancer that activates CDKN1B expression and is lost in ETV6-rearranged acute lymphoblastic leukemia, which contributes to glucocorticoid resistance via downstream activation of the NF-κB pathway.
中文摘要:ETV6重排的急性淋巴细胞白血病(ALL)在成人中与不良预后相关。此前在罕见融合基因ETV6::ACSL6中发现位于ETV6基因内区域的超增强子(ETV6-SE),但ETV6-SE是否广泛存在于ALL以及ETV6重排如何影响该超增强子功能仍需进一步研究。本研究发现ETV6通过ETV6-SE在ALL中发挥调控元件作用,CDKN1B是其关键靶基因。CRISPR干扰和敲除实验确定了ETV6-SE内负责调控CDKN1B的核心增强子区域。ETV6重排破坏ETV6-SE,损害其与CDKN1B基因座的远距离染色质相互作用,导致CDKN1B下调,进而激活NF-κB通路并提高抗凋亡蛋白BCL-2/BCL-XL的表达。在患者来源异种移植模型中,使用维奈克拉或navitoclax抑制BCL-2/BCL-XL与地塞米松联合显示叠加效应。这些发现确立ETV6-SE-CDKN1B调控轴是ETV6重排ALL治疗耐药的一个机制。ETV6包含一个激活CDKN1B表达的超增强子,该超增强子在ETV6重排的急性淋巴细胞白血病中丢失,并通过下游激活NF-κB通路促进糖皮质激素耐药。
Inappropriate activation of the mitogen-activated protein kinase (MAPK) pathway, often stemming from activating mutations in RAS or RAF, represents one of the most common oncogenic events in human cancer. However, currently approved RAS/RAF inhibitors target specific mutants that are only present in a small proportion of RAS- or RAF-activated tumors. Current MEK inhibitors (MEKi) are associated with class-effect toxicities and tumor escape via CRAF bypass of MEK blockade. To address these issues, we designed atebimetinib to resist CRAF-mediated bypass and enable a pharmacokinetic/pharmacodynamic profile termed deep cyclic inhibition (DCI), an approach that transiently but deeply suppresses oncogenic signaling while allowing daily physiologic reset. Unlike chronic or intermittent approaches, DCI optimizes depth and duration of MEK suppression on a daily cycle, blunting rebound signaling while preserving recovery windows for normal tissues. Functioning as an allosteric, selective MEKi, atebimetinib potently inhibited ERK phosphorylation in vitro and in vivo, resisted CRAF bypass, and was well tolerated and more efficacious in xenograft models of cancer compared with current MEKis. Overall, these findings establish atebimetinib as a dual-MEKi with the potential to provide mutation-agnostic inhibition of the MAPK pathway while leveraging DCI, designed to avoid toxicities associated with existing MEKis. Atebimetinib offers MEK inhibition that is durable and tolerable, supporting the potential of this therapeutic paradigm. Atebimetinib, a deep cyclic inhibitor of MEK, blocks MAPK signaling, resists RAF bypass, and is active in RAS- and RAF-mutant tumors, representing a mechanistically differentiated approach in the field of targeted therapies. See related commentary by Gaire and Poulikakos, p. 5017.
中文摘要:MAPK 通路的异常激活常源于 RAS 或 RAF 的激活突变,是人癌中最常见的致癌事件之一。现有获批的 RAS/RAF 抑制剂只针对特定突变型,而这些突变仅见于少部分 RAS 或 RAF 激活的肿瘤。现有 MEK 抑制剂(MEKi)存在类效应毒性,并可通过 CRAF 旁路绕过 MEK 阻断而导致肿瘤逃逸。为应对这些问题,研究设计 atebimetinib,使其抵抗 CRAF 介导的旁路,并实现称为深度周期性抑制(DCI)的药代动力学/药效学特征;该策略短暂而深度地压制致癌信号,同时保留每日的生理性恢复。与持续给药或间歇给药不同,DCI 以每日为周期优化 MEK 抑制的深度与持续时间,削弱信号反弹,并为正常组织保留恢复窗口。作为变构选择性 MEKi,atebimetinib 在体外和体内均强效抑制 ERK 磷酸化,抵抗 CRAF 旁路,在移植瘤模型中耐受良好,疗效优于现有 MEKi。这些结果确立 atebimetinib 为双重 MEKi,有望实现对 MAPK 通路的突变不可知抑制,并借助 DCI 设计规避现有 MEKi 相关毒性。Atebimetinib 提供的 MEK 抑制持久且可耐受,支持这一治疗范式的潜力。作为 MEK 的深度周期性抑制剂,atebimetinib 阻断 MAPK 信号、抵抗 RAF 旁路,在 RAS 与 RAF 突变肿瘤中具有活性,代表了靶向治疗领域一种机制上有区分度的策略。参见 Gaire 与 Poulikakos 的评论,第 5017 页。
KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2A-r B-ALL) is an aggressive subtype of leukemia, characterized by high relapse rates, therapy resistance, and poor prognosis. Although CD19-targeted immunotherapies have significantly benefited patients with relapsed/refractory disease, relapses remain common and long-term survival is especially poor in patients with KMT2A-r B-ALL. We recently identified the membrane-bound proteoglycan, neuron-glial antigen 2 (NG2; CSPG4), as a direct transcriptional target of KMT2A fusions, with its expression associated with poor prognosis, early relapse, and glucocorticoid resistance in KMT2A-r B-ALL. However, the molecular mechanism underlying the aggressiveness of KMT2A-r B-ALL remains poorly understood. Here, we identify the α4 integrin subunit (ITGA4) and NG2 as a key biological axis contributing to leukemic aggressiveness. NG2 expression promotes proliferation and migration of KMT2A-r B-ALL cells, and it is associated with Rho GTPase activity in an ITGA4-dependent manner. In vivo studies using immunodeficient mice demonstrated that ITGA4 and NG2 cooperate to promote leukemia progression, as combined genetic ablation of both genes significantly delayed disease onset and prolonged survival. Notably, natalizumab (NTZ), a clinically approved monoclonal antibody targeting ITGA4, delayed leukemia progression and potentiated the efficacy of standard-of-care chemotherapy in patient-derived KMT2A-r B-ALL xenograft models. Collectively, our findings define a novel ITGA4-NG2 signaling axis that drives the aggressiveness of KMT2A-r B-ALL and support the repurpose of NTZ as an adjuvant therapeutic strategy for this high-risk leukemia subtype.
中文摘要:KMT2A重排B细胞急性淋巴细胞白血病(KMT2A-r B-ALL)是一种侵袭性白血病亚型,以高复发率、治疗耐受和预后不良为特征。CD19靶向免疫治疗使复发/难治患者显著获益,但复发仍常见,KMT2A-r B-ALL患者的长期生存尤其差。我们近期发现膜结合蛋白聚糖神经元-胶质抗原2(NG2;CSPG4)是KMT2A融合的直接转录靶点,其表达与KMT2A-r B-ALL预后不良、早期复发和糖皮质激素耐受相关。KMT2A-r B-ALL侵袭性的分子机制仍不清楚。α4整合素亚基(ITGA4)与NG2被确定为促进白血病侵袭性的关键生物学轴。NG2表达促进KMT2A-r B-ALL细胞增殖和迁移,并以ITGA4依赖的方式与Rho GTP酶活性相关。免疫缺陷小鼠体内研究显示,ITGA4和NG2协同促进白血病进展,同时敲除这两个基因显著延迟疾病发生并延长生存。靶向ITGA4的临床已批准单克隆抗体natalizumab(NTZ)在患者来源的KMT2A-r B-ALL异种移植模型中延迟白血病进展,并增强标准治疗化疗的疗效。这些结果定义了一条驱动KMT2A-r B-ALL侵袭性的新ITGA4-NG2信号轴,支持将NTZ重新定位为该高危白血病亚型的辅助治疗策略。
TNF-α (Tumor Necrosis Factor) is a proinflammatory cytokine that amplifies inflammatory response and promotes leukocyte recruitment. TNF-α is primarily produced by activated macrophages, among others, in response to infection, inflammation, or tissue damage. Given its central role in normal and abnormal immune responses, it is the target of several therapeutics, such as adalimumab and etanercept. TNF-α is also a prognostic and diagnostic biomarker associated with rheumatoid arthritis, Alzheimer's disease, multiple sclerosis, several kidney diseases, cancers, type 2 diabetes, sepsis, and others. Because TNF-α levels change dynamically during inflammatory responses, tools capable of sensitive and spatially resolved detection could enable improved monitoring of immune activity and disease progression. Single-walled carbon nanotubes (SWCNT) are cylindrical carbon lattices that emit distinct near-infrared bandgap photoluminescence. In this work, we evaluated three aptamer-based sensor constructs, plus an additional two iterations of one aptamer sequence, and two antibody-based sensor constructs for TNF-α that use SWCNT near-infrared photoluminescence signal transduction. Several, but not all, of these aptamer and antibody-based sensors sensitively and selectively detected TNF-α in human and bovine serum in a physiologically relevant range, and we found that their sensing was impacted by both passivation and incorporating an exogenous quencher onto the aptamer sequence. This study highlights the importance and challenges of translating previously-validated molecular recognition elements to new detection conditions, in this case on the surface of SWCNT and in challenging serum conditions. It also validated a lead sensor, the VR11-SWCNT aptamer construct with or without quencher chemistry and with surface passivation, that builds upon constructs that failed in serum. These results demonstrate a strategy toward synthesis of nanoscale optical sensors capable of detecting TNF-α. We anticipate that the sensors evaluated here will have utility in both the diagnosis and study of inflammation-driven chronic disease, while the sensor assessment framework will help drive the broader field of molecularly specific diagnostics.
中文摘要:TNF-α(肿瘤坏死因子)是一种促炎细胞因子,可放大炎症反应并促进白细胞募集。TNF-α主要由活化巨噬细胞等产生,以应对感染、炎症或组织损伤。鉴于其在正常和异常免疫反应中的核心作用,它已成为阿达木单抗、依那西普等多种治疗药物的靶点。TNF-α也是与类风湿关节炎、阿尔茨海默病、多发性硬化、多种肾脏疾病、癌症、2型糖尿病、脓毒症等相关的预后和诊断生物标志物。由于TNF-α水平在炎症反应中动态变化,具备灵敏且空间分辨检测能力的工具可能有助于改进对免疫活动和疾病进展的监测。单壁碳纳米管(SWCNT)是圆柱形碳晶格,可发出独特的近红外带隙光致发光。本工作评估了三种基于适配体的传感器构建体,另有一个适配体序列的两次迭代,以及两种基于抗体的传感器构建体,均针对TNF-α并利用SWCNT近红外光致发光信号转导。这些基于适配体和抗体的传感器中,有若干种而非全部能够在生理相关范围内灵敏且选择性地检测人血清和牛血清中的TNF-α;我们发现其传感受到钝化处理以及在适配体序列上引入外源淬灭剂的影响。该研究凸显了将先前验证过的分子识别元件转化到新的检测条件中的重要性和挑战,此处即SWCNT表面和具有挑战性的血清条件。它还验证了一种领先传感器,即VR11-SWCNT适配体构建体,无论是否采用淬灭剂化学和表面钝化,该构建体建立在曾在血清中失败的构建体之上。这些结果展示了一种合成能够检测TNF-α的纳米级光学传感器的策略。我们预计,此处评估的传感器将可用于炎症驱动慢性病的诊断和研究,而传感器评估框架将有助于推动分子特异性诊断的更广泛领域。
Stimulus-responsive nucleic acid nanomaterials are attractive for label-free electrochemical biosensing because their programmable structures enable target-triggered signal generation in homogeneous systems. Herein, we report a one-step electrochemical strategy for rapid and highly sensitive detection of ovarian cancer (OC)-derived exosomes based on target-responsive Cu2+-coordinated DNA nanoparticles (Cu2+@DNA-NPs). In this design, aptamer sequences are incorporated into Cu2+@DNA-NPs to endow the nanostructures with target-recognition capability, while the coordinated Cu2+ ions serve directly as intrinsic electrochemical reporters. Upon aptamer-mediated recognition of exosomal surface markers, the DNA structure switching may expose the initiator strands that trigger a localized hybridization chain reaction (HCR) within the nanoparticles, thereby promoting the nanoparticle disassembly and subsequent Cu2+ release for amplified electrochemical signal generation. Notably, this strategy enables label-free signal amplification in a homogeneous solution-phase format without electrode modification or additional redox labels. Moreover, the fabricated biosensor based on this strategy achieves rapid analysis within approximately 35 min, together with a low detection limit of 9 particles/mL, good selectivity against non-target exosomes and other interferents, as well as satisfactory stability and reproducibility. The biosensor has been further validated by using clinical samples, where it can clearly discriminate patients from healthy controls. Overall, this work establishes a rational and efficient electrochemical sensing strategy for rapid exosome analysis and the strategy-based biosensor may have potential utility in early OC diagnosis and metastasis monitoring.
中文摘要:刺激响应型核酸纳米材料具有可编程结构,可在均相体系中实现靶标触发的信号生成,因此适用于无标记电化学生物传感。本工作报道了一种基于靶标响应型Cu2+配位DNA纳米颗粒(Cu2+@DNA-NPs)的一步电化学策略,用于快速、高灵敏检测卵巢癌(OC)来源外泌体。该设计中,适配体序列被引入Cu2+@DNA-NPs,使纳米结构具备靶标识别能力,配位的Cu2+离子直接作为内在电化学报告分子。适配体识别外泌体表面标志物后,DNA结构转换可暴露引发链,在纳米颗粒内部触发局部杂交链式反应(HCR),促进纳米颗粒解组装并释放Cu2+,从而实现放大的电化学信号生成。该策略可在均相溶液体系中实现无标记信号放大,无需电极修饰或额外氧化还原标记。基于该策略构建的生物传感器可在约35分钟内完成快速分析,检测限低至9 particles/mL,对非靶标外泌体及其他干扰物具有良好选择性,并具备满意的稳定性和重现性。该生物传感器进一步用临床样本验证,可清晰区分患者与健康对照。总体而言,这项工作建立了一种合理、高效的电化学传感策略,用于快速外泌体分析,基于该策略的生物传感器可能在卵巢癌早期诊断和转移监测中具有应用潜力。
In this paper, we proposed a low-cost and easily fabricated microfluidic impedance cytometer (HF-MIC) based on 3D hydrodynamic focusing for the electrical characterization and identification of tumor cells with high-accuracy. The detection electrodes and detection channel of HF-MIC were easily fabricated by laser cutting conductive film of indium tin oxide (ITO) glass and double-sided adhesive tapes, respectively. The fabrication and assembly period of the HF-MIC is shortened to less than 1 h and the cost is less than $4 per device. First, numerical methods explored the positional dependence of impedance signals and particle focusing behaviors. Then, the performance tests of the HF-MIC using polystyrene particles verified its ability to acquire impedance signals with high focusing efficiency (>94%), high focusing stability (CV < 0.08) and high SNR (>8 dB). Finally, key dielectric parameters-cell diameter (Dcell), impedance amplitude opacity |Z|HF/|Z|LF, phase opacity ϴ(ZHF)/ϴ(ZLF), opacity X (Re(ZHF)/Re(ZLF)), and opacity Y (Im(ZHF)/Im(ZLF))-were used to analyze the cell dielectric properties and divided into four groups to train four BPNN models. For all identification tasks (WBCs vs. tumor cells, tumor cells from different organs, and tumor cells with the same phenotype from the same type of organs), the TPR given by Model Ⅳ all reached 99%. Our HF-MIC enables the detection of cells without causing clogging and offers the advantages of simple fabrication, low cost, and high-accuracy electrical characterization and identification of tumor cells.
中文摘要:研究提出一种基于三维流体动力学聚焦的低成本、易加工微流控阻抗细胞仪(HF-MIC),用于高精度肿瘤细胞电学表征与识别。HF-MIC的检测电极和检测通道分别通过激光切割氧化铟锡(ITO)玻璃导电膜和双面胶带制作,制作与装配周期缩短至1小时内,每器件成本低于4美元。数值方法考察了阻抗信号的位置依赖性和颗粒聚焦行为。采用聚苯乙烯颗粒的性能测试验证了其获取阻抗信号的能力,聚焦效率高于94%,聚焦稳定性高(CV<0.08),信噪比高于8 dB。以细胞直径(Dcell)、阻抗幅度不透明度|Z|HF/|Z|LF、相位不透明度ϴ(ZHF)/ϴ(ZLF)、不透明度X(Re(ZHF)/Re(ZLF))和不透明度Y(Im(ZHF)/Im(ZLF))等关键介电参数分析细胞介电特性,并分为四组训练四个BP神经网络模型。对于全部识别任务(白细胞与肿瘤细胞、不同器官来源的肿瘤细胞、同类型器官来源且表型相同的肿瘤细胞),模型Ⅳ给出的真阳性率均达到99%。HF-MIC可实现无堵塞细胞检测,并具有制作简单、成本低以及高精度肿瘤细胞电学表征与识别的优势。
Circulating tumor cells (CTCs) are promising biomarkers for liquid biopsies in early cancer detection and monitoring, but their rarity and phenotypic heterogeneity make selective capture and non-destructive release challenging. Herein, we designed a novel DNA-inspired three-dimensional (3D) conjugating polymer-aptamer biointerface for selective capture and fringe-field pulsed electric field (FF-PEF)-triggered release of CEA-positive tumor cells. The platform was prepared by facile dip-coating a poly (para-aminophenol-co-thiophene) (PpAPT)-polyurethane (PU) blend onto a nonwoven carbon fabric (NCF) and was functionalized with carcinoembryonic antigen (CEA)-specific DNA aptamer to produce CEA/PpAPT-PU@NCF. The conjugated backbone and polar group (-OH/-NH2/-S-) functionalities of PpAPT, together with conductive fibrous 3D substrate, provided a hydrated and nucleic-acid-compatible interface for stable aptamer immobilization, low nonspecific binding and acceptable hemocompatibility. The CEA/PpAPT-PU@NCF composite exhibited high capture efficiency rate of 93% for CEA-positive HCT116 cells, with low nonspecific adhesion. More significantly, captured cells were released under optimized FF-PEF conditions, achieving up to 62.65% release efficiency through field-driven interfacial perturbation while preserving cell viability. These results demonstrate that CEA/PpAPT-PU@NCF provides a scalable platform for selective tumor-cell capture and non-destructive release, offering potential for liquid biopsy, downstream cellular analysis, and next-generation of bioelectronics applications.
中文摘要:循环肿瘤细胞(CTC)是用于癌症早期检测和监测的液体活检 promising biomarker,但其稀有性和表型异质性使选择性捕获和无损释放面临挑战。为此,研究设计了一种受DNA启发的三维共轭聚合物-适配体生物界面,用于选择性捕获CEA阳性肿瘤细胞,并通过 fringe-field pulsed electric field(FF-PEF)触发释放。该平台通过将聚对氨基苯酚-co-噻吩(PpAPT)与聚氨酯(PU)共混物简便浸涂于非织造碳织物(NCF)上制备,并以癌胚抗原(CEA)特异性DNA适配体功能化,得到CEA/PpAPT-PU@NCF。PpAPT的共轭主链和极性基团(-OH/-NH2/-S-)以及导电纤维状三维基底共同提供了水合且核酸相容的界面,有利于适配体稳定固定、低非特异性结合和可接受的血液相容性。CEA/PpAPT-PU@NCF复合材料对CEA阳性HCT116细胞表现出93%的高捕获效率,非特异性黏附较低。更重要的是,在优化的FF-PEF条件下,捕获细胞可通过场驱动的界面扰动实现最高62.65%的释放效率,同时保持细胞活力。这些结果表明,CEA/PpAPT-PU@NCF为选择性肿瘤细胞捕获和无损释放提供了可扩展平台,在液体活检、下游细胞分析及下一代生物电子学应用方面具有潜力。
T-cell-based therapies have shown remarkable efficacy in multiple myeloma (MM), yet the disease remains largely incurable. MM cells secrete excessive monoclonal immunoglobulins (M proteins) that drive complications but are inaccessible to chimeric antigen receptor (CAR) T-cell or antibody targeting. Here, we investigated the constant domains of the immunoglobulin heavy chain (IGH) as novel targets for therapeutic T-cell receptors (TCRs) after confirming high and homogeneous IGH expression in >95% of patients with MM. Peptides from immunoglobulin A and immunoglobulin G constant regions were eluted from HLA-A∗02:01, and reactive TCRs were isolated from healthy donors using allo-HLA-A∗02:01 presentation to circumvent self-tolerance. T cells engineered with TCRs specific for IgA or IgG passed a stringent multitier safety screen and selectively eliminated HLA-A∗02:01+ MM cells from 20 patients secreting the relevant IgH in vitro. In vivo, IgA-TCR T cells eradicated IgA+HLA-A∗02:01+ MM cells in xenograft models and reduced circulating IgA in humanized mice. These findings establish immunoglobulin constant domains as viable TCR targets in MM, potentially making ∼40% of patients of European descent eligible for TCR T-cell therapy, and extension to additional HLA alleles could further broaden eligibility. The approach may also be applicable to lymphoma and antibody-mediated autoimmune diseases.
中文摘要:基于T细胞的疗法在多发性骨髓瘤(MM)中已显示出显著疗效,但该病在很大程度上仍无法治愈。MM细胞分泌过量单克隆免疫球蛋白(M蛋白),可导致并发症,却无法被嵌合抗原受体(CAR)T细胞或抗体靶向。在确认超过95%的MM患者中免疫球蛋白重链(IGH)高表达且表达均一后,研究将IGH恒定区作为治疗性T细胞受体(TCR)的新靶点。从HLA-A*02:01洗脱免疫球蛋白A和免疫球蛋白G恒定区来源的肽段,并利用异体HLA-A*02:01递呈从健康供者中分离反应性TCR,以规避自身耐受。经IgA或IgG特异性TCR改造的T细胞通过严格的多层级安全性筛选,并在体外选择性清除20例分泌相应IgH的患者来源的HLA-A*02:01+ MM细胞。在体内,IgA-TCR T细胞在异种移植模型中清除IgA+HLA-A*02:01+ MM细胞,并降低人源化小鼠循环IgA。这些发现确立免疫球蛋白恒定区可作为MM中可行的TCR靶点,可能使约40%欧洲血统患者符合TCR T细胞治疗条件,扩展至其他HLA等位基因可进一步扩大适用人群。该方法也可能适用于淋巴瘤和抗体介导的自身免疫病。
The dynamic and reversible N6-methyladenosine (m6A) RNA modification has emerged as a pivotal layer of epitranscriptomic regulation in cancer, governing RNA metabolism and function. Concurrently, deubiquitylating enzymes (DUBs), key components of the post-translational modifications (PTMs) system, orchestrate protein stability and signaling pathways crucial for tumorigenesis. Recent evidence reveals extensive and intricate crosstalk between these two regulatory systems, forming a complex network that can influence cancer progression. This review systematically explores the bidirectional interplay between DUBs and m6A modification. On one hand, specific DUBs can deubiquitinate and stabilize core m6A "writers" (methyltransferases), "erasers" (demethylases), or "readers" (recognition proteins), thereby influencing RNA metabolism and downstream gene expression. On the other hand, m6A modification can regulate the expression of certain DUBs, either by influencing the stability and translation of their mRNAs or by controlling associated regulatory factors. This reciprocal regulation profoundly impacts key oncogenic processes, including cell proliferation, metastasis, metabolic reprogramming, and therapy resistance. By integrating current findings, this review highlights the significance of the DUB-m6A axis as a critical regulatory hub in cancer biology. Deciphering this crosstalk not only provides novel insights into tumor mechanisms but also unveils promising therapeutic targets for overcoming drug resistance and developing innovative anti-cancer strategies.
中文摘要:动态且可逆的N6-甲基腺苷(m6A)RNA修饰已成为癌症表观转录组调控的重要层面,调控RNA代谢与功能。去泛素化酶(DUBs)是翻译后修饰(PTMs)系统的关键组分,控制蛋白质稳定性及对肿瘤发生至关重要的信号通路。近期证据显示,这两类调控系统之间存在广泛而复杂的交互,形成可影响癌症进展的复杂网络。本综述系统探讨DUBs与m6A修饰之间的双向相互作用。一方面,特定DUBs可使核心m6A「写入器」(甲基转移酶)、「擦除器」(去甲基化酶)或「阅读器」(识别蛋白)去泛素化并稳定其表达,从而影响RNA代谢和下游基因表达。另一方面,m6A修饰可调控某些DUBs的表达,方式包括影响其mRNA的稳定性与翻译,或控制相关调控因子。这种相互调控深刻影响细胞增殖、转移、代谢重编程和治疗耐药等关键致癌过程。整合现有发现,本综述强调DUB-m6A轴作为癌症生物学关键调控枢纽的重要意义。解析这一交互不仅为肿瘤机制提供新见解,也揭示有希望的治疗靶点,用于克服耐药并开发创新抗癌策略。
A major barrier to cancer therapy is the emergence of drug-tolerant states that allow tumor cells to bypass the targeted pathway. These refractory states arise through reversible cellular plasticity, a process that also occurs during development and regeneration, giving rise to new lineages or phenotypes and restoring drug sensitivity upon treatment withdrawal. Over time, genetic mutations may accumulate, leading to permanent resistance. This paradigm expands the focus from targeting genetic mechanisms alone to also exploiting nongenetic vulnerabilities, driving clinical strategies that prevent or eliminate plastic and transformed populations. Here, we provide an overview of nongenetic plasticity mechanisms and their emerging clinical applications.
中文摘要:癌症治疗的一大障碍是出现药物耐受状态,使肿瘤细胞能够绕过被靶向的通路。这些难治状态通过可逆的细胞可塑性产生,该过程也见于发育和再生,可形成新的谱系或表型,并在停止治疗后恢复药物敏感性。随着时间推移,基因突变可能积累,导致永久性耐药。这一范式将关注点从仅靶向遗传机制扩展到同时利用非遗传性脆弱点,推动旨在预防或清除可塑性细胞及转化后细胞群体的临床策略。该文概述非遗传可塑性机制及其新兴临床应用。
Single-cell resolution spatial transcriptomics provides a great opportunity to explore the complex cellular contents in different tissues. Here we introduce SpatialZoomer, a spectral graph-based method that applies a set of low-pass filters to efficiently extract spatial molecular features from spatial transcriptomics data at multiple resolutions or scales, including the single cell scale, the niche scale with dozens of closely interacting cells and the domain scale with spatially organized cell contents. The corresponding critical scales can be automatically identified by partitioning a cross-scale similarity map. Results show that SpatialZoomer can identify disease-progression signals at specific scales in Alzheimer's disease and spatial context-dependent cell subtypes in tumour microenvironment. The extracted multi-scale features also uncovered spatially heterogeneous niches in cancer. SpatialZoomer achieves comparable or superior performance to existing methods for single-scale tasks, and it also has the advantages of high computational efficiency and low hardware requirements.
中文摘要:单细胞分辨率空间转录组为探索不同组织中复杂的细胞内容提供了重要契机。这里介绍 SpatialZoomer,一种基于谱图的方法,对空间转录组数据施加一组低通滤波器,在多种分辨率或尺度上高效提取空间分子特征,涵盖单细胞尺度、由数十个紧密相互作用细胞构成的微环境尺度,以及具有空间组织化细胞内容的结构域尺度。相应地,关键尺度可通过划分跨尺度相似性图谱自动识别。结果表明,SpatialZoomer 能在阿尔茨海默病中识别特定尺度上的疾病进展信号,也能在肿瘤微环境中识别依赖空间背景的细胞亚型。所提取的多尺度特征还揭示了癌症中空间异质的微环境。在单尺度任务上,SpatialZoomer 的性能与现有方法相当或更优,同时具有计算效率高、硬件要求低的优势。
Atherosclerosis remains a leading cause of cardiovascular mortality, driven by macrophage dysfunction and necrotic core expansion. Ferroptosis, an iron-dependent cell death, is a critical driver of plaque instability; however, pharmacological interventions targeting ferroptosis remain scarce. Lentinan (LNT), a bioactive β-(1,3)-glucan extracted from shiitake mushrooms, exhibits potent antioxidant properties but its potential role in the modulation of macrophage ferroptosis remains unexplored. We investigated the therapeutic potential and molecular mechanisms of action of LNT in atherosclerosis. LNT administration significantly attenuated atherosclerotic progression in mice. Specifically, LNT mitigated macrophage ferroptosis by enhancing glutathione homeostasis and reducing lipid peroxidation. Notably, these protective effects were significantly abrogated in mice deficient in solute carrier family 7 member 11 (SLC7A11), indicating that the effect of LNT is dependent on this molecule. We found that LNT directly binds to far upstream binding protein 1 (FUBP1) and that T559 is required for FUBP1 O-GlcNAcylation and subsequent nuclear translocation. In the nucleus, FUBP1 binds to tumor protein p53 (Tp53), thereby relieving the transcriptional repression of SLC7A11. The resulting activation of the SLC7A11 signaling axis not only inhibits ferroptosis but also promotes scavenger receptor B type 1 (SR-B1)-mediated cholesterol efflux. These findings highlight LNT as a novel modulator of the FUBP1/Tp53/SLC7A11 axis, offering a promising natural therapeutic strategy to stabilize atherosclerotic plaques.
中文摘要:动脉粥样硬化仍是心血管死亡的主要原因,其发生与巨噬细胞功能障碍和坏死核心扩大有关。铁死亡是一种铁依赖性细胞死亡,是斑块不稳定的关键驱动因素;但针对铁死亡的药物干预仍然很少。香菇多糖(LNT)是从香菇中提取的一种具有生物活性的β-(1,3)-葡聚糖,具有较强抗氧化特性,但其在调控巨噬细胞铁死亡中的潜在作用尚未被探索。我们研究了LNT在动脉粥样硬化中的治疗潜力及分子作用机制。LNT给药显著减轻小鼠动脉粥样硬化进展。LNT通过增强谷胱甘肽稳态和减少脂质过氧化来减轻巨噬细胞铁死亡。这些保护效应在溶质载体家族7成员11(SLC7A11)缺陷小鼠中显著消失,表明LNT的作用依赖该分子。我们发现LNT直接结合远端上游结合蛋白1(FUBP1),且T559是FUBP1发生O-GlcNAc糖基化及随后核转位所必需。在细胞核中,FUBP1与肿瘤蛋白p53(Tp53)结合,从而解除对SLC7A11的转录抑制。由此激活的SLC7A11信号轴不仅抑制铁死亡,还促进清道夫受体B1型(SR-B1)介导的胆固醇外流。这些发现凸显LNT作为FUBP1/Tp53/SLC7A11轴的新型调节剂,为稳定动脉粥样硬化斑块提供了一种有前景的天然治疗策略。
The incidence and mortality of high-grade endometrial cancers are increasing, and heterozygous hotspot mutations in PPP2R1A are drivers of the most aggressive forms of uterine cancer. PPP2R1A encodes the Aα scaffolding subunit of the heterotrimeric phosphatase PP2A. These recurrent mutations, specifically at the Pro179 and Ser256 residues, disrupt the binding of tumor-suppressive substrate-directing B56 and B55 subunits to the PP2A scaffolding subunit while maintaining binding to other regulatory subunits. Here, we identified a series of molecular glues that correct PP2A trimer formation in the context of the P179R (Pro179→Arg) and S256F (Ser256→Phe) mutants. A small-molecule library was designed to fit into the pocket at the binding interface of the Aα/B56α/C heterotrimer. The lead molecule, RPT04402, promoted B56α heterotrimerization to the AαP179R and AαS256F mutant scaffolds. In mice, RPT04402 treatment drove tumor regressions and extended median survival in multiple independent mutant cell lines and patient-derived xenografts, proving a robust single-agent activity. This activity was abrogated upon knockout of B56α. Combined, these data demonstrate that PP2A molecular glues are a promising first-in-class therapy that might benefit patients with PPP2R1A mutant uterine cancer by targeting a driver of this aggressive disease.
中文摘要:高级别子宫内膜癌的发病率和死亡率持续上升,PPP2R1A 的杂合热点突变是侵袭性最强子宫癌的驱动因素。PPP2R1A 编码异源三聚体磷酸酶 PP2A 的 Aα 支架亚基。这些反复出现的突变,特别是 Pro179 和 Ser256 位点,破坏肿瘤抑制性底物导向 B56 和 B55 亚基与 PP2A 支架亚基的结合,同时保持与其他调节亚基的结合。我们鉴定了一系列分子胶,可在 P179R(Pro179→Arg)和 S256F(Ser256→Phe)突变背景下纠正 PP2A 三聚体形成。设计了一个小分子库以适配 Aα/B56α/C 异源三聚体结合界面的口袋。先导分子 RPT04402 促进 B56α 与 AαP179R 和 AαS256F 突变支架形成异源三聚体。在小鼠中,RPT04402 治疗在多个独立突变细胞系和患者来源异种移植瘤中驱动肿瘤消退并延长中位生存期,证明稳健的单药活性。敲除 B56α 后该活性消失。这些数据表明,PP2A 分子胶是有前景的首创疗法,可能通过靶向这一侵袭性疾病驱动因素使 PPP2R1A 突变子宫内膜癌患者获益。
Oral squamous cell carcinoma (OSCC) frequently metastasizes to regional lymph nodes, yet the metabolic adaptations that enable invasive dissemination remain incompletely understood. Although lipid metabolic reprogramming has emerged as a hallmark of metastatic dissemination, the upstream signaling pathways coordinating these processes remain poorly defined. Here, we combined transcriptomic, epigenomic, and lipidomic analyses with genetic and pharmacological perturbation of lymphocyte cell-specific protein tyrosine kinase (LCK) and peroxisome proliferator-activated receptor gamma (PPARG) to define the signaling network linking oncogenic kinase activity to lipid metabolism. We identify PPARG as a critical downstream effector of LCK that promotes invasion by reprogramming lipid metabolism. Mechanistically, LCK maintained PPARG expression, which induced stearoyl-CoA desaturase (SCD), increased monounsaturated fatty acid synthesis, and limited lipid peroxide accumulation. Pharmacological inhibition of SCD suppressed cancer cell invasion, impaired viability, and sensitized PPARG-activated cells to ferroptosis-associated cell death. Together, these findings establish an LCK/PPARG/SCD signaling axis that couples oncogenic signaling to lipid metabolic plasticity during OSCC invasion. Our study identifies SCD as a potential therapeutic vulnerability and suggests that therapeutic activation of PPARG signaling should be approached with caution in patients with established oral cancer and carefully evaluated in biomarker-guided clinical studies.
中文摘要:口腔鳞状细胞癌(OSCC)常转移至区域淋巴结,促成侵袭性播散的代谢适应仍未充分阐明。脂质代谢重编程已被视为转移播散的特征,协调这些过程的上游信号通路仍不明确。研究将转录组、表观基因组和脂质组分析与淋巴细胞特异性蛋白酪氨酸激酶(LCK)及过氧化物酶体增殖物激活受体γ(PPARG)的遗传学和药理学干预结合,界定连接致癌激酶活性与脂质代谢的信号网络。PPARG被确定为LCK的关键下游效应分子,通过重编程脂质代谢促进侵袭。机制上,LCK维持PPARG表达,PPARG诱导硬脂酰辅酶A去饱和酶(SCD),增加单不饱和脂肪酸合成并限制脂质过氧化物积累。药理学抑制SCD可抑制癌细胞侵袭、损害活力,并使PPARG激活的细胞对铁死亡相关细胞死亡敏感。这些发现确立了一条LCK/PPARG/SCD信号轴,在OSCC侵袭过程中将致癌信号与脂质代谢可塑性耦联。SCD被识别为潜在治疗脆弱点,提示在已确诊口腔癌患者中治疗性激活PPARG信号应谨慎,并在生物标志物指导的临床研究中仔细评估。
Targeted lipid nanoparticles (LNPs) offer a nonviral approach for in vivo cell engineering but efficient programming of natural killer (NK) cells remains underexplored. Here we develop NK cell-targeted LNPs (NtLNPs) using engineered biparatopic NK cell ligands to drive receptor-specific uptake and mRNA delivery. Lead NtLNPs achieve up to ~80% NK cell transfection with minimal off-target effects in mice. Systemic delivery of chimeric antigen receptor (CAR) mRNA using NtLNPs generates CAR NK cells in vivo. CD19-targeted CAR NKs completely deplete circulating B cells in healthy mice and CD3-targeted CAR NKs eliminate nearly all autoreactive T cells in an autoimmune hepatitis model, highlighting a potential advantage over CAR T therapies for T cell-driven disease. In solid tumors, NtLNPs targeting the inhibitory checkpoint NKG2A enhance antitumor efficacy by relieving Qa-1b-mediated immunosuppression. Lastly, we optimized NtLNPs for in vivo engineering of human CAR NK cells, enabling regression of two humanized hematologic malignancy models and establishing NtLNPs as a modular immunotherapy system.
中文摘要:靶向脂质纳米颗粒(LNPs)为体内细胞工程提供了非病毒途径,但高效编程自然杀伤(NK)细胞仍未充分探索。我们利用工程化双旁位NK细胞配体构建NK细胞靶向LNPs(NtLNPs),驱动受体特异性摄取和mRNA递送。先导NtLNPs在小鼠中实现高达约80%的NK细胞转染,脱靶效应很低。使用NtLNPs系统性递送嵌合抗原受体(CAR)mRNA可在体内生成CAR NK细胞。靶向CD19的CAR NK细胞在健康小鼠中完全清除循环B细胞,靶向CD3的CAR NK细胞在自身免疫性肝炎模型中清除几乎全部自身反应性T细胞,显示其相较CAR T疗法在T细胞驱动疾病中的潜在优势。在实体瘤中,靶向抑制性检查点NKG2A的NtLNPs通过解除Qa-1b介导的免疫抑制增强抗肿瘤疗效。最后,我们优化NtLNPs用于人体CAR NK细胞的体内工程化,使两种人源化血液恶性肿瘤模型消退,并确立NtLNPs作为一种模块化免疫治疗系统。
Ribosome biogenesis is highly upregulated in cancer and essential for malignant growth, yet efforts to selectively target this process pharmacologically have been unsuccessful. Here we identify nuclear valosin-containing protein-like (NVL), a hexameric AAA+ ATPase required for large ribosomal subunit (60S) assembly, as a druggable target in this pathway. Using forward genetics, we discovered that the cytotoxic dibenzothiazepinone MM17 inhibits NVL. Mutations conferring resistance to MM17 in cancer cells also rendered recombinant NVL refractory to enzymatic inhibition in vitro, providing convergent genetic and biochemical evidence of target engagement. Cryo-electron microscopy structures revealed two MM17-binding sites within the NVL hexamer, with resistance mutations clustering around the ligand pocket. NVL inhibition disrupts 60S biogenesis and activates p53 without inducing DNA damage. A more potent, bioavailable analog, MM927, recapitulates these effects and suppresses tumor growth in vivo without detectable toxicity. These findings establish NVL inhibitors as first-in-class therapeutics targeting ribosome biogenesis in cancer.
中文摘要:核糖体生物合成在肿瘤中高度上调,是恶性生长所必需,但通过药理学手段选择性靶向该过程一直未获成功。研究识别出核缬酪肽蛋白样蛋白(NVL)——一种参与大核糖体亚基(60S)组装、以六聚体形式存在的AAA+ ATP酶——是该通路中的可成药靶点。通过正向遗传学,发现细胞毒性二苯并硫氮杂环酮类化合物MM17可抑制NVL。在肿瘤细胞中赋予MM17抗性的突变,也使重组NVL在体外对酶学抑制不敏感,提供了靶点结合的遗传学与生物化学汇聚证据。冷冻电镜结构显示NVL六聚体内存在两个MM17结合位点,抗性突变聚集在配体口袋周围。抑制NVL会破坏60S生物合成并激活p53,且不诱导DNA损伤。活性更强、具有生物利用度的类似物MM927重现了这些效应,并在体内抑制肿瘤生长,未检测到毒性。这些发现确立了NVL抑制剂作为靶向肿瘤核糖体生物合成的首创疗法。
Medical AI requires governance preserving safety during continuous improvement. FDA Predetermined Change Control Plans (PCCP) and EU post-market surveillance address iterative updates but lack operational tooling. We present AEGIS, an internal governance and post-market-monitoring infrastructure designed to support the documentation of predetermined governance pathways for PCCP and Medical Devices Regulation alignment. AEGIS comprises dataset assimilation and retraining, model monitoring, and conditional decision-making modules. It utilizes a four-category taxonomy (APPROVE, CONDITIONAL APPROVAL, CLINICAL REVIEW, REJECT) and an independent ALARM signal. Instantiating AEGIS for sepsis prediction (PhysioNet) and brain-tumor segmentation (BraTS) exercised all decision categories, successfully routing failures to the critical REJECT + ALARM state (no deployable model; released model at risk). On real cross-site data, drift detection ROC-AUC rose from 0.82 to 1.00, reliably triggering near 500-patient batches with zero false alarms. This proof-of-concept utilizes illustrative clinical models; drift scoring quantifies covariate shift only, leaving concept drift for future work.
中文摘要:医疗AI在持续改进过程中需要治理以保障安全性。FDA的预设变更控制计划(PCCP)与欧盟上市后监测针对迭代更新作出安排,但缺少可操作的工具。我们提出AEGIS,一套内部治理与上市后监测基础设施,用于支持PCCP及欧盟医疗器械法规对齐所需的预设治理路径文档化。AEGIS包含数据汇集与再训练、模型监测、条件决策模块,采用四类分类体系(APPROVE、CONDITIONAL APPROVAL、CLINICAL REVIEW、REJECT)以及独立的ALARM信号。以脓毒症预测(PhysioNet)和脑肿瘤分割(BraTS)实例化AEGIS,覆盖了全部决策类别,并将失败案例成功导向关键的REJECT+ALARM状态(无可部署模型;已发布模型存在风险)。在真实跨站点数据上,漂移检测ROC-AUC由0.82升至1.00,能在接近500例患者的批次中可靠触发,且零误报。该概念验证使用示例性临床模型;漂移评分仅量化协变量偏移,概念漂移留待后续工作。
Tumor drug resistance is still the core obstacle limiting the long-term benefit of modern anticancer therapy, especially in the context of treatment tolerance, persistence of minimal residual disease (MRD) and recurrence after treatment. Increasing evidence has shown that therapy-associated myeloid niches can involve cell recruitment, enrichment of pre-existing populations, or state reprogramming, together with local relationships among myeloid cells, tumor cells, stroma, vessels, and other immune cells. These niches can support residual tumor-cell survival, immune escape, local regrowth, and distant dissemination through overlapping mechanisms linking fibrotic exclusion and perivascular organization with hypoxic metabolic suppression and myeloid replenishment. The formation of neutrophil extracellular traps, failure of antigen uptake and presentation, impaired T-cell priming, and phagocytic escape can further sustain treatment tolerance. Focusing on the myeloid cell state and common molecular circuits, this article presents an evidence assessment framework that interprets spatial and clinical associations alongside functional and pharmacologic findings without assigning hierarchical ranks. It summarizes lessons from clinical failure, considering potentially limited target contributions, compensatory pathways, inadequate exposure, and toxicity, while distinguishing drug exposure and local pharmacodynamic changes from clinical benefit. Candidate biomarkers, intervention windows, and selective delivery approaches require validation to guide mechanism-matched combinations. In the future, longitudinal tissue analyses, functional validation, and prospective studies should test whether these combinations provide durable benefit with acceptable safety in defined patient populations and treatment settings.
中文摘要:肿瘤耐药仍是限制现代抗癌治疗长期获益的核心障碍,尤其在治疗耐受、微小残留病(MRD)持续和治疗后复发的情况下。越来越多证据表明,治疗相关髓系生态位可涉及细胞招募、既有细胞群扩增或状态重编程,并与髓系细胞、肿瘤细胞、基质、血管及其他免疫细胞之间的局部关系相关。这些生态位可通过纤维化排斥和血管周围构筑与缺氧代谢抑制及髓系补充相互重叠的机制,支持残留肿瘤细胞存活、免疫逃逸、局部再生长和远处播散。中性粒细胞胞外诱捕网形成、抗原摄取和呈递失败、T细胞始动受损以及吞噬逃逸可进一步维持治疗耐受。本文聚焦髓系细胞状态和共同分子环路,提出一个证据评估框架,在不对各项发现作等级排序的前提下,将空间与临床关联同功能和药理学结果一起解读。文章总结临床失败的经验,考虑靶点贡献可能有限、代偿通路、暴露不足和毒性,并将药物暴露及局部药效学变化与临床获益区分开。候选生物标志物、干预窗口和选择性递送策略仍需验证,以指导机制匹配的联合方案。未来应通过纵向组织分析、功能验证和前瞻性研究,在明确患者人群和治疗情境中检验这些联合方案能否带来持久获益且安全性可接受。
Mapping how genetic perturbations influence cell fate is key to understanding human development and disease. Here, we developed a massively parallel single-cell CRISPR (scCRISPR) screening platform in primary human hematopoietic stem and progenitor cells (HSPCs), profiling 322 regulators across 172,382 single-perturbed cells. The resulting multi-layered regulatory framework captured known associations and enabled functional annotation of regulator-phenotype relationships. Specifically, our atlas revealed that regulators acted within perturbation clusters to govern distinct gene programs that shaped cell fate. As proof of concept, we illustrated several examples. SMYD3 emerged as a negative regulator of long-term regenerative capacity. Analysis of lineage output further identified KMT5B, TRIM24, SETD7, and NSD3 as regulators associated with lineage-biased outputs. Finally, integration with clinical datasets identified PRDM10 as a candidate dependency in acute myeloid leukemia (AML). This work establishes a scalable functional genomics platform in a primary human stem cell system.
中文摘要:解析遗传扰动如何影响细胞命运,是理解人类发育与疾病的关键。我们在原代人造血干/祖细胞(HSPCs)中建立了大规模并行单细胞CRISPR(scCRISPR)筛选平台,对172,382个单扰动细胞中的322个调控因子进行了分析。由此得到的多层调控框架捕获了已知关联,并实现了调控因子-表型关系的功能注释。该图谱显示,调控因子在扰动簇内发挥作用,控制塑造细胞命运的不同基因程序。作为概念验证,我们展示了若干示例。SMYD3被鉴定为长期再生能力的负调控因子。对谱系输出的分析进一步发现,KMT5B、TRIM24、SETD7和NSD3是与谱系偏向输出相关的调控因子。与临床数据集的整合鉴定出PRDM10是急性髓系白血病(AML)的候选依赖靶点。这项工作在原代人干细胞系统中建立了一个可扩展的功能基因组学平台。
Clear cell renal cell carcinoma (ccRCC) is characterized by profound metabolic reprogramming and substantial inherited susceptibility. The molecular mechanisms linking germline risk variation to tumor metabolic reprogramming could potentially be exploited for precision interventions. Here, we aimed to delineate the germline regulatory architecture underlying ccRCC susceptibility and to determine how inherited noncoding variation influences mitochondrial metabolism and tumor progression. Whole-genome sequencing and transcriptomic profiling of matched ccRCC tumor and adjacent normal kidney tissues were integrated with cross-ancestry genome-wide association, cis-expression quantitative trait locus, transcriptome-wide association, and fine-mapping analyses. LINC02068 was identified as a genetically regulated tumor suppressor associated with inherited ccRCC susceptibility, and cross-ancestry fine-mapping prioritized rs234043 as a candidate causal variant. The rs234043 risk allele preferentially recruited HOXC8 and repressed LINC02068 transcription. Reduced LINC02068 expression promoted malignant cellular phenotypes and was associated with adverse clinical outcomes. Mechanistically, LINC02068 localized to mitochondria, interacted with the co-chaperone DNAJA3, and promoted DNAJA3 destabilization, thereby attenuating mitochondrial oxidative phosphorylation. Allele-specific editing and genetic rescue experiments further supported a functional rs234043-HOXC8-LINC02068-DNAJA3 regulatory axis driving ccRCC progression. Pharmacologic impairment of mitochondrial complex I suppressed ccRCC cell migration and proliferation. These findings establish a mechanistic link between a germline noncoding variation and mitochondrial metabolic reprogramming in ccRCC and identify targeting oxidative phosphorylation as a potential avenue for precision therapy.
中文摘要:透明细胞肾细胞癌(ccRCC)以显著代谢重编程和较强遗传易感性为特征。连接胚系风险变异与肿瘤代谢重编程的分子机制可能为精准干预提供靶点。研究旨在刻画ccRCC易感性的胚系调控架构,并确定遗传性非编码变异如何影响线粒体代谢和肿瘤进展。将配对ccRCC肿瘤与癌旁正常肾组织的全基因组测序和转录组分析与跨人群全基因组关联、顺式表达定量性状位点、全转录组关联及精细定位分析整合。LINC02068被鉴定为受遗传调控的抑癌因子,与遗传性ccRCC易感性相关,跨人群精细定位将rs234043列为候选因果变异。rs234043风险等位基因优先招募HOXC8并抑制LINC02068转录。LINC02068表达降低促进恶性细胞表型,并与不良临床结局相关。机制上,LINC02068定位于线粒体,与共伴侣蛋白DNAJA3相互作用并促进DNAJA3去稳定化,从而减弱线粒体氧化磷酸化。等位基因特异性编辑和遗传拯救实验进一步支持功能性rs234043-HOXC8-LINC02068-DNAJA3调控轴驱动ccRCC进展。药物抑制线粒体复合物I可抑制ccRCC细胞迁移和增殖。这些发现建立了胚系非编码变异与ccRCC线粒体代谢重编程之间的机制联系,并确定靶向氧化磷酸化作为精准治疗的潜在途径。
Posterior Fossa A (PFA) is the most frequent and clinically aggressive ependymoma (EPN) subgroup, with relapse typically representing a terminal event despite intensive multimodal therapy. Ultra-high-risk PFA EPNs are characterised by chromosome 6q loss (6q-) with or without chromosome 1q gain (1q +). While the molecular mechanisms driving 1q+ have been elucidated, 6q- PFA pathobiology remains poorly understood. Here, we show that loss of 6q in PFA EPN results in deletion of LATS1 (Large Tumour Suppressor Kinase 1), thereby dysregulating the Hippo signalling pathway and enhancing YAP/TEAD activity. Integrated analyses of primary and recurrent PFA EPNs, incorporating clinical, multiomic, and functional assays, were performed to define the biology and therapeutic susceptibility of 6q- PFA EPNs. Cumulative 6q loss was associated with nearly half of PFA EPN-related deaths. Copy number profiling identified the LATS1 locus as recurrently deleted across all 6q- cases, including 10/60 with partial 6q deletions. Restoration of LATS1 expression in 6q- PFA cell lines re-established protein levels and suppressed proliferation. Tumour analyses showed marked Hippo pathway disruption with elevated YAP expression and TEAD2-related transcriptional activity. TEAD2 palmitoylation inhibitor VT107, and Proteolysis Targeted Chimera (PROTAC) degrader H122, exhibited PFA 6q- selective activity in vitro. TEAD2 upregulation was further observed in a previously described undifferentiated, progenitor-like population of PFA EPN cells. In conclusion, 6q loss defines an aggressive biological subset of PFA associated with dismal outcomes. Identification of LATS1 as a recurrently lost tumour suppressor implicates Hippo pathway dysregulation as a central driver of malignancy, and we identify YAP/TEAD signalling as a potential therapeutic target.
中文摘要:后颅窝A型(PFA)是最常见且临床侵袭性最强的室管膜瘤(EPN)亚组,尽管采用强化多模式治疗,复发通常仍意味着终末事件。超高危PFA EPN以6号染色体长臂缺失(6q-)为特征,可伴或不伴1号染色体长臂获得(1q+)。驱动1q+的分子机制已得到阐明,6q- PFA的病理生物学仍认识不足。研究显示,PFA EPN中的6q缺失导致LATS1(大肿瘤抑制激酶1)缺失,使Hippo信号通路失调并增强YAP/TEAD活性。为界定6q- PFA EPN的生物学特征和治疗易感性,对原发和复发PFA EPN开展了整合分析,纳入临床、多组学和功能实验数据。累积性6q缺失与近半数PFA EPN相关死亡有关。拷贝数分析显示,所有6q-病例均存在LATS1位点反复缺失,其中10/60例为部分6q缺失。在6q- PFA细胞系中恢复LATS1表达可重建蛋白水平并抑制增殖。肿瘤分析显示Hippo通路明显紊乱,YAP表达升高,TEAD2相关转录活性增强。TEAD2棕榈酰化抑制剂VT107和蛋白降解靶向嵌合体(PROTAC)降解剂H122在体外对PFA 6q-表现出选择性活性。在先前描述的一群未分化、祖细胞样PFA EPN细胞中,还观察到TEAD2上调。结论:6q缺失界定了PFA中一个与不良结局相关的侵袭性生物学亚群。将LATS1识别为反复缺失的肿瘤抑制因子,提示Hippo通路失调是恶性进展的核心驱动因素,并确定YAP/TEAD信号可作为潜在治疗靶点。
Precise regulation of homologous recombination is essential for genome stability. Multiple helicases and translocases prevent toxic, unscheduled association of the Rad51 recombinase with chromatin, and their levels are frequently dysregulated in cancer. It remains unclear how anti-recombinogenic enzymes act on distinct pools of Rad51. Using Schizosaccharomyces pombe, we show that the Srs2 helicase and Rrp1 translocase may target distinct Rad51 species through recombinase substrate specificity and activity control. Genetic analyses support a model in which Srs2 may preferentially regulate Rad52-dependent Rad51 nucleofilaments associated with single-stranded DNA (ssDNA), whereas Rrp1 may preferentially regulate a distinct Rad51 population associated with double-stranded DNA. Accordingly, Rrp1 can alleviate the toxicity caused by Rad51 overproduction, a function not shared by Srs2. Unexpectedly, both loss and overproduction of Srs2 promote Rad51 accumulation, suggesting that excessive helicase levels may generate ssDNA substrates that promote Rad51 nucleation. Both Srs2 and Rrp1 fail to remove strand-exchange-deficient Rad51 from DNA. Both enzymes restrict Rad51 occupancy at centromeric regions, whereas only Srs2 acts within ribosomal DNA (rDNA) repeats, revealing locus-specific regulation. Our findings support a model in which anti-recombinogenic enzymes differentially regulate Rad51 according to its DNA substrate, thereby contributing to a regulatory system that balances Rad51 functions during DNA repair across different genomic regions.
中文摘要:同源重组的精确调控对基因组稳定性至关重要。多种解旋酶和转位酶阻止Rad51重组酶与染色质发生有毒的、非计划性的结合,它们的水平在癌症中常出现失调。抗重组酶如何作用于不同的Rad51库仍不清楚。利用粟酒裂殖酵母,我们发现Srs2解旋酶和Rrp1转位酶可能通过重组酶底物特异性和活性控制靶向不同的Rad51形式。遗传学分析支持一个模型:Srs2可能优先调控与单链DNA(ssDNA)相关的、依赖Rad52的Rad51核蛋白丝,而Rrp1可能优先调控与双链DNA相关的另一Rad51群体。据此,Rrp1能够缓解Rad51过量产生造成的毒性,而Srs2不具备这一功能。出乎意料的是,Srs2的缺失和过量产生都会促进Rad51积累,提示过高的解旋酶水平可能产生促进Rad51成核的ssDNA底物。Srs2和Rrp1均不能将链交换缺陷的Rad51从DNA上移除。两种酶都限制Rad51在着丝粒区域的占据,但只有Srs2作用于核糖体DNA(rDNA)重复序列内,揭示位点特异性调控。我们的发现支持一个模型:抗重组酶根据Rad51的DNA底物对其差异调控,从而构成一个在基因组不同区域的DNA修复过程中平衡Rad51功能的调控系统。
The promyelocytic leukemia protein (PML) is a stress-response factor that assembles into PML nuclear bodies, dynamic subnuclear compartments involved in tumor suppression and antiviral defense. The most abundant isoform, PML-1, has been linked to transcriptional regulation, genome stability, and antiviral responses, yet the molecular basis of these functions remains unclear and is generally attributed to proteins associated with PML nuclear bodies. Here, we report that PML-1 itself harbors a previously structurally uncharacterized nucleic acid-binding domain. The domain, termed PXL, is encoded by exon 9 of the PML gene and is unique to isoform 1. Its structure reveals an exonuclease III fold, but lacks the catalytic residues required for activity, defining PXL as a pseudo-exonuclease. Biochemical, structural, mutational, and cellular analyses demonstrate that PXL specifically binds G-rich oligonucleotides implicated in G-quadruplex formation and displays a strong in vitro preference for polyUG RNA. Furthermore, deletion of the PXL domain significantly decreases PML colocalization with G-quadruplexes in cells, downregulates genomic maintenance pathways, and modulates the expression of E2F target and interferon-α response genes. These findings provide a molecular basis for previous observations implicating PML in nucleic acid-associated functions and establish a mechanistic framework for future studies of PML-mediated stress responses, nuclear organization, and gene regulation.
中文摘要:早幼粒细胞白血病蛋白(PML)是一种应激反应因子,可组装成PML核体,这些动态的核内区室参与肿瘤抑制和抗病毒防御。最丰富的亚型PML-1与转录调控、基因组稳定性和抗病毒反应有关,但这些功能的分子基础仍不清楚,通常归因于与PML核体相关的蛋白。我们发现,PML-1本身含有一个此前未在结构上表征的核酸结合结构域。该结构域称为PXL,由PML基因第9外显子编码,为亚型1所特有。其结构呈现核酸外切酶III折叠,但缺少活性所需的催化残基,因此PXL被定义为假核酸外切酶。生化、结构、突变和细胞分析表明,PXL特异性结合与G四链体形成相关的富含G的寡核苷酸,并在体外对polyUG RNA表现出强烈偏好。删除PXL结构域后,细胞中PML与G四链体的共定位显著降低,基因组维持通路下调,E2F靶基因和干扰素-α反应基因的表达受到调节。这些发现为先前将PML与核酸相关功能联系起来的观察提供了分子基础,并为未来研究PML介导的应激反应、核组织和基因调控建立了机制框架。
CUE domain-containing 2 (CUEDC2) regulates ubiquitin-mediated protein turnover, cell-cycle progression, and inflammatory signaling, but its role in diffuse large B-cell lymphoma (DLBCL) remains unclear. DLBCL is the most common aggressive non-Hodgkin lymphoma, and a substantial proportion of patients develop relapsed or refractory disease. Here, by integrating clinical bioinformatics, immunohistochemistry, and functional studies in DLBCL cell lines, we demonstrate that CUEDC2 is overexpressed in DLBCL and is associated with advanced disease stage and poor prognosis. Mechanistically, proteomic and ubiquitination analyses revealed that CUEDC2 interacts with the protein phosphatase 2A (PP2A) regulatory subunit B55 and promotes its ubiquitination-associated proteasomal degradation, accompanied by activation of NF-κB and mTOR signaling. Rescue studies support the role of PP2A-B55 as a downstream effector contributing to CUEDC2-associated proliferation and chemoresistance, and isoform-specific experiments identify PP2A-B55β as a preferentially regulated isoform. In addition, CUEDC2 knockdown in macrophages promoted M1-like polarization, enhanced phagocytosis, and supported CD8+ T cell activation and lymphoma cell apoptosis in vitro, without a detectable change in PP2A-B55 protein abundance. These immune effects were accompanied by changes in cellular metabolism and histone lactylation, although their causal relationships remain unresolved. Together, these findings support a tumor cell-intrinsic CUEDC2-PP2A-B55β-NF-κB/mTOR axis in DLBCL and suggest a potentially distinct immunomodulatory role for CUEDC2. Further mechanistic studies and in vivo validation are required to establish its therapeutic potential.
中文摘要:含CUE结构域蛋白2(CUEDC2)参与调控泛素介导的蛋白周转、细胞周期进程和炎症信号,但其在弥漫大B细胞淋巴瘤(DLBCL)中的作用尚不清楚。DLBCL是最常见的侵袭性非霍奇金淋巴瘤,相当一部分患者会出现复发或难治性疾病。通过整合临床生物信息学、免疫组化和DLBCL细胞系功能研究,发现CUEDC2在DLBCL中高表达,并与疾病晚期和不良预后相关。机制上,蛋白质组学和泛素化分析显示CUEDC2与蛋白磷酸酶2A(PP2A)调节亚基B55相互作用,促进其泛素化相关的蛋白酶体降解,并伴随NF-κB和mTOR信号激活。挽救实验支持PP2A-B55作为下游效应分子参与CUEDC2相关的增殖和化疗耐药,亚型特异性实验鉴定PP2A-B55β为优先受调控的亚型。在巨噬细胞中敲低CUEDC2可促进M1样极化、增强吞噬作用,并在体外支持CD8+ T细胞活化和淋巴瘤细胞凋亡,而未检测到PP2A-B55蛋白丰度变化。这些免疫效应伴随细胞代谢和组蛋白乳酸化改变,但其因果关系尚未明确。这些结果支持DLBCL中存在肿瘤细胞内在的CUEDC2-PP2A-B55β-NF-κB/mTOR轴,并提示CUEDC2可能具有不同的免疫调节作用。仍需进一步机制研究和体内验证以确定其治疗潜力。
Human embryonic stem cell (hESC)- or induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells serve as promising adoptive cell therapies for cancer patients and as valuable models for studying the regulation of human NK cell development and effector functions. In this study, we used shRNA to knock down the expression of FTO in hESCs and differentiated these cells into NK cells to explore the role of FTO in regulating human NK cell development and effector functions. Our data revealed that the FTO knockdown in hESCs resulted in a comparable effect on haematopoietic progenitor cell generation but significantly impaired CD45⁺CD56⁺ NK cell production, which might be attributed to impaired proliferation, as indicated by reduced Ki-67 expression. Functional assays demonstrated that FTO knockdown in hESC-NK cells effectively increased per-cell cytotoxicity, including the expression of perforin, granzyme B, and IFN-γ, and increased degranulation (as indicated by the CD107a level). Integrated MeRIP-seq and RNA-seq analyses identified ADAMTS1 and ZAP70 as key target genes of FTO, demonstrating that FTO knockdown increased m⁶A methylation near the 3'UTR regions of ADAMTS1 and ZAP70 mRNAs and upregulated their transcript levels. ADAMTS1 is a known proliferation inhibitor, whereas increased ZAP70 expression is accompanied by increased phosphorylation of ERK1/2, a downstream component of ZAP70 signalling cascades, which positively regulates the effector functions of NK cells. Overall, our results demonstrate that FTO maintains human NK cell proliferation but restricts their per-cell effector functions, possibly through regulating the m⁶A methylation of ADAMTS1 and ZAP70 mRNAs. Exploring methods to achieve stage-specific FTO knockdown in mature NK cells may provide a potential strategy to optimize hESC-NK cell-based immunotherapy.
中文摘要:人胚胎干细胞(hESC)或诱导多能干细胞(iPSC)来源的自然杀伤(NK)细胞可作为癌症患者有前景的过继细胞疗法,也是研究人NK细胞发育与效应功能调控的重要模型。本工作用shRNA敲低hESC中FTO表达,并将这些细胞分化为NK细胞,以探讨FTO在人NK细胞发育和效应功能调控中的作用。数据显示,hESC中FTO敲低对造血祖细胞生成的影响与对照相当,但显著降低CD45⁺CD56⁺ NK细胞产量,这可能源于增殖受损,表现为Ki-67表达下降。功能实验显示,hESC-NK细胞中FTO敲低有效提高了每个NK细胞的细胞毒性,包括穿孔素、颗粒酶B和IFN-γ表达升高,以及CD107a水平反映的脱颗粒增强。整合MeRIP-seq和RNA-seq分析确定ADAMTS1和ZAP70为FTO的关键靶基因,FTO敲低增加了ADAMTS1和ZAP70 mRNA 3'UTR附近区域的m⁶A甲基化并上调其转录本水平。ADAMTS1是已知的增殖抑制因子,ZAP70表达升高伴随ERK1/2磷酸化增加,ERK1/2是ZAP70信号级联的下游组分,正向调控NK细胞效应功能。这些结果说明,FTO维持人NK细胞增殖但限制其单细胞效应功能,可能通过调控ADAMTS1和ZAP70 mRNA的m⁶A甲基化实现。探索在成熟NK细胞中实现阶段特异性FTO敲低的方法,可能为优化基于hESC-NK细胞的免疫治疗提供策略。
Accurate prediction of T cell receptor (TCR) reactivity is a long-standing goal in immunology. Here, we asked whether functional validation of TCR-peptide-major histocompatibility complex (MHC) (TCR-pMHC) pairs at scale alters performance estimates of TCR-pMHC reactivity prediction models. We developed a TCR rapid assembly platform (T-RAP) that allowed the generation of large and uniform TCR libraries. T-RAP enabled evaluation of TCR signaling or MHC multimer binding of thousands of previously reported TCR-pMHC pairs under standardized conditions. In this setting of systematic standardized evaluation, only ∼50% of these TCRs showed the previously reported TCR reactivity. Notably, AlphaFold3 structural predictions showed good performance in identifying reactive TCR-pMHC pairs within the set of TCRs that experimentally validated without any task-specific training. AlphaFold3 structural predictions could likewise be used to shortlist TCRs reactive to patient-specific cancer neoantigens. In silico prediction of TCR-pMHC reactivity thus has greater feasibility than previously assumed, with implications for basic research and clinical application.
中文摘要:准确预测T细胞受体(TCR)反应性一直是免疫学的长期目标。我们在此提出,规模化开展TCR-肽-主要组织相容性复合体(MHC)(TCR-pMHC)配对的功能验证是否会改变TCR-pMHC反应性预测模型的性能估计。我们开发了TCR快速组装平台(T-RAP),可生成大规模且均一的TCR文库。T-RAP能够在标准化条件下评估数千个既往报道的TCR-pMHC配对的TCR信号或MHC多聚体结合。在这一系统标准化评估中,这些TCR中仅有约50%显示出既往报道的TCR反应性。AlphaFold3结构预测在未经任何任务特异性训练的情况下,于实验验证的TCR集合中识别反应性TCR-pMHC配对表现良好。AlphaFold3结构预测同样可用于筛选对患者特异性肿瘤新抗原有反应的TCR。TCR-pMHC反应性的计算预测可行性高于此前假设,这对基础研究和临床应用均有意义。
TP53 mutations occur early in malignant transformation as truncal events in tumor evolution and are therefore generally present in all descendant tumor cells, creating an immunological vulnerability. Here, we examined the immunogenicity and antigenicity of p53 neoantigens emerging from these truncal mutations. Comprehensive immunopeptidomics revealed that hotspot mutations in human tumors preferentially localize to p53 regions resistant to antigen processing, thereby avoiding display altogether. Moreover, for neoantigens presentable by HLA-A∗02:01 or HLA-B∗07:02 and structurally divergent from corresponding wild-type p53 peptide-HLA complexes, clinical tumors commonly lacked the relevant presenting HLA allele. Tumor cells further resisted T cell killing through increased activity of the aminopeptidase ERAP1, preventing display of high-affinity HLA-A∗02:01 complexes containing an immunogenic p53I195F-derived 11-mer, or by expressing low-affinity HLA-A∗02:01 complexes containing a p53R175H-derived 9-mer with poor antigenicity despite high-quality human TCRs. These findings define mechanisms by which tumors restrict targetable truncal neoantigen display and suggest immunopeptidome shift strategies to circumvent immune escape.
中文摘要:TP53突变在恶性转化早期即以肿瘤演化中的主干事件出现,因此通常存在于所有后代肿瘤细胞中,形成免疫脆弱性。我们检测了这些主干突变产生的p53新抗原的免疫原性与抗原性。综合免疫肽组学显示,人类肿瘤中的热点突变优先位于抵抗抗原加工的p53区域,从而完全逃避展示。对于可由HLA-A*02:01或HLA-B*07:02呈递、且与相应野生型p53肽-HLA复合物结构差异明显的新抗原,临床肿瘤常缺乏相关呈递HLA等位基因。肿瘤细胞还通过氨肽酶ERAP1活性升高来抵抗T细胞杀伤,阻止含免疫原性p53I195F来源11肽的高亲和力HLA-A*02:01复合物展示;或表达含p53R175H来源9肽的低亲和力HLA-A*02:01复合物,该9肽抗原性差,即便存在高质量人源TCR。这些发现明确了肿瘤限制可靶向主干新抗原展示的机制,并提出通过免疫肽组偏移策略绕过免疫逃逸。
Region-specific dysregulation of glutathione (GSH) reflects neuropsychiatric disorders and tumor progression. Microscale precision sampling combined with timely monitoring of GSH provides region-specific molecular information that may aid in disease diagnosis. To enable minimally invasive brain-compatible intraoperative detection of GSH within a limited surgical time window, we designed a 5 mm × 5 mm on-surface microneedle nanozyme sensing platform by adopting a seed-mediated sacrificial template method. The peroxidase (POD)-like nanozyme Prussian blue (PB) probe was grown in situ on a sacrificial ZIF-67 nanotemplate, which was first anchored to the microneedle surface via in situ nucleation to prevent probe detachment in tissue. The dense PB coating substantially increases the immobilization efficiency of GSH aptamers, enabling selective in situ sampling and accumulation of GSH on the nanozyme. This creates a redox antagonistic effect between PB and GSH, which enables the platform to exhibit high selectivity toward GSH over common redox-active interferents. The quantitative concentration range of 271.3-900 μM (R2 > 0.99) for GSH is demonstrated in a simulated gelatinous tissue, and GSH levels in brain interstitial fluid could be distinguished within 20 min. Less biopsy tissue and shorter analysis time may help minimize tissue damage and could provide timely intraoperative molecular information, potentially complementing histopathology.
中文摘要:谷胱甘肽(GSH)的区域特异性失调反映神经精神疾病和肿瘤进展。微尺度精准采样结合GSH的及时监测可提供区域特异性分子信息,可能有助于疾病诊断。为在有限手术时间窗内实现微创、脑兼容的术中GSH检测,我们采用种子介导的牺牲模板法设计了5 mm × 5 mm的表面微针纳米酶传感平台。具有类过氧化物酶(POD)活性的纳米酶普鲁士蓝(PB)探针在牺牲性ZIF-67纳米模板上原位生长,该模板先通过原位成核锚定在微针表面,以防止探针在组织中脱落。致密PB涂层大幅提高GSH适配体的固定效率,使GSH能够在纳米酶上选择性原位采样并富集。这在PB与GSH之间形成氧化还原拮抗效应,使平台对GSH相对于常见氧化还原活性干扰物表现出高选择性。在模拟凝胶组织中展示了GSH的定量浓度范围271.3-900 μM(R2 > 0.99),并可在20 min内区分脑间质液中的GSH水平。更少的活检组织和更短的分析时间可能有助于减少组织损伤,并可提供及时的术中分子信息,可能补充组织病理学。
The mechanisms underlying renal cell carcinoma (RCC) progression remain incompletely understood. Here, we identify phytanoyl-CoA dioxygenase domain containing 1 (PHYHD1) as a tumor suppressor that regulates translational homeostasis and RCC progression. Progressive PHYHD1 loss promotes tumor advancement and predicts poor prognosis, as revealed by integrative deep learning analysis of pan-cancer datasets. Restoring PHYHD1 suppresses tumor growth in RCC cell and patient-derived xenograft (PDX) models independently of its dioxygenase activity. Mechanistically, PHYHD1 interacts with translation elongation factor eEF1A1, alters its association with ribosomes, and restrains protein translation. Ribosome profiling and RNA-seq identify ceramide transporter 1 (CERT1) as a key effector of the PHYHD1-eEF1A1 axis. PHYHD1 depletion enhances CERT1 translation, whereas targeting CERT1 impairs proliferation of PHYHD1-deficient cells. These findings define a PHYHD1-eEF1A1-CERT1 axis that controls translation during RCC progression and highlight CERT1 as a potential therapeutic target in PHYHD1-deficient tumors.
中文摘要:肾细胞癌(RCC)进展的机制仍未完全阐明。我们确定含植烷酰辅酶A双加氧酶结构域1(PHYHD1)是一个调控翻译稳态和RCC进展的抑癌因子。对泛癌数据集的整合深度学习分析显示,PHYHD1进行性缺失促进肿瘤进展并预示不良预后。恢复PHYHD1可在RCC细胞和患者来源异种移植(PDX)模型中抑制肿瘤生长,且不依赖其双加氧酶活性。机制上,PHYHD1与翻译延伸因子eEF1A1相互作用,改变其与核糖体的结合,并抑制蛋白质翻译。核糖体图谱和RNA测序鉴定神经酰胺转运蛋白1(CERT1)为PHYHD1-eEF1A1轴的关键效应因子。PHYHD1缺失增强CERT1翻译,而靶向CERT1削弱PHYHD1缺陷细胞的增殖。这些发现定义了一个在RCC进展中控制翻译的PHYHD1-eEF1A1-CERT1轴,并提示CERT1是PHYHD1缺陷肿瘤的潜在治疗靶点。
Exercise delivers a wide variety of health benefits through many mechanisms, including the release of exerkines, signaling molecules secreted by multiple tissues during physical activity. We evaluated 34 exerkines with therapeutic potential alongside IC7Fc (an engineered IL-6/CNTF derivative), classifying them based on (a) their translational readiness as therapeutics and (b) their primary clinical domains (cardiovascular, metabolic, neurological, musculoskeletal, anti-inflammatory, and oncology). Only four have clear clinical validation, and nine others have reached clinical testing or late preclinical development. Across these molecular entities, three challenges emerge: context-dependent effects, drug-delivery constraints, and network dynamics. We conclude with an assessment of opportunities and strategies for the creation of exerkine-based biomarkers and for using exerkines to facilitate therapeutic discovery. Finally, we present the Exerkine Atlas (https://exerkineatlas.org/), an open-access web resource integrating curated literature and clinical trial data for all 35 molecules.
中文摘要:运动通过多种机制带来广泛的健康获益,其中包括运动因子的释放;运动因子是身体活动时由多种组织分泌的信号分子。我们评估了34种具有治疗潜力的运动因子以及IC7Fc(一种经工程改造的IL-6/CNTF衍生物),并依据两方面对其进行分类:(a)作为治疗药物的转化成熟度;(b)其主要临床领域(心血管、代谢、神经、肌肉骨骼、抗炎和肿瘤)。其中仅4种具有明确的临床验证,另有9种已进入临床试验或后期临床前开发。在这些分子实体中浮现出三项挑战:效应依赖情境、药物递送限制以及网络动力学。最后,我们评估了创建基于运动因子的生物标志物以及利用运动因子促进治疗发现的机会与策略,并介绍了Exerkine Atlas(https://exerkineatlas.org/),这是一个开放获取的网络资源,整合了全部35种分子的精选文献与临床试验数据。
Circadian rhythms organize mammalian physiology across the 24-h day through molecular clocks coordinated by the central clock in the suprachiasmatic nucleus and distributed to peripheral oscillators. These clocks regulate processes central to pharmacology, including drug absorption, distribution, metabolism, elimination, and target responsiveness. Consequently, drug efficacy and toxicity can vary substantially depending on the time of administration. Despite decades of progress in pharmacogenomics and systems pharmacology, consideration of time of day remains largely absent from clinical drug development and prescription. In this review, we evaluate emerging research on circadian regulation of drug responses, considering both pharmacokinetics and pharmacodynamics. We review chronotherapeutic strategies to treat diseases, including cancer, cardiovascular disease, and bipolar disorder. We also discuss the use of wearable technologies to enable time-resolved drug evaluation. Finally, we discuss the challenges to clinical translation and the integration of circadian timing into precision medicine and optimized dosing strategies.
中文摘要:昼夜节律通过视交叉上核中枢时钟协调、并分布到外周振荡器的分子时钟,在24小时周期内组织哺乳动物生理。这些时钟调控药理学核心过程,包括药物吸收、分布、代谢、消除和靶点反应性。因此,药物疗效和毒性可随给药时间而显著变化。尽管药物基因组学和系统药理学已有数十年进展,临床药物开发和处方仍基本未考虑一天中的给药时间。本综述评估昼夜节律调控药物反应的新兴研究,兼顾药代动力学和药效学。我们回顾治疗癌症、心血管疾病和双相情感障碍等疾病的时间治疗策略,也讨论利用可穿戴技术实现时间分辨的药物评估。最后,我们讨论临床转化的挑战,以及将昼夜节律时机整合进精准医学和优化给药策略的问题。
In this issue of Blood Cancer Discovery, Corona, Gillmor, and colleagues show that quantitative CD19 density measured before chimeric antigen receptor (CAR) T-cell infusion stratifies progression-free survival in large B-cell lymphoma, yet low antigen density rarely reflects a genetic lesion at the CD19 locus itself, suggesting that other mechanisms of CD19 downregulation may promote CAR T-cell escape. Moreover, Newsam and colleagues offer one explanation-recurrent del(3p21.31)/RHOA loss that results in decreased CD19 in trans and impairs CAR T-cell efficacy. See related article by Corona, Gillmor, and colleagues, p. XX . See related article by Newsam and colleagues, p. XX .
中文摘要:在本期 Blood Cancer Discovery 中,Corona、Gillmor 及其同事显示,在嵌合抗原受体(CAR)T细胞输注前测得的CD19定量密度可对大B细胞淋巴瘤的无进展生存进行分层,但低抗原密度很少反映CD19位点本身的遗传学病变,提示CD19下调的其他机制可能促进CAR T细胞逃逸。Newsam及其同事则提供了一种解释:复发性del(3p21.31)/RHOA缺失导致反式CD19降低,并削弱CAR T细胞疗效。参见Corona、Gillmor及其同事的相关文章,第XX页。参见Newsam及其同事的相关文章,第XX页。
Pulmonary nodules are highly prevalent in adult human populations, with a substantial proportion representing dormant cancerous lesions. We hypothesized that these pulmonary dormant cancers debilitate in growth owing to the lack of an angiogenic switch in tumors. In this study, we comprehensively investigated the hypothesis that specific pathological triggers can activate this angiogenic switch utilizing severe acute respiratory coronavirus 2 (SARS-CoV-2) infection-induced hypoxia as a primary physiological stimulus. Our findings provide compelling experimental evidence demonstrating that SARS-CoV-2 infection induces profound pulmonary hypoxia and severe tissue inflammation in animal models. This microenvironmental disruption markedly upregulates the expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR2) within lung tissues. The resulting hyperactivation of the downstream VEGF-VEGFR2 signaling pathway effectively drives robust pulmonary neovascularization, a phenomenon frequently documented in clinical observations of COVID-19 patients. Furthermore, employing an established experimental tumor model, we demonstrated that SARS-CoV-2 infection directly accelerates tumor outgrowth via this specific VEGF angiogenesis-dependent cascade. Crucially, the targeted administration of a neutralizing antibody to block VEGF significantly suppressed tumor progression and outgrowth in SARS-CoV-2-infected, tumor-bearing animals. Our data show that the COVID-19-induced hypoxia-VEGF-angiogenesis axis serves as one of the mechanisms for initiating tumor outgrowth in pulmonary tissues.
中文摘要:肺部结节在成人人群中非常普遍,其中相当一部分为休眠的癌性病变。我们假设这些肺部休眠癌因肿瘤缺乏血管生成开关而生长受限。本研究利用严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染诱导的缺氧作为主要生理刺激,系统检验了特定病理触发因素可激活该血管生成开关的假说。研究结果提供了有力的实验证据,显示SARS-CoV-2感染在动物模型中引起显著的肺缺氧和严重组织炎症。这种微环境紊乱明显上调肺组织内血管内皮生长因子(VEGF)和血管内皮生长因子受体2(VEGFR2)的表达。由此导致的下游VEGF-VEGFR2信号通路过度激活有效驱动强烈的肺新生血管形成,这一现象在COVID-19患者的临床观察中常有记录。进一步采用已建立的实验性肿瘤模型,我们证明SARS-CoV-2感染通过这一特定的VEGF血管生成依赖级联直接加速肿瘤生长。关键的是,给予中和抗体阻断VEGF可显著抑制SARS-CoV-2感染荷瘤动物的肿瘤进展和生长。数据表明,COVID-19诱导的缺氧-VEGF-血管生成轴是启动肺组织肿瘤生长的机制之一。
In this issue of Cancer Cell, García-Gómez et al. show that brain-seeding cancer cells exploit an MXD4-dependent proliferative pause that enables survival under stress before metastatic outgrowth. By restraining MYC and activating protective stress responses, this pause becomes an Achilles' heel, potentially targetable to eradicate micrometastases before clinical relapse.
中文摘要:本期 Cancer Cell 中,García-Gómez 等表明,播散至脑的癌细胞利用一种依赖 MXD4 的增殖暂停,在应激下存活,直至转移灶生长。通过抑制 MYC 并激活保护性应激反应,这一暂停成为「阿喀琉斯之踵」,有望在临床复发前靶向清除微转移灶。
Successful metastatic colonization requires cancer cells to survive multiple stresses during early organ adaptation, yet how metastasis-initiating cells overcome this bottleneck remains unknown. Here, we identify a transient MXD4-dependent proliferative pause that enables aggressive cancer cells to survive early brain colonization. Before vascular co-option-associated outgrowth, metastatic cells temporarily restrain proliferation through the MYC antagonist MXD4, buffering stresses encountered after extravasation. Genetic disruption of MXD4 compromises survival of micrometastases, preventing their progression to macrometastases. Analyses of human brain micrometastases validate this transient adaptive state in patients. Exploiting vulnerabilities associated with the proliferative pause reveals preventive therapeutic opportunities across experimental settings, including spontaneous brain metastasis models and minimal residual disease following neurosurgical resection. In addition, patient-derived organotypic cultures confirm the feasibility of targeting this state with clinically available drugs. These findings uncover a previously unrecognized adaptive stage during metastatic colonization and identify actionable vulnerabilities to prevent brain metastasis progression and relapse.
中文摘要:成功的转移定植需要癌细胞在早期器官适应过程中经受多种应激而存活,但转移起始细胞如何克服这一瓶颈仍不清楚。本研究识别出一种短暂的、依赖MXD4的增殖暂停,使侵袭性癌细胞得以在早期脑定植中存活。在与血管共选相关的生长之前,转移细胞通过MYC拮抗因子MXD4暂时抑制增殖,从而缓冲外渗后遇到的应激。遗传性破坏MXD4会损害微转移灶的存活,阻止其进展为大转移灶。对人脑微转移灶的分析在患者中验证了这种短暂适应状态。利用与增殖暂停相关的脆弱性,在多种实验环境中揭示了预防性治疗机会,包括自发性脑转移模型和神经外科切除后的微小残留病。患者来源的器官型培养证实了用临床可用药物靶向该状态的可行性。这些发现揭示了一个此前未被认识的转移定植适应阶段,并确定了可操作的脆弱性,以预防脑转移进展和复发。
Chimeric antigen receptor (CAR) T cell therapy has shown promising activity in solid tumors, yet translational progress remains limited by preclinical models that incompletely capture human tumor biology. Patient-derived organoids (PDOs) preserve key features of human tumors, including cellular heterogeneity and tissue architecture, thereby enabling functional evaluation of CAR T cell targets, next-generation approaches, resistance mechanisms, and selected safety considerations. We discuss how PDOs complement existing preclinical platforms to support CAR T cell development for solid tumors.
中文摘要:嵌合抗原受体(CAR)T细胞疗法在实体瘤中已显示出有希望的活性,但现有临床前模型无法完整再现人类肿瘤生物学特征,限制了其转化进展。患者来源类器官(PDO)保留了人类肿瘤的关键特征,包括细胞异质性与组织结构,因而可用于对CAR T细胞靶点、新一代设计方案、耐药机制以及部分安全性考量的功能性评估。本文讨论PDO如何与现有临床前平台互补,以支持实体瘤CAR T细胞疗法的开发。
Interpreting the biological and clinical significance of somatic mutations in cancer genomes remains challenging. In this issue of Cancer Cell, Hyeon et al. identify and map significantly mutated regions to protein domains and structural features, establishing a proteo-genomics framework for interpreting cancer mutations beyond genes and hotspots.
中文摘要:解读癌症基因组中体细胞突变的生物学和临床意义仍具挑战。在本期 Cancer Cell 中,Hyeon 等识别显著突变区域并将其定位到蛋白质结构域和结构特征,建立了一个超越基因和热点、用于解读癌症突变的蛋白质基因组学框架。
Predicting drug efficacy across diverse patient contexts remains a major challenge in oncology, as models trained on cancer cell lines often fail to capture patient-specific biology. Emerging biological foundation models and patient-derived technologies offer a promising solution. Here, we present UniCure, a multi-modal model that combines biological and chemical foundation models to predict drug-induced transcriptomic responses across diverse cell and tissue contexts, enabling individualized drug ranking. Trained on 1.9 million transcriptomic perturbation profiles spanning >22,000 compounds, 166 cell types, and 24 tissues, UniCure accurately predicts dose-dependent and combination responses and generalizes across bulk and single-cell data. We further fine-tune UniCure on 345 patient-derived tumor-like cluster (PTC) transcriptomic profiles and validate performance on 396 real-world clinical profiles, demonstrating effective patient-level prediction. The model supports response-based patient stratification and is experimentally validated in cell line and patient-derived models. Overall, UniCure provides a practical framework for translating preclinical data into personalized therapeutic strategies.
中文摘要:在肿瘤学中,跨不同患者情境预测药物疗效仍是一项主要挑战,因为基于癌细胞系训练的模型往往无法捕捉患者特异性生物学特征。新兴的生物学基础模型与患者来源技术提供了有希望的解决路径。这里提出 UniCure,一种多模态模型,将生物学基础模型与化学基础模型结合,用于预测不同细胞和组织情境下药物诱导的转录组反应,从而实现个体化药物排序。UniCure 在覆盖超过22,000种化合物、166种细胞类型和24种组织的190万条转录组扰动谱上训练,能够准确预测剂量依赖性和联合用药反应,并在 bulk 与单细胞数据间泛化。我们进一步在345例患者来源肿瘤样簇(PTC)转录组谱上微调 UniCure,并在396例真实世界临床谱上验证性能,显示出有效的患者层面预测能力。该模型支持基于反应的患者分层,并在细胞系和患者来源模型中得到实验验证。UniCure 为将临床前数据转化为个体化治疗策略提供了实用框架。
In Cell Press Blue, Carvalho et al. identify spatially organized tumor-macrophage niches, EMT-like CD44high cancer cells paired with SPP1/PARP14high macrophages, that drive chemoresistance in bladder cancer. PARP14 inhibition can flip this protective niche into an inflammatory, cisplatin-sensitizing state.
中文摘要:在 Cell Press Blue 中,Carvalho 等识别出空间组织化的肿瘤-巨噬细胞生态位,即 EMT 样 CD44 高表达癌细胞与 SPP1/PARP14 高表达巨噬细胞配对,这类生态位驱动膀胱癌的化疗耐药。抑制 PARP14 可将这一保护性生态位转变为炎症性、对顺铂敏感的状态。
Disposal of radioactive waste containing hazardous chemicals can generate post-closure radiological cancer risks, chemical cancer risks, and chemical non-cancer hazards. Existing assessments often treat radiological and chemical endpoints separately. This study develops an integrated post-closure assessment and screening framework that combines United States Environmental Protection Agency risk methods with AMBER dynamic compartment modeling, using the International Atomic Energy Agency Trench Case as a reference disposal system. A normalized generic assessment of selected metallic elements was used to compare radiological and chemical risk behavior and derive two endpoint-specific screening metrics: a critical radioactivity concentration for identifying when chemical cancer risk is small relative to radiological cancer risk, and a preliminary non-cancer trigger based on maximum leachate concentration relative to the drinking-water standard. A case-study application using documented mixed-waste inventory data from nuclear facilities evaluated complex waste types with associated radionuclides under normal-evolution and human-intrusion scenarios. Several cases triggered total cancer risk screening criteria under human intrusion, indicating the need for detailed assessment. The results are reference-scenario screening outcomes, not site-specific predictions. The framework supports prioritization of radioactive mixed waste for constituent-specific, pathway-specific, and site-specific assessment. This structure links time-dependent transport outputs with endpoint-specific decisions for waste management and regulation.
中文摘要:含危险化学品的放射性废物的处置可能在关闭后产生放射性癌症风险、化学癌症风险和化学非癌症危害。现有评估常将放射学终点与化学终点分开处理。本研究建立了一个关闭后综合评估与筛选框架,将美国环境保护署的风险方法与AMBER动态隔室模型相结合,并以国际原子能机构的沟槽案例作为参考处置系统。对选定金属元素进行归一化通用评估,用于比较放射性与化学风险行为,并推导两个终点特定的筛选指标:一个关键放射性浓度,用于识别化学癌症风险相对于放射性癌症风险较小时的情形;一个基于最大渗滤液浓度相对于饮用水标准的初步非癌症触发值。利用核设施中已记录的混合废物清单数据进行案例研究应用,在正常演化和人类入侵情景下评估了含相关放射性核素的复杂废物类型。若干案例在人类入侵情景下触发了总癌症风险筛选标准,表明需要进行详细评估。结果是参考情景筛选结果,不是场址特定预测。该框架支持对放射性混合废物按组分、路径和场址进行详细评估的优先排序。这一结构将随时间变化的迁移输出与废物管理和监管的终点特定决策联系起来。
Foundation models (FM) have transformed computational pathology but remain computationally prohibitive for clinical deployment due to their massive parameter counts and high-magnification processing requirements. Here, we introduce XMAG, a lightweight FM developed through cross-magnification distillation that transfers knowledge from a state-of-the-art 20x magnification teacher to an efficient 5x magnification student architecture. XMAG employs a compact backbone and operates entirely at 5x, requiring 11.3 times fewer patches per whole slide image (WSI) compared to existing approaches. Our novel distillation framework incorporates dual-level knowledge transfer, aligning both global image representations and local spatial features across magnification levels through carefully designed projection heads and spatial token mapping. We trained XMAG on 3.49 million images curated from publicly available datasets and evaluated performance across seven clinically relevant histopathology analysis tasks spanning multiple cancer types. Across four WSI-level classification tasks, XMAG achieved an average AUC within 1% of substantially larger foundation models while delivering up to 29.5-fold faster encoder-level processing, corresponding to an encoder throughput of 8.8 WSIs per minute in a controlled patch-encoding benchmark. We also found that performance differences remained task-dependent, with larger gaps observed for fine-grained tasks such as ISUP grading and patch-level phenotyping. We further explore end-to-end XMAG training as a direction for task-specific adaptation of the compact model. These results suggest that cross-magnification distillation is a promising strategy for developing efficient low-magnification pathology foundation models and may support more scalable WSI analysis in computationally constrained research and translational settings.
中文摘要:基础模型改变了计算病理学,但其参数量庞大且需在高放大倍数下处理,临床部署的计算成本仍难以承受。作者提出 XMAG,一种通过跨放大倍数蒸馏得到的轻量基础模型,把 20 倍放大倍数的最先进教师模型的知识迁移到 5 倍放大倍数的高效学生架构。XMAG 采用紧凑主干网络,全程在 5 倍下运行,每张全切片图像(WSI)所需图块数比现有方法少 11.3 倍。新的蒸馏框架包含双层知识转移,通过精心设计的投影头与空间 token 映射,在不同放大倍数之间对齐全局图像表示与局部空间特征。XMAG 在来自公开数据集的 349 万张图像上训练,并在覆盖多种癌种的 7 项临床相关组织病理分析任务上评估。在 4 项 WSI 级分类任务中,XMAG 的平均 AUC 与规模大得多的基础模型相差在 1% 以内,同时编码器级处理速度最高提升 29.5 倍,在受控的图块编码基准中对应每分钟 8.8 张 WSI 的编码器吞吐。性能差异仍依任务而定,ISUP 分级与图块级表型分析等细粒度任务的差距更大。作者进一步探索了 XMAG 的端到端训练,作为紧凑模型任务特异性适配的方向。结果提示,跨放大倍数蒸馏是构建高效低倍病理基础模型的有前景策略,可能支持计算受限的研究与转化场景中更具可扩展性的 WSI 分析。
Redox biology represents a universal molecular language that encodes biochemical gradients, distinguishing healthy from diseased tissues with significant precision. The convergence of redox signaling and peptide self-assembly results in a versatile chemical framework for next-generation theranostics. Peptides, programmable, biocompatible, and hierarchically organized, can translate subtle oxidative cues into structural transitions, functional activation, and real-time diagnostic output. Redox-responsive molecular assemblies leveraging disulfide exchange, thiol oxidation, methionine sulfoxidation, and dithiane chemistry enable dynamic assembly, phase transition, or disintegration based on local redox potential. Redox dysregulation, encompassing reactive oxygen species and reactive nitrogen species imbalance, glutathione depletion, and iron-driven lipid peroxidation - governs diverse pathologies from cancer to neurodegeneration. In parallel, beyond traditional delivery platforms, redox-activated phase-separating peptides forming coacervate microdroplets have emerged as versatile drug vectors with high-capacity recruitment of nucleic acids, proteins, and small molecules, with cytosolic release triggered by glutathione. These condensate-like materials exhibit rapid and very high encapsulation efficiency, intracellular uptake, and redox-coded responsiveness. Additionally, imaging probes coupling redox-triggered bond cleavage with optical or magnetic signal activation allow real-time visualization of redox landscapes during therapy. From a translational perspective, progress is accelerated by advances in large-scale solid-phase peptide synthesis, redox-stable manufacturing workflows, and evolving regulatory frameworks. Future redox-responsive peptide coacervates are envisioned as programmable "chemical processors" that sense oxidative flux, interpret biochemical input, and deliver microenvironment-specific outputs. Such adaptive, information-rich architectures position peptide-based redox nanotheranostics as an emerging class of biomaterials capable of combining therapeutic action with the dynamic redox logic of diseases.
中文摘要:氧化还原生物学是一种通用的分子语言,以生化梯度编码信息,能够以较高精确度区分健康组织与病变组织。氧化还原信号与肽自组装的交汇形成了一个多功能的化学框架,可用于下一代诊疗一体化。肽具有可编程性、生物相容性和层级组织能力,可把细微的氧化线索转化为结构转变、功能激活和实时诊断输出。利用二硫键交换、硫醇氧化、甲硫氨酸亚磺酰化及二噻烷化学的氧化还原响应分子组装体,能够依据局部氧化还原电位实现动态组装、相变或解离。氧化还原失调涵盖活性氧与活性氮失衡、谷胱甘肽耗竭以及铁驱动的脂质过氧化,参与从癌症到神经退行性疾病的多种病理过程。除传统递送平台外,经氧化还原激活、可相分离并形成凝聚层微滴的肽已成为多功能药物载体,可高容量招募核酸、蛋白质和小分子,并由谷胱甘肽触发胞质释放。这类类凝聚体材料表现出快速且很高的包封效率、细胞内摄取以及氧化还原编码的响应性。将氧化还原触发的键断裂与光学或磁信号激活相偶联的成像探针,可在治疗过程中实时显示氧化还原景观。从转化角度看,大规模固相肽合成、氧化还原稳定的生产流程以及不断演进的监管框架正在加速相关进展。未来的氧化还原响应肽凝聚层有望成为可编程的「化学处理器」,感知氧化通量、解读生化输入并输出微环境特异性结果。此类自适应、信息丰富的结构使基于肽的氧化还原纳米诊疗体系成为一类新兴生物材料,能够把治疗作用与疾病动态氧化还原逻辑结合起来。
Transcriptomic surveys of aging tissues routinely report hundreds to thousands of differentially expressed long non-coding RNAs (lncRNAs), and the field has no agreed way of separating causal drivers from passengers that merely track the aging phenotype. I translate Sir Austin Bradford Hill's nine criteria for causal inference, formulated in 1965, into operational tests for aging-associated lncRNAs. Each criterion is recorded as 0, 1 or 2, and the per-criterion profile is the result: no sum or band decides a category. Hill offered viewpoints, not independent quantities to be added; here half of the cited studies support two or more criteria, so a total counts some evidence twice. Two axes are reported separately - molecular causal evidence, and organism-level validation (criterion 8), recorded as supportive, not evaluated, or in vivo at a non-aging endpoint - so that an animal experiment on development, reproduction, cancer or injury is not read as a negative test of aging. Applied to ten worked examples chosen to illustrate rather than to sample the field - NEAT1, MEG3, lincRNA-p21, MALAT1, MIR31HG, SALNR, TERRA, PANDAR, HOTAIR, TUG1 - the profiles separate candidates awaiting an animal experiment from those whose animal experiments addressed something else. MALAT1 is instructive: of six in-vivo perturbation studies, one assays a senescence endpoint. No candidate has an aging experiment that returned a negative result, and none reaches the top of criterion 8, which requires conditional deletion or a titrated antisense regimen with rescue. Organism-level evidence, not literature volume, is the structural bottleneck.
中文摘要:衰老组织的转录组调查常报告数百至数千个差异表达的长链非编码RNA(lncRNA),该领域尚无公认方法区分因果驱动者与仅随衰老表型变化的伴随者。将Austin Bradford Hill于1965年提出的九条因果推断标准转化为针对衰老相关lncRNA的可操作检验。每条标准记为0、1或2分,逐条标准谱即结果:不以总分或分段决定类别。Hill提供的是观点而非可独立相加的量;此处被引研究中有一半支持两条或以上标准,因此总分会使部分证据被重复计数。分别报告两个轴——分子因果证据与生物体层面验证(第8条标准),后者记为支持、未评估或在非衰老终点的体内实验,以免针对发育、生殖、癌症或损伤的动物实验被误读为对衰老的阴性检验。应用于十个示例——NEAT1、MEG3、lincRNA-p21、MALAT1、MIR31HG、SALNR、TERRA、PANDAR、HOTAIR、TUG1——这些示例用于说明而非抽样该领域;其谱系可将尚待动物实验的候选者与动物实验针对其他问题的候选者区分开。MALAT1具有启发性:六项体内扰动研究中,仅一项检测衰老终点。尚无候选者拥有返回阴性结果的衰老实验,也无候选者达到第8条标准的最高层级,该层级要求条件性敲除或带救援的滴定反义方案。结构瓶颈在于生物体层面证据,而非文献数量。
Tumor invasion and malignant transformation are spatiotemporally coordinated processes that shape clinical behavior, diagnostic classification, and treatment response. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive tumors that can arise sporadically or in people with neurofibromatosis type 1 (NF-1) yet how distinct spatial niches underlie MPNST intra-tumor heterogeneity, local invasion or malignant transformation from benign precursors are not fully understood. We integrate spatial analysis of 50,896 transcriptomes from 15 human MPNSTs with deep learning image analysis to define the interplay between genetic alterations, the immune microenvironment, and epigenetic cell fate regulation in MPNST invasion and transformation. Spatial transcriptomics reveal distinct infiltrating immune cells and immunomodulatory spatial clusters in sporadic compared to NF-1 associated MPNSTs. Local invasion is marked by spatially defined immunomodulatory and dedifferentiation programs. Analysis of two NF-1 associated MPNSTs with contiguous morphologically defined neurofibroma and MPNST components demonstrates NF-1 associated tumors identified a similar malignant transformation process associated with dynamic immune infiltration, chromosome 9p loss, and dedifferentiation concomitant with increased cell proliferation. Finally, deep learning morphology encoders were trained on spatial transcriptomic data to predict spatial transcriptomic cluster identity and chromosome 9p loss from hematoxylin and eosin stained (H&E) images although the generalizability of such encoders remains a challenge. Our data provide a spatial framework for peripheral nerve sheath tumor transformation although the limited sample size of the present cohort will require additional validation of the proposed model.
中文摘要:肿瘤侵袭和恶性转化是时空协调的过程,影响临床行为、诊断分类和治疗反应。恶性外周神经鞘瘤(MPNSTs)是侵袭性肿瘤,可散发或发生于1型神经纤维瘤病(NF-1)患者,但不同空间生态位如何构成MPNST瘤内异质性、局部侵袭或从良性前驱病变发生恶性转化的基础,尚未完全清楚。我们将15例人类MPNST的50,896个转录组的空间分析与深度学习图像分析相结合,以界定遗传改变、免疫微环境和表观遗传细胞命运调控在MPNST侵袭和转化中的相互作用。空间转录组学显示,与NF-1相关MPNST相比,散发性MPNST具有不同的浸润免疫细胞和免疫调节空间簇。局部侵袭以空间界定的免疫调节和去分化程序为标志。对两例具有相邻形态学定义的神经纤维瘤和MPNST成分的NF-1相关MPNST的分析表明,NF-1相关肿瘤识别出相似的恶性转化过程,该过程与动态免疫浸润、9p染色体缺失和去分化同时伴随细胞增殖增加有关。深度学习形态编码器在空间转录组数据上训练,以从苏木精-伊红染色(H&E)图像预测空间转录组簇身份和9p染色体缺失,尽管此类编码器的泛化性仍是挑战。我们的数据为外周神经鞘瘤转化提供了空间框架,但当前队列样本量有限,需要对所提出的模型进行额外验证。
Cuproptosis is a type of recently reported cell death characterized by aberrant accumulation of copper ions within cells, leading to mitochondrial stress and protein aggregation. Recent studies suggest that certain cancer cells are particularly susceptible to cuproptosis-inducing agents. However, the genetic determinants of cellular sensitivity to cuproptosis and the therapeutic potential of cuproptosis inducers in cancer treatment remain unclear. Here, we report the discovery of a small molecule, N1,N1-dimethyl-N4-(4-(pyridin-2-yl)thiazol-2-yl)benzene-1,4-diamine (dPTBD), that targets KRAS-driven cancer via a tetracycline-inducible cell-based drug screening. dPTBD exhibited significant antitumor efficacy in KRAS-driven cancers both in vitro and in vivo. Mechanistic studies revealed that dPTBD acted as a copper ionophore, promoting intracellular copper accumulation particularly in the mitochondria, leading to metabolic disruption and cuproptotic cell death. Adding trace amount of copper massively enhanced the cytotoxic effect of dPTBD, resulting in an immediate mitochondrial dysfunction and cuproptosis. In preclinical models, dPTBD, either alone or combined with physiologically tolerable amount of copper, significantly suppressed tumor growth in KRAS-mutant pancreatic and colon cancer xenografts. Taken together, our study reveals that induction of cuproptosis is a new therapeutic strategy for KRAS-driven cancer and identifies dPTBD as a lead compound for future development.
中文摘要:铜死亡是近年报道的一种细胞死亡方式,特征是细胞内铜离子异常积累,引起线粒体应激和蛋白聚集。已有研究提示某些癌细胞对铜死亡诱导剂特别敏感。但细胞对铜死亡的遗传决定因素以及铜死亡诱导剂在癌症治疗中的治疗潜力仍不清楚。本研究报告发现小分子N1,N1-二甲基-N4-(4-(吡啶-2-基)噻唑-2-基)苯-1,4-二胺(dPTBD),通过四环素诱导的细胞药物筛选靶向KRAS驱动癌症。dPTBD在体外和体内对KRAS驱动癌症均表现出显著抗肿瘤效果。机制研究显示dPTBD作为铜离子载体,促进细胞内铜积累,尤其在在线粒体中,导致代谢紊乱和铜死亡。加入痕量铜大幅增强dPTBD的细胞毒作用,引起即刻线粒体功能障碍和铜死亡。在临床前模型中,dPTBD单独或与生理可耐受量的铜联合,显著抑制KRAS突变胰腺癌和结肠癌异种移植瘤生长。这些结果共同表明,诱导铜死亡是KRAS驱动癌症的新治疗策略,并确定dPTBD为未来开发的先导化合物。
Here, we examined the consequences of biologically relevant vitamin D deficiency, a known risk factor for aggressive prostate cancer, using ex vivo and in vivo models. Phenotypic and single-cell RNA sequencing of mouse prostate organoids showed that vitamin D deficiency stunted luminal cell differentiation more than androgen deficiency, which is a known driver of prostate development. Mice fed a vitamin D-deficient diet showed significantly altered expression of androgen-responsive genes in their prostate luminal cells, as determined by single-cell RNA sequencing. MDA-PCa-2b and 22Rv1 human prostate cancer cells, when maintained for 6 months in 1,25-dihydroxyvitamin D, had very different responses compared to short-term treatments. Notably, the MDA-PCa-2b cells lost the ability to form xenografts, despite normal proliferation in vitro. RNA sequencing showed that these cells also had disruptions in androgen signaling and in multiple cancer-related pathways, which differed by treatment duration. This study offers new insights and validation of vitamin D's role in both benign and malignant prostate biology, underscoring its essential hormonal functions and supporting strategies for vitamin D supplementation to reduce prostate cancer risk in vulnerable populations.
中文摘要:本研究利用离体和在体模型,考察生物学相关维生素D缺乏这一已知侵袭性前列腺癌危险因素的后果。小鼠前列腺类器官的表型分析和单细胞RNA测序显示,维生素D缺乏对腔细胞分化的阻滞强于雄激素缺乏,而后者是已知的前列腺发育驱动因素。单细胞RNA测序显示,接受维生素D缺乏饮食的小鼠其前列腺腔细胞中雄激素反应基因表达显著改变。MDA-PCa-2b和22Rv1人前列腺癌细胞在1,25-二羟基维生素D中维持6个月后,与短期处理相比反应差异很大。MDA-PCa-2b细胞尽管体外增殖正常,却失去形成异种移植瘤的能力。RNA测序显示这些细胞还存在雄激素信号及多条癌症相关通路的紊乱,且随处理时长不同而变化。该研究为维生素D在良性和恶性前列腺生物学中的作用提供了新见解和验证,强调其重要激素功能,并支持对易感人群补充维生素D以降低前列腺癌风险的策略。
Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in children and adolescents and is characterized by expression of myogenic regulatory factors without terminal differentiation. Treatment of RMS remains challenging, with nearly one-third of patients experiencing relapse due to chemotherapy resistance. However, the molecular mechanisms underlying RMS growth and chemoresistance remain poorly understood. Fibroblast growth factor-inducible 14 (FN14), a receptor for the TWEAK cytokine, has been implicated in tumor progression in several cancers, but its role in RMS is unknown. Here, we demonstrate that FN14 expression is highly upregulated in human RMS samples and in the RD and RH30 RMS cell lines. Silencing FN14 reduced proliferation and survival of RMS cells. In a xenograft model, inducible FN14 knockdown transiently delayed tumor growth, supporting a functional role for FN14 in RMS growth in vivo. FN14 expression was further increased in vincristine-resistant RD cells, and FN14 knockdown suppressed the proliferation and survival of these chemoresistant cells. Mechanistic studies performed primarily in RD cells showed that FN14 promotes ERK1/2 signaling. Consistent with this finding, pharmacological inhibition of ERK1/2 reduced RD cell proliferation and survival. Furthermore, both FN14 silencing and ERK1/2 inhibition decreased mitochondrial oxidative phosphorylation in RD cells. Finally, inhibition of either FN14 or ERK1/2 promoted myogenic differentiation in parental and vincristine-resistant RD cells. Collectively, our experiments support FN14 as an important regulator of proliferation, survival, chemoresistance, and differentiation in RMS and support further investigation of FN14-mediated signaling in RMS pathogenesis.
中文摘要:横纹肌肉瘤(RMS)是儿童和青少年最常见的软组织恶性肿瘤,其特征为表达肌源性调节因子但缺乏终末分化。RMS治疗仍具挑战性,近三分之一患者因化疗耐药而复发。RMS生长和化疗耐药背后的分子机制仍不清楚。成纤维细胞生长因子诱导型14(FN14)是TWEAK细胞因子的受体,在多种癌症中与肿瘤进展相关,但其在RMS中的作用未知。本研究报告FN14在人RMS样本以及RD和RH30 RMS细胞系中高度上调。沉默FN14降低RMS细胞的增殖和存活。在异种移植模型中,可诱导的FN14敲低短暂延缓肿瘤生长,支持FN14在体内RMS生长中的功能作用。FN14表达在长春新碱耐药的RD细胞中进一步升高,FN14敲低抑制这些化疗耐药细胞的增殖和存活。主要在RD细胞中进行的机制研究表明FN14促进ERK1/2信号。与此一致,药理学抑制ERK1/2降低RD细胞增殖和存活。FN14沉默和ERK1/2抑制均降低RD细胞的线粒体氧化磷酸化。抑制FN14或ERK1/2均促进亲本和长春新碱耐药RD细胞的肌源性分化。这些实验支持FN14是RMS增殖、存活、化疗耐药和分化的重要调控因子,并支持进一步研究FN14介导的信号在RMS发病机制中的作用。
AR pathway-independent prostate cancer (ARIPC), particularly neuroendocrine prostate cancer (NEPC), represents one of the most lethal states of metastatic castration-resistant prostate cancer. However, how fatty acid synthesis (FAS) is organized in ARIPC and whether distinct lipogenic states shape neuroendocrine lineage transdifferentiation remain unclear. By integrating single-cell and bulk transcriptomic analyses of mCRPC cohorts, we identify NEPC as a fatty-acid-synthesis-low state associated with poor survival. Within this context, fatty acid synthase (FASN) emerges as a key indicator and functional contributor to lipogenic activity. FASN depletion suppresses lipogenesis while increasing NEPC-associated programs, migration, and metastatic colonization. We further identify FGFRL1 as the FGF family member most consistently associated with fatty acid synthesis activity in ARIPC. FGFRL1 depletion reduces FASN expression and relative free fatty-acid content, while targeted GC-MS supports broader fatty-acid remodeling and fluorescent uptake assays show increased exogenous fatty-acid uptake. FASN restoration partially restores relative free fatty-acid content and attenuates NEPC-associated and migratory phenotypes. Directional perturbation, rescue, AKT phosphorylation, and co-immunoprecipitation analyses further support the functional FGFRL1-FASN relationship. ONECUT2 is prioritized as a candidate downstream transcriptional regulator whose expression correlates with the neuroendocrine program. Together, these findings support an FGFRL1-FASN metabolic axis that regulates neuroendocrine lineage transdifferentiation and metastatic progression in ARIPC.
中文摘要:AR通路非依赖型前列腺癌(ARIPC),尤其是神经内分泌前列腺癌(NEPC),是转移性去势抵抗性前列腺癌中最致命的状态之一。脂肪酸合成(FAS)在ARIPC中如何组织,以及不同脂生成状态是否塑造神经内分泌谱系转分化,仍不清楚。通过整合mCRPC队列的单细胞和整体转录组分析,我们识别NEPC为与生存不良相关的脂肪酸合成低状态。在此背景下,脂肪酸合酶(FASN)成为脂生成活动的关键指标和功能贡献者。FASN耗竭抑制脂生成,同时增加NEPC相关程序、迁移和转移定植。我们进一步识别FGFRL1为ARIPC中与脂肪酸合成活性最一致相关的FGF家族成员。FGFRL1耗竭降低FASN表达和相对游离脂肪酸含量,靶向气相色谱-质谱支持更广泛的脂肪酸重塑,荧光摄取实验显示外源性脂肪酸摄取增加。FASN恢复部分恢复相对游离脂肪酸含量,并减弱NEPC相关和迁移表型。定向扰动、回补、AKT磷酸化和共免疫沉淀分析进一步支持FGFRL1-FASN的功能关系。ONECUT2被优先列为候选下游转录调节因子,其表达与神经内分泌程序相关。这些发现支持一个FGFRL1-FASN代谢轴,调控ARIPC中的神经内分泌谱系转分化和转移进展。
Extrachromosomal circular DNA (eccDNA), characterized by abundant amplicons and high chromatin accessibility, contributes to tumor heterogeneity and transcriptional activity; however, its single-cell dynamics in cutaneous squamous cell carcinoma (CSCC) remain poorly understood. Here, we developed a single-cell framework eccDNAscope that reconstructs eccDNA structures and infers clonal trajectories from scATAC-seq data. Integrative analysis of 154,624 single cells revealed that eccDNAs were broadly distributed across diverse cell types but exhibited striking enrichment at promoter regions (79.94%), where they were associated with elevated expression of cell type-specific eccDNA-associated genes. The framework identified both known oncogenic eccDNAs (MYC) and previously unrecognized eccDNAs (PTMA, NRP2, and KLF7), which were independently validated by DNA fluorescence in situ hybridization (FISH), super-resolution microscopy, Immuno-FISH, and Circle-seq. These eccDNAs displayed enhanced transcriptional activity in the epithelial cell populations in which they were detected. We further identified CSCC-specific eccDNAs that were enriched in cell cycle-related pathways, including CACYBP, which was exclusively detected in CSCC, but was not observed in actinic keratosis (AK) or para-tumor tissues. Finally, eccDNA-based phylogenetic reconstruction identified conserved and tissue-specific eccDNA programs during disease evolution, and highlighted recurrent eccDNAs, particularly PTMA and CACYBP, as potential drivers of CSCC progression. Collectively, our single-cell analysis provides a framework for dissecting eccDNA-mediated oncogenesis and offers insights into therapeutic strategies targeting eccDNA-positive clones in cancer.
中文摘要:染色体外环状DNA(eccDNA)以扩增子丰富和染色质可及性高为特征,参与肿瘤异质性和转录活性;但其在皮肤鳞状细胞癌(CSCC)中的单细胞动态仍知之甚少。我们建立了单细胞框架eccDNAscope,可从scATAC-seq数据重建eccDNA结构并推断克隆轨迹。对154,624个单细胞的整合分析显示,eccDNA广泛分布于多种细胞类型,但在启动子区域显著富集(79.94%),并与细胞类型特异性eccDNA相关基因表达升高相关。该框架识别出已知致癌eccDNA(MYC)和此前未发现的eccDNA(PTMA、NRP2和KLF7),并经DNA荧光原位杂交(FISH)、超分辨显微镜、免疫FISH和Circle-seq独立验证。这些eccDNA在检测到它们的上皮细胞群体中表现出增强的转录活性。我们进一步识别出富集于细胞周期相关通路的CSCC特异性eccDNA,包括CACYBP,后者仅在CSCC中检测到,而在光化性角化病(AK)或瘤旁组织中未观察到。最后,基于eccDNA的系统发育重建识别出疾病演化过程中保守和组织特异性的eccDNA程序,并突出反复出现的eccDNA,尤其是PTMA和CACYBP,作为CSCC进展的潜在驱动因素。这些单细胞分析为解析eccDNA介导的肿瘤发生提供了框架,并为靶向癌症中eccDNA阳性克隆的治疗策略提供了见解。
2肿瘤免疫/微环境 (77篇)
临床研究 (11篇)
Over recent years, chimeric antigen receptor T-cell (CAR-T) therapy has markedly improved outcomes for patients with relapsed or refractory hematological malignancies. Nevertheless, a substantial proportion of patients still experience relapse or progression after treatment, driven by factors including antigen escape, suboptimal CAR-T cell expansion and persistence, functional exhaustion, and remodeling of the tumor microenvironment. In the context of managing patients who fail initial CAR-T therapy, CAR-T-centered sequential therapy has been increasingly investigated as a potential therapeutic approach. The selection of therapeutic targets and treatment approaches may be informed by resistance mechanisms, changes in target antigen expression, and disease progression patterns following prior treatment, with the aim of prolonging disease control and improving long-term outcomes. This review summarizes recent progress in CAR-T-centered sequential therapy, with particular emphasis on same-target retreatment, switching to different antigens, multi-target stepwise CAR-T regimens, and the sequential integration of CAR-T with hematopoietic stem cell transplantation, radiotherapy, immune checkpoint inhibitors, and other immunomodulatory approaches. We further discuss the biological rationale and clinical settings of these CAR-T-centered sequential approaches in the context of antigen escape, CAR-T cell functional decline, tumor clonal evolution, and immune microenvironment remodeling. Additionally, we discuss factors that may inform the selection of subsequent regimens, including the initial treatment response, antigen status at relapse, CAR-T cell persistence, and the patient's therapeutic window, as well as the clinical settings in which these sequential approaches have been explored.
中文摘要:近年来,嵌合抗原受体T细胞(CAR-T)治疗显著改善了复发或难治性血液肿瘤患者的结局。但仍有相当比例的患者在治疗后出现复发或进展,其原因包括抗原逃逸、CAR-T细胞扩增与持久性不足、功能耗竭以及肿瘤微环境重塑。针对初始CAR-T治疗失败患者的处理,以CAR-T为核心的序贯治疗正被越来越多地研究,作为潜在的治疗策略。靶点与治疗方式的选择可依据耐药机制、靶抗原表达变化以及既往治疗后的疾病进展模式,目标是延长疾病控制时间并改善长期结局。本综述总结以CAR-T为核心的序贯治疗近期进展,重点涉及同靶点再治疗、换用不同抗原、多靶点序贯CAR-T方案,以及CAR-T与造血干细胞移植、放疗、免疫检查点抑制剂和其他免疫调节手段的序贯整合。文章进一步在抗原逃逸、CAR-T细胞功能衰退、肿瘤克隆演化与免疫微环境重塑的背景下,讨论这些以CAR-T为核心的序贯策略的生物学依据与临床适用情形。同时讨论可能影响后续方案选择的因素,包括初始治疗反应、复发时抗原状态、CAR-T细胞持久性以及患者的治疗窗口,并说明这些序贯策略已被探索的临床场景。
Approximately 85% of colorectal cancers (CRCs) are microsatellite stable (MSS) and thus exhibit intrinsic resistance to anti-programmed death-1 (PD-1) therapy. In this study, we demonstrate that oral administration of Akkermansia muciniphila (Akk) suppresses tumorigenesis and reprograms the tumor microenvironment in MSS CRC mouse models. Akk attenuates macrophage efferocytosis through the TLR2/NF-κB pathway, an effect that leads to the accumulation of apoptotic cancer cells, which activates the cGAS-STING pathway and potentiates type I interferon production. This immunostimulatory cascade activates effector CD8+ T cells and enhances the response to anti-PD-1 therapy. We conducted a phase 1 trial (NCT06865521) combining Akk probiotics with PD-1 antibody in patients with metastatic MSS CRC after ≥1 prior line of therapy. The combination therapy was safe and achieved an objective response rate of 19%, with responders exhibiting enhanced antitumor immunity. Our multilevel investigation provides a promising strategy to overcome immunotherapy resistance in MSS CRC through targeted modulation of the gut microbiome.
中文摘要:约85%的结直肠癌为微卫星稳定型,对PD-1抗体治疗存在内在耐药。口服嗜黏蛋白阿克曼菌(Akk)可在MSS结直肠癌小鼠模型中抑制肿瘤发生并重塑肿瘤微环境。Akk通过TLR2/NF-κB通路减弱巨噬细胞胞葬作用,使凋亡癌细胞积聚,进而激活cGAS-STING通路并增强I型干扰素产生。该免疫刺激级联反应激活效应CD8+ T细胞,并提高PD-1抗体治疗反应。研究开展1期试验NCT06865521,在既往至少接受1线治疗的转移性MSS结直肠癌患者中联合使用Akk益生菌与PD-1抗体。联合治疗安全性良好,客观缓解率为19%,缓解者表现出增强的抗肿瘤免疫。多层面研究提示,通过靶向调节肠道菌群克服MSS结直肠癌免疫治疗耐药具有前景。
Natural killer (NK) cells have emerged as central players in cancer immunotherapy, progressing from basic discovery to clinically validated platforms over five decades. This review synthesizes the evolving understanding of NK cell biology, including subset heterogeneity, epigenetic regulation, and metabolic control, and, as innovative focal points, intratumoral NK heterogeneity, epigenetic modulation, and intracellular immune checkpoints, forming the foundation for rational therapeutic engineering. We examine the clinical trajectory from unmodified adoptive transfer to cytokine-induced memory-like NK cells and, most transformatively, to chimeric antigen receptor (CAR)-NK cells. Landmark trials have established the remarkable efficacy and superior safety of CAR-NK cells in B-cell malignancies, with recent studies extending these benefits to autoimmune diseases such as systemic lupus erythematosus and systemic sclerosis, demonstrating durable immune reset with a favorable safety profile. Despite these advances, solid tumors remain formidable challenges, hindered by antigen heterogeneity, physical barriers, and a metabolically hostile microenvironment. We therefore analyze next-generation engineering strategies that move beyond single modifications toward systems-level reprogramming, encompassing intrinsic enhancements (cytokine signaling, metabolic fitness, checkpoint disruption), extrinsic tumor microenvironment remodeling, and advanced delivery platforms. We further synthesize the practical dimensions of clinical translation by systematically examining key optimization parameters that will guide the path toward precision NK cell therapy. These include rational dosing and scheduling regimens, strategies to reduce lymphodepletion intensity, context-dependent persistence requirements across different disease indications and the emerging biomarker landscape.
中文摘要:自然杀伤(NK)细胞已成为肿瘤免疫治疗的核心参与者,在过去五十年间从基础发现发展为经临床验证的治疗平台。本综述整合对NK细胞生物学不断演变的认识,包括亚群异质性、表观遗传调控和代谢控制,并以瘤内NK异质性、表观遗传调节和细胞内免疫检查点作为创新焦点,这些构成了理性治疗工程的基础。我们考察从未修饰过继转移至细胞因子诱导的记忆样NK细胞、并进一步到嵌合抗原受体(CAR)-NK细胞的临床轨迹,后者最具变革性。里程碑试验已确立CAR-NK细胞在B细胞恶性肿瘤中的显著疗效和更优安全性,近期研究将这些获益扩展至系统性红斑狼疮和系统性硬化症等自身免疫病,显示持久免疫重置且安全性良好。尽管有这些进展,实体瘤仍是严峻挑战,受抗原异质性、物理屏障和代谢不利微环境阻碍。因此我们分析超越单一修饰、转向系统层面重编程的新一代工程策略,涵盖内在增强(细胞因子信号、代谢适应性、检查点破坏)、外在肿瘤微环境重塑和先进递送平台。我们进一步系统考察指导精准NK细胞治疗路径的关键优化参数,综合临床转化的实践维度,包括合理给药与调度方案、降低淋巴清除强度的策略、不同疾病适应证下依赖情境的持久性需求以及新兴生物标志物格局。
Neoadjuvant nivolumab plus ipilimumab in localized deficient mismatch repair/microsatellite instability-high gastric or gastroesophageal junction (GEJ) adenocarcinoma was evaluated in the NEONIPIGA study. The primary end point of pathological complete response (pCR) was previously reported. To report long-term follow-up results and secondary end points, including event-free survival (EFS) and overall survival (OS), of the NEONIPIGA study. The NEONIPIGA study is a French, multicenter, single-arm, phase 2 nonrandomized clinical trial that included patients with histologically proven cT2-T4NXM0 deficient mismatch repair/microsatellite instability-high GEJ adenocarcinoma who were eligible for surgery. Patients were enrolled between October 23, 2019, and June 4, 2021, and the database was locked on November 13, 2025. Neoadjuvant nivolumab, 240 mg, every 2 weeks for 6 cycles plus ipilimumab, 1 mg/kg, every 6 weeks for 2 cycles, followed by surgery 5 weeks after the last nivolumab dose, and adjuvant nivolumab, 480 mg, every 4 weeks for 9 cycles. EFS and OS. A total of 32 patients (median [range] age, 65 [40-80] years; 8 [28%] female and 21 [72%] were male) were included: 16 (50%) with gastric cancer and 16 (50%) with GEJ cancer. Three patients did not undergo surgery (1 with metastatic disease and 2 who refused). Twenty-seven patients (84%) completed neoadjuvant therapy and 14 (44%) received all treatment as planned. Neoadjuvant and adjuvant therapy-related grade 3/4 adverse events occurred in 6 (19%) and 4 patients (17%), respectively. Median follow-up was 48.3 months (95% CI, 44.8-52.0 months). Among the 32 patients in the intention-to-treat population, 4-year OS was 84.1% (95% CI, 65.8%-93.0%). In the 31 patients eligible for surgery, 4-year EFS was 83.5% (95% CI, 64.8%-92.8%). One patient relapsed with cerebral metastases. Six deaths occurred: 2 related to gastric cancer or treatment (1 patient had postoperative complications and 1 cerebral metastases) and 4 unrelated. All patients who did not undergo surgery achieved a clinical complete response after immune checkpoint inhibitor therapy. One patient subsequently died of causes unrelated to their cancer. Overall, 17 of 29 patients (59%) achieved pCR on surgical specimen. Safety was previously reported, and no additional late toxic effects were observed. In this phase 2 nonrandomized clinical trial, the immunotherapy regimen evaluated was associated with sustained long-term survival, but no clear evidence of improved survival over outcomes reported in other studies evaluating surgery alone in this patient population was observed. The high pCR rates and durable responses observed may provide useful information for designing future clinical studies, including randomized trials investigating organ-preserving strategies. ClinicalTrials.gov Identifier: NCT04006262.
中文摘要:NEONIPIGA研究评估了新辅助纳武利尤单抗联合伊匹木单抗治疗局限性错配修复缺陷/微卫星高度不稳定胃或胃食管交界腺癌。病理完全缓解(pCR)这一主要终点此前已有报告。本文报告NEONIPIGA研究的长期随访结果和次要终点,包括无事件生存期(EFS)和总生存期(OS)。NEONIPIGA研究是一项法国多中心、单臂、2期非随机临床试验,纳入组织学证实为cT2-T4NXM0、错配修复缺陷/微卫星高度不稳定、适合手术的胃或胃食管交界腺癌患者。患者于2019年10月23日至2021年6月4日入组,数据库于2025年11月13日锁定。治疗为新辅助纳武利尤单抗240 mg每2周1次共6个周期,联合伊匹木单抗1 mg/kg每6周1次共2个周期,末次纳武利尤单抗后5周手术,术后辅助纳武利尤单抗480 mg每4周1次共9个周期。终点为EFS和OS。共纳入32例患者(中位[范围]年龄65[40-80]岁;女性8例[28%],男性21例[72%]):胃癌16例(50%),胃食管交界癌16例(50%)。3例未接受手术(1例转移性疾病,2例拒绝)。27例(84%)完成新辅助治疗,14例(44%)按计划接受全部治疗。新辅助和辅助治疗相关3/4级不良事件分别发生于6例(19%)和4例(17%)患者。中位随访48.3个月(95% CI,44.8-52.0个月)。在意向治疗人群32例中,4年OS为84.1%(95% CI,65.8%-93.0%)。在31例适合手术的患者中,4年EFS为83.5%(95% CI,64.8%-92.8%)。1例患者复发为脑转移。共发生6例死亡:2例与胃癌或治疗相关(1例术后并发症,1例脑转移),4例无关。所有未接受手术的患者在接受免疫检查点抑制剂治疗后均达到临床完全缓解。其中1例随后死于与癌症无关的原因。总体而言,29例患者中17例(59%)在手术标本中达到pCR。安全性此前已有报告,未观察到额外迟发毒性反应。在这项2期非随机临床试验中,所评估的免疫治疗方案与持续长期生存相关,但未观察到明确证据表明其生存优于其他评估单纯手术的研究在该患者人群中的报告结局。观察到的高pCR率和持久缓解可为设计未来临床研究提供有用信息,包括探索保留器官策略的随机试验。ClinicalTrials.gov注册号:NCT04006262。
Personalized neoantigen-targeting cancer vaccines in the adjuvant setting are of increasing interest across malignancies. Here we report the results of a phase 1 clinical trial testing the feasibility and safety of personalized neoantigen-targeting cancer vaccines for high-grade epithelial ovarian cancer. 'NeoVax' consisted of pools of synthetic long peptides targeting patient-specific neoantigens admixed with the immunostimulant poly-ICLC, was combined with delayed administration of anti-PD-1 antibody, and was tested in ten patients (one newly diagnosed patient (Cohort A) and nine patients at first recurrence (Cohort B)) with platinum-sensitive ovarian cancer following standard-of-care platinum doublet chemotherapy. Nine of 12 evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%) and 1 of 9 Cohort A patients (11%, 90% CI 0.6-43%). No unexpected safety signals were encountered and no patients discontinued treatment due to toxicity. Across patients, >70% selected targets remained detectable by noninvasive cell-free DNA analysis despite a median of 6.5 months from the time of diagnostic biopsy to vaccine administration, during which, patients received standard-of-care chemotherapy. Biomarker analysis was suggestive of biologic activity of the vaccine in six of ten patients and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination. Resistant tumor clones reflected diverse mechanisms affecting antigen presentation, indicative of immune-selective pressure exerted by vaccination. Overall, the interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination. ClinicalTrials.gov identifier: NCT04024878 .
中文摘要:个性化新抗原靶向癌症疫苗用于辅助治疗正受到多种恶性肿瘤关注。本项1期临床试验报告了针对高级别上皮性卵巢癌的个性化新抗原靶向癌症疫苗的可行性和安全性结果。NeoVax由靶向患者特异性新抗原的合成长肽池与免疫刺激剂poly-ICLC混合组成,联合延迟给药抗PD-1抗体,在10例铂敏感卵巢癌患者中测试,这些患者在接受标准化疗铂双药后入组,其中1例为新诊断患者(A队列),9例为首次复发患者(B队列)。在可评估的B队列12例患者中有9例接种疫苗(75%,90% CI 47-93%),在可评估的A队列9例患者中有1例接种(11%,90% CI 0.6-43%)。未遇到非预期安全性信号,无患者因毒性停止治疗。尽管从诊断性活检到疫苗给药的中位时间为6.5个月,期间患者接受标准化疗,非侵入性游离DNA分析仍可在患者中检出超过70%的所选靶点。生物标志物分析提示10例患者中有6例存在疫苗生物学活性,这与接种后血液和肿瘤中更广泛的肿瘤及疫苗特异性免疫应答相关。耐药肿瘤克隆反映出影响抗原呈递的多种机制,提示疫苗接种施加了免疫选择压力。总体而言,肿瘤所呈递抗原库与诱导免疫广度之间的相互作用似乎决定了接种后的临床疗效。ClinicalTrials.gov标识符:NCT04024878。
Predicting pathological complete response (pCR) after neoadjuvant short-course radiotherapy combined with immunotherapy and chemotherapy remains challenging in microsatellite-stable (MSS) locally advanced rectal cancer. In this prospective exploratory study (ClinicalTrials.gov identifier: NCT06608537), 49 patients received short-course radiotherapy followed by sintilimab plus CAPOX and subsequently underwent radical surgery. We investigated whether treatment response could be better characterized by integrating two complementary biological dimensions: baseline immune organization and treatment-related stromal remodeling captured by multi-time-point 1 8F-FAPI PET/CT. The pCR rate was 49.0% (24/49), and serial 1 8F-FAPI imaging revealed distinct stromal kinetic patterns between response groups. Integration of intratumoral tertiary lymphoid structure (iTLS) count, B-cell density, preoperative tumor-to-iliacus muscle ratio (TIMR) at 30 min, and the delayed TIMR retention index from 90 to 120 min (RI34) yielded a four-variable model with a mean AUC of 0.874 in repeated nested cross-validation. Complementary preclinical experiments provided functional support for a CAF-TGFβ-B-cell/TLS axis linking stromal regulation, immune organization, and treatment resistance. These findings highlight the complementary value of spatial immune organization and dynamic FAPI-defined stromal kinetics and provide a biologically informed framework for post-neoadjuvant, preoperative response stratification, pending prospective multicenter validation.
中文摘要:在微卫星稳定(MSS)局部晚期直肠癌中,新辅助短程放疗联合免疫治疗和化疗后的病理完全缓解(pCR)预测仍具挑战。这项前瞻性探索性研究(ClinicalTrials.gov注册号NCT06608537)纳入49例患者,接受短程放疗后行信迪利单抗联合CAPOX方案,随后接受根治性手术。我们探讨整合两个互补生物学维度能否更好刻画治疗反应:基线免疫组织状态,以及多时间点18F-FAPI PET/CT捕捉的治疗相关间质重塑。pCR率为49.0%(24/49),系列18F-FAPI显像显示应答组之间不同的间质动力学模式。将瘤内三级淋巴结构(iTLS)计数、B细胞密度、术前30分钟肿瘤与髂肌摄取比(TIMR)以及90至120分钟延迟TIMR滞留指数(RI34)整合,构建四变量模型,在重复嵌套交叉验证中平均AUC为0.874。互补的临床前实验为CAF-TGFβ-B细胞/TLS轴提供功能支持,该轴连接间质调控、免疫组织与治疗抵抗。这些发现突出空间免疫组织与FAPI定义的动态间质动力学的互补价值,并为新辅助治疗后、术前反应分层提供具生物学依据的框架,尚待前瞻性多中心验证。
In this issue of Cancer Cell, Shi et al. report encouraging early-phase results combining HRS-4642, an allele-specific KRAS G12D inhibitor, with the PD-L1 inhibitor adebrelimab in previously treated metastatic pancreatic cancer. The intravenous combination was safe and well tolerated, notably sparing patients the gastrointestinal toxicity common to oral KRAS inhibitors, and achieved a promising 43% response rate at the recommended dose.
中文摘要:在本期 Cancer Cell 中,Shi 等报告了 HRS-4642(一种等位基因特异性 KRAS G12D 抑制剂)联合 PD-L1 抑制剂 adebrelimab 在既往接受过治疗的转移性胰腺癌患者中的早期研究结果,结果令人鼓舞。该静脉联合方案安全且耐受性良好,尤其使患者免于口服 KRAS 抑制剂常见的胃肠道毒性,并在推荐剂量下取得 43% 的缓解率。
Small cell lung cancer (SCLC) is a highly aggressive neoplasm with limited sensitivity to anti-PD-(L)1 blockade, which is likely caused by the epigenetic silencing of MHC-I. Elucidating MHC-I-independent immune recognition mechanisms is therefore crucial for enhancing treatment responses and improving clinical outcomes in a greater number of patients. Leveraging single-cell approaches, we discovered γδ T cell infiltration in biospecimens from patients with SCLC. Despite PD-1 expression, γδ T cells maintained a cytotoxic transcriptional profile, suggesting an anti-tumor role. Indeed, high γδ T cell infiltration in two practice-changing clinical trials predicted improved response to anti-PD-L1 immunotherapy in patients with SCLC. Moreover, using preclinical models, we demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate, an FDA-approved compound, can sensitize SCLC cells to γδ T cell-mediated killing. Thus, our findings suggest that engaged γδ T cells are potentially valuable targets for SCLC therapy.
中文摘要:小细胞肺癌(SCLC)是一种高度侵袭性的肿瘤,对PD-(L)1阻断治疗敏感性有限,这可能由MHC-I的表观遗传沉默所致。阐明不依赖MHC-I的免疫识别机制,对提高治疗反应并改善更多患者的临床结局至关重要。利用单细胞技术,我们在SCLC患者的生物标本中发现了γδ T细胞浸润。尽管表达PD-1,γδ T细胞仍保持细胞毒性转录谱,提示其具有抗肿瘤作用。在两项改变临床实践的临床试验中,γδ T细胞高浸润预测SCLC患者对抗PD-L1免疫治疗的反应改善。利用临床前模型,我们证明γδ T细胞能有效执行由tarlatamab(δ样配体3 [DLL3]-CD3双特异性T细胞衔接器 [BiTE])重定向的SCLC杀伤,且FDA批准的化合物唑来膦酸可使SCLC细胞对γδ T细胞介导的杀伤更敏感。这些发现提示,被激活的γδ T细胞可能是SCLC治疗中有价值的靶点。
KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metastatic KRAS G12D-mutant PDAC. Dose escalation revealed no dose-limiting toxicities, establishing the recommended phase 2 dose (RP2D), and no treatment-related deaths occurred; hypercholesterolemia and anemia (each 50%) were the most common treatment-related adverse events. In the RP2D cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5), disease control rate was 81.1% (95% CI, 64.8-92.0), median duration of response was 6.9 months (95% CI, 4.8-8.6), median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9). This chemotherapy-free regimen is tolerable and shows encouraging antitumor activity in refractory KRAS G12D-mutant PDAC, warranting further investigation.
中文摘要:KRAS G12D突变驱动约40%的胰腺导管腺癌(PDAC)病例,并促进免疫抑制性肿瘤微环境。这项1/2期试验(NCT06427239)评估选择性KRAS G12D抑制剂HRS-4642联合PD-L1阻断剂adebrelimab,在48例既往接受过治疗的转移性KRAS G12D突变PDAC患者中进行。剂量递增未发现剂量限制性毒性,确定了2期推荐剂量(RP2D),未发生治疗相关死亡;高胆固醇血症和贫血(各50%)为最常见的治疗相关不良事件。在RP2D队列(n=37)中,确认的客观缓解率为43.2%(95%置信区间[CI] 27.1-60.5),疾病控制率为81.1%(95%CI 64.8-92.0),中位缓解持续时间为6.9个月(95%CI 4.8-8.6),中位无进展生存期为5.7个月(95%CI 4.0-7.5),中位总生存期为11.5个月(95%CI 9.2-16.9)。该无化疗方案可耐受,并在难治性KRAS G12D突变PDAC中显示出令人鼓舞的抗肿瘤活性,值得进一步研究。
Emerging data indicate that immune checkpoint inhibitors can exhibit time-of-day-dependent effects in pre-clinical models. Furthermore, multiple retrospective clinical trials associate earlier anti-tumor treatment timing with improved outcomes. However, key questions remain regarding the reproducibility of these findings, the underlying mechanisms, and their clinical implications. This commentary discusses these open questions and provides an outlook on the field.
中文摘要:新出现的数据提示,免疫检查点抑制剂在临床前模型中可表现出依赖于一日中给药时机的效应。多项回顾性临床试验也把更早的抗肿瘤治疗时间与更好的结局联系起来。这些发现能否重复、背后的机制为何、临床意义如何,仍是关键未解问题。本评论讨论这些开放性问题,并对该领域作出展望。
The tumor vasculature is a dynamic and heterogeneous component of the tumor microenvironment (TME) that influences tumor progression, immune infiltration, metastasis, and therapeutic response. This review explores the factors that contribute to the unique vascular characteristics of the TME and highlights the potential for molecular and imaging biomarkers to predict treatment outcomes. We discuss structural and functional abnormalities of tumor vessels, including altered architecture, permeability, interstitial pressure, endothelial phenotype, and impaired drug delivery. We also examine angiogenic signaling through hypoxia-inducible factors (HIFs) and vascular endothelial growth factor (VEGF), in addition to emphasizing non-angiogenic mechanisms such as vessel co-option. The review then turns to the current clinical landscape of angiogenesis, assessing the success and limitations of current therapies, emerging treatment strategies, biomarkers associated with angiogenesis, and AI-assisted prognostication. The establishment and clinical utilization of angiogenesis and tumor vasculature biomarkers is critical for disease diagnosis, prognosis, and the development of targeted therapies. This review ultimately aims to inform future innovation in vasculature-targeted therapies and their personalized clinical implementation to improve cancer care.
中文摘要:肿瘤血管是肿瘤微环境(TME)中动态且异质的组成部分,影响肿瘤进展、免疫浸润、转移和治疗反应。该综述探讨形成TME独特血管特征的因素,并强调分子与影像生物标志物预测治疗结局的潜力。文章讨论肿瘤血管的结构和功能异常,包括结构改变、通透性、间质压力、内皮表型以及药物递送受损。也考察通过缺氧诱导因子(HIFs)和血管内皮生长因子(VEGF)介导的血管生成信号,并强调血管共选择等非血管生成机制。综述随后转向血管生成当前的临床格局,评估现有疗法的成功与局限、新兴治疗策略、与血管生成相关的生物标志物以及AI辅助预后预测。血管生成和肿瘤血管生物标志物的建立及临床使用对疾病诊断、预后和靶向治疗开发至关重要。该综述最终旨在为血管靶向治疗的未来创新及其个性化临床实施提供参考,以改善肿瘤诊疗。
基础研究 (66篇)
The intratumoral microbiome critically influences immunotherapy efficacy by modulating the host immune microenvironment and epigenetic landscape through its metabolites. Microbial derived metabolites such as short chain fatty acids, secondary bile acids, trimethylamine N oxide, and tryptophan derivatives reprogram host cell epigenetics via DNA methylation, histone modifications, and non-coding RNAs, thereby shaping anti-tumor immunity and driving either immune activation or resistance. In turn, the hypoxic, acidic, and nutrient deprived tumor microenvironment reshapes microbial composition and metabolism, forming a vicious cycle that further affects therapeutic outcomes. Given these pivotal roles, targeting the intratumoral microbiota has emerged as a promising strategy. Advances in synthetic biology have enabled the development of engineered bacteria as programmable living therapeutics. These engineered strains achieve tumor specific colonization, controlled drug release, and multimodal functions such as cytokine secretion, immune checkpoint blockade, STING pathway activation, and metabolic reprogramming. By enhancing immune checkpoint inhibitor efficacy and synergizing with cell therapies, engineered bacterial therapy represents a highly promising approach to improve immunotherapy efficiency. Despite challenges in clinical translation including heterogeneity, anti-vector immunity, and manufacturing complexity, this strategy offers a new paradigm for precision cancer treatment.
中文摘要:瘤内微生物组通过其代谢物调节宿主免疫微环境和表观遗传景观,对免疫治疗疗效产生关键影响。微生物来源的代谢物如短链脂肪酸、次级胆汁酸、氧化三甲胺和色氨酸衍生物,经DNA甲基化、组蛋白修饰和非编码RNA重编程宿主细胞表观遗传,进而塑造抗肿瘤免疫,推动免疫激活或免疫耐药。反过来,缺氧、酸性和营养匮乏的肿瘤微环境重塑微生物组成与代谢,形成恶性循环,进一步影响治疗结局。鉴于这些关键作用,靶向瘤内微生物群已成为有前景的策略。合成生物学的进步使工程菌能够作为可编程的活体治疗药物。这些工程菌株实现肿瘤特异性定植、受控药物释放以及细胞因子分泌、免疫检查点阻断、STING通路激活和代谢重编程等多模态功能。通过增强免疫检查点抑制剂疗效并与细胞治疗协同,工程菌治疗是提高免疫治疗效率的很有前景的途径。尽管临床转化面临异质性、抗载体免疫和制造复杂性等挑战,该策略为精准癌症治疗提供了新范式。
Tumor-associated macrophages (TAMs) are key regulators of tumor progression and immune suppression within the tumor microenvironment (TME). Emerging evidence identifies ubiquitination, a dynamic post-translational modification that regulates protein stability, localization, and signaling activity, as a critical determinant of TAM function. Ubiquitin signaling orchestrates macrophage inflammatory responses, metabolic reprogramming, and tumor cell-immune cell crosstalk through coordinated actions of ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, ubiquitin-protein ligases (E3s), and deubiquitinating enzymes (DUBs). Dysregulation of these ubiquitin networks fosters an immunosuppressive microenvironment, thereby promoting tumor growth, metastasis, and therapeutic resistance. In this review, we summarize recent advances in the role of ubiquitination in TAM biology, focusing on key E3 ubiquitin ligases and DUBs in TAM immunity. We further discuss emerging ubiquitin-dependent signaling pathways that integrate metabolic and inflammatory cues within TAMs. Finally, we highlight the therapeutic potential of targeting ubiquitination machinery to reprogram TAMs and remodel the TME. Collectively, this review provides a comprehensive framework for understanding ubiquitin-mediated regulation of TAM function and offers novel perspectives for developing ubiquitination-based cancer immunotherapies.
中文摘要:肿瘤相关巨噬细胞(TAMs)是肿瘤微环境(TME)中肿瘤进展和免疫抑制的关键调控者。越来越多证据表明,泛素化作为一种动态翻译后修饰,可调节蛋白稳定性、定位和信号活性,是TAM功能的重要决定因素。泛素信号通过泛素激活酶、泛素结合酶、泛素蛋白连接酶(E3s)和去泛素化酶(DUBs)的协同作用,协调巨噬细胞炎症反应、代谢重编程以及肿瘤细胞与免疫细胞间的串扰。这些泛素网络失调会促成免疫抑制性微环境,推动肿瘤生长、转移和治疗耐药。该综述总结泛素化在TAM生物学中作用的最新进展,聚焦TAM免疫中的关键E3泛素连接酶和DUBs。文章进一步讨论整合TAM内代谢与炎症信号的新兴泛素依赖性信号通路。靶向泛素化机器以重编程TAM和重塑TME的治疗潜力亦被强调。总体而言,该综述为理解泛素介导的TAM功能调控提供综合框架,并为开发基于泛素化的肿瘤免疫治疗提供新视角。
Immune checkpoint blockade (ICB) therapy has achieved clinical progress in various malignancies, yet primary and acquired resistance limits its efficacy in solid tumors. Myeloid cells in the tumor microenvironment (TME), including tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs), undergo metabolic reprogramming under hypoxia and nutrient stress. They impair effector T cell function and may contribute to exhaustion-associated states via nutrient competition, release of toxic metabolites, and formation of physical barriers, representing a critical resistance mechanism. This review summarizes the spatiotemporal heterogeneity of myeloid cells and the metabolic networks underlying their immunosuppressive phenotypes, focusing on dysregulated lipid and cholesterol metabolism, amino acid remodeling, the glycolytic switch, and subcellular stress responses. We analyze how metabolic dysregulation causes T cell dysfunction and, in defined contexts, contributes to exhaustion-associated transcriptional programs through nutrient competition, toxic metabolite accumulation, and upregulation of inhibitory receptor ligands, and summarize intervention strategies targeting myeloid recruitment, phenotypic remodeling, metabolic reprogramming, and pathological structures combined with ICB. We discuss challenges of efficacy heterogeneity and safety in clinical translation, and highlight the prospects of multi-omics and computational biology in guiding next-generation combination immunotherapy. Understanding myeloid metabolic plasticity may provide a basis for overcoming immunotherapy resistance and establishing precise synergistic strategies.
中文摘要:免疫检查点阻断(ICB)治疗已在多种恶性肿瘤中取得临床进展,但原发性和获得性耐药限制其在实体瘤中的疗效。肿瘤微环境(TME)中的髓系细胞,包括肿瘤相关巨噬细胞(TAM)、肿瘤相关中性粒细胞(TAN)和髓源性抑制细胞(MDSC),在缺氧和营养应激下发生代谢重编程。它们通过营养竞争、释放毒性代谢物和形成物理屏障损害效应T细胞功能,并可能促成耗竭相关状态,是关键的耐药机制。本综述总结髓系细胞的时空异质性及其免疫抑制表型背后的代谢网络,重点涉及脂质与胆固醇代谢失调、氨基酸重塑、糖酵解转换和亚细胞应激反应。分析代谢失调如何导致T细胞功能障碍,并在特定情境下通过营养竞争、毒性代谢物蓄积和抑制性受体配体上调促成耗竭相关转录程序,归纳靶向髓系细胞募集、表型重塑、代谢重编程和病理结构并与ICB联合的干预策略。讨论临床转化中疗效异质性和安全性的挑战,并强调多组学和计算生物学在指导下一代联合免疫治疗中的前景。理解髓系细胞代谢可塑性可为克服免疫治疗耐药和建立精准协同策略提供依据。
The rapidly global deployment of COVID-19 mRNA-LNP vaccines established the clinical feasibility of combining RNA medicine with LNP delivery systems, transforming a long-standing experimental concept into a scalable therapeutic modality, previously considered impossible. Currently, the value of mRNA-LNPs has been expanding from infectious disease vaccines to cancer immunotherapy, personalized neoantigen vaccination, in vivo immune-cell engineering, protein replacement therapy, mRNA-encoded biologics and genome editing, with particular relevance to hematology and oncology. However, in hematologic and oncologic settings, therapeutic success is constrained by biological barriers that less prominent in prophylactic vaccination. Systemically administered LNPs are strongly influenced by hepatic sequestration, protein corona formation and mononuclear-phagocyte clearance; solid tumors additionally present heterogeneous vasculature, variable enhanced permeability and retention, dense extracellular matrix, elevated interstitial pressure and limited intratumoral diffusion. Hematologic applications face a different set of constraints, including access to spleen and bone marrow, selective delivery to T cells, NK cells and hematopoietic stem and progenitor cells (HSPCs), and preservation of the normal marrow niche. In this Review, we therefore discuss the molecular and principles of formulation that underpin mRNA-LNP performance in hematology and oncology, including mRNA engineering, lipid nanoparticle architecture, intracellular trafficking and selective organ targeting(SORT) delivery strategies, oncology applications spanning neoantigen vaccines, tumor-microenvironment reprogramming, mRNA-encoded biologics, gene editing and combination therapy; and hematology applications including in vivo CAR-T, CAR-NK and HSPC engineering. We further consider how inefficient extrahepatic delivery, limited endosomal escape, context-dependent reactogenicity, repeat-dosing constraints and the manufacturing complexity of individualized products continue to limit broader clinical translation. Emerging strategies, including artificial-intelligence-guided RNA and lipid design, self-amplifying RNA, circular RNA and next-generation thermostable formulations, may help address these application limitations in the fields of hematology and oncology.
中文摘要:COVID-19 mRNA-LNP 疫苗在全球范围的快速部署,确立了 RNA 药物与 LNP 递送系统结合的临床可行性,使一个长期停留在实验阶段、此前被认为无法实现的概念转化为可规模化的治疗方式。目前,mRNA-LNP 的价值正从传染病疫苗扩展到肿瘤免疫治疗、个体化新抗原疫苗、体内免疫细胞工程、蛋白替代治疗、mRNA 编码生物制品和基因组编辑,与血液学和肿瘤学的关系尤为密切。但在血液学和肿瘤学治疗场景中,治疗成功受到预防性接种中较不突出的生物屏障限制。全身给药的 LNP 明显受肝脏截留、蛋白冠形成和单核吞噬细胞清除影响;实体瘤还存在血管异质性、增强渗透与滞留效应不一、细胞外基质致密、间质压力升高和瘤内扩散受限。血液学应用面临另一组约束,包括进入脾脏和骨髓、选择性递送至 T 细胞、NK 细胞和造血干/祖细胞(HSPCs),以及维持正常骨髓龛。本综述讨论支撑 mRNA-LNP 在血液学和肿瘤学中表现的分子与制剂原理,包括 mRNA 工程、脂质纳米颗粒结构、细胞内转运和选择性器官靶向(SORT)递送策略;肿瘤学应用涵盖新抗原疫苗、肿瘤微环境重编程、mRNA 编码生物制品、基因编辑和联合治疗;血液学应用包括体内 CAR-T、CAR-NK 和 HSPC 工程。文章还讨论肝外递送效率低、内体逃逸有限、反应原性依赖具体情境、重复给药限制和个体化产品生产复杂性如何持续制约更广泛的临床转化。人工智能引导的 RNA 与脂质设计、自扩增 RNA、环状 RNA 和下一代热稳定制剂等新兴策略,可能有助于应对血液学和肿瘤学领域的这些应用限制。
Cancer progression does not occur in isolation: malignant-cell states and fates are shaped by specialized microenvironments, or cancer niches. Within primary tumors, vascular, stromal, immune and neural interactions create local hypoxic, metabolic and mechanical conditions that together influence malignant-cell behavior. These local environments sustain stem-like states, regulate immune surveillance and vascular remodeling, and influence dissemination and treatment response. Tumor-derived extracellular vesicles and other systemic signals connect primary tumors to distant organs, conditioning tissues before tumor-cell arrival and subsequently modulating disseminated tumor-cell seeding, dormancy, reactivation and outgrowth. Cancer niches therefore operate across spatial scales and disease stages, shaping tumor behavior in ways that cannot be explained by tumor-cell-intrinsic properties alone. Advances in single-cell and spatial profiling, organoid systems and intravital imaging are revealing their cellular composition, local architecture and evolution. In this review, we integrate primary, pre-metastatic and metastatic niche biology, examine how local environments evolve and influence one another during cancer progression, compare organ-specific metastatic niches and assess emerging therapeutic strategies. Effective niche-directed therapy will require identifying the interactions that sustain disease, showing that treatment disrupts them and determining which patients are most likely to benefit. Greater spatial, temporal and functional resolution may reveal new therapeutic vulnerabilities and create opportunities to prevent relapse and achieve more durable disease control.
中文摘要:癌症进展并非孤立发生:恶性细胞的状态与命运受特化微环境即癌症龛的塑造。在原发肿瘤内,血管、基质、免疫和神经相互作用形成局部缺氧、代谢与力学条件,共同影响恶性细胞行为。这些局部环境维持干样状态,调控免疫监视和血管重塑,并影响播散及治疗反应。肿瘤来源的细胞外囊泡及其他全身信号将原发肿瘤与远处器官连接起来,在肿瘤细胞到达前对组织进行预适应,随后调节播散肿瘤细胞的定植、休眠、再激活和生长。因此,癌症龛跨越空间尺度和疾病阶段发挥作用,以单纯肿瘤细胞内在特性无法解释的方式塑造肿瘤行为。单细胞与空间分析、类器官系统和活体成像的进展正在揭示其细胞组成、局部结构和演化。在本综述中,我们整合原发龛、转移前龛和转移龛生物学,考察局部环境在癌症进展中如何演化并相互影响,比较器官特异性转移龛,并评估新兴治疗策略。有效的龛定向治疗需要识别维持疾病的关键相互作用,证明治疗能够破坏这些相互作用,并确定最可能获益的患者。更高的空间、时间和功能分辨率可能揭示新的治疗脆弱点,并为预防复发和实现更持久的疾病控制创造机会。
Antibody-drug conjugates (ADCs) are an important class of targeted cancer therapeutics that selectively deliver potent cytotoxic payloads to tumor cells through antibody-mediated targeting. However, the efficacy of some ADCs can be limited by inefficient target protein (e.g., membrane receptor) internalization and lysosomal trafficking, which determine intracellular payload release. In addition, persistent disease-driving proteins sustain oncogenic signaling, promoting tumor progression and therapeutic resistance. Recent advances in targeted protein degradation (TPD) offer a strategy to overcome these limitations by controlling the trafficking and degradation fate of target proteins. Building on the limitations of ADCs and the capabilities of TPD, we propose degradation-coupled antibody conjugates, a conceptual framework that integrates degradation-driven programmable protein fate control with antibody conjugates to enhance payload delivery and expand therapeutic functionality.
中文摘要:抗体-药物偶联物(ADCs)是一类重要的靶向抗肿瘤治疗药物,通过抗体介导的靶向作用将强效细胞毒性载荷选择性递送至肿瘤细胞。但部分ADCs的疗效会受到靶蛋白(如膜受体)内化效率不足及溶酶体转运不畅的限制,而这些过程决定载荷在细胞内的释放。持续存在的疾病驱动蛋白还会维持致癌信号,促进肿瘤进展和治疗耐药。靶向蛋白降解(TPD)的最新进展通过调控靶蛋白的转运与降解命运,为克服上述限制提供了策略。基于ADCs的局限与TPD的能力,我们提出降解耦联抗体偶联物这一概念框架,将降解驱动的可编程蛋白命运控制与抗体偶联物整合,以增强载荷递送并拓展治疗功能。
The specific mechanisms of Verbascoside (VB) in ovarian cancer (OC) remain insufficient. This study aimed to explore the anti-tumor mechanisms of VB in OC, focusing on its ability to modulate the immunosuppressive tumor microenvironment (TME), particularly through targeting neutrophil infiltration and neutrophil extracellular traps (NETs). The anti-tumor and anti-NETosis efficacy of VB was evaluated in vivo using subcutaneous, orthotopic, and pulmonary metastasis mouse models of OC. Microproteomics and bioinformatics analysis identified the direct molecular target of VB and the key neutrophil chemoattractant. The underlying mechanisms were validated in vitro and in vivo (using SKOV3, ID8, and neutrophils), alongside loss-of-function approaches. The combination of VB with anti-PD-1 immunotherapy was also assessed. VB inhibited OC proliferation/metastasis, promoted anti-tumor immunity, and suppressed neutrophil infiltration and NETosis. Neutrophil depletion attenuated VB's anti-metastatic effect. Microproteomics and bioinformatics screening identified IRAK4 as a direct molecular target of VB and CXCL5 as a key neutrophil chemoattractant. SPR confirmed the direct binding between VB and IRAK4, and molecular docking revealed specific hydrogen bond interactions. Mechanistically, VB treatment or IRAK4 knockdown suppressed CXCL5 expression, and consequently reduced neutrophil infiltration and NETosis. Consistently, CXCL5 overexpression abrogated the inhibitory effects of VB on neutrophil NETosis and recruitment. Furthermore, VB synergized with anti-PD-1 therapy, thereby achieving superior tumor growth inhibition, reduced Ki67 expression, and enhanced CD8+ T cell infiltration. In conclusion, VB exerts potent anti-tumor effects in OC by targeting the IRAK4/CXCL5 axis, thereby inhibiting neutrophil infiltration and NETosis, reshaping the immunosuppressive TME, and restoring anti-tumor immunity.
中文摘要:毛蕊花糖苷(VB)在卵巢癌(OC)中的具体机制尚不充分。本研究旨在探讨VB在OC中的抗肿瘤机制,重点考察其调节免疫抑制性肿瘤微环境(TME)的能力,尤其是靶向中性粒细胞浸润和中性粒细胞胞外诱捕网(NETs)。研究采用OC皮下、原位和肺转移小鼠模型在体内评价VB的抗肿瘤和抗NETosis作用。微量蛋白质组学和生物信息学分析确定了VB的直接分子靶点及关键中性粒细胞趋化因子。研究在体外和体内(使用SKOV3、ID8和中性粒细胞)结合功能缺失策略验证相关机制,并评估了VB与抗PD-1免疫治疗的联合应用。VB抑制OC增殖和转移,促进抗肿瘤免疫,并抑制中性粒细胞浸润和NETosis。清除中性粒细胞削弱了VB的抗转移作用。微量蛋白质组学和生物信息学筛选确定IRAK4为VB的直接分子靶点,CXCL5为关键中性粒细胞趋化因子。SPR证实VB与IRAK4直接结合,分子对接显示二者存在特定氢键相互作用。机制上,VB处理或IRAK4敲低抑制CXCL5表达,进而减少中性粒细胞浸润和NETosis。与之相符,CXCL5过表达消除了VB对中性粒细胞NETosis和募集的抑制作用。VB与抗PD-1治疗具有协同作用,可实现更强的肿瘤生长抑制、降低Ki67表达并增强CD8+ T细胞浸润。结论是,VB通过靶向IRAK4/CXCL5轴抑制中性粒细胞浸润和NETosis,重塑免疫抑制性TME并恢复抗肿瘤免疫,从而在OC中发挥强效抗肿瘤作用。
The tumor immune microenvironment (TIME) in ovarian cancer is highly immunosuppressive, and existing immunotherapies are not effective in 85-90% of patients. To address this, we fabricated nanoparticles (NPs) composed of biodegradable poly(β-amino ester) (PBAE) complexed with plasmids encoding 4-1BB ligand and interleukin-12, for delivery into ovarian cancer cells. Collectively with the intrinsic major histocompatibility complex (MHC):antigen signals in tumor cells, these NPs generate tumor-associated antigen-presenting cells (tAPCs), leading to a T-cell-mediated anti-tumor response in an antigen-agnostic manner. Ovarian cancer-bearing mice treated with tAPC NPs + anti-PD1 result in over 13% of long-term survivors and a significantly longer median survival compared to the control. In the spleen, we observe a significant (over half) reduction in FOXP3+ Tregs and over a 4X increase in the percentage of double-positive CD4+ CD8+ T cells in the tAPC NPs + anti-PD1 group compared to the control group. Depletion of T cells eliminates the therapeutic efficacy of tAPC NPs, suggesting that the anti-tumor response generated by tAPC NPs is T-cell-dependent. This work demonstrates the ability of the tAPC NP platform to be used in combination with checkpoint inhibitors to reduce immunosuppressive TIME and represents an effective, personalized yet off-the-shelf immunotherapy for ovarian cancer. STATEMENT OF SIGNIFICANCE: This study reports the development and administration of non-viral nanoparticle DNA delivery via the intraperitoneal route, aiming to overcome the immunosuppression in ovarian cancer that prevents effective activation of the large number of T cells that are normally found in the tumor microenvironment. By supplying co-stimulation and immunostimulatory cytokines directly to tumor cells, our polymeric nanoparticles reprogram tumor cells to act like antigen-presenting cells, allowing them to directly activate T cells in an antigen-agnostic manner for enhanced T-cell activation.
中文摘要:卵巢癌的肿瘤免疫微环境(TIME)具有高度免疫抑制性,现有免疫治疗对85%–90%的患者无效。为此,我们制备了由可生物降解的聚(β-氨基酯)(PBAE)与编码4-1BB配体和白细胞介素-12的质粒复合而成的纳米颗粒(NPs),用于递送至卵巢癌细胞。结合肿瘤细胞固有的主要组织相容性复合体(MHC):抗原信号,这些NPs产生肿瘤相关抗原呈递细胞(tAPCs),以不依赖抗原的方式引发T细胞介导的抗肿瘤反应。接受tAPC NPs + anti-PD1治疗的卵巢癌荷瘤小鼠中,长期生存者超过13%,中位生存期较对照组显著延长。在脾脏中,与对照组相比,tAPC NPs + anti-PD1组的FOXP3+ Tregs显著减少(超过一半),CD4+CD8+双阳性T细胞比例增加超过4倍。清除T细胞消除了tAPC NPs的治疗效果,提示tAPC NPs产生的抗肿瘤反应依赖T细胞。这项工作证明tAPC NP平台可与检查点抑制剂联用以降低免疫抑制性TIME,并代表一种有效、个性化又可即用的卵巢癌免疫治疗。意义声明:本研究报道通过腹腔途径给予非病毒纳米颗粒DNA递送,旨在克服卵巢癌中的免疫抑制,这种免疫抑制阻碍了肿瘤微环境中通常存在的大量T细胞的有效激活。通过直接向肿瘤细胞提供共刺激和免疫刺激性细胞因子,我们的聚合物纳米颗粒重编程肿瘤细胞,使其像抗原呈递细胞一样发挥作用,从而以不依赖抗原的方式直接激活T细胞,增强T细胞激活。
Tumors progress within a mechanically dynamic tumor microenvironment (TME), where extracellular matrix (ECM) stiffening, solid stress, and elevated interstitial fluid pressure remodel tumor cell and tumor-associated cell behavior. This TME-related mechanical remodeling often leads to tumor progression, metastasis and therapy resistance. In this review, we highlight recent advances in tumor mechanobiology, emphasizing how biophysical forces generated by cross-talk between tumor cells and tumor-associated cells precisely drive TME remodeling-ECM stiffening, hypoxia, leaky vasculature, invasion and therapy resistance-to support cancer progression. We discuss emerging interventions for selective tumor targeting that exploit the mechanical properties of the TME and biomechanical vulnerabilities of tumors and tumor-associated cells. Finally, this review explores the potential to leverage mechanobiological insights into the TME using New Approach Methodologies (NAMs), such as 3D bioprinted models and organ-on-chip platforms, coupled with AI-powered image analysis and modeling, to enable personalized cancer diagnosis and treatment.
中文摘要:肿瘤在力学动态的肿瘤微环境中进展,细胞外基质硬化、实体应力与升高的间质液压力重塑肿瘤细胞及肿瘤相关细胞行为。这类TME相关力学重塑常导致肿瘤进展、转移和治疗抵抗。本综述聚焦肿瘤力学生物学近期进展,强调肿瘤细胞与肿瘤相关细胞交互产生的生物物理力如何精确驱动TME重塑——ECM硬化、缺氧、渗漏血管、侵袭和治疗抵抗——以支持癌症进展。讨论利用TME力学特性以及肿瘤和肿瘤相关细胞生物力学弱点的选择性靶向新兴干预策略。最后,综述探讨借助新方法学(NAM),如3D生物打印模型和器官芯片平台,结合AI驱动的图像分析和建模,将TME力学生物学洞见用于个性化癌症诊断和治疗的潜力。
Uridine phosphorylase 1 (UPP1) has recently emerged as a metabolic regulator with critical roles in tumor cell biology. However, its expression pattern and functional significance in nonmalignant components of the tumor microenvironment (TME) remain largely unexplored. Here, we performed a comprehensive pan-cancer single-cell transcriptomic analysis revealing that UPP1 is highly expressed not only in tumor cells but also in tumor-associated macrophages (TAMs) and neutrophils (TANs). Clinically, UPP1 expression in TAMs and TANs correlates with poor prognosis and diminished response to immunotherapy across multiple cancer types. Mechanistically, UPP1 up-regulation could be driven by NF-κB signaling. Functionally, UPP1 reprograms macrophages toward a tumor-promoting phenotype, characterized by enhanced glycolysis, ATP-adenosine signaling activation, and increased production of immunosuppressive cytokines such as granulocyte colony-stimulating factor. In neutrophils, UPP1 also supports TAN polarization, influences neutrophil extracellular trap release, and contributes to broad immunosuppressive remodeling. In vivo, targeting UPP1 in macrophages or neutrophils reprograms the immune landscape and restrains tumor progression. Together, our findings uncover a previously underappreciated role of UPP1 in nonmalignant immune populations and establish it as a key immune mediator within the TME, offering a potentially promising therapeutic target for enhancing antitumor immunity.
中文摘要:尿苷磷酸化酶1(UPP1)近年来被视为一种代谢调节因子,在肿瘤细胞生物学中发挥关键作用。但它在肿瘤微环境(TME)非恶性成分中的表达模式与功能意义仍待阐明。本研究开展泛癌单细胞转录组分析,发现UPP1不仅在肿瘤细胞中高表达,在肿瘤相关巨噬细胞(TAM)和中性粒细胞(TAN)中也高表达。临床上,TAM和TAN中的UPP1表达与多种癌症的不良预后及免疫治疗应答减弱相关。机制上,UPP1上调可由NF-κB信号驱动。功能上,UPP1将巨噬细胞重编程为促肿瘤表型,表现为糖酵解增强、ATP-腺苷信号激活以及粒细胞集落刺激因子等免疫抑制性细胞因子产生增加。在中性粒细胞中,UPP1还支持TAN极化,影响中性粒细胞胞外诱捕网释放,并参与广泛的免疫抑制性重塑。体内靶向巨噬细胞或中性粒细胞中的UPP1可重编程免疫格局并抑制肿瘤进展。这些结果揭示了UPP1在非恶性免疫细胞群体中此前未被充分认识的作用,并确立其为TME中的关键免疫介质,为增强抗肿瘤免疫提供了有潜力的治疗靶点。
The exquisite antigen specificity of T cells is one foundation of modern cancer immunotherapy. The therapeutic efficacy of checkpoint blockade, cancer vaccines, and engineered T-cell therapies, all appear to depend on T cells capable of recognizing specific antigens displayed by tumor cells. In a recent issue of Nature Immunology, Smith and colleagues challenge this paradigm by demonstrating that local activation of virus-specific memory T cells can eliminate tumors without direct tumor-cell recognition. Instead, activated T cells initiate a multicellular inflammatory response involving IFNγ, TNF, nitric oxide and recruited myeloid cells that collectively induce tumor-cell death. These findings separate the antigen specificity required for T-cell activation from that required for tumor killing and expand the role of T cells from direct cytotoxic effectors to organizers of a broader antitumor response. Together, these findings broaden the potential scope of T-cell-mediated antitumor immunity beyond the constraints of direct tumor-antigen recognition.
中文摘要:T细胞精细的抗原特异性是现代癌症免疫治疗的基础之一。免疫检查点阻断、癌症疫苗和工程化T细胞疗法的疗效似乎都依赖于T细胞能够识别肿瘤细胞呈递的特定抗原。在近期《Nature Immunology》的一篇论文中,Smith等挑战了这一范式,证明局部激活病毒特异性记忆T细胞可在不直接识别肿瘤细胞的情况下清除肿瘤。激活的T细胞启动涉及IFNγ、TNF、一氧化氮和招募而来的髓系细胞的多细胞炎症反应,这些因素共同诱导肿瘤细胞死亡。这些发现把T细胞激活所需的抗原特异性与肿瘤杀伤所需的抗原特异性区分开来,并将T细胞的作用从直接细胞毒性效应细胞扩展到更广泛抗肿瘤反应的组织者。这些发现拓宽了T细胞介导抗肿瘤免疫的潜在范围,使其不再受直接识别肿瘤抗原的限制。
Sex differences in cancer therapy response remain poorly understood. Using a "phase II-like preclinical trial" across 55 CLDN18.2+ pancreatic cancer patient-derived xenografts, we identify marked female-biased resistance to CLDN18.2-targeted antibody-drug conjugate (ADC) therapy despite equivalent antigen expression. Mechanistically, estrogen signals through GPER1 to upregulate TRAF6, redirecting tumor-intrinsic STING signaling from IRF3-mediated interferon production toward nuclear factor κB (NF-κB) activation. This drives CXCL1 secretion, neutrophil recruitment, and neutrophil extracellular trap (NET) formation. NETs form a charged extracellular network that restricts antibody access to tumor-cell-surface antigens-a mechanism we term functional antigen shielding-reducing ADC cytotoxicity independently of antigen expression. The NET burden also correlated with poorer responses to trastuzumab, cetuximab, and enfortumab vedotin across three clinical cohorts. Pharmacologic NET disruption with sivelestat restored ADC efficacy in female mice. These findings reveal an estrogen-driven resistance mechanism with broad implications for antibody-based cancer therapy.
中文摘要:癌症治疗反应中的性别差异仍未被充分理解。研究者在55例CLDN18.2阳性胰腺癌患者来源异种移植瘤中开展「II期样临床前试验」,发现尽管抗原表达相当,雌性仍表现出对CLDN18.2靶向抗体偶联药物(ADC)治疗的明显耐药。机制上,雌激素通过GPER1信号上调TRAF6,使肿瘤内在STING信号由IRF3介导的干扰素产生转向核因子κB(NF-κB)激活。该转向驱动CXCL1分泌、中性粒细胞募集和中性粒细胞胞外诱捕网(NET)形成。NET形成带电荷的细胞外网络,限制抗体接近肿瘤细胞表面抗原,这一机制被称为「功能性抗原屏蔽」,可在不依赖抗原表达的情况下降低ADC细胞毒性。NET负荷也与三个临床队列中对曲妥珠单抗、西妥昔单抗和enfortumab vedotin的较差反应相关。使用西维来司他进行药理学NET破坏可在雌性小鼠中恢复ADC疗效。这些发现揭示了一种由雌激素驱动的耐药机制,对基于抗体的癌症治疗具有广泛意义。
Multi-specific antibodies that engage CD3 to redirect T cells have provided substantial clinical benefit in the treatment of hematologic malignancies, but their application to solid tumors remains constrained by a narrow therapeutic window and fixed molecular geometries that limit systematic optimization. Here we used a modular nano-adaptor framework to adjust anti-CD3 (αCD3) surface valency while maintaining antibody affinity, total antibody loading, and tumor-targeting capacity. By titrating the αCD3 stoichiometric fraction, we identified an activation-optimized conformation that preserves tumor-directed cytotoxicity while reducing non-specific immune activation and T cell exhaustion. This platform enabled rapid screening of 91 tetraspecific nanoantibody configurations that integrate immune checkpoint blockade, co-stimulatory signaling, and innate immune modulation. The lead candidates enhanced immune-tumor engagement, promoted intra-tumoral immune infiltration, and suppressed tumor growth in peripheral blood mononuclear cell (PBMC)-humanized mouse models with acceptable tolerability. These findings demonstrate that anti-CD3 valency control combined with modular combinatorial assembly is a potentially valuable and scalable strategy for the development of multi-specific immunotherapies against solid tumors.
中文摘要:通过结合CD3重定向T细胞的多特异性抗体已在血液恶性肿瘤治疗中带来显著临床获益,但其在实体瘤中的应用仍受限于狭窄的治疗窗和固定的分子构型,难以系统优化。我们采用模块化纳米适配器框架,在保持抗体亲和力、总抗体载量和肿瘤靶向能力的同时调节抗CD3(αCD3)表面价数。通过滴定αCD3化学计量比例,我们识别出一种活化优化构象,既保留肿瘤定向细胞毒性,又减少非特异性免疫激活和T细胞耗竭。该平台可快速筛选91种四特异性纳米抗体构型,这些构型整合免疫检查点阻断、共刺激信号和固有免疫调节。先导候选物增强了免疫-肿瘤相互作用,促进瘤内免疫浸润,并在外周血单个核细胞(PBMC)人源化小鼠模型中抑制肿瘤生长,耐受性可接受。这些发现表明,抗CD3价数控制结合模块化组合组装,是开发针对实体瘤的多特异性免疫疗法的一种有潜在价值且可扩展的策略。
The postoperative therapy for breast cancer is significantly restricted by local immunosuppression and the non-healing of infected wounds. We developed a botanical/nanozyme/polysaccharide metabolic immunomodulator (BCZG), using alginate as the primary scaffold, integrating baicalein-loaded carbon nanozyme into a polydopamine-modified alginate hydrogel. In the acidic tumor microenvironment, the BCZG mimicked NOX, OXD, and GSHOx activities, which could deplete NADH/ATP and glutathione to block heat shock protein synthesis and amplify ROS storms for achieving robust immunogenic cell death. Meanwhile, the loaded baicalein as a heat shock protein inhibitor synergistically enhanced PTT sensitivity in conjunction with the energy metabolism-blocking effect of the nanozymes. In the neutral/alkaline wound microenvironment, the BCZG hydrogel switched to catalase- and superoxide dismutase-like activities, scavenging excess ROS, relieving inflammation, and exerting potent antibacterial effects to promote postoperative wound healing. The alginate-based biomimetic nanozyme system disrupted the vicious cycle of wound infection, persistent inflammation, immunosuppressive niche formation, and tumor recurrence. Consequently, it reprogrammed energy metabolism and activated antitumor immunity, offering a novel strategy for postoperative breast cancer treatment.
中文摘要:乳腺癌术后治疗受到局部免疫抑制和感染创面不愈合的明显限制。我们构建了一种植物成分/纳米酶/多糖代谢免疫调节剂BCZG,以海藻酸盐为主要支架,将负载黄芩素的碳纳米酶整合到聚多巴胺修饰的海藻酸盐水凝胶中。在酸性肿瘤微环境中,BCZG模拟NOX、OXD和GSHOx活性,消耗NADH/ATP和谷胱甘肽,阻断热休克蛋白合成并放大活性氧风暴,从而实现强效免疫原性细胞死亡。负载的黄芩素作为热休克蛋白抑制剂,与纳米酶阻断能量代谢的作用协同增强光热治疗敏感性。在中性/碱性创面微环境中,BCZG水凝胶转为类过氧化氢酶和类超氧化物歧化酶活性,清除过量活性氧、减轻炎症并发挥强抗菌作用,促进术后创面愈合。该海藻酸盐基仿生纳米酶系统打断创面感染、持续炎症、免疫抑制微环境形成和肿瘤复发的恶性循环。它重编程能量代谢并激活抗肿瘤免疫,为乳腺癌术后治疗提供了新策略。
Cancer vaccines hold strong therapeutic promise, but their development is often hindered by the need to identify effective tumor antigens-a challenge amplified by tumor heterogeneity. Here, we report a tumor-confined nano-activator (iCLANTSP-SAg) that circumvents antigen dependence by driving localized expression of bacterial superantigens (SAgs) within tumors. This platform integrates tumor-specific promoter-driven SAg plasmids with lipid-assisted polymeric nanoparticles to enable efficient cytosolic delivery and tumor-restricted SAg production. The locally expressed SAgs elicit broad, antigen-independent activation of intratumoral CD4+ and CD8+ T cells through direct crosslinking of T-cell receptors and major histocompatibility complex class II molecules. By confining SAg expression to the tumor site, iCLANTSP-SAg minimizes systemic T-cell activation and off-target toxicity. When co-administered with anti-PD-1 antibodies, iCLANTSP-SAg eliminates established tumors in two-thirds of treated mice and induces durable immune memory that confers complete protection upon rechallenge. This strategy offers a potent and clinically translatable solution to the central challenge of antigen identification in cancer vaccine development.
中文摘要:癌症疫苗具有较强治疗潜力,但其开发常受制于需要鉴定有效肿瘤抗原,肿瘤异质性使这一问题更加突出。本研究报告一种肿瘤局限型纳米激活剂iCLANTSP-SAg,通过在肿瘤内驱动细菌超抗原的局部表达来规避抗原依赖。该平台将肿瘤特异性启动子驱动的超抗原质粒与脂质辅助聚合物纳米颗粒整合,实现高效胞质递送和肿瘤受限的超抗原产生。局部表达的超抗原通过直接交联T细胞受体与主要组织相容性复合体II类分子,广泛且不依赖抗原地激活瘤内CD4+和CD8+ T细胞。将超抗原表达限定于肿瘤部位,可减少全身性T细胞激活和脱靶毒性。与抗PD-1抗体联合给药时,iCLANTSP-SAg使三分之二受治小鼠的已建立肿瘤消退,并诱导持久免疫记忆,在再次挑战时提供完全保护。该策略为癌症疫苗开发中抗原鉴定这一核心难题提供了有效且具临床转化潜力的解决方案。
Women who carry a pregnancy to term have long been known to have a reduced lifetime risk of breast cancer, yet the mechanisms underlying this protection remain poorly understood. Although parity-induced differentiation and hormonal remodeling of the mammary epithelium have been considered primary drivers of breast cancer protection, the contribution of immune adaptation has remained largely unexplored. In a recent issue of Nature Immunology, Hussain and colleagues identify pregnancy-induced tissue-resident memory-like (TRM-like) CD8+ T cells as key mediators of parity-associated breast cancer protection. The authors show that pregnancy establishes a nurturing niche in the mammary gland that supports the expansion of TRM-like cells through epithelial-derived IL15 and TGFβ and that depletion of these cells abolishes the cancer-protective effect of parity. Moreover, using therapeutic agents to enhance IL2Rβ signaling was sufficient to induce the expansion of breast cancer-protective TRM-like cells in nulliparous mice, raising the possibility that pregnancy's protective imprint could be pharmacologically induced. Given the established link between TRM cells and immune checkpoint blockade responsiveness in breast cancer, these findings also raise the possibility that pregnancy-induced TRM-like populations could be leveraged to improve immunotherapy outcomes. By linking physiologic developmental tissue remodeling to durable local immunosurveillance, this study expands current concepts of tissue-resident immunity and positions pregnancy as an immune-educating event with lasting consequences for breast cancer susceptibility.
中文摘要:长期以来已知,将妊娠维持至足月的女性终生乳腺癌风险较低,但这种保护背后的机制仍不清楚。经产诱导的乳腺上皮分化与激素重塑曾被视为乳腺癌保护的主要驱动因素,免疫适应的贡献则基本未被探索。在近期一期 Nature Immunology 中,Hussain 及其同事发现,妊娠诱导的组织驻留记忆样(TRM样)CD8+ T 细胞是经产相关乳腺癌保护的关键介质。作者显示,妊娠在乳腺中建立一个支持性微环境,通过上皮来源的 IL15 和 TGFβ 支持 TRM样细胞扩增;清除这些细胞会消除经产的防癌效应。使用治疗性药物增强 IL2Rβ 信号足以在未产小鼠中诱导具有乳腺癌保护作用的 TRM样细胞扩增,提示妊娠的保护性印记可能通过药理学方式诱导。鉴于 TRM 细胞与乳腺癌免疫检查点阻断反应性之间的已知联系,这些发现也提示妊娠诱导的 TRM样细胞群可用于改善免疫治疗结局。该研究将生理性发育中的组织重塑与持久的局部免疫监视联系起来,拓展了组织驻留免疫的现有概念,并将妊娠定位为对乳腺癌易感性具有持久影响的免疫教育事件。
Immune aging impairs T cell-mediated tumor control as well as cancer immunotherapy outcomes. The most important drivers of T cell dysfunction in aged tumors remain unknown. We performed single-cell CRISPR screens to identify Dusp5 and Zfp219 as key regulators of CD8+ T cell persistence and effector differentiation within aged tumors. Loss of Dusp5 increased extracellular signal-regulated kinase (ERK) phosphorylation and globally enhanced T cell proliferation. Conversely, Zfp219 deletion induced epigenetic reprogramming and increased expression of cytotoxic molecules, enhancing antitumor immunity specifically in aging. Levels of the human ortholog ZNF219 were higher within intratumoral CD8+ T cells from older cancer patients, which correlates with worse survival following immunotherapy. Zfp219 ablation synergized with immune checkpoint inhibitors to expand effector-like CD8+ T cells, leading to tumor clearance in aged mice. Our findings highlight Dusp5 and Zfp219 as critical drivers of age-related T cell dysfunction that can be targeted to rejuvenate antitumor immunity in older cancer patients.
中文摘要:免疫衰老会削弱T细胞介导的肿瘤控制以及癌症免疫治疗的效果。老年肿瘤中T细胞功能障碍的最重要驱动因素仍不清楚。我们开展单细胞CRISPR筛选,发现Dusp5和Zfp219是老年肿瘤内CD8+ T细胞持久性和效应分化的关键调控因子。Dusp5缺失增加细胞外信号调节激酶(ERK)磷酸化,并整体增强T细胞增殖。相反,Zfp219缺失诱导表观遗传重编程并提高细胞毒性分子表达,特异性地在衰老状态下增强抗肿瘤免疫。来自老年癌症患者的肿瘤内CD8+ T细胞中,人同源基因ZNF219水平更高,这与免疫治疗后更差的生存相关。Zfp219敲除与免疫检查点抑制剂协同,扩增效应样CD8+ T细胞,使老年小鼠肿瘤清除。我们的发现表明Dusp5和Zfp219是年龄相关T细胞功能障碍的关键驱动因素,可作为靶点以恢复老年癌症患者的抗肿瘤免疫。
KRAS mutations, present in about 40% of colorectal cancers, are strongly associated with an immunosuppressive tumor microenvironment characterized by restricted immune infiltration and poor responses to immunotherapy. In this study, we found that KRAS mutations remodel the N6-methyladenosine (m6A) epitranscriptome to promote immune evasion. Methylated RNA immunoprecipitation sequencing revealed that KRAS-mutant cells exhibit increased m6A deposition on CD73 mRNA, enhancing its stability through IGF2BP3. TEAD4-dependent recruitment of the METTL3 methyltransferase complex induced the m6A modification, identifying TEAD4 as a spatial regulator of m6A deposition. Functionally, METTL3 knockdown in KRAS-mutant syngeneic tumors suppressed tumor growth and restored antitumor immunity by increasing CD8+ T-cell and NK cell infiltration in a CD73-dependent manner. Moreover, METTL3 inhibition synergized with anti-PD-1 therapy and a CD73 inhibitor to reduce tumor burden. Together, these findings demonstrate that KRAS-driven m6A remodeling is a key mechanism of immune suppression in colorectal cancer and highlight METTL3 as a promising therapeutic target. KRAS mutations suppress immune cell infiltration by increasing CD73 expression through m6A reprogramming driven by TEAD4-mediated relocalization of METTL3, providing a targetable axis to promote antitumor immunity.
中文摘要:约40%的结直肠癌存在KRAS突变,这类突变与免疫抑制性肿瘤微环境密切相关,表现为免疫浸润受限和对免疫治疗反应差。研究发现KRAS突变重塑N6-甲基腺苷(m6A)表观转录组,从而促进免疫逃逸。甲基化RNA免疫沉淀测序显示,KRAS突变细胞中CD73 mRNA的m6A沉积增加,并通过IGF2BP3增强其稳定性。TEAD4依赖性地招募METTL3甲基转移酶复合物,诱导该m6A修饰,表明TEAD4是m6A沉积的空间调控因子。功能上,在KRAS突变同系肿瘤中敲低METTL3可抑制肿瘤生长,并以CD73依赖的方式增加CD8+ T细胞和NK细胞浸润,恢复抗肿瘤免疫。抑制METTL3与抗PD-1治疗及CD73抑制剂联用可协同减轻肿瘤负荷。这些结果说明,KRAS驱动的m6A重塑是结直肠癌免疫抑制的关键机制,METTL3是有前景的治疗靶点。KRAS突变通过TEAD4介导的METTL3重定位所驱动的m6A重编程上调CD73表达,抑制免疫细胞浸润,由此形成一个可靶向的轴以促进抗肿瘤免疫。
Cross-talk between Schwann Cells and CD4+ T Cells Promotes Perineural Invasion in Colorectal Cancer.
Perineural invasion (PNI) is a common pathologic feature associated with poor prognosis in colorectal cancer. A better understanding of the mechanisms underlying PNI formation could help identify potential strategies to inhibit tumor progression. In this study, we revealed an integral role of CD4+ T cells in the development and progression of PNI in colorectal cancer. Single-cell RNA sequencing, spatial transcriptomics, and multiplex IHC profiling uncovered a distinct HSPA6+ CD4+ T-cell subset expressing T stress (Tstr) cell markers in colorectal cancer PNI tissues. Schwann cells (SC) colocalized with the HSPA6+ CD4+ Tstr cells in PNI, and functional studies showed that SCs promoted Tstr cell differentiation, whereas Tstr cells enhanced SC migration. Interaction between SCs and CD4+ T cells activated the mitogen-activated protein kinase (MAPK) pathway in SCs and the JAK-STAT pathway in Tstr cells, and inhibition of MAPK and STAT signaling suppressed nerve invasion of colorectal cancer cells in vivo. Moreover, SCs in contact with tumor cells possessed the ability to recruit CD4+ T cells; tumor-derived TNFα stimulated SCs to secrete CCL4, thereby recruiting CD4+ T cells toward SCs. The anti-TNFα mAb infliximab reversed the proinvasive and promigratory effects of SCs on colorectal cancer cells and reduced intratumoral CD4+ Tstr cells, and the combination of infliximab with anti-PD-1 treatment produced a combinatorial tumor-suppressive effect. Together, this study suggests that SCs near colorectal cancer tissues recruit CD4+ T cells and promote their conversion to CD4+ Tstr cells to establish an immunosuppressive microenvironment and simultaneously enhance the migration and tumor-promoting capabilities of SCs, thereby accelerating PNI development. A CD4+ T-cell subtype forms a feedback loop with Schwann cells that promotes perineural invasion in colorectal cancer and can be targeted to suppress tumor progression and enhance PD-1 blockade efficacy.
中文摘要:神经周围侵犯(PNI)是结直肠癌中与不良预后相关的常见病理特征。更清楚地理解PNI形成的机制有助于寻找抑制肿瘤进展的潜在策略。研究揭示了CD4+ T细胞在结直肠癌PNI发生和进展中的关键作用。单细胞RNA测序、空间转录组学和多色免疫组化分析在结直肠癌PNI组织中识别出一群独特的HSPA6+ CD4+ T细胞亚群,其表达T细胞应激(Tstr)细胞标志物。雪旺细胞(SC)在PNI中与HSPA6+ CD4+ Tstr细胞共定位,功能研究显示SC促进Tstr细胞分化,而Tstr细胞增强SC迁移。SC与CD4+ T细胞的相互作用激活SC中的丝裂原活化蛋白激酶(MAPK)通路和Tstr细胞中的JAK-STAT通路,抑制MAPK和STAT信号可在体内抑制结直肠癌细胞的神经侵袭。与肿瘤细胞接触的SC具有招募CD4+ T细胞的能力;肿瘤来源的TNFα刺激SC分泌CCL4,从而将CD4+ T细胞招募至SC周围。抗TNFα单克隆抗体英夫利昔单抗逆转SC对结直肠癌细胞的促侵袭和促迁移作用,并减少瘤内CD4+ Tstr细胞,英夫利昔单抗与抗PD-1治疗联合产生联合抑瘤效应。研究提示,结直肠癌组织附近的SC招募CD4+ T细胞并促进其转化为CD4+ Tstr细胞,建立免疫抑制微环境,同时增强SC的迁移和促肿瘤能力,从而加速PNI发展。一种CD4+ T细胞亚型与雪旺细胞形成反馈环路,促进结直肠癌神经周围侵犯,并可被靶向以抑制肿瘤进展并增强PD-1阻断疗效。
Neoadjuvant immunochemotherapy (nICT) has emerged as a promising neoadjuvant strategy for esophageal squamous cell carcinoma (ESCC). Identification of the factors affecting responsiveness to nICT could help further improve treatment efficacy. In this study, we performed single-cell analysis on 14 patients with ESCC undergoing nICT and revealed tumor microenvironment (TME) features associated with differential treatment responses. Nonnegative matrix factorization (NMF) identified five coordinated cellular programs with distinct response associations. Specifically, the NMF3 program, mainly comprising immunosuppressive cell subsets, was enriched in the minimal or no pathologic tumor regression [tumor regression staging 3 (TRS3)] group, in which regulatory T cells (Treg) and dendritic cells (DC) exhibited a close correlation. In addition, elevated expression of mitochondrial transcription factor A (TFAM) in DCs was associated with increased Treg infiltration in the TRS3 group. A myeloid-specific Tfam knockout mouse model showed that TFAM deficiency reversed the immunosuppressive TME, inhibited tumor growth, and enhanced the response to anti-programmed cell death protein 1 therapy in ESCC. Mechanistically, TFAM deficiency in DCs activated the stimulator of IFN genes (STING)-TBK1-IRF3 pathway, thereby promoting DC maturation to enhance antitumor immunity. Overall, this study characterized the TME in residual ESCC after nICT and revealed an association between elevated TFAM expression in DCs and poor responsiveness to nICT. These findings indicate the critical role of TFAM deficiency in DCs in activating antitumor immunity, highlighting the potential of targeting TFAM to improve the efficacy of immunotherapy and optimize therapeutic strategies. TFAM mediates dendritic cell activation through the STING-TBK1-IRF3 pathway and is associated with responsiveness to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma, identifying TFAM as a putative immunotherapeutic target and biomarker.
中文摘要:新辅助免疫化疗(nICT)已成为食管鳞状细胞癌(ESCC)有前景的新辅助治疗策略。识别影响nICT应答的因素有助于进一步提高疗效。本研究对14例接受nICT的ESCC患者进行单细胞分析,揭示了与治疗应答差异相关的肿瘤微环境(TME)特征。非负矩阵分解(NMF)识别出五个协同的细胞程序,其与应答的关联各不相同。具体而言,NMF3程序主要由免疫抑制性细胞亚群组成,在病理肿瘤退缩极少或无退缩[肿瘤退缩分期3(TRS3)]组中富集,该组中调节性T细胞(Treg)与树突状细胞(DC)呈现密切相关性。在TRS3组中,DC线粒体转录因子A(TFAM)表达升高与Treg浸润增加相关。髓系特异性Tfam敲除小鼠模型显示,TFAM缺失可逆转免疫抑制性TME,抑制肿瘤生长,并增强ESCC对抗日程序性细胞死亡蛋白1治疗的应答。机制上,DC中TFAM缺失激活干扰素基因刺激因子(STING)-TBK1-IRF3通路,促进DC成熟,从而增强抗肿瘤免疫。本研究刻画了nICT后残留ESCC的TME,并揭示DC中TFAM表达升高与nICT应答不佳之间的关联。这些发现表明DC中TFAM缺失在激活抗肿瘤免疫中的关键作用,凸显靶向TFAM以提高免疫治疗疗效并优化治疗策略的潜力。TFAM通过STING-TBK1-IRF3通路介导树突状细胞活化,并与食管鳞状细胞癌新辅助免疫化疗的应答相关,提示TFAM可作为潜在的免疫治疗靶点和生物标志物。
Although checkpoint inhibitors have revolutionized cancer treatment, responses are largely restricted to targeting CTLA-4 and PD-(L)1. TNFR2 has been identified as a promising target, but further therapeutic development requires a better understanding of whether agonists or blockers should be used and whether FcγR interactions promote efficacy. In this study, we engineered two distinct α-TNFR2 antibody types: ligand-blocking FcγR-engaging versus non-ligand-blocking agonist antibodies. Both showed potent antitumor efficacy across multiple syngeneic mouse tumor models and combined effectively with α-PD-1. The ligand-blocking antibody depleted intratumoral regulatory T cells (Treg) and reprogrammed the myeloid compartment, directing monocytes toward a proinflammatory macrophage and dendritic cell trajectory. Interestingly, this effect depended on both inhibitory and activating FcγRs, reflecting the simultaneous action on Tregs and myeloid cells. In contrast, the agonist directly costimulated T and NK cells, partially through FcγR-independent mechanisms. Both antibodies converged on activating tumor-specific CD8+ T cells mediating tumor rejection. Clinical assessment of both ligand-blocking (BI-1808) and agonist (BI-1910) α-TNFR2 antibodies is currently ongoing. Identification and mechanistic characterization of two functionally distinct TNFR2 targeting antibodies highlights factors important for leveraging this target for successful cancer immunotherapy.
中文摘要:检查点抑制剂虽已改变肿瘤治疗格局,但其应答基本局限于靶向CTLA-4与PD-(L)1。TNFR2被视为有前景的靶点,但要推进治疗开发,需进一步明确应使用激动型还是阻断型抗体,以及FcγR相互作用是否增强疗效。本研究构建了两类不同的抗TNFR2抗体:结合FcγR的配体阻断型抗体与不阻断配体的激动型抗体。两者在多种同系小鼠肿瘤模型中均显示出强效抗肿瘤作用,并与抗PD-1抗体有效联合。配体阻断型抗体清除瘤内调节性T细胞(Treg)并重编程髓系细胞区室,使单核细胞向促炎巨噬细胞与树突状细胞轨迹分化。这一效应依赖抑制性FcγR与激活性FcγR两者,反映其对Treg与髓系细胞的同时作用。激动型抗体则直接共刺激T细胞与NK细胞,部分通过不依赖FcγR的机制实现。两类抗体最终均汇聚于激活肿瘤特异性CD8+ T细胞以介导肿瘤排斥。配体阻断型(BI-1808)与激动型(BI-1910)抗TNFR2抗体的临床评估正在进行中。两种功能不同的TNFR2靶向抗体的发现与机制刻画,突出显示了将这一靶点用于成功肿瘤免疫治疗所需考量的关键因素。
Most patients with solid tumors fail to sustain antitumor immunity, in part because immune cells cannot outcompete cancer cells inside the immunosuppressive tumor microenvironment. Here, we show the lipid-sensing transcription factor PPARδ is a compartment-specific determinant of cancer-immune fitness balance and immunotherapy efficacy. Activating PPARδ in cancer cells promotes their growth and impairs antitumor immunity, whereas activating it in immune cells drives tumor suppression and overrides tumor-promoting effects of cancer-intrinsic activation. Mechanistically, PPARδ enhances CD8+ T cell fitness against cancer through effector-associated chromatin remodeling and Cpt1a-mediated fatty acid oxidation. Therapeutically, PPARδ-activated CD8+ T cells sensitize immunotherapy-resistant microsatellite stable metastatic colorectal cancer to checkpoint blockade in mice, and pharmacological or genetic PPARδ activation enhances human chimeric antigen receptor T cell function. These findings identify compartment-specific PPARδ activity as a targetable driver of immune cell fitness that can be harnessed to improve outcomes in immunotherapy-resistant tumors.
中文摘要:实体瘤患者多数难以维持抗肿瘤免疫,部分原因是免疫细胞在免疫抑制性肿瘤微环境中无法胜过癌细胞。这里我们展示脂质感应转录因子PPARδ是癌症-免疫适应度平衡与免疫治疗疗效的区室特异性决定因素。在癌细胞中激活PPARδ促进其生长并损害抗肿瘤免疫,而在免疫细胞中激活它则驱动肿瘤抑制,并压过癌细胞内在激活的促瘤效应。机制上,PPARδ通过效应相关的染色质重塑和Cpt1a介导的脂肪酸氧化增强CD8+ T细胞对抗癌症的适应度。治疗上,PPARδ激活的CD8+ T细胞使免疫治疗耐药的小鼠微卫星稳定转移性结直肠癌对检查点阻断敏感,药物或遗传学激活PPARδ增强人嵌合抗原受体T细胞功能。这些发现确定区室特异性PPARδ活性是可靶向的免疫细胞适应度驱动因素,可用于改善免疫治疗耐药肿瘤的结局。
Traditional tumor therapies have limited efficacy, leading to a high mortality rate. Although immunotherapy holds considerable therapeutic promise, clinical immunotherapy for solid tumors only elicits durable responses in a minority of patients. This limitation is largely attributed to the highly immunosuppressive nature of the tumor microenvironment (TME). Notably, conventional chemodynamic therapy (CDT) is hampered by endogenous hydrogen peroxide (H2O2) shortage in tumor cells, and AZP compensates this defect via in-situ H2O2 self-supplementation to amplify hydroxyl radical generation. To develop a nanoplatform capable of systematically enhancing anti-tumor immunity, we rationally constructed a PEGylated zinc peroxide-coated gold nanorod (AZP) as a therapeutic adjuvant with acid-responsive properties for the combination therapy of cancer. Gold nanorod-based adjuvants coated with zinc peroxide were successfully prepared via chemical oxidation, followed by PEGylation. The morphology and size of the AZP were characterized using transmission electron microscopy (TEM) and hydrodynamic diameter measurements. The elemental composition of AZP was determined by X-ray photoelectron spectroscopy and energy-dispersive X-ray spectroscopy analysis. The acid-responsive degradation and photothermally enhanced catalytic properties of AZP were evaluated using TEM, inductively coupled plasma mass spectrometry, absorption spectroscopy, and thermal imaging tracing. The therapeutic mechanism of AZP at the cellular level was investigated through a series of experiments, including TEM, fluorescence imaging, immunofluorescence assays, Seahorse analysis, western blotting, and bioinformatics approaches, which comprehensively clarified the anti-tumor mechanism of AZP. Bilateral tumor and metastatic tumor models were established to verify the anti-tumor efficacy and mechanism of AZP at the animal level. Specifically, fluorescence imaging, immunofluorescence staining, tissue staining analysis, enzyme-linked immunosorbent assay, and flow cytometry were performed to assess the in vivo therapeutic effects. In the acidic TME, the AZP nanoplatform releases H2O2 and zinc ions, which increases the reactive oxygen species level in cancer cells. Additionally, due to its photothermally enhanced peroxidase-like activity, AZP induces the generation of more hydroxyl radicals under light irradiation. These effects synergistically disrupt lysosomes and mitochondria in tumor cells, block autophagy, and ultimately lead to tumor cell death. Furthermore, zinc supplementation by AZP enhances the activation of the cyclic GMP-AMP synthase and stimulator of interferon genes (cGAS-STING) pathway. Meanwhile, the combined treatment induces immunogenic cell death of cancer cells, which promotes the release of tumor-associated antigens and activates robust anti-tumor immune responses. Notably, intratumoral injection of the AZP adjuvant combined with irradiation effectively eradicates in situ tumors. When further combined with PD-1 antibody, this regimen can induce anti-tumor immunity, significantly inhibiting tumor growth, metastasis, and recurrence in a murine model without causing obvious toxicity. The AZP nanoplatform exhibits excellent therapeutic efficacy, providing a rational design strategy for a potent adjuvant that integrates photothermally enhanced chemodynamic therapy and metalloimmunotherapy for the treatment of solid tumors.
中文摘要:传统肿瘤治疗疗效有限,死亡率高。免疫治疗具有较大治疗前景,但实体瘤临床免疫治疗仅在少数患者中产生持久应答,这一限制很大程度上归因于肿瘤微环境(TME)的高度免疫抑制特性。常规化学动力学治疗(CDT)受肿瘤细胞内源性过氧化氢(H2O2)不足制约,AZP通过原位H2O2自补充弥补这一缺陷,放大羟自由基生成。为构建能够系统性增强抗肿瘤免疫的纳米平台,我们合理设计了一种具有酸响应特性的聚乙二醇化过氧化锌包覆金纳米棒(AZP)作为治疗佐剂,用于癌症联合治疗。通过化学氧化制备过氧化锌包覆的金纳米棒基佐剂,随后进行聚乙二醇化。采用透射电子显微镜(TEM)和水合粒径测量表征AZP的形貌与尺寸。通过X射线光电子能谱和能量色散X射线光谱分析确定AZP的元素组成。利用TEM、电感耦合等离子体质谱、吸收光谱和热成像示踪评估AZP的酸响应降解及光热增强催化性能。通过TEM、荧光成像、免疫荧光分析、Seahorse分析、蛋白质印迹和生物信息学方法等一系列实验研究AZP在细胞水平的治疗机制,全面阐明其抗肿瘤机制。建立双侧肿瘤和转移性肿瘤模型,在动物水平验证AZP的抗肿瘤疗效与机制。具体而言,采用荧光成像、免疫荧光染色、组织染色分析、酶联免疫吸附测定和流式细胞术评估体内治疗效果。在酸性TME中,AZP纳米平台释放H2O2和锌离子,提高癌细胞内活性氧水平。由于其光热增强的类过氧化物酶活性,AZP在光照下诱导生成更多羟自由基。这些作用协同破坏肿瘤细胞的溶酶体和线粒体,阻断自噬,最终导致肿瘤细胞死亡。AZP补充锌可增强环鸟苷酸-腺苷酸合成酶和干扰素基因刺激因子(cGAS-STING)通路的激活。联合治疗诱导癌细胞免疫原性细胞死亡,促进肿瘤相关抗原释放并激活强效抗肿瘤免疫应答。瘤内注射AZP佐剂联合照射可有效清除原位肿瘤。进一步联合PD-1抗体后,该方案可诱导抗肿瘤免疫,在小鼠模型中显著抑制肿瘤生长、转移和复发,未引起明显毒性。AZP纳米平台表现出优异的治疗效果,为整合光热增强化学动力学治疗与金属免疫治疗以治疗实体瘤的高效佐剂提供了合理设计策略。
Prolonged colonic inflammation and ulcerative colitis lead to colon cancer. The rapid growth and treatment-resistant nature of these tumors are primarily influenced by an immunosuppressive tumor microenvironment, which is led by tumor-associated macrophages (TAMs). However, factors influencing or regulating the immunosuppressive nature of TAMs have not been sufficiently studied. In this manuscript, we use a mouse model of colitis-associated colorectal cancer (CRC) to demonstrate that WNT expression in TAMs regulates their immunosuppressive function by inhibiting Glycogen synthase kinase-3 beta (GSK-3β) within the macrophages, possibly through an autofeedback loop. GSK3β is a positive regulator of PD-1 and PD-L1 expression in macrophages and promotes an immunosuppressive microenvironment. Therefore, GSK-3β inhibition alters the immunosuppressive nature of the immune microenvironment and effectively controls tumor growth. In Csf1r.iCre; Porcnfl/fl mice, the absence of macrophage-derived WNT promotes tumor growth in the model of colitis-associated colon cancer. Absence of macrophage-derived WNT stabilizes GSK-3β in macrophages and promotes an immunosuppressive tumor microenvironment. We also show that pharmacological inhibition of GSK-3β in a macrophage-specific manner, achieved by systemic delivery of a lipo-GSK3β inhibitor, effectively inhibits tumor growth. Therefore, this manuscript demonstrates for the first time that the macrophage-specific modulation of GSK3β can be a potential target to treat colitis-associated colon cancer.
中文摘要:持续性结肠炎症和溃疡性结肠炎可导致结肠癌。这类肿瘤的快速生长和治疗抵抗主要受免疫抑制性肿瘤微环境影响,而肿瘤相关巨噬细胞(TAMs)在其中起主导作用。影响或调控TAMs免疫抑制特性的因素尚未得到充分研究。本稿利用结肠炎相关结直肠癌(CRC)小鼠模型证明,TAMs中的WNT表达可通过抑制巨噬细胞内的糖原合成酶激酶-3β(GSK-3β)来调控其免疫抑制功能,可能经由自身反馈环路实现。GSK3β是巨噬细胞中PD-1和PD-L1表达的正向调控因子,并促进免疫抑制性微环境。因此,抑制GSK-3β可改变免疫微环境的免疫抑制特性并有效控制肿瘤生长。在Csf1r.iCre; Porcnfl/fl小鼠中,巨噬细胞来源WNT缺失会促进结肠炎相关结肠癌模型中的肿瘤生长。巨噬细胞来源WNT缺失使巨噬细胞中的GSK-3β稳定,并促进免疫抑制性肿瘤微环境。我们还显示,通过全身递送脂质体GSK3β抑制剂实现巨噬细胞特异性药理抑制GSK-3β,可有效抑制肿瘤生长。因此,本稿首次证明,巨噬细胞特异性地调控GSK3β可作为治疗结肠炎相关结肠癌的潜在靶点。
Metal ions serve as key regulators of the dynamic equilibrium within the tumor microenvironment (TME). In recent years, the TME has emerged as a central regulatory hub for tumor initiation, progression, and metastasis; its complexity has become both a frontier and a major challenge in oncology research. Current therapies are often constrained by immune tolerance, metabolic heterogeneity, and microenvironment-mediated escape mechanisms, necessitating breakthroughs in novel targets and strategies. Metal ions, functioning as enzyme cofactors, signaling molecules, and redox regulators, profoundly affect tumor progression by modulating redox homeostasis, immune responses, and metabolic reprogramming. This review provides a comprehensive overview of recent advances in metal ion-mediated regulation of the TME. It focuses on elucidating the multidimensional mechanisms by which metal ions facilitate immunogenic remodeling and metabolic interactions, and prospectively explores innovative metal-ion-based diagnostic and therapeutic strategies. It further highlights the potential of personalized metal metabolomics to advance precision oncology and facilitate the clinical translation of metal ion-based theranostic strategies.
中文摘要:金属离子是肿瘤微环境(TME)动态平衡的关键调控因子。近年来,TME已成为肿瘤发生、进展和转移的核心调控枢纽,其复杂性既是肿瘤学研究的前沿,也是主要挑战。现有治疗常受免疫耐受、代谢异质性及微环境介导的逃逸机制限制,亟需在新靶点与新策略上取得突破。金属离子作为酶辅因子、信号分子和氧化还原调控因子,通过调节氧化还原稳态、免疫应答和代谢重编程深刻影响肿瘤进展。该综述系统梳理金属离子介导TME调控的最新进展,重点阐释金属离子促进免疫原性重塑与代谢相互作用的多维机制,并前瞻性探讨基于金属离子的创新诊断与治疗策略。文章进一步强调个性化金属代谢组学在推进精准肿瘤学及促进金属离子诊疗一体化策略临床转化方面的潜力。
Reciprocal interactions between immune and stromal cells are increasingly recognized as major determinants of colorectal cancer (CRC) progression. However, the specific macrophage and fibroblast states cooperating to establish and sustain a tumor-promoting microenvironment remains incompletely understood. Here, we identify a self-reinforcing inflammatory circuit linking monocyte-derived IL-1β+ macrophages with IL1R1+ cancer-associated fibroblasts (CAFs) in CRC. Integrated single-cell transcriptomic analyses of human CRC revealed a marked expansion of IL1B-associated inflammatory macrophages and IL1R1+ inflammatory CAFs, with their respective and combined transcriptional signatures associated with adverse clinical outcomes. Pseudotime analysis and Ms4a3 lineage tracing supported a predominantly monocyte-derived origin of IL-1β+ macrophages in the tumor microenvironment. Mechanistically, macrophage-derived IL-1β activated IL1R1 signaling in fibroblasts, promoting the acquisition and expansion of an inflammatory CAF state. Myeloid Il1b deletion or fibroblast-lineage Il1r1 deletion disrupted this interaction and suppressed tumor growth in vivo. In turn, IL1R1+ CAFs produced abundant CCL2, which recruited CCR2+ monocytes and replenished the IL-1β+ macrophage population. Fibroblast-lineage Ccl2 deletion, myeloid Ccr2 deletion, and CCL2 rescue experiments established the functional requirement of the CCL2-CCR2 axis for closure of this reciprocal circuit. Acquisition of the IL-1β+ inflammatory macrophage program was further supported by coordinated NF-κB and AP-1 activity, with RELA and JUN/FOS contributing to IL1B transcriptional regulation. Finally, therapeutic blockade of either IL-1β or CCL2 disrupted the macrophage-CAF circuit, increased intratumoral CD8+ T-cell responses, and enhanced the antitumor efficacy of anti-PD-1 therapy. Collectively, our findings establish the IL-1β-IL1R1-CCL2-CCR2 axis as a self-amplifying immune-stromal circuit that sustains a tumor-promoting and immunosuppressive microenvironment in CRC. By demonstrating that disruption of this circuit restores antitumor immune activity and sensitizes tumors to PD-1 blockade, our study provides a mechanistic and preclinical rationale for targeting IL-1β-CCL2-mediated macrophage-CAF crosstalk as a combination strategy to improve immunotherapy responses in CRC.
中文摘要:免疫细胞与基质细胞之间的相互互作日益被视为结直肠癌(CRC)进展的重要决定因素。然而,哪些巨噬细胞和成纤维细胞状态协同建立并维持促瘤微环境仍不完全清楚。研究在CRC中识别出一个自我强化的炎症回路,将单核细胞来源的IL-1β+巨噬细胞与IL1R1+癌症相关成纤维细胞(CAF)连接起来。对人类CRC的单细胞转录组整合分析显示,IL1B相关炎症巨噬细胞和IL1R1+炎症CAF明显扩增,其各自及联合的转录特征与不良临床结局相关。拟时序分析和Ms4a3谱系追踪支持肿瘤微环境中IL-1β+巨噬细胞主要来源于单核细胞。机制上,巨噬细胞来源的IL-1β激活成纤维细胞中的IL1R1信号,促进炎症性CAF状态的获得和扩增。髓系Il1b缺失或成纤维细胞谱系Il1r1缺失破坏这一互作并在体内抑制肿瘤生长。反过来,IL1R1+ CAF产生大量CCL2,招募CCR2+单核细胞并补充IL-1β+巨噬细胞群体。成纤维细胞谱系Ccl2缺失、髓系Ccr2缺失以及CCL2挽救实验确立了CCL2-CCR2轴对这一互惠回路闭合的功能必要性。NF-κB与AP-1活性协同进一步支持IL-1β+炎症巨噬细胞程序的获得,RELA和JUN/FOS参与IL1B的转录调控。最后,治疗性阻断IL-1β或CCL2可破坏巨噬细胞-CAF回路,增加瘤内CD8+ T细胞反应,并增强抗PD-1治疗的抗肿瘤疗效。总体而言,这些发现确立IL-1β-IL1R1-CCL2-CCR2轴是一个自我放大的免疫-基质回路,在CRC中维持促瘤和免疫抑制微环境。破坏该回路可恢复抗肿瘤免疫活性并使肿瘤对PD-1阻断敏感,这为靶向IL-1β-CCL2介导的巨噬细胞-CAF交互作为改善CRC免疫治疗反应的联合策略提供了机制与临床前依据。
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is characterized by a highly infiltrated yet immunosuppressive tumor microenvironment (TME), in which tumor-associated macrophages (TAMs) contribute to disease progression. Here, we identify an extracellular vesicle (EV)-mediated LMP1-NF-κB-LIF signaling axis that promotes macrophage reprogramming and immune suppression in NPC. Single-cell transcriptomic analysis revealed that EV exposure induces transcriptional remodeling across tumor and immune-cell populations, accompanied by an increased proportion of TAMs within the myeloid compartment. NPC-derived EVs were taken up by macrophages, where EV-associated LMP1 induced NF-κB activation, LIF expression, and polarization toward an immunosuppressive phenotype. Loss- and gain-of-function studies, together with structure-function analyses of the LMP1 CTAR1/CTAR2 domains, further supported the requirement of these CTAR domains for efficient NF-κB activation and LIF induction. Functionally, EV-educated macrophages exhibited impaired phagocytic activity and promoted inhibitory T-cell responses. In zebrafish, 3D spheroid, and mouse xenograft models, EV-educated macrophages promoted NPC growth and vascular dissemination, whereas blockade of LIF signaling with soluble LIFR attenuated these effects. Tumor LIF expression positively correlated with CTLA4 expression. In NPC tissues, LIF expression was preferentially associated with stromal macrophages, and elevated stromal LIF expression was associated with metastasis, advanced nodal disease, and advanced clinical stage. Stromal immune-cell LMP1 expression also correlated with LIF expression and was higher in patients who developed metastasis. Collectively, these findings support an EV-associated LMP1-NF-κB-LIF axis that links EBV-positive NPC cells to macrophage-mediated immune suppression and tumor progression and provide a basis for further investigating this pathway as a potential therapeutic target.
中文摘要:EBV相关鼻咽癌具有高度浸润但免疫抑制的肿瘤微环境(TME),其中肿瘤相关巨噬细胞(TAM)促进疾病进展。研究识别出一条由细胞外囊泡(EV)介导的LMP1-NF-κB-LIF信号轴,促进鼻咽癌中的巨噬细胞重编程和免疫抑制。单细胞转录组分析显示,EV暴露引起肿瘤细胞和免疫细胞群体的转录重塑,并伴随髓系细胞区室中TAM比例增加。鼻咽癌来源EV被巨噬细胞摄取,EV相关LMP1诱导NF-κB活化、LIF表达及向免疫抑制表型极化。功能缺失和功能获得研究,结合LMP1 CTAR1/CTAR2结构域的结构-功能分析,进一步支持这些CTAR结构域对有效NF-κB活化和LIF诱导的必要性。功能上,经EV驯化的巨噬细胞吞噬活性受损,并促进抑制性T细胞反应。在斑马鱼、3D球体和小鼠异种移植模型中,经EV驯化的巨噬细胞促进鼻咽癌生长和血管播散,而用可溶性LIFR阻断LIF信号可减弱这些效应。肿瘤LIF表达与CTLA4表达正相关。在鼻咽癌组织中,LIF表达优先与间质巨噬细胞相关,间质LIF表达升高与转移、晚期淋巴结病变和晚期临床分期相关。间质免疫细胞LMP1表达也与LIF表达相关,并且在发生转移的患者中更高。这些发现支持EV相关LMP1-NF-κB-LIF轴将EBV阳性鼻咽癌细胞与巨噬细胞介导的免疫抑制和肿瘤进展联系起来,并为进一步研究该通路作为潜在治疗靶点提供依据。
Immunotherapy has improved outcomes for patients with breast cancer, yet therapeutic resistance remains a major clinical challenge. Therefore, we integrated single-cell and spatial transcriptomic data from breast cancer cohorts treated with immune checkpoint inhibitors to identify resistance-associated cellular populations and pathways, with validation across eight independent bulk RNA-seq immunotherapy cohorts. Cancer-associated fibroblasts (CAFs) were isolated from anti-PD-1-resistant breast tumors for functional studies, including in vitro co-culture and in vivo models. Mitochondrial function and metabolic alterations were assessed by flow cytometry, transmission electron microscopy, ATP and adenosine quantification, and JC-1 staining. Tumor mitochondrial metabolism was markedly upregulated in anti-PD-1 non-responders and consistently associated with poor therapeutic response across validation cohorts. MDK-expressing CAFs were enriched in resistant tumors, exhibited strong interactions with tumor cells, and were negatively associated with intratumoral CD8+ T cell infiltration. Single-cell source contribution and depletion analyses identified CAF-derived MDK as the major paracrine mediator linking stromal signaling to tumor metabolic adaptation and immune suppression. Mechanistically, MDK activated SDC1-dependent PI3K/AKT/mTOR signaling in cancer cells, promoting mitochondrial metabolic reprogramming, ATP production, and CD38/CD73-dependent extracellular adenosine accumulation, thereby suppressing CD8+ T cell cytotoxicity. Receptor-depletion experiments further identified SDC1 as the principal functional receptor mediating these effects. Importantly, CAF-specific MDK depletion or pharmacological MDK inhibition enhanced anti-PD-1 efficacy and restored CD8+ T cell effector activity in vivo. Collectively, MDK+ CAFs facilitate anti-PD-1 resistance via mitochondrial rewiring and adenosine-mediated immunosuppression, supporting the MDK-SDC1 axis as a potential therapeutic target for overcoming resistance and improving immunotherapy efficacy in breast cancer.
中文摘要:免疫治疗改善了乳腺癌患者的结局,但治疗耐药仍是主要临床挑战。为识别耐药相关细胞群体和通路,整合了接受免疫检查点抑制剂治疗的乳腺癌队列的单细胞与空间转录组数据,并在八个独立的批量RNA测序免疫治疗队列中进行验证。从抗PD-1耐药的乳腺肿瘤中分离癌症相关成纤维细胞(CAFs)开展功能研究,包括体外共培养和体内模型。通过流式细胞术、透射电子显微镜、ATP与腺苷定量以及JC-1染色评估线粒体功能和代谢改变。抗PD-1无应答者的肿瘤线粒体代谢明显上调,并在验证队列中一致与较差的治疗反应相关。表达MDK的CAFs在耐药肿瘤中富集,与肿瘤细胞存在强相互作用,并与瘤内CD8+ T细胞浸润呈负相关。单细胞来源贡献与缺失分析确定CAF来源的MDK是连接基质信号与肿瘤代谢适应及免疫抑制的主要旁分泌介质。机制上,MDK激活癌细胞中依赖SDC1的PI3K/AKT/mTOR信号,促进线粒体代谢重编程、ATP产生以及依赖CD38/CD73的细胞外腺苷积累,从而抑制CD8+ T细胞细胞毒性。受体缺失实验进一步确定SDC1是介导这些作用的主要功能受体。CAF特异性MDK缺失或药物抑制MDK增强了体内抗PD-1疗效并恢复CD8+ T细胞效应活性。MDK+ CAFs通过线粒体重塑和腺苷介导的免疫抑制促进抗PD-1耐药,支持将MDK-SDC1轴作为克服耐药、提高乳腺癌免疫治疗疗效的潜在治疗靶点。
Atovaquone is an approved antimalarial drug which could sensitise tumours to radiation and may modulate tumour immune microenvironment. Here we evaluated the triple combination of radiation with atovaquone plus anti-PD-L1 in HNSCC syngeneic mouse tumour models. We observed significant tumour growth delay induced by the triple combination treatment with differential responses in three different mouse models. There was complete tumour eradication in 6 of 12 mice in the MOCL1 model but not in the other two murine models. The triple combination was associated with increased populations of CD8+-T Granzyme B+ cells as well as decreased populations of Tregs, CD11b+Gr1+ granulocytic MDSCs and CD11b+ Ly.6G+ neutrophils. Atovaquone inhibited EGFR and its downstream signalling as well as reduced PD-L1 expression. The differential antitumour effects of the triple combination may be due to different basal and post-treatment levels of PD-L1, pERK1/2 and pS6, in particular, their levels were reduced by atovaquone +/- RT in MOCL1 models and not in the other two murine models. Radiotherapy plus atovaquone combination increased cell cycle arrest in G2/M phase, which led to inhibition of DNA damage repair by homologous recombination and increased cell death. We also observed increased activation of CD8+-T cells that led to enhanced killing in our HNSCC patient-derived organoid models treated with the triple combination of radiotherapy and atovaquone plus PD-1/PD-L1 blockade. Overall, our results suggest that the triple combination of radiotherapy and atovaquone plus PD-1/PD-L1 blockade has the potential to increase the efficacy of radiotherapy and/or immunotherapy. Thus, this may provide a rationale to further validate this triple combination of radiotherapy and atovaquone plus PD-1/PD-L1 blockade in clinical trials to improve treatment outcomes.
中文摘要:阿托伐醌是已获批的抗疟药,可使肿瘤对放疗更敏感,并可能调节肿瘤免疫微环境。本研究在HNSCC同系小鼠肿瘤模型中评估放疗联合阿托伐醌及抗PD-L1的三联方案。三联治疗显著延迟肿瘤生长,三种小鼠模型反应存在差异。MOCL1模型中12只小鼠有6只肿瘤完全消退,另两种模型未见此现象。三联方案与CD8+颗粒酶B+ T细胞增多以及Treg、CD11b+Gr1+粒细胞系MDSC和CD11b+Ly.6G+中性粒细胞减少相关。阿托伐醌抑制EGFR及其下游信号,并降低PD-L1表达。三联方案抗肿瘤作用差异可能源于PD-L1、pERK1/2和pS6基线与治疗后水平不同,尤其MOCL1模型中阿托伐醌联合或不联合放疗可降低这些指标,另两种模型未降低。放疗联合阿托伐醌增加G2/M期细胞周期阻滞,进而抑制同源重组DNA损伤修复并增加细胞死亡。在HNSCC患者来源类器官模型中,放疗联合阿托伐醌及PD-1/PD-L1阻断的三联治疗也观察到CD8+ T细胞活化增强,杀伤作用提高。这些结果提示,放疗联合阿托伐醌及PD-1/PD-L1阻断的三联方案可能提高放疗和/或免疫治疗疗效,为在临床试验中进一步验证该三联方案以改善治疗结局提供了依据。
Two recent papers in Cell Host & Microbe move microbiome therapeutics beyond selecting "beneficial" strains. By turning bacterial surfaces into oral vaccine couriers and resident microbial metabolism into a controllable reactor, they show how location, control, and measurable output can transform the gut into a precision platform for cancer immunotherapy.
中文摘要:《Cell Host & Microbe》近期两篇论文让微生物组疗法不再局限于筛选「有益」菌株。通过把细菌表面变成口服疫苗载体、把常驻微生物代谢变成可控反应器,它们展示了位置、控制与可测量输出如何将肠道转化为癌症免疫治疗的精准平台。
Lung squamous cell carcinoma (LUSC) is an aggressive subtype of non-small cell lung cancer with limited targeted therapeutic options and incompletely defined immune-regulatory dependencies. Here, we identified atypical chemokine receptor 3 (ACKR3) as a squamous-enriched regulator that restrains malignant progression in LUSC. Integrative analyses of human LUSC datasets, autochthonous genetically engineered mouse models, and ex vivo organoid systems showed that ACKR3 loss accelerated tumor growth and remodeled the immune microenvironment, marked by reduced CD8⁺ T cell infiltration and increased T cell exhaustion. Mechanistically, ACKR3 limited activation of the MIF-CD74-PD-L1 axis, thereby constraining tumor-cell PD-L1 expression and preserving antitumor immune surveillance. In preclinical LUSC models, treatment with the ACKR3-directed PD-L1 degrader KineTAC, a bispecific molecule that co-engages ACKR3 and PD-L1 to promote lysosomal degradation of PD-L1, enhanced antitumor efficacy, particularly in combination with chemotherapy. Together, these findings define ACKR3 as a squamous-associated immune checkpoint regulator and nominate ACKR3-directed PD-L1 degradation as a tumor-selective therapeutic strategy for LUSC.
中文摘要:肺鳞状细胞癌(LUSC)是非小细胞肺癌中侵袭性较强的一个亚型,靶向治疗选择有限,其免疫调控依赖关系也尚未完全阐明。研究将非典型趋化因子受体3(ACKR3)鉴定为在鳞癌中富集、并抑制LUSC恶性进展的调控因子。对人类LUSC数据集、自发型基因工程小鼠模型及离体类器官系统的整合分析显示,ACKR3缺失加快肿瘤生长并重塑免疫微环境,表现为CD8⁺ T细胞浸润减少、T细胞耗竭增加。机制上,ACKR3限制MIF-CD74-PD-L1轴的激活,从而抑制肿瘤细胞PD-L1表达、维持抗肿瘤免疫监视。在LUSC临床前模型中,靶向ACKR3的PD-L1降解剂KineTAC(一种同时结合ACKR3与PD-L1、促使PD-L1经溶酶体降解的双特异性分子)增强抗肿瘤疗效,与化疗联合时尤为明显。这些结果将ACKR3界定为鳞癌相关的免疫检查点调控因子,并提出以ACKR3为靶向的PD-L1降解可作为LUSC的肿瘤选择性治疗策略。
Hepatocellular carcinoma (HCC) driven by gain-of-function mutations in CTNNB1 (CTNNB1GOF) that stabilize β-catenin exhibits a profoundly immunosuppressive tumor microenvironment (TME), rendering it resistant to immune checkpoint blockade (ICB). Metabolic reprogramming is increasingly recognized as a crucial mediator of immune activity, highlighting the need to elucidate the specific metabolic mechanisms underlying immune exclusion in CTNNB1GOF HCC. Here, we identified a critical metabolic-immune network orchestrated by co-mutations of CTNNB1 and ARID2. Integrative analysis of HCC patient cohorts and a de novo MYC/CTNNB1GOF HCC mouse model revealed that tumors harboring concurrent CTNNB1 and ARID2 mutations exhibited a more immune-active TME and improved survival compared to tumors with CTNNB1 mutations alone. Mechanistically, β-catenin and ARID2 cooperatively enhanced the transcription of tryptophan 2,3-dioxygenase (TDO2), leading to accelerated kynurenine production and activation of the aryl hydrocarbon receptor (AhR) in myeloid-derived suppressor cells (MDSCs). This metabolic axis established an immunosuppressive milieu characterized by MDSC accumulation and impaired T cell function. Genetic ablation of Arid2 in CTNNB1GOF HCC attenuated TDO2-dependent kynurenine synthesis, reduced MDSC infiltration, and enhanced CD8⁺ T cell cytotoxicity, thereby sensitizing tumors to anti-PD-1 therapy. Clinically, co-mutations of CTNNB1 and ARID2 correlated with elevated immune infiltration and favorable ICB responses across multiple human cancers, including HCC. Importantly, pharmacological inhibition of AhR phenocopied the immunomodulatory effect of ARID2 loss and, when combined with anti-PD-1, robustly reversed the immune-cold phenotype of CTNNB1GOF HCC. These findings reveal TDO2-kynurenine-AhR signaling as a pivotal metabolic pathway enforcing immune evasion in CTNNB1-mutant HCC.
中文摘要:由CTNNB1功能获得性突变(CTNNB1GOF)稳定β-catenin所驱动的肝细胞癌(HCC)具有深度免疫抑制的肿瘤微环境(TME),对免疫检查点阻断(ICB)耐药。代谢重编程日益被视为免疫活性的关键介导因素,因此需要阐明CTNNB1GOF HCC免疫排斥背后的特定代谢机制。我们鉴定出由CTNNB1与ARID2共突变协调的关键代谢-免疫网络。对HCC患者队列及新构建的MYC/CTNNB1GOF HCC小鼠模型进行整合分析显示,与仅携带CTNNB1突变的肿瘤相比,同时携带CTNNB1和ARID2突变的肿瘤表现出更活跃的免疫TME和更好的生存。机制上,β-catenin与ARID2协同增强色氨酸2,3-双加氧酶(TDO2)的转录,导致犬尿氨酸生成加速并激活髓源性抑制细胞(MDSC)中的芳香烃受体(AhR)。这一代谢轴建立了以MDSC积聚和T细胞功能受损为特征的免疫抑制环境。在CTNNB1GOF HCC中遗传性敲除Arid2可减弱TDO2依赖的犬尿氨酸合成,减少MDSC浸润,增强CD8⁺ T细胞细胞毒性,从而使肿瘤对抗PD-1治疗敏感。临床上,CTNNB1与ARID2共突变与包括HCC在内的多种人类癌症中免疫浸润升高和有利的ICB反应相关。AhR的药理抑制可重现ARID2缺失的免疫调节效应,并与抗PD-1联合时强力逆转CTNNB1GOF HCC的免疫冷表型。这些发现揭示TDO2-犬尿氨酸-AhR信号是CTNNB1突变HCC中维持免疫逃逸的关键代谢通路。
Immunotherapy shows great promise against cancer, yet imbalanced tryptophan (Trp) metabolism drives tumor immune tolerance, severely limiting its efficacy. To address this, we advance a synergistic host-microbe metabolism-regulated strategy that concurrently amplifies microbial indole pathway while suppressing the host kynurenine (Kyn) pathway to correct metabolic and immune dysregulation, thereby enhancing antitumor immunity. To produce an oral co-delivery nanoparticle, mesoporous silica nanoparticles are loaded with Trp via ester bonds and coated with agar containing the metabolism inhibitor NLG919 (NLG). This design enables enzyme-responsive release of Trp and NLG in the large intestine, where microbiota and colorectal tumors coexist. Unlike conventional strategies that either block the Kyn pathway or non-selectively activate both pathways, this platform enhances Trp metabolism toward immunostimulatory microbial indole derivatives while suppressing the immunosuppressive Kyn pathway, thereby synergistically enhancing antitumor immunity and achieving potent efficacy with favorable biosafety, offering a promising metabolism-guided paradigm for safe and effective cancer immunotherapy.
中文摘要:免疫治疗在癌症治疗中展现出很大前景,但色氨酸(Trp)代谢失衡会驱动肿瘤免疫耐受,严重限制其疗效。为此,我们推进一种宿主-微生物代谢协同调控策略,同时增强微生物吲哚通路并抑制宿主犬尿氨酸(Kyn)通路,以纠正代谢与免疫失调,从而增强抗肿瘤免疫。为构建口服共递送纳米颗粒,将Trp通过酯键负载于介孔二氧化硅纳米颗粒,并用含代谢抑制剂NLG919(NLG)的琼脂包覆。该设计可在微生物群与结直肠肿瘤共存的大肠中实现Trp和NLG的酶响应释放。与传统仅阻断Kyn通路或非选择性激活两条通路的策略不同,该平台促进Trp向免疫刺激性微生物吲哚衍生物代谢,同时抑制免疫抑制性Kyn通路,协同增强抗肿瘤免疫,并获得强效疗效和良好生物安全性,为安全有效的癌症免疫治疗提供了一种有前景的代谢导向范式。
First-line treatment for gastric cancer (GC) includes PD-1 blockade with chemotherapy, but resistance challenges treatment success. We identify Streptococcus anginosus (SA) as a tumor-resident oncobacterium driving GC progression and immune evasion. SA is enriched in GC patient tumors and drives tumor growth in mice. SA extracellular vesicles (saEVs) translocate the bacterial chromatin remodeler saSNF2 into host cells. saSNF2 partners with host transcription factor TEAD1-through its ATPase activity and participation in BRG1/BRM-associated factor (BAF) complex assembly-to activate oncogenic transcription. This transkingdom interaction upregulates the palmitoyltransferase ZDHHC11, which stabilizes PD-L1 via palmitoylation to establish an immunosuppressive niche, while amplifying other TEAD1 target genes to fuel tumor progression. saEVs promote tumor growth and limit CD8+ T cell infiltration in vivo. Pharmacological inhibition of ZDHHC11 reverses immune evasion and synergizes with anti-PD-1 checkpoint blockade. These findings establish SA as a multifaceted driver of GC and highlight the saSNF2-ZDHHC11 axis as a target to potentiate immunotherapy.
中文摘要:胃癌一线治疗包括PD-1阻断联合化疗,但耐药影响治疗成功。研究发现咽峡炎链球菌(SA)是驱动胃癌进展和免疫逃逸的肿瘤驻留致癌细菌。SA在胃癌患者肿瘤中富集,并在小鼠中驱动肿瘤生长。SA细胞外囊泡(saEVs)将细菌染色质重塑因子saSNF2转运至宿主细胞。saSNF2通过其ATP酶活性并参与BRG1/BRM相关因子(BAF)复合物组装,与宿主转录因子TEAD1协同激活致癌转录。这种跨界相互作用上调棕榈酰转移酶ZDHHC11,后者通过棕榈酰化稳定PD-L1以建立免疫抑制微环境,同时放大其他TEAD1靶基因以推动肿瘤进展。saEVs在体内促进肿瘤生长并限制CD8+ T细胞浸润。药物抑制ZDHHC11可逆转免疫逃逸,并与抗PD-1检查点阻断产生协同作用。这些发现确立SA是胃癌的多方面驱动因素,并提示saSNF2-ZDHHC11轴可作为增强免疫治疗的靶点。
Nanocatalytic medicine offers an innovative paradigm for disease treatment, yet systemic administration of nanomaterials raises critical biosafety concerns that restrict its application potential. While implant catalytic medicine represents a promising alternative, insufficient surface-active sites weaken its catalytic therapeutic performance. Here, we propose a universal confined sono-enhanced catalytic strategy realized by integrating nanozymes and metastructures into implants. The porous acoustic metastructure afforded abundant nanozyme immobilization sites and captured ultrasound to generate turbulent flow for fast mass transfer and thermal energy to activate the reaction system, synergistically improving the nanozyme's catalytic activity. As a proof of concept, the biocompatible FeOx nanozyme was modified onto the acoustic metastructured TiO2 coating on a titanium implant to achieve enhanced catalytic therapy against infection/tumor. In the infection/tumor microenvironments, the FeOx nanozyme could catalyze H2O2 to ˙OH for bacteria/tumor killing, which was significantly amplified by the synergistic acoustic-thermal and acoustic streaming effects of TiO2 metastructures activated by ultrasound. Meanwhile, this hierarchical micro-nanostructured coating exhibited good biocompatibility and promoted osteogenesis. Importantly, this strategy can be extended to other material systems to achieve sono-enhanced catalytic therapies and repairs for different diseases. The concept of confined sono-enhanced catalytic therapy based on nanozyme-decorated metastructures may make a difference in implant catalytic medicine and smart-responsive biomaterials.
中文摘要:纳米催化医学为疾病治疗提供了新范式,但纳米材料的全身给药会带来关键生物安全性问题,限制其应用潜力。植入式催化医学是有前景的替代方案,但表面活性位点不足会削弱其催化治疗性能。这里提出一种通用的限域声增强催化策略,通过将纳米酶与超结构集成到植入物中实现。多孔声学超结构提供大量纳米酶固定位点,并捕获超声以产生湍流,促进快速传质,同时产生热能激活反应体系,协同提高纳米酶的催化活性。作为概念验证,将生物相容的FeOx纳米酶修饰到钛植入物上的声学超结构TiO2涂层,实现对感染/肿瘤的增强催化治疗。在感染/肿瘤微环境中,FeOx纳米酶可催化H2O2生成·OH以杀灭细菌/肿瘤细胞,超声激活的TiO2超结构所产生的声热协同效应和声流效应显著放大这一作用。同时,这种分级微纳结构涂层表现出良好生物相容性并促进成骨。该策略可扩展到其他材料体系,实现针对不同疾病的声增强催化治疗与修复。基于纳米酶修饰超结构的限域声增强催化治疗概念可能为植入式催化医学和智能响应生物材料带来改变。
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by profound desmoplasia and cellular heterogeneity, which cannot be fully resolved using traditional bulk sequencing approaches. To understand how this heterogeneity contributes to PDAC biology, we analyzed a large cohort of primary tumors (n = 62) profiled using single-cell RNA sequencing (443,451 single cells), including a subset of 11 tumors with matched spatial transcriptomics (53,236 spots), to map clonal, transcriptional and spatial diversity. Moreover, our sample set includes a unique cohort of matched samples from six tumors collected before and after treatment with chemotherapy. Our analysis revealed notable intratumoral heterogeneity, with multiple genetically distinct neoplastic clones coexisting within individual tumors. We observed clone-specific ligand-receptor programs that are modulated by genomic dosage: amplifications of ligands or receptors enriched corresponding interactions, while deletions suppressed them, with genetically encoded differences supported by spatial transcriptomics and multiplex immunofluorescence. Phylogenetic integration identified focal 8q24 (MYC) amplification as recurrently associated with classical-to-basal transitions occurring within tumor lineages at a frequency above chance; these transitions were accompanied by coordinated depletion of immune-response programs. Functional perturbation experiments in murine and primary human models showed that MYC knockdown reactivates classical transcriptional programs and restores immune-response pathways, supporting a role for MYC in maintaining a basal, immune-depleted state. Spatial analyses further revealed dispersed clones enriched for epithelial-to-mesenchymal transition activity and immune suppression, correlating with metastatic potential and colonization of lymph node niches. These dispersed clones shifted toward a basal phenotype, contributing to disease progression. Our findings highlight the critical role of clonal diversity, transcriptional plasticity and tumor microenvironment interactions in shaping human PDAC biology. This work provides a detailed view of the molecular and spatial heterogeneity of PDAC and offers potential avenues for therapeutic intervention targeting clonal evolution and the mechanisms driving metastasis.
中文摘要:胰腺导管腺癌(PDAC)是一种侵袭性强的癌症,以显著的促结缔组织增生和细胞异质性为特征,传统批量测序难以完全解析。为理解这种异质性如何参与 PDAC 生物学,我们分析了一个大型原发肿瘤队列(n=62),采用单细胞 RNA 测序(443,451 个单细胞)进行刻画,其中 11 个肿瘤配有空间转录组(53,236 个空间位点),用以绘制克隆、转录与空间多样性图谱。样本集还包括一个独特队列:6 个肿瘤在化疗前后配对的样本。分析显示明显的瘤内异质性,同一肿瘤内共存多个遗传上不同的肿瘤性克隆。我们观察到受基因组剂量调控的克隆特异性配体-受体程序:配体或受体扩增会富集相应互作,缺失则抑制互作,空间转录组和多重免疫荧光支持这些遗传编码差异。系统发育整合发现,局灶性 8q24(MYC)扩增反复与肿瘤谱系内发生的经典型向基底样转变相关,其频率高于随机预期;这些转变伴随免疫应答程序的协同耗竭。小鼠和原代人模型中的功能扰动实验显示,MYC 敲低可重新激活经典型转录程序并恢复免疫应答通路,支持 MYC 在维持基底样、免疫耗竭状态中的作用。空间分析进一步发现,富集上皮-间质转化活性和免疫抑制的播散克隆与转移潜能及淋巴结生态位定植相关。这些播散克隆向基底样表型偏移,促进疾病进展。这些发现强调克隆多样性、转录可塑性和肿瘤微环境相互作用在塑造人 PDAC 生物学中的关键作用。该工作提供对 PDAC 分子与空间异质性的详细认识,并为靶向克隆演化及驱动转移机制的治疗干预提供潜在途径。
Engineering autologous T cells for adoptive therapies has revolutionized cancer treatment, yet limited persistence remains a major barrier to robust clinical responses and durable disease control. Although costimulation with 4-1BB markedly improves CAR-T-cell persistence, no comparably effective approach has been identified to enhance persistence in T-cell therapies that rely on native TCR signaling, including conventional TCR-T cells and synthetic T-cell receptor and antigen receptor (STAR) T cells. To identify intrinsic persistence regulators in a TCR-based context, we performed an in vivo CRISPR activation screen in STAR-T cells and identified the noncanonical NF-κB axis, with RELB as the top hit. Direct RELB overexpression, however, exhibited dose-dependent cytotoxicity, motivating a translational alternative: overexpression of p52, the ncNF-κB transcription partner of RELB. Under prolonged antigen exposure, p52 overexpression sustained proliferation, preserved effector functions, and increased the intratumoral trafficking potential, particularly in CD8⁺ T cells, thereby yielding superior tumor control. Mechanistically, transcriptomic profiling revealed coordinated upregulation of cell cycle programs and chemokine receptors, along with downregulation of apoptosis and exhaustion-associated modules. Moreover, p52 overexpression restored RELB nuclear translocation in the context of PD-1/PD-L1 engagement, indicating partial resistance to checkpoint-mediated suppression and sustained ncNF-κB activity in PD-L1hi immunosuppressive environments. Collectively, our findings identify p52 as an antigen-dependent enhancer of ncNF-κB, conferring durable persistence and checkpoint resilience on TCR-based T cells and providing a feasible strategy to improve therapeutic effects in solid tumors.
中文摘要:通过工程化自体T细胞进行过继治疗已经改变了肿瘤治疗格局,但T细胞持久性有限仍是获得稳健临床应答和持久疾病控制的主要障碍。4-1BB共刺激可显著提高CAR-T细胞持久性,然而对于依赖天然TCR信号的T细胞疗法,包括常规TCR-T细胞以及合成T细胞受体与抗原受体(STAR)T细胞,尚未找到同样有效的持久性增强策略。为在TCR依赖背景下鉴定内在持久性调控因子,我们在STAR-T细胞中开展体内CRISPR激活筛选,发现非经典NF-κB轴,其中RELB为排名最高的命中基因。直接过表达RELB表现出剂量依赖性细胞毒性,促使我们采用更具转化可行性的替代方案:过表达p52,即RELB在ncNF-κB中的转录伙伴。在长期抗原暴露下,p52过表达维持增殖、保留效应功能并提高瘤内迁移潜能,尤其在CD8⁺ T细胞中更为明显,从而获得更优的肿瘤控制。机制上,转录组分析显示细胞周期程序和趋化因子受体协同上调,凋亡及耗竭相关模块下调。p52过表达还在PD-1/PD-L1结合背景下恢复RELB核转位,提示其对检查点介导的抑制具有部分抵抗,并在PD-L1高表达免疫抑制环境中维持ncNF-κB活性。这些结果共同表明,p52是ncNF-κB的抗原依赖性增强因子,使TCR依赖T细胞获得持久存续能力和检查点韧性,并为改善实体瘤治疗效果提供了可行策略。
Understanding which molecular signals recruit specific cells to precise tissue locations is fundamental to tissue biology, immunity and disease. Existing computational tools for spatially resolved transcriptomics (SRT) describe where cells reside but cannot explain why. Here we introduce SPACER, a fully interpretable multi-instance learning framework that decodes gene-level recruitment rules directly from SRT data. Applied to 37 SRT datasets spanning multiple human tumour types and mouse heart, SPACER achieved 4-21-fold improvement over existing methods in various tasks of recovering biologically meaningful recruitment signals. SPACER revealed (1) that tumour-expressed mucins are associated with physical barriers to T cell engagement, which predicts resistance to immune checkpoint inhibitors and patient prognosis, (2) that local antigen presentation is the dominant correlate of T cell engagement across cancer types and (3) that Cd4+ T cells are the dominant functional effectors in severe immune checkpoint inhibitor-induced myocarditis. These findings establish SPACER as a discovery engine for cellular recruitment biology with direct translational applications.
中文摘要:理解哪些分子信号将特定细胞招募到精确的组织位置,是组织生物学、免疫学和疾病研究的基础。现有空间分辨转录组学(SRT)计算工具能描述细胞所在位置,却无法解释其原因。这里提出SPACER,一种完全可解释的多示例学习框架,可直接从SRT数据中解码基因水平的招募规则。将SPACER应用于涵盖多种人类肿瘤类型和小鼠心脏的37个SRT数据集,在恢复具有生物学意义的招募信号的各项任务中,相较现有方法取得4至21倍提升。SPACER揭示:(1)肿瘤表达的黏蛋白与T细胞接触的物理屏障相关,可预测免疫检查点抑制剂耐药和患者预后;(2)局部抗原呈递是跨癌种T细胞接触的主要相关因素;(3)Cd4+ T细胞是严重免疫检查点抑制剂诱导心肌炎中的主要功能效应细胞。这些发现确立SPACER作为细胞招募生物学的发现引擎,并具有直接转化应用。
Sensory neurons innervate the tumor microenvironment (TME) and are active contributors to tumor progression and immune evasion. Across multiple cancer types, higher intratumoral nerve density is associated with worse clinical outcomes, including increased lymph node metastasis, local recurrence, and reduced survival. This relationship is driven, at least in part, by local immunosuppression arising from neuropeptide and neurotransmitter paracrine signaling within the TME. Nociceptive sensory neurotransmission impacts tumor-infiltrating immune cells to promote T-cell exhaustion, mast cell degranulation, and stromal remodeling, collectively constructing a barrier to effective antitumor immunity. Beyond paracrine signaling, sensory neurons themselves express immune checkpoint proteins, including programmed cell death ligand-1, providing an additional mechanism by which the sensory nervous system participates in local immune regulation. Preclinical studies have established that targeting sensory neuron signaling, whether through denervation, neuropeptide antagonism, or axon guidance inhibition, can relieve TME immunosuppression and improve the efficacy of immune-based therapies. Several Food and Drug Administration (FDA)-approved agents developed for non-oncologic indications, including calcitonin gene-related peptide receptor antagonists approved for migraine, and the NK-1R antagonist Aprepitant, represent immediately available candidates for repurposing in combination immunotherapy strategies. The relationship between sensory neurons and immunotherapy is bidirectional; however, immunotherapies also act on sensory neurons, and this interaction likely contributes to the development and severity of immune-related adverse events through disruption of constitutive neuronal checkpoint signaling and neurogenic amplification of tissue inflammation. Sensory neurons in densely innervated barrier organs may serve as neuroimmune amplifiers that worsen the severity of colitis, pneumonitis, and dermatitis during checkpoint blockade. This review examines the evidence for how sensory neural signaling shapes immunotherapy efficacy, and how immunotherapies impinge on sensory neuron biology to promote adverse events. Throughout, we highlight translational opportunities where modulation of the sensory nervous system may improve therapeutic outcomes or reduce treatment toxicity.
中文摘要:感觉神经元支配肿瘤微环境(TME),并积极参与肿瘤进展和免疫逃逸。在多种癌种中,较高的瘤内神经密度与更差的临床结局相关,包括淋巴结转移增加、局部复发和生存期缩短。这一关系至少部分由TME内神经肽和神经递质旁分泌信号引起的局部免疫抑制所驱动。伤害性感觉神经传递作用于肿瘤浸润免疫细胞,促进T细胞耗竭、肥大细胞脱颗粒和基质重塑,共同构建有效抗肿瘤免疫的屏障。除旁分泌信号外,感觉神经元自身表达免疫检查点蛋白,包括程序性死亡配体1,这提供了感觉神经系统参与局部免疫调节的另一机制。临床前研究已证实,靶向感觉神经元信号,无论通过去神经支配、神经肽拮抗还是轴突导向抑制,均可缓解TME免疫抑制并提高免疫治疗疗效。数种为非肿瘤适应证开发的美国食品药品监督管理局(FDA)批准药物,包括获批用于偏头痛的降钙素基因相关肽受体拮抗剂以及NK-1受体拮抗剂阿瑞匹坦,是可直接用于联合免疫治疗策略再利用的候选药物。感觉神经元与免疫治疗之间的关系是双向的;免疫治疗也作用于感觉神经元,这种相互作用可能通过破坏组成性神经元检查点信号和神经源性放大组织炎症,促进免疫相关不良事件的发生并加重其严重程度。神经支配密集的屏障器官中的感觉神经元可能作为神经免疫放大器,在检查点阻断期间加重结肠炎、肺炎和皮炎。本综述考察感觉神经信号如何影响免疫治疗疗效,以及免疫治疗如何影响感觉神经元生物学并促进不良事件的证据。全文关注调节感觉神经系统可能改善治疗结局或降低治疗毒性的转化机会。
Therapeutic options for clear cell renal cell carcinoma (ccRCC) are limited. Recent clinical trials showed the efficacy of chimeric antigen receptor (CAR)-T cell therapy in treating ccRCC. However, heterogeneous expression of targeting antigen drives immune escape and impairs therapeutic efficacy. Bispecific CARs co-targeting two tumor-associated antigens may overcome this limitation. Human leucocyte antigen-G (HLA-G) and CD70 expression in normal and cancer tissues were analyzed using public RNA sequencing databases and immunohistochemistry of patient samples. An HLA-G CAR was engineered using its natural receptor human inhibitory receptors Ig-like transcript 4 (ILT4). The binding affinity of ILT4 to HLA-G was improved through structure-based rational design. A CD70 nanobody sequence was then incorporated into the HLA-G CAR to generate an HLA-G/CD70 bispecific CAR, together with a CD70-targeting short hairpin RNA (shRNA) to prevent CAR-T cell fratricide. A panel of linkers between the two antigen-binding domains was compared with optimize the CAR signal, and lead candidates were evaluated in vitro and in vivo using heterogeneous tumor models. HLA-G and CD70 were identified as ideal bispecific CAR-T targets to overcome the heterogeneity of ccRCC. An ILT4 mutant (Mut-5) with enhanced binding affinity to HLA-G was obtained. The HLA-G CAR derived from this high-affinity ILT4 mutant elicited enhanced antigen-specific cytotoxicity. An HLA-G/CD70 bispecific CAR was subsequently developed by connecting the affinity-optimized ILT4 mutant and a CD70 nanobody via an optimized (G4S)2 linker. To avoid fratricide of the bispecific CAR-T cells mediated by the expression of CD70, we incorporated a CD70 shRNA into the vector. The bispecific CAR showed specific cytotoxicity against both antigens, respectively, and mediated high antitumor activity toward double-positive tumor cells. Bispecific CAR-T cells effectively suppressed heterogeneous tumor growth in vivo and displayed less exhaustion compared with single-target CAR-T cells. We established an affinity-optimized HLA-G/CD70 bispecific CAR as a promising strategy to overcome antigen heterogeneity-mediated resistance and immune escape in ccRCC.
中文摘要:透明细胞肾细胞癌(ccRCC)的治疗选择有限。近期临床试验显示嵌合抗原受体(CAR)-T细胞疗法治疗ccRCC有效,但靶抗原表达异质性会驱动免疫逃逸并削弱疗效。双特异性CAR共同靶向两种肿瘤相关抗原可能克服这一限制。利用公共RNA测序数据库和患者样本免疫组织化学分析了人白细胞抗原G(HLA-G)与CD70在正常组织和癌组织中的表达。以HLA-G天然受体人抑制性受体免疫球蛋白样转录本4(ILT4)为基础构建HLA-G CAR,并通过基于结构的理性设计提高ILT4与HLA-G的结合亲和力。随后将CD70纳米抗体序列引入HLA-G CAR,生成HLA-G/CD70双特异性CAR,同时加入靶向CD70的短发夹RNA(shRNA)以防止CAR-T细胞自相残杀。比较两种抗原结合结构域之间的多种连接肽以优化CAR信号,并在异质性肿瘤模型中于体外和体内评价先导候选分子。HLA-G和CD70被确定为克服ccRCC异质性的理想双特异性CAR-T靶点。获得与HLA-G结合亲和力增强的ILT4突变体Mut-5。由该高亲和力ILT4突变体衍生的HLA-G CAR可产生增强的抗原特异性细胞毒性。随后通过优化的(G4S)2连接肽将亲和力优化的ILT4突变体与CD70纳米抗体连接,开发出HLA-G/CD70双特异性CAR。为避免CD70表达介导的双特异性CAR-T细胞自相残杀,将CD70 shRNA整合入载体。该双特异性CAR分别对两种抗原表现出特异性细胞毒性,并对双阳性肿瘤细胞介导较高的抗肿瘤活性。双特异性CAR-T细胞在体内有效抑制异质性肿瘤生长,与单靶点CAR-T细胞相比耗竭更少。研究建立了亲和力优化的HLA-G/CD70双特异性CAR,作为克服ccRCC抗原异质性介导的耐药和免疫逃逸的有前景策略。
Activation of the cGAS-STING pathway has emerged as a promising strategy in cancer immunotherapy due to the ability to trigger robust innate and adaptive immune response within the immunosuppressive tumor microenvironment. However, its clinical translation is restricted by multiple intractable challenges, particularly the severe inflammatory side effects caused by non-specific cGAS-STING activation. We herein developed a nucleus-targeted nanodrug with a unique characteristic of tumor-triggered DNA fragmentation and precise cGAS-STING activation. This nanodrug is engineered by encapsulating a protein (DNA fragmentation factor, DFF) and an agonist (procaspase-activating compound 1, PAC-1) into a nucleus-targeted nanoplatform. Using breast cancer (BCa) tumor models, we demonstrated this nanodrug could be efficiently internalized by BCa cells to achieve the cytosolic delivery of PAC-1 and nuclear delivery of DFF. Upon the activation of over-expressed procaspase-3 in BCa cells by PAC-1, the DNA degradation ability of DFF could be liberated, which could dramatically improve the cytosolic release of DNA fragments and thus enhance interferon-β (IFN-β) expression and secretion by activating the cGAS-STING pathway in BCa cells, ultimately inducing a significant inhibition of BCa tumor growth by enhancing the maturation of dendritic cells (DCs) and antitumor immunity of CD8+ T cells. STATEMENT OF SIGNIFICANCE: Activation of the cGAS-STING pathway has demonstrated the ability to reshape the immunosuppressive TME by triggering both the innate and adaptive immunity, but its clinical translation is restricted due to the severe inflammatory side effects caused by non-specific activation. We herein propose a concept of tumor-triggered cytosolic release of DNA fragments for precise cGAS-STING activation and enhanced cancer immunotherapy. To this end, a nanodrug is engineered by encapsulating DFF and PAC-1 into a nucleus-targeted nanoplatform. In this nanodrug, PAC-1 could induce the apoptosis of BCa cells by activating their over-expressed procaspase-3 into caspase-3, which could further trigger the DNA degradation ability of DFF to improve the cytosolic release of DNA fragments for precise cGAS-STING activation, thereby promoting IFN-β secretion from BCa cells to enhance the maturation of DCs and antitumor immunity of CD8+ T cells. The concept of tumor-triggered cytosolic release of DNA fragments demonstrated herein provides a potential immunotherapeutic strategy for tumor therapy, particularly the immune cold tumors with low response to immunotherapy.
中文摘要:激活cGAS-STING通路能够在免疫抑制性肿瘤微环境中触发强烈的固有免疫和适应性免疫应答,因而成为癌症免疫治疗中一种有前景的策略。但其临床转化受到多个棘手问题限制,尤其是非特异性cGAS-STING激活引起的严重炎症副作用。我们据此开发了一种具有肿瘤触发DNA片段化和精准cGAS-STING激活特性的核靶向纳米药物。该纳米药物通过将一种蛋白(DNA片段化因子,DFF)和一种激动剂(procaspase激活化合物1,PAC-1)包载于核靶向纳米平台中构建而成。利用乳腺癌肿瘤模型,我们证明该纳米药物可被乳腺癌细胞高效内吞,实现PAC-1的胞质递送和DFF的核内递送。PAC-1激活乳腺癌细胞中过表达的procaspase-3后,DFF的DNA降解能力被释放,可显著提高DNA片段的胞质释放,并通过激活乳腺癌细胞中的cGAS-STING通路增强干扰素-β(IFN-β)的表达和分泌,最终通过促进树突状细胞(DCs)成熟和CD8+ T细胞抗肿瘤免疫,显著抑制乳腺癌肿瘤生长。意义声明:激活cGAS-STING通路已被证明可通过触发固有免疫和适应性免疫重塑免疫抑制性肿瘤微环境,但非特异性激活导致的严重炎症副作用限制了其临床转化。我们提出通过肿瘤触发的DNA片段胞质释放实现精准cGAS-STING激活并增强癌症免疫治疗的概念。为此,我们将DFF和PAC-1包载于核靶向纳米平台,构建了一种纳米药物。在该纳米药物中,PAC-1可通过将乳腺癌细胞过表达的procaspase-3激活为caspase-3而诱导细胞凋亡,进一步触发DFF的DNA降解能力,提高DNA片段的胞质释放,实现精准cGAS-STING激活,从而促进乳腺癌细胞分泌IFN-β,增强DCs成熟和CD8+ T细胞抗肿瘤免疫。此处展示的肿瘤触发DNA片段胞质释放概念为肿瘤治疗提供了一种潜在免疫治疗策略,尤其适用于对免疫治疗响应低的免疫冷肿瘤。
Shared cancer driver mutations offer attractive targets for cancer immunotherapy, but their expression does not necessarily put them within the reach of a T cell response. In this issue of Immunity, Haratani et al. identify distinct barriers to the processing, presentation, and recognition of neoantigens generated from mutant p53 that help explain this gap.
中文摘要:共享的癌症驱动突变为肿瘤免疫治疗提供了有吸引力的靶点,但这些突变的表达并不必然使它们进入T细胞应答的可及范围。在本期《Immunity》中,Haratani等人识别了突变p53产生的新抗原在加工、呈递和识别环节面临的不同屏障,有助于解释这一差距。
The introduction of immune checkpoint blockade revolutionized cancer treatments. Since then, the field of immunotherapy has expanded exponentially, both in therapeutic innovations and applicable disease contexts. Investigators across disciplines discuss how they are reimagining strategies to drive the immune system in contexts of cancer, autoimmunity, and beyond.
中文摘要:免疫检查点阻断疗法的出现使肿瘤治疗发生了革命性变化。此后,免疫治疗领域在治疗创新和适用疾病范围两方面迅速扩展。来自不同学科的研究者讨论了各自如何重新构想策略,以在肿瘤、自身免疫病及其他场景中驱动免疫系统。
Surgical removal of tumor-draining lymph nodes (tdLNs) is commonly performed in cancer patients. Here, we investigated whether immune checkpoint blockade (ICB) responses persist after resection of tdLNs, important sites for the initiation and maintenance of anti-cancer immunity. Melanoma patients remained responsive to programmed death 1 (PD-1) blockade after regional LN dissection. Similarly, ICB efficacy persisted after tdLN resection in orthotopic murine melanoma and mammary carcinoma models. Following tdLN removal, interstitial fluid containing soluble antigen was diverted through interstitial spaces across lymphosome boundaries to distant LNs, wherein cancer-derived antigen was acquired and presented to T cells by LN-resident type I conventional dendritic cells. These responses persisted after primary tumor resection and supported ICB-induced systemic immunity. Locoregional delivery of ICB to compensatory LNs enhanced anti-cancer responses after tdLN resection. Consistently, ICB responses in head and neck cancer patients were associated with reactive LNs at distant sites. Thus, antigen rerouting enables distant LNs to compensate for resected tdLNs and sustain anti-cancer immunity, including responses enhanced by immunotherapy.
中文摘要:手术切除肿瘤引流淋巴结(tdLNs)在癌症患者中较为常见。本研究探讨切除tdLNs后免疫检查点阻断(ICB)应答是否持续,tdLNs是启动和维持抗肿瘤免疫的重要部位。黑色素瘤患者在区域淋巴结清扫后仍对程序性死亡1(PD-1)阻断有应答。同样,在原位小鼠黑色素瘤和乳腺癌模型中,切除tdLN后ICB疗效仍持续。tdLN切除后,含可溶性抗原的间质液经间质间隙跨越淋巴小体边界分流至远端淋巴结,肿瘤来源抗原在远端淋巴结被驻留的I型经典树突状细胞获取并呈递给T细胞。这些应答在原发肿瘤切除后仍持续,并支持ICB诱导的全身免疫。将ICB局部递送至代偿性淋巴结可增强tdLN切除后的抗肿瘤应答。与此一致,头颈癌患者的ICB应答与远端反应性淋巴结相关。因此,抗原改道使远端淋巴结能够代偿被切除的tdLN并维持抗肿瘤免疫,包括免疫治疗增强的应答。
The hypoxic and immunosuppressive tumor microenvironment limits photodynamic therapy (PDT) and antitumor immunity. To address this, we construct a hypoxia-adaptive nanoplatform PG@Mn-ZIF8 by co-encapsulating a J-aggregating platinum photosensitizer Pt-3T and the nitric oxide (NO) donor S-nitrosoglutathione (GSNO) within Mn2+/Zn2+ doped ZIF-8. This nanoplatform can decompose endogenous H2O2 to O2 via Pt aggregate-mediated catalase (CAT)-mimetic activity, alleviating hypoxia before light irradiation. Upon illumination, Pt-3T generates a robust Type I/II reactive oxygen species (ROS) storm, which triggers rapid NO release from GSNO, and further convert ROS and NO into highly cytotoxic peroxynitrite (ONOO•-), thereby amplifying an ROS/RNS storm within the confined MOF space. This co storm disrupts redox homeostasis to induce both necroptosis and ferroptosis alongside immunogenic cell death (ICD). Moreover, the released Mn2+ and Zn2+ upon MOF degradation synergistically potentiate the cyclic GMP-AMP (cGAMP) synthase (cGAS)-stimulator of interferon genes (STING) pathway. Consequently, the spatiotemporal "O2-ROS/RNS-metal ions" cascade enables the nanoplatform to trigger multimodal cell death and ignite cGAS-STING-driven innate and adaptive immunity, eradicating solid tumors, establishing long-term immune memory, and reversing the "cold" tumor phenotype.
中文摘要:乏氧且免疫抑制的肿瘤微环境限制了光动力治疗(PDT)与抗肿瘤免疫的效力。为此,我们构建了乏氧自适应纳米平台 PG@Mn-ZIF8,将J型聚集的铂类光敏剂 Pt-3T 与一氧化氮(NO)供体S-亚硝基谷胱甘肽(GSNO)共同包载于Mn2+/Zn2+掺杂的ZIF-8中。该平台借助铂聚集体介导的类过氧化氢酶(CAT)活性,将内源性H2O2分解为O2,在光照前缓解乏氧。光照下Pt-3T产生强烈的I/II型活性氧(ROS)风暴,促使GSNO快速释放NO,ROS与NO进一步转化为细胞毒性很强的过氧亚硝酸盐(ONOO•-),在MOF受限空间内放大ROS/RNS风暴。这一联合风暴破坏氧化还原稳态,同时诱导坏死性凋亡与铁死亡,并伴随免疫原性细胞死亡(ICD)。MOF降解释放的Mn2+与Zn2+协同增强环鸟苷酸-腺苷酸合成酶(cGAS)-干扰素基因刺激因子(STING)通路。由此,时空上的「O2-ROS/RNS-金属离子」级联使该纳米平台触发多模式细胞死亡,并点燃cGAS-STING驱动的固有免疫与适应性免疫,清除实体瘤、建立长期免疫记忆、逆转「冷」肿瘤表型。
Hepatocellular carcinoma (HCC) is driven by cancer stemness and an immunosuppressive tumor microenvironment, which collectively contribute to therapeutic resistance. While the RNA-binding protein HNRNPC has been implicated in tumor progression, it has primarily been characterized as a downstream effector, and its autonomous regulatory functions, particularly in governing cancer stemness, remain entirely unexplored. Through multi-omics analyses of HCC cohorts, we identified HNRNPC as a pivotal driver of a high-risk molecular subtype. Mechanistically, HNRNPC expression was transcriptionally activated via WDR5/KMT2A complex-mediated deposition of H3K4me3 at its promoter. Functionally, HNRNPC was essential for maintaining cancer stemness, promoting tumor growth and metastasis, and conferring oxaliplatin resistance. Notably, depletion of HNRNPC reprogrammed the immunosuppressive microenvironment by enhancing CD8+ T cell infiltration, reducing T cell exhaustion, and polarizing macrophages toward an M1-like anti-tumor phenotype. At the molecular level, HNRNPC bound to the m6A-modified 3'UTR of CD24 mRNA in an RNP2 motif-dependent manner, thereby enhancing its stability and elevating CD24 protein expression. Therapeutically, we developed a novel lipid nanoparticle (LNP) encapsulating siRNA against HNRNPC. Systemically administered AP-EG-si potently suppressed tumor growth, attenuated stemness, and synergized with anti-PD-L1 therapy to enhance anti-tumor immunity. Our findings thus unveil the H3K4me3-HNRNPC-CD24 axis as a central epigenetic and post-transcriptional regulatory pathway that coordinately drives HCC stemness and immune evasion, nominating HNRNPC-targeted nanotherapy as a promising strategy for advanced HCC.
中文摘要:肝细胞癌(HCC)由肿瘤干性和免疫抑制性肿瘤微环境驱动,二者共同导致治疗耐药。RNA结合蛋白HNRNPC已被认为参与肿瘤进展,但多被视作下游效应分子,其自主调控功能,尤其是在控制肿瘤干性方面的作用,仍完全未知。通过对HCC队列的多组学分析,我们发现HNRNPC是高危分子亚型的关键驱动因子。机制上,WDR5/KMT2A复合物介导其启动子区H3K4me3沉积,从而转录激活HNRNPC表达。功能上,HNRNPC对维持肿瘤干性、促进肿瘤生长和转移以及赋予奥沙利铂耐药至关重要。敲低HNRNPC可重编程免疫抑制性微环境,表现为CD8+ T细胞浸润增强、T细胞耗竭减少以及巨噬细胞向M1样抗肿瘤表型极化。分子层面,HNRNPC以RNP2基序依赖的方式结合CD24 mRNA的m6A修饰3'UTR,增强其稳定性并提高CD24蛋白表达。治疗层面,我们开发了一种新型脂质纳米颗粒(LNP),包载靶向HNRNPC的siRNA。全身给予AP-EG-si可有效抑制肿瘤生长、削弱干性,并与抗PD-L1治疗协同增强抗肿瘤免疫。这些发现揭示了H3K4me3-HNRNPC-CD24轴作为协调驱动HCC干性和免疫逃逸的核心表观遗传与转录后调控通路,并提示靶向HNRNPC的纳米治疗是晚期HCC的潜在策略。
While tertiary lymphoid structures (TLSs) broadly correlate with immunotherapy efficacy, their functional heterogeneity can translate into divergent clinical outcomes. In this issue of Cancer Cell, Hu et al. uncover a microbiota-orchestrated stem-like lymphoid niche in which CD70+ ILC2s sustain progenitor exhausted T cells, and their findings redefine the functional organization underlying TLS-associated antitumor immunity.
中文摘要:三级淋巴结构(TLSs)与免疫治疗疗效广泛相关,但其功能异质性可导致临床结局出现差异。在本期《Cancer Cell》中,Hu 等揭示了一个由微生物群调控的干样淋巴生态位,其中 CD70+ ILC2s 维持祖耗竭 T 细胞,其发现重新界定了 TLS 相关抗肿瘤免疫的功能组织方式。
Receptor tyrosine kinases (RTKs), constituting a major family of cell-surface transmembrane receptors, are essential for intracellular tyrosine phosphorylation and signal transduction. RTK signaling is crucial for cellular fate regulation and tissue homeostasis, and its disruption is linked to numerous diseases. Herein, we present a comprehensive review of signaling pathways involving RTKs, with a focus on their signal transduction mechanisms and key components, along with their interactions with major signaling cascades such as G protein-coupled receptors, Wnt, and transforming growth factor β pathways. We also elucidate the multidimensional roles of RTKs in cancer development and progression, highlighting their key effects on cancer stem cell maintenance, tumor microenvironment modulation, and other factors. Furthermore, we systematically summarize the roles of RTKs in noncancerous diseases, including cardiovascular disorders, neurodegenerative diseases, metabolic syndrome, autoimmune conditions, and fibrotic disorders. We then examine current RTK-targeted therapeutics, including small-molecule inhibitors and monoclonal antibodies, for the treatment of various cancers. Finally, novel therapeutic strategies, along with the challenges associated with their development and application, are discussed. In summary, this review will enhance the understanding of the mechanistic aspects of RTK signaling in major disease pathways and provide a detailed overview of recent advancements in targeted therapeutic interventions.
中文摘要:受体酪氨酸激酶(RTKs)构成细胞表面跨膜受体的一大类,对细胞内酪氨酸磷酸化和信号转导至关重要。RTK信号在细胞命运调控和组织稳态中发挥关键作用,其功能紊乱与多种疾病相关。本综述系统梳理涉及RTKs的信号通路,重点讨论其信号转导机制和关键组分,以及它们与G蛋白偶联受体、Wnt和转化生长因子β等主要信号级联的相互作用。同时阐述RTKs在癌症发生和进展中的多维作用,强调其对癌症干细胞维持、肿瘤微环境调控等因素的关键影响。系统总结RTKs在非癌症疾病中的作用,包括心血管疾病、神经退行性疾病、代谢综合征、自身免疫性疾病和纤维化疾病。随后审视当前用于多种癌症治疗的RTK靶向疗法,包括小分子抑制剂和单克隆抗体。最后讨论新型治疗策略及其开发和应用中的挑战。总体而言,本综述有助于理解RTK信号在重大疾病通路中的机制,并详细概述靶向治疗干预的最新进展。
Therapeutic cancer vaccines are increasingly tested in clinical settings alongside standard-of-care treatments that often include chemotherapy, yet whether chemotherapy synergizes with cancer vaccines remains unclear. Here, we tested heterologous prime-boost viral vector vaccines in combination with various chemotherapy regimens. Both carboplatin plus paclitaxel (CarboTaxol) and cyclophosphamide improve vaccine efficacy and enhance antigen-specific CD8+ T cell responses. These chemotherapies act as immunological adjuvants independently of tumor presence. Mechanistically, CarboTaxol induces an early, antigen-independent expansion of stem-like T cell factor 1 (TCF1)+CD8+ T cells, an effect also observed in patients with different cancer types. Genetic or pharmacological disruption of TCF1 impairs the immunological adjuvant effect of CarboTaxol. Adding programmed cell death 1 (PD-1) blockade to viral vector vaccines and CarboTaxol further improves tumor control and survival. Together, these findings identify a TCF1-dependent mechanism underlying the immune adjuvant effect of chemotherapy and provide a rationale for clinical evaluation of this triple combination therapy.
中文摘要:治疗性癌症疫苗正日益在与标准治疗(常含化疗)联合的临床场景中接受测试,但化疗能否与癌症疫苗产生协同作用仍不清楚。在此,我们测试了异源初免-加强病毒载体疫苗与多种化疗方案的联合。卡铂联合紫杉醇(CarboTaxol)和环磷酰胺均提高疫苗效力并增强抗原特异性CD8+ T细胞应答。这些化疗药物在不依赖肿瘤存在的情况下发挥免疫佐剂作用。机制上,CarboTaxol诱导干性样T细胞因子1(TCF1)+CD8+ T细胞的早期、抗原非依赖性扩增,这一效应也在不同癌种患者中观察到。遗传学或药理学干扰TCF1会削弱CarboTaxol的免疫佐剂效应。在病毒载体疫苗和CarboTaxol基础上加入程序性细胞死亡1(PD-1)阻断进一步改善肿瘤控制与生存。这些发现确定了化疗免疫佐剂效应背后依赖TCF1的机制,并为该三联联合治疗的临床评估提供了依据。
Radiation induces immunosuppressive myeloid cells that drive therapeutic resistance and metastasis. We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy. Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses; spatiotemporal mapping shows that this fate program initiates rapidly in the bone marrow. Mechanistically, a radiation-responsive p53-TET2 axis decreases m5C on chromatin-associated RNAs (caRNAs), enforcing immunosuppressive chromatin compaction and silencing interferon signaling, whereas Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity. Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors. These findings define MDACs as an immunogenic myeloid subset and establish myeloid reprogramming as a strategy to improve radiotherapy-immunotherapy outcomes.
中文摘要:放疗会诱导免疫抑制性髓系细胞,推动治疗抵抗和转移。研究识别TET2为放疗诱导的髓源性抑制细胞调控因子,其表达与接受放疗-免疫治疗的晚期肺癌患者不良结局相关。放疗后,髓系特异性Tet2缺失可抑制肿瘤进展,并将单核细胞分化重定向为抗原提呈型髓源性激活细胞(MDACs),增强抗肿瘤T细胞应答;时空图谱显示该命运程序在骨髓中快速启动。机制上,放疗响应的p53-TET2轴降低染色质相关RNA(caRNAs)上的m5C,促使免疫抑制性染色质压缩并沉默干扰素信号,而Tet2缺失恢复染色质可及性并增强CD8+ T细胞细胞毒性。药物性抑制TET2可重现该表型,并增强放疗与PD-L1阻断对原发和转移肿瘤的控制。这些发现将MDACs定义为免疫原性髓系亚群,并将髓系重编程确立为改善放疗-免疫治疗结局的策略。
Histopathology is essential for cancer diagnosis and treatment selection, and pathology foundation models learn visual representations from whole-slide images (WSIs). However, existing foundation models are trained on disparate datasets with varying strategies, leading to inconsistent performance and limited generalizability. Here, we introduce ELF (Ensemble Learning of Foundation models), which integrates five pretrained pathology foundation models into unified slide-level representations. Trained on 53,699 WSIs spanning 20 anatomical sites, ELF leverages ensemble learning to capture complementary information across models. ELF's slide-level architecture is designed for data-efficient downstream evaluation, including settings with limited data such as therapeutic response prediction. We evaluate ELF for disease classification and biomarker detection, as well as anticancer and immunotherapy response prediction across multiple cancer types. ELF achieves higher performance than the evaluated constituent and slide-level foundation models across the tested tasks, supporting further evaluation of ensemble learning for pathology applications in oncology.
中文摘要:组织病理学是癌症诊断与治疗方案选择的基础,病理基础模型则从全切片图像(WSI)中学习视觉表征。现有基础模型基于不同数据集和不同训练策略构建,导致性能不一致、泛化能力有限。为此,我们提出 ELF(基础模型集成学习),将五个预训练的病理基础模型整合为统一的切片级表征。ELF 在覆盖 20 个解剖部位的 53,699 张 WSI 上训练,通过集成学习捕获不同模型间的互补信息。其切片级架构面向数据高效的下游评估而设计,包括治疗反应预测等数据有限的情形。我们在多种癌种中评估 ELF 用于疾病分类、生物标志物检测以及抗癌治疗与免疫治疗反应预测的表现。在所测试的任务上,ELF 的性能优于参与集成的各基础模型以及切片级基础模型,支持进一步评估集成学习在肿瘤病理应用中的价值。
Tertiary lymphoid structures (TLSs) drive antitumor immunity, but their functional heterogeneity translates into inconsistent immunotherapy responses in hepatocellular carcinoma (HCC), raising the question of which immune niches actually predict efficacy. Using spatial multi-omics analysis, we uncover a distinct niche, the stem-like lymphoid niches (SLNs), that correlates with stronger responses to PD-1/PD-L1 blockade. Unlike conventional TLS, SLNs feature a specialized niche of CD70+ type 2 innate lymphoid cells (ILC2s) and progenitor exhausted T (Tpex) cells. Intriguingly, intratumoral Bacillus cereus promotes SLN accumulation via triggering endothelial IL-33 release, which rewires ILC2s metabolism and enhances H3K4me3-mediated epigenetic activation of CD70, Lta, and Ltb genes, reinforcing the niche's lymphoid-organizing function. We identify the bacterial phosphoinositide-specific phospholipase C (PI-PLC) as the effector behind this endothelial IL-33 release. Combining PI-PLC with αPD-L1 synergistically amplifies antitumor immunity, highlighting SLNs as a promising target for boosting immunotherapy in HCC.
中文摘要:三级淋巴结构(TLSs)驱动抗肿瘤免疫,但其功能异质性导致肝细胞癌(HCC)免疫治疗反应不一致,由此引出哪些免疫微环境真正预测疗效的问题。利用空间多组学分析,我们发现一种与PD-1/PD-L1阻断更强反应相关的独特微环境,即干样淋巴微环境(SLNs)。与常规TLS不同,SLNs以CD70阳性2型固有淋巴细胞(ILC2s)和前体耗竭T细胞(Tpex)组成的特化微环境为特征。肿瘤内蜡样芽孢杆菌通过触发内皮细胞释放IL-33促进SLN积聚,重塑ILC2代谢并增强H3K4me3介导的CD70、Lta和Ltb基因表观遗传激活,强化该微环境的淋巴组织形成功能。我们确定细菌磷脂酰肌醇特异性磷脂酶C(PI-PLC)是内皮细胞IL-33释放背后的效应分子。将PI-PLC与αPD-L1联合可协同增强抗肿瘤免疫,提示SLNs是提升HCC免疫治疗效果的潜在靶点。
Immune checkpoint blockade (ICB) has reshaped the therapeutic landscape of solid tumors. However, durable clinical benefit remains limited to a subset of patients because of primary or acquired resistance. Beyond tumor-intrinsic factors, the tumor microenvironment (TME) plays a critical role in shaping responsiveness to immunotherapy. As a major stromal component, cancer-associated fibroblasts (CAFs) contribute to immune suppression through dynamic metabolic reprogramming and modulate the spatial organization and functional state of immune cells. Recent advances in single-cell transcriptomics, spatial omics, and metabolomic profiling have provided new insights into the metabolic heterogeneity of CAF subsets and their interactions with immune cells. Metabolic reprogramming not only sustains CAF activation but also remodels the local immune environment through nutrient competition, metabolite accumulation, and coordination with extracellular matrix remodeling. These processes reinforce immunosuppression within the TME and contribute to resistance to ICB. This review integrates emerging multi-omics insights into CAF metabolic heterogeneity, summarizes how metabolic reprogramming shapes tumor immunity, and discusses therapeutic strategies targeting CAF metabolism to enhance immunotherapy efficacy, together with the major challenges facing clinical translation.
中文摘要:免疫检查点阻断(ICB)改变了实体瘤的治疗格局,但持久的临床获益仍局限于部分患者,原发性和获得性耐药是主要限制。除肿瘤自身因素外,肿瘤微环境(TME)在决定免疫治疗反应性上起关键作用。癌相关成纤维细胞(CAF)作为主要间质成分,通过动态的代谢重编程参与免疫抑制,并调节免疫细胞的空间分布与功能状态。单细胞转录组、空间组学与代谢组学分析的进展,为认识 CAF 亚群的代谢异质性及其与免疫细胞的相互作用提供了新线索。代谢重编程既维持 CAF 的活化状态,也通过营养竞争、代谢物蓄积以及与细胞外基质重塑的协同作用改造局部免疫环境。这些过程强化了 TME 内的免疫抑制,并促成 ICB 耐药。围绕 CAF 代谢异质性的多组学证据在此加以整合,梳理代谢重编程塑造肿瘤免疫的方式,并讨论以 CAF 代谢为靶点提升免疫治疗疗效的策略以及临床转化面临的主要难题。
Colorectal cancer (CRC) remains a leading cause of cancer mortality. Tumor-associated macrophages (TAMs) regulate CRC progression through functional polarization and metabolic reprogramming. Beyond the classical M1/M2 paradigm, single-cell and spatial studies reveal heterogeneous TAM subsets with distinct metabolic programs, spatial organization, and stage-dependent functions. This review delineates how TAM metabolic reprogramming drives CRC via metabolite-induced PD-L1 expression, oncogenic signaling, and crosstalk with chronic inflammation and gut microbiota. We emphasize spatial metabolic heterogeneity, TAM-tumor metabolic symbiosis, the stage-dependent duality of M2-like macrophages in colitis versus CRC, and pathogen-driven cross-kingdom manipulation. Clinical evidence linking TAM metabolic features to molecular subtypes, metastasis, prognosis, and treatment response is integrated, and methodological challenges in distinguishing true metabolic reprogramming from phenotypic changes are discussed. Therapeutic strategies targeting TAM metabolism, including small molecules, chemotherapeutics, TCM, nanomedicine, probiotics, and combinations, are summarized, offering precise TAM reprogramming to reverse immunosuppression and overcome CRC therapeutic bottlenecks.
中文摘要:结直肠癌仍是癌症死亡的主要原因之一。肿瘤相关巨噬细胞通过功能极化和代谢重编程调控结直肠癌进展。单细胞与空间研究显示,肿瘤相关巨噬细胞存在异质性亚群,具有不同的代谢程序、空间组织和分期依赖功能,已超出经典M1/M2范式。该综述梳理肿瘤相关巨噬细胞代谢重编程如何通过代谢物诱导PD-L1表达、致癌信号传导以及与慢性炎症和肠道菌群的交互作用驱动结直肠癌。重点讨论空间代谢异质性、肿瘤相关巨噬细胞与肿瘤的代谢共生、M2样巨噬细胞在结肠炎与结直肠癌中的分期依赖双重作用,以及病原体驱动的跨物种调控。整合将肿瘤相关巨噬细胞代谢特征与分子亚型、转移、预后和治疗反应联系起来的临床证据,并讨论区分真实代谢重编程与表型变化的方法学挑战。总结靶向肿瘤相关巨噬细胞代谢的治疗策略,包括小分子、化疗药、中药、纳米药物、益生菌及联合方案,为精准重编程肿瘤相关巨噬细胞以逆转免疫抑制、突破结直肠癌治疗瓶颈提供思路。
The infiltration of tumors by CD8⁺ T lymphocytes is a critical determinant of antitumor immunity and response to immunotherapy. However, the presence of tumor-specific CD8⁺ T cells does not necessarily translate into effective tumor control, as multiple biological barriers can prevent their recruitment, spatial distribution, persistence, and functional activity. This review provides a comprehensive overview of the multistep mechanisms regulating CD8⁺ T-cell infiltration, from immune priming and systemic trafficking to vascular entry, intratumoral migration, and tissue residency. We discuss how alterations in chemokine networks, dysfunctional tumor vasculature, extracellular matrix remodeling, stromal barriers, and immunosuppressive signals collectively drive immune exclusion and resistance to therapy. Unlike previous reviews that have focused on individual aspects of T-cell trafficking, tumor immune contexture, or immune exclusion, we integrate these interconnected mechanisms as successive biological checkpoints and link them to therapeutic strategies aimed at overcoming specific barriers. These include restoration of antigen presentation and dendritic cell function, reprogramming of chemokine pathways, vascular normalization, stromal remodeling, innate immune activation, and induction of tertiary lymphoid structures. This integrated framework highlights why increasing CD8⁺ T-cell infiltration alone may be insufficient and supports the development of rational, sequential, and spatially guided combination strategies. Advances in spatial transcriptomics, single-cell technologies, and multiplex imaging are expected to enable personalized identification of dominant immune barriers and rational design of combination therapies. Ultimately, the goal is shifting from simply activating T cells toward engineering tumor ecosystems that support sustained CD8⁺ T-cell infiltration, organization, and effector function.
中文摘要:CD8⁺ T淋巴细胞对肿瘤的浸润是抗肿瘤免疫及免疫治疗反应的关键决定因素。肿瘤特异性CD8⁺ T细胞的存在并不必然带来有效的肿瘤控制,多种生物学屏障可阻碍其招募、空间分布、持续存在和功能活性。本综述系统概述调控CD8⁺ T细胞浸润的多步骤机制,从免疫启动、全身转运到血管进入、瘤内迁移和组织驻留。讨论趋化因子网络改变、肿瘤血管功能障碍、细胞外基质重塑、基质屏障和免疫抑制信号如何共同驱动免疫排斥和治疗抵抗。与既往聚焦T细胞转运、肿瘤免疫微环境或免疫排斥某一方面的综述不同,本综述将这些相互关联的机制整合为连续的生物学检查点,并联系针对特定屏障的治疗策略。这些策略包括恢复抗原提呈和树突状细胞功能、重编程趋化因子通路、血管正常化、基质重塑、先天免疫激活和诱导三级淋巴结构。这一整合框架说明仅增加CD8⁺ T细胞浸润可能不够,并支持开发合理、序贯和空间引导的联合策略。空间转录组学、单细胞技术和多重成像的进展有望实现个体化识别主要免疫屏障并合理设计联合治疗。最终目标是从单纯激活T细胞转向构建支持CD8⁺ T细胞持续浸润、组织化和效应功能的肿瘤生态系统。
Refined immunotherapeutic modalities for the treatment of primary central nervous system (CNS) tumors - vaccines, virotherapies, immune checkpoint inhibitors, and cell therapies - are starting to show efficacy in selected patients with primary CNS tumors. Still most patients do not derive a meaningful clinical benefit, despite evidence of biological activity. While the unique immunosuppressive environment of the CNS, cellular heterogeneity and brain borders prohibiting access present substantial challenges for effective treatment, there is a need to define robust biomarkers for response to immunotherapies. As immunotherapies critically depend on multiple tumor intrinsic as well as host factors, this task is substantially more challenging than defining biomarkers for response to targeted therapies. Recent advances in biomarker identification and characterization for immunotherapies have opened new avenues for precision immunotherapy approaches. This review examines the current state of biomarker-guided immunotherapy for primary CNS tumors, focusing on key biomarkers including immunogenic antigens, HLA ligandomics, tumor immune microenvironment characteristics, cell-free DNA, tumor mutational burden, and T cell populations in tumor tissue, blood, and cerebrospinal fluid. We discuss how these biomarkers can guide the selection and optimization of immunotherapeutic strategies including cancer vaccines, T cell therapy, and immune checkpoint inhibitors particularly for glioblastoma, and highlight current challenges and future directions in the field.
中文摘要:用于治疗原发性中枢神经系统(CNS)肿瘤的改良免疫治疗方式——疫苗、病毒治疗、免疫检查点抑制剂和细胞治疗——开始在部分原发性CNS肿瘤患者中显示疗效。尽管有生物学活性证据,大多数患者仍未获得有意义的临床获益。CNS独特的免疫抑制环境、细胞异质性以及脑屏障阻碍进入,给有效治疗带来重大挑战,也需要确定可靠的免疫治疗应答生物标志物。免疫治疗关键取决于多种肿瘤内在因素和宿主因素,因此这项任务比确定靶向治疗应答生物标志物更具挑战性。近期免疫治疗生物标志物识别与表征的进展为精准免疫治疗开辟了新途径。本综述考察原发性CNS肿瘤生物标志物指导免疫治疗的现状,重点关注关键生物标志物,包括免疫原性抗原、HLA配体组学、肿瘤免疫微环境特征、游离DNA、肿瘤突变负荷,以及肿瘤组织、血液和脑脊液中的T细胞群体。我们讨论这些生物标志物如何指导免疫治疗策略的选择与优化,包括癌症疫苗、T细胞治疗和免疫检查点抑制剂,尤其针对胶质母细胞瘤,并强调该领域当前挑战和未来方向。
Immune-resistant colorectal cancer (irCRC), represented by microsatellite stable/proficient mismatch repair (MSS/pMMR) tumors, responds poorly to immune checkpoint blockade (ICB). Here, we developed an ultrasound-targeted nanodroplet destruction (UTND) strategy combined with surface anti-PD-L1-decorated nanodroplets (PPP@P@map) to enhance ICB responsiveness in MSS colorectal cancer. In CT26 and CMT93 murine subcutaneous MSS colorectal cancer models, PPP@P@map combined with UTND markedly suppressed tumor growth compared with control treatments. Single-cell RNA sequencing identified CAF_Pi16 as a candidate therapy-associated cancer-associated fibroblast subset that showed a treatment-related increase after PPP@P@map + UTND, which was further supported by flow cytometry and multiplex immunofluorescence validation. Mechanistically, UTND induced oxidative stress in tumor cells and promoted the generation of advanced glycation end products (AGEs), which activated the AGE-RAGE/PKCα/NF-κB pathway in CAF_Pi16 and increased CCL7 secretion. CAF_Pi16-derived CCL7 provided a CCR2-dependent functional cue to CD8+ T cells. In purified CD8+ T cells, CCL7 activated NF-κB-related signalling, enhanced activation and cytotoxic effector features, and promoted NKG2D expression; these effects were attenuated by CCR2 blockade or NF-κB inhibition. Functionally, CCL7 enhanced CD8+ T cell-mediated tumor-cell killing, whereas NKG2D blockade reduced this effect and weakened the antitumor efficacy of PPP@P@map + UTND in vivo. Together, these findings reveal a UTND-induced tumor cell-CAF_Pi16-CCL7-CD8+ T-cell signalling axis that enhances NKG2D-associated antitumor immunity and provides a mechanistic basis for further investigation of UTND-based strategies to improve ICB responsiveness in MSS/pMMR colorectal cancer.
中文摘要:以微卫星稳定/错配修复完整(MSS/pMMR)肿瘤为代表的免疫抵抗性结直肠癌(irCRC)对免疫检查点阻断(ICB)反应差。我们开发了超声靶向纳米液滴破坏(UTND)策略,并与表面抗PD-L1修饰的纳米液滴(PPP@P@map)联合,以增强MSS结直肠癌的ICB反应性。在CT26和CMT93小鼠皮下MSS结直肠癌模型中,PPP@P@map联合UTND较对照治疗显著抑制肿瘤生长。单细胞RNA测序鉴定CAF_Pi16为候选的治疗相关癌相关成纤维细胞亚群,该亚群在PPP@P@map + UTND后呈治疗相关增加,流式细胞术和多重免疫荧光验证支持这一结果。机制上,UTND诱导肿瘤细胞氧化应激并促进晚期糖基化终末产物(AGEs)生成,AGEs激活CAF_Pi16中的AGE-RAGE/PKCα/NF-κB通路并增加CCL7分泌。CAF_Pi16来源的CCL7向CD8+ T细胞提供CCR2依赖性功能线索。在纯化的CD8+ T细胞中,CCL7激活NF-κB相关信号,增强活化及细胞毒效应特征,并促进NKG2D表达;CCR2阻断或NF-κB抑制可减弱这些效应。功能上,CCL7增强CD8+ T细胞介导的肿瘤细胞杀伤,NKG2D阻断降低该效应并削弱PPP@P@map + UTND的体内抗肿瘤疗效。这些发现揭示UTND诱导的肿瘤细胞-CAF_Pi16-CCL7-CD8+ T细胞信号轴增强NKG2D相关抗肿瘤免疫,为进一步研究基于UTND的策略改善MSS/pMMR结直肠癌ICB反应性提供机制基础。
Deciphering CD8+ T cell exhaustion in human cancers through single-cell and spatial transcriptomics.
Exhausted CD8+ T cells (Tex) within the tumor microenvironment (TME) represents a critical barrier limiting anti-tumor immune responses. Tex cells are characterized by upregulated inhibitory immune checkpoint receptors, reduced cytotoxicity, and functional heterogeneity. Their genomic features and regulatory networks remain poorly defined, and only a minority of patients respond to immune checkpoint blockade (ICB) therapy. Single-cell RNA sequencing (scRNA-seq), through high-resolution transcriptomic profiling, has revealed diverse Tex subpopulations, identified subpopulation-specific marker genes and regulatory pathways. Spatial transcriptomics has further mapped the spatial distribution of Tex and their interaction networks with immune cells, tumor cells, and stromal cells, elucidating the impact of spatial heterogeneity on Tex functionality. Current studies indicate that the exhausted state of Tex is dynamic and modifiable, with functional differences among subpopulations closely associated with tumor progression and therapeutic response. However, the genomic characteristics, epigenetic regulation, and spatial interaction mechanisms of Tex require further exploration. This review summarizes recent advances in high-resolution omics technologies for precisely dissecting Tex heterogeneity, functional features, and interactions with other cells. It emphasizes the central value of optimizing Tex-targeted tumor immunotherapy strategies, providing theoretical foundations and directional guidance for developing more effective anti-tumor immunotherapies.
中文摘要:肿瘤微环境中的耗竭型CD8+ T细胞(Tex)是限制抗肿瘤免疫应答的关键屏障。Tex细胞表现为抑制性免疫检查点受体上调、细胞毒性下降和功能异质性。其基因组特征与调控网络仍缺乏明确界定,仅少数患者对免疫检查点阻断(ICB)治疗产生应答。单细胞RNA测序(scRNA-seq)通过高分辨率转录组图谱揭示了多种Tex亚群,识别出亚群特异性标记基因和调控通路。空间转录组学进一步绘制了Tex的空间分布及其与免疫细胞、肿瘤细胞和基质细胞的相互作用网络,阐明了空间异质性对Tex功能的影响。现有研究表明,Tex的耗竭状态具有动态性和可调控性,亚群间的功能差异与肿瘤进展和治疗应答密切相关。Tex的基因组特征、表观遗传调控和空间相互作用机制仍需深入探索。本综述总结高分辨率组学技术在精细解析Tex异质性、功能特征及其与其他细胞相互作用方面的近期进展,强调优化靶向Tex的肿瘤免疫治疗策略的核心价值,为开发更有效的抗肿瘤免疫治疗提供理论基础和方向指引。
Conventional cancer therapy has largely been organized around maximal cytotoxic elimination, yet intense tumor killing can impose evolutionary selection pressures that promote resistance, clonal escape, and relapse. Here, we propose therapeutic super-competitor cells (TSCs) as a programmable, evolution-aware extension of educative cancer care rather than as an established clinical platform. In this framework, TSCs are engineered cells designed to home to or be locally positioned within tumor-associated niches, sense malignant ecological cues, transiently acquire bounded competitive fitness, restrict malignant access to space, metabolites, and stromal support, and then undergo monitored clearance or benign differentiation. TSCs are therefore not defined by direct target-cell cytolysis, although competitive pressure, metabolic restriction, or immune remodeling may secondarily reduce tumor viability. This Review integrates concepts from cancer ecology, tumor microenvironment biology, developmental cell competition, immunotherapy, and synthetic biology while distinguishing established principles from speculative engineering applications, evaluating feasible early disease contexts, and outlining measurable endpoints for ecological replacement, including spatial occupancy, clonal displacement, resource gradients, persistence kinetics, and responsiveness to safety triggers. We further discuss organoid and tumor-on-chip competition assays, spatial and lineage tracking, response biomarkers, therapeutic-window definition, layered containment, and ethical/regulatory safeguards. By reframing engineered cell therapy as a controllable ecological intervention rather than simply a vehicle for maximal killing, the TSC framework provides a testable but still hypothetical direction for educative cancer care and evolution-aware oncology.
中文摘要:传统癌症治疗在很大程度上围绕最大程度的细胞毒杀灭来组织,但强烈的肿瘤杀伤会施加进化选择压力,促进耐药、克隆逃逸和复发。在此,我们提出治疗性超级竞争者细胞(TSCs)作为教育性癌症照护的可编程、进化感知延伸,而非已经建立的临床平台。在该框架中,TSCs是工程化细胞,设计为归巢至或局部置于肿瘤相关生态位,感知恶性生态线索,短暂获得有界竞争适应度,限制恶性细胞对空间、代谢物和基质支持的可及性,随后经历受监测的清除或良性分化。因此,TSCs并不以直接裂解靶细胞来定义,尽管竞争压力、代谢限制或免疫重塑可能继发性降低肿瘤活力。本综述整合癌症生态学、肿瘤微环境生物学、发育性细胞竞争、免疫治疗和合成生物学的概念,同时区分已确立原理与推测性工程应用,评估可行的早期疾病情境,并概述生态替代的可测量终点,包括空间占据、克隆置换、资源梯度、持续动力学和对安全触发器的响应性。我们进一步讨论类器官和肿瘤芯片竞争实验、空间与谱系追踪、反应生物标志物、治疗窗定义、分层遏制以及伦理与监管保障。通过将工程化细胞治疗重构为可控生态干预而非单纯的最大杀伤载体,TSC框架为教育性癌症照护和进化感知肿瘤学提供了可检验但仍属假设的方向。
The immunosuppressive tumor microenvironment is a major driver of tumor progression and therapeutic resistance. Basal-like breast cancer (BLBC), which largely overlaps with triple-negative breast cancer, generally displays an immunosuppressive tumor microenvironment enriched with tumor-associated macrophages and other immunosuppressive cell populations. However, the driving mechanisms that establish and maintain these tumor microenvironment features remain not fully understood. This study identifies tumor cell-intrinsic POU4F1 as a key regulator of the immunosuppressive tumor microenvironment in BLBC. Tumors with high POU4F1 expression exhibited a lower IFNγ-related signature and poor responses to immunotherapy. In immunocompetent 4T1 tumor-bearing mice, POU4F1 knockout led to decreased infiltration of M2-like macrophages and increased infiltration of proliferative and functional CD8+ T cells and NK cells. In vitro assays using human immune cells demonstrated that POU4F1 directly promoted monocyte recruitment and macrophage polarization, which in turn suppressed the proliferation and effector function of tumor-specific CD8+ T cells and NK cells. Mechanistically, POU4F1 upregulated CCL2 expression through NIK-mediated activation of the non-canonical NF-κB signaling pathway, thereby promoting monocyte recruitment and immunosuppressive phenotype polarization. Genetic ablation or pharmacological targeting of POU4F1 with Bobcat339 significantly inhibited tumor growth, remodeled the tumor immune microenvironment, and synergized with anti-PD-1 therapy in mouse models and patient-derived breast cancer organoids. These findings provide mechanistic insights into how POU4F1, a BLBC-specific transcription factor, orchestrates intercellular crosstalk to establish an immunosuppressive, tumor-supportive microenvironment, and indicate that targeting POU4F1 may represent a promising therapeutic strategy for BLBCs.
中文摘要:免疫抑制性肿瘤微环境是肿瘤进展和治疗耐药的主要驱动因素。基底样乳腺癌(BLBC)与三阴性乳腺癌高度重叠,通常呈现富含肿瘤相关巨噬细胞及其他免疫抑制细胞群的免疫抑制性肿瘤微环境。然而,建立和维持这些微环境特征的驱动机制尚未完全阐明。本研究确定肿瘤细胞内在的POU4F1是BLBC免疫抑制性肿瘤微环境的关键调控因子。POU4F1高表达的肿瘤表现出较低的IFNγ相关特征和对免疫治疗的不良反应。在免疫功能正常的4T1荷瘤小鼠中,敲除POU4F1导致M2样巨噬细胞浸润减少,增殖性和功能性CD8+ T细胞及NK细胞浸润增加。使用人免疫细胞的体外实验表明,POU4F1直接促进单核细胞募集和巨噬细胞极化,进而抑制肿瘤特异性CD8+ T细胞和NK细胞的增殖与效应功能。机制上,POU4F1通过NIK介导的非经典NF-κB信号通路激活上调CCL2表达,从而促进单核细胞募集和免疫抑制表型极化。基因敲除或使用Bobcat339对POU4F1进行药理靶向,在小鼠模型和患者来源乳腺癌类器官中显著抑制肿瘤生长、重塑肿瘤免疫微环境,并与抗PD-1治疗协同。这些发现提供了机制见解,说明BLBC特异性转录因子POU4F1如何协调细胞间串扰以建立免疫抑制、支持肿瘤的微环境,并表明靶向POU4F1可能是BLBC的有前景治疗策略。
Although there are several ongoing clinical trials using neoantigen peptide-based cancer vaccines, challenges still exist to implement in clinical approval such as poor antigen stability, inefficient delivery, and inadequate immune activation. To address these limitations, we developed a polymer-based polyvalent peptide and adjuvant (SPPA) that co-delivers lipid-conjugated tumor-specific peptides with Toll-like receptor 7/8 (3M - 052) and a STING (2'3'-cGAMP) agonist. This nanoplatform enables efficient peptide encapsulation, sustained release, and targeted delivery to antigen-presenting cells (APCs), thereby enhancing both innate and adaptive immune responses. We synthesized and characterized a library of lipid-conjugated tumor-associated and neoantigenic peptides. In vitro, SPPA significantly upregulated pro-inflammatory genes and cytokine secretion, confirming robust innate immune activation and demonstrated effective cellular uptake and lymphatic trafficking. In vivo, SPPA alone or in combination with anti-PD-1 antibody (αPD-1) elicited strong cytotoxic T lymphocyte (CTL) responses and inhibited tumor growth in four aggressive syngeneic mouse models: Triple-negative breast cancer (4T1), HER2+ breast cancer (TUBO), lung carcinoma (LLC1), and renal cell carcinoma (RENCA). The combination therapy led to pronounced tumor growth inhibition, survival benefit, and immune cell infiltration, including elevated CD8+IFN-γ+ T cells and M1 macrophages, and reduced regulatory T cells and MDSCs. Spatial transcriptomics revealed localized transcriptional reprogramming, with downregulation of extracellular matrix genes and activation of inflammatory pathways. Collectively, these findings establish SPPA as a potent and versatile nanovaccine platform capable of inducing durable antitumor immunity, especially when combined with immune checkpoint blockade. This approach offers strong translational potential for personalized immunotherapy across diverse solid tumor types.
中文摘要:尽管已有若干利用新抗原肽的癌症疫苗临床试验在进行,临床获批仍受抗原稳定性差、递送效率低和免疫激活不足等问题限制。为克服这些限制,我们构建了基于聚合物的多价肽与佐剂系统(SPPA),将脂质偶联的肿瘤特异性肽与Toll样受体7/8激动剂(3M-052)及STING激动剂(2'3'-cGAMP)共同递送。该纳米平台可实现高效的肽包封、持续释放和向抗原提呈细胞(APC)的靶向递送,从而增强固有免疫和适应性免疫应答。我们合成并表征了一系列脂质偶联的肿瘤相关肽和新抗原肽。体外实验中,SPPA显著上调促炎基因和细胞因子分泌,证实了强效的固有免疫激活,并显示出有效的细胞摄取和淋巴转运。体内实验中,SPPA单用或与抗PD-1抗体(αPD-1)联用,在四种侵袭性同系小鼠模型中均诱导强烈的细胞毒性T淋巴细胞(CTL)应答并抑制肿瘤生长:三阴性乳腺癌(4T1)、HER2阳性乳腺癌(TUBO)、肺癌(LLC1)和肾细胞癌(RENCA)。联合治疗产生明显的肿瘤生长抑制、生存获益和免疫细胞浸润,包括CD8+IFN-γ+ T细胞和M1巨噬细胞升高,调节性T细胞和髓源性抑制细胞减少。空间转录组学显示局部转录重编程,细胞外基质基因下调,炎症通路激活。这些结果确立SPPA为一个强效且通用的纳米疫苗平台,能够诱导持久的抗肿瘤免疫,尤其在与免疫检查点阻断联用时。该方法为多种实体瘤的个性化免疫治疗提供了较强的转化潜力。
This study was carried out to screen PANoptosis-related biomarker genes and the involved underlying mechanism in clear cell renal cell carcinoma (ccRCC). Differentially expressed (DE) PANoptosis-related genes were identified. Then prognostic biomarker genes were screened, and used to construct a prognostic model. The predictive ability of the model was explored by receiver operating characteristic (ROC) curves. Then the correlation between risk score with clinical features and immune cell infiltration were evaluated. The expression level and prognosis of gelsolin (GSN) were examined in datasets. Furthermore, in vivo and in vitro experiments were employed to investigate underlying mechanisms. ScRNA-seq analysis uncovered that PANoptosis scores varied significantly across 9 cell types in the tumor microenvironment. A total of 26 DE-PANoptosis-related genes were identified by intersecting DEGs and PANoptosis-related genes. Then 3 prognosis biomarker genes were screened and used to build the prognostic model, namely TLR3, GSN and TNFRSF1A. The risk score was associated with tumor grade, stage (I, II, III, IV), pathologic T-Stage, etc, and also significantly correlated with immune cells and expression of immune checkpoint proteins. In addition, GSN was upregulated in ccRCC, and high expression of GSN indicated a favorable OS. In vivo and in vitro experiments revealed that GSN liquid-liquid phase separation (LLPS) directly induces PANoptosis in ccRCC by inhibiting YAP-dependent glycolysis. In conclusion, using TLR3, GSN and TNFRSF1A, the established PANoptosis-related prognostic model was established and showed good predictive performance for predicting prognosis of ccRCC patients. GSN LLPS directly induces PANoptosis in ccRCC by inhibiting YAP-dependent glycolysis.
中文摘要:本研究旨在筛选透明细胞肾细胞癌(ccRCC)中PANoptosis相关生物标志基因并探讨其潜在机制。研究识别了差异表达(DE)的PANoptosis相关基因,随后筛选预后生物标志基因并构建预后模型,通过受试者工作特征(ROC)曲线评估模型的预测能力,并分析风险评分与临床特征及免疫细胞浸润之间的相关性。研究还在数据集中检测了凝溶胶蛋白(GSN)的表达水平与预后意义,并用体内和体外实验探讨潜在机制。单细胞RNA测序分析显示,肿瘤微环境中9种细胞类型的PANoptosis评分存在显著差异。将差异表达基因与PANoptosis相关基因取交集后,共识别出26个差异表达的PANoptosis相关基因。随后筛选出3个预后生物标志基因TLR3、GSN和TNFRSF1A,并用于构建预后模型。风险评分与肿瘤分级、分期(I、II、III、IV)、病理T分期等相关,也与免疫细胞及免疫检查点蛋白表达显著相关。GSN在ccRCC中上调,GSN高表达提示总生存期(OS)较好。体内和体外实验显示,GSN液-液相分离(LLPS)通过抑制YAP依赖的糖酵解直接诱导ccRCC中的PANoptosis。总之,利用TLR3、GSN和TNFRSF1A建立的PANoptosis相关预后模型对ccRCC患者预后具有较好的预测性能,GSN LLPS通过抑制YAP依赖的糖酵解直接诱导ccRCC中的PANoptosis。
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors, such as ribociclib (RB), limits breast cancer therapy. Although PEG10 siRNA (siPEG10) can counteract this resistance, achieving targeted, synchronized co-delivery to reshape the immunosuppressive tumor microenvironment (TME) remains a formidable challenge. By loading RB and siPEG10 into PEG-β-CD-modified mesoporous silica nanoparticles (PMSNs) and coating them with breast cancer cell membranes (CM), the nanocomposite RB/siPEG10@PMSNs-CM was synthesized. The nanomaterials were characterized for their size, charge, drug loading, and pH-responsive release. Therapeutic efficacy, immunotherapy-related potentials, and underlying mechanisms were evaluated using in vitro functional assays, an anoikis resistance model, and in vivo breast cancer models. Toxicity was assessed in liver and kidney tissue. The nanodrug RB/siPEG10@PMSNs-CM (<200 nm) exhibited enhanced cellular uptake and pH-dependent drug release. The zeta potential of the RB/siPEG10@PMSNs-CM was negative. The nanodrug significantly inhibited tumor cell growth, migration, invasion, and metastasis, while inducing apoptosis. Crucially, the nanodrug overcame anoikis resistance, upregulated cleaved caspase-3 and cleaved PARP, reversed epithelial-mesenchymal transition (EMT) markers (increased E-cadherin and decreased Vimentin), and inhibited p-STAT3 and p-ERK signaling. Furthermore, the nanodrug exhibited lower toxicity to liver and kidney than RB. In Conclusion, the developed biomimetic nano-delivery system RB/siPEG10@PMSNs-CM successfully co-delivers RB and siPEG10 and exhibits a favorable safety profile. This platform exhibits anti-primary tumor and anti-metastatic efficacy and effectively overcomes anoikis resistance in breast cancer, which correlated with the suppression of the MEK/ERK and STAT3 signaling pathways, offering a promising combination strategy for advanced breast cancer immunotherapy and targeted treatment.
中文摘要:CDK4/6 抑制剂(如瑞波西利 RB)耐药限制了乳腺癌治疗。PEG10 siRNA(siPEG10)虽可对抗该耐药,但实现靶向、同步共递送以重塑免疫抑制性肿瘤微环境(TME)仍十分困难。将 RB 与 siPEG10 载入 PEG-β-CD 修饰的介孔二氧化硅纳米粒(PMSNs),并以乳腺癌细胞膜(CM)包覆,合成了纳米复合物 RB/siPEG10@PMSNs-CM。对该材料的粒径、电荷、载药量及 pH 响应释放进行了表征。通过体外功能实验、失巢凋亡耐受模型及体内乳腺癌模型评价疗效、免疫治疗相关潜力与作用机制,并在肝、肾组织中评估毒性。该纳米药物粒径小于 200 nm,细胞摄取增强,药物释放呈 pH 依赖,zeta 电位为负。纳米药物显著抑制肿瘤细胞生长、迁移、侵袭与转移,并诱导凋亡。该纳米药物克服失巢凋亡耐受,上调 cleaved caspase-3 与 cleaved PARP,逆转上皮-间质转化(EMT)标志(E-cadherin 升高、Vimentin 降低),并抑制 p-STAT3 与 p-ERK 信号。其对肝、肾的毒性低于 RB。所构建的仿生纳米递送系统 RB/siPEG10@PMSNs-CM 可成功共递送 RB 与 siPEG10,安全性良好,兼具抗原发肿瘤与抗转移作用,并有效克服乳腺癌失巢凋亡耐受,该作用与 MEK/ERK 及 STAT3 信号通路受抑相关,为晚期乳腺癌免疫治疗与靶向治疗提供了有前景的联合策略。
Gemcitabine remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet the emergence of resistance constitutes a major clinical challenge with poorly understood epigenomic mechanisms. Here, we identified the pioneer transcription factor Foxa1 as a master regulator of gemcitabine resistance through multi-omics analysis. Mechanistically, Foxa1 drives widespread super-enhancer (SE) reprogramming and 3D genome remodelling in resistant cells, which coordinately activates the expression of key resistance genes, notably Rrm1 and Cdadc1. This is accompanied by increased chromatin accessibility, elevated H3K27ac enrichment at SEs, and enhanced Foxa1 binding at regulatory elements. Moreover, post-translational stabilization of Foxa1 via USP7-mediated deubiquitination sustains this epigenomic program. Genetic ablation of Foxa1 or specific SE regions near Rrm1 resensitizes resistant cells to gemcitabine. Building upon this mechanism, we demonstrate that bromodomain and extraterminal (BET) inhibitors, which disrupt SE function, potently reverse resistance. Notably, the clinical-stage BET inhibitor AZD5153, in combination with gemcitabine, achieves robust tumor suppression and overcomes resistance in cell-derived xenograft (CDX) models by dismantling the Foxa1-mediated resistant transcriptome and reinvigorating drug sensitivity. Our findings establish Foxa1-orchestrated enhancer reprogramming as a fundamental mechanism of gemcitabine resistance and unveil a promising epigenetic therapy to restore treatment efficacy in PDAC.
中文摘要:吉西他滨仍是胰腺导管腺癌(PDAC)治疗的基石,但耐药的出现构成重大临床挑战,其表观基因组机制尚不清楚。本研究通过多组学分析将先锋转录因子Foxa1鉴定为吉西他滨耐药的主调控因子。机制上,Foxa1在耐药细胞中驱动广泛的超级增强子(SE)重编程和三维基因组重塑,协同激活关键耐药基因的表达,尤其是Rrm1和Cdadc1。这一过程伴随染色质可及性增加、SE区域H3K27ac富集升高以及调控元件处Foxa1结合增强。USP7介导的去泛素化使Foxa1蛋白翻译后稳定,从而维持该表观基因组程序。敲除Foxa1或Rrm1附近特定SE区域可使耐药细胞对吉西他滨重新敏感。基于该机制,破坏SE功能的溴结构域和超末端(BET)抑制剂能有效逆转耐药。临床阶段BET抑制剂AZD5153与吉西他滨联合,在细胞来源异种移植(CDX)模型中通过瓦解Foxa1介导的耐药转录组并恢复药物敏感性,实现强效肿瘤抑制并克服耐药。这些发现确立Foxa1编排的增强子重编程作为吉西他滨耐药的基本机制,并揭示一种有前景的表观遗传治疗策略以恢复PDAC疗效。
Glioma recurrence and resistance to therapy remain major challenges in neuro-oncology, driven in part by profound cellular and spatial heterogeneity within the tumor microenvironment. Malignant and immune populations dynamically coexist and transition during disease progression, yet their coordinated organization remains poorly understood, and standard bulk RNA sequencing cannot resolve cell-type composition. To address these limitations, we established GliomaDeconv, a glioma-specific reference and interpretation framework for bulk RNA-seq deconvolution, derived from multi-subtype scRNA-seq datasets and implemented using established probabilistic deconvolution architecture. Application of GliomaDeconv to spatially annotated IVY GAP datasets and large bulk RNA-seq cohorts enabled systematic mapping of cellular composition, spatial organization, and dynamic evolution across glioma subtypes and disease stages. Single-cell analyses identified distinct malignant cell states, including a neural progenitor-like (NPC-like) population with strong tumor-propagating capacity, as well as multiple functionally specialized tumor-associated macrophage subsets enriched in grade- and subtype-specific patterns. GliomaDeconv-derived estimates showed biological concordance with single-cell-derived molecular programs in bulk datasets and suggested that histologically defined tumor regions are associated with distinct malignant and immune cell-state enrichments. Large-cohort analyses further identified subtype-specific cellular programs and therapy-associated phenotypic transitions. Functional validation in an orthotopic model showed that SNAP25-high/NPC-like glioma cells exhibited enhanced tumor-propagating capacity, supporting an association between this cell state and glioma progression. Collectively, GliomaDeconv bridges single-cell resolution and large-cohort transcriptomics, enabling precise dissection of glioma microenvironmental composition across subtypes and disease stages. The tool provides a practical framework for biological interpretation and is freely available at http://www.szflab.site/gliomadeconv/.
中文摘要:胶质瘤复发和治疗耐药仍是神经肿瘤学的主要挑战,部分由肿瘤微环境内显著的细胞与空间异质性驱动。疾病进展过程中,恶性细胞与免疫细胞群体动态共存并发生转变,但其协同组织方式仍知之甚少,常规 bulk RNA 测序无法解析细胞类型组成。为应对这些限制,我们建立了 GliomaDeconv,一个针对 bulk RNA-seq 去卷积的胶质瘤特异性参考与解释框架,其源自多亚型 scRNA-seq 数据集,并采用已有的概率去卷积架构实现。将 GliomaDeconv 应用于具空间注释的 IVY GAP 数据集和大型 bulk RNA-seq 队列,系统绘制了跨胶质瘤亚型与疾病阶段的细胞组成、空间组织和动态演化图谱。单细胞分析识别出不同的恶性细胞状态,包括具有强肿瘤传播能力的神经祖细胞样(NPC-like)群体,以及多个功能特化的肿瘤相关巨噬细胞亚群,后者在分级和亚型特异性模式中富集。GliomaDeconv 得出的估计与 bulk 数据集中的单细胞来源分子程序具有生物学一致性,并提示组织学定义的肿瘤区域与不同的恶性和免疫细胞状态富集相关。大型队列分析进一步识别出亚型特异性细胞程序及治疗相关表型转变。在原位模型中的功能验证显示,SNAP25-high/NPC-like 胶质瘤细胞表现出增强的肿瘤传播能力,支持该细胞状态与胶质瘤进展之间的关联。GliomaDeconv 将单细胞分辨率与大型队列转录组学连接起来,可跨亚型和疾病阶段精确解析胶质瘤微环境组成。该工具为生物学解释提供了实用框架,并可在 http://www.szflab.site/gliomadeconv/ 免费获取。
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and a poor prognosis. Immunotherapies, particularly immune checkpoint inhibitors (ICIs), have expanded the therapeutic options for TNBC. Despite the revolutionary breakthroughs in the treatment of TNBC, some patients still exhibit primary or acquired resistance to immunotherapy. A comprehensive understanding of the mechanisms of immunotherapy resistance is crucial for developing new strategies to overcome the resistance. In this review, we discuss the multifactorial resistance mechanisms to immunotherapy in TNBC, including tumor cell-intrinsic mechanisms (low tumor mutation burden, driver gene mutations, antigen presentation defect, and aberrant PD-L1 expression) and alterations in the tumor microenvironment (T cells, dendritic cells, cancer-associated fibroblasts, tumor-associated macrophages, mast cells, B cells, myeloid-derived suppressor cells, cytokines, hypoxia, metabolic reprogramming, neurological factors, ferroptosis, cuproptosis, and microbiome). Furthermore, we discuss strategies to overcome immunotherapy resistance (including combination of ICIs with other existing treatments and nanotechnology-assisted immunotherapy), and identify emerging biomarkers enabling the selection of patients who may benefit from immunotherapy. Therefore, our review provides insights into immunotherapy resistance mechanisms, developing novel therapeutic strategies, and guiding treatment plans.
中文摘要:三阴性乳腺癌(TNBC)是乳腺癌中侵袭性强、治疗选择有限且预后较差的亚型。免疫治疗尤其是免疫检查点抑制剂(ICIs)拓宽了TNBC的治疗选择。尽管TNBC治疗已取得突破性进展,部分患者仍对免疫治疗表现为原发或获得性耐药。全面理解免疫治疗耐药机制对于开发克服耐药的新策略至关重要。该综述讨论TNBC免疫治疗的多因素耐药机制,包括肿瘤细胞内在机制(低肿瘤突变负荷、驱动基因突变、抗原提呈缺陷和PD-L1表达异常)以及肿瘤微环境改变(T细胞、树突状细胞、癌相关成纤维细胞、肿瘤相关巨噬细胞、肥大细胞、B细胞、髓源性抑制细胞、细胞因子、缺氧、代谢重编程、神经因素、铁死亡、铜死亡和微生物组)。同时讨论克服免疫治疗耐药的策略(包括ICIs与其他现有治疗联合以及纳米技术辅助免疫治疗),并识别可用于筛选可能从免疫治疗获益患者的新兴生物标志物。该综述为理解免疫治疗耐药机制、开发新型治疗策略和指导治疗方案提供见解。
3消化系统肿瘤 (32篇)
临床研究 (10篇)
Sensitive biomarkers for recurrence risk stratification, recurrence surveillance and adjuvant therapy guidance are of unmet need for patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT). Herein, we explored the potential of profiling circulating tumor DNA (ctDNA) for prediction and prevention of recurrence in HCC after LT. HCC patients (n=91) who underwent LT were prospectively enrolled. ctDNA was assayed using next-generation sequencing from perioperative plasma (n=408). Associations between ctDNA status with clinicopathological parameters, tumor recurrence, and adjuvant treatment effect were analyzed. Higher preoperative ctDNA burden correlated with microvascular invasion (median: 45.0 vs 5.1 MTM/mL, P=0.003) and recurrence (156.2 vs 7.7 MTM/mL, P<0.001). ctDNA clearance was noted in 87.7% patients after LT and patients who kept positive postoperative ctDNA showed higher recurrence risk (HR=8.86, P<0.001), especially early recurrence (within 1 year; 75.0% vs 10.1%, P<0.001). During follow-up, positive longitudinal ctDNA was similarly predictive of recurrence (HR=36.50, P<0.001). The AUC of longitudinal ctDNA for predicting recurrence was 0.930-significantly higher than alpha-fetoprotein (0.655, P<0.001). Longitudinal ctDNA detected radiologically evidenced recurrence with a median lead time of 5.1 months compared to standard-of-care surveillance. Among patients who received adjuvant therapy, those with positive postoperative ctDNA could benefit (HR=0.11, P=0.003) and those with decreased ctDNA burden following treatment experienced longer interval from ctDNA positivity to recurrence (HR=0.17, P=0.006). Serial ctDNA analysis demonstrates strong prognostic value, capable of heralding tumor recurrence prior to radiological recurrence and measuring treatment efficacy. Its integration into clinical practice of HCC provides unique opportunities for adjuvant therapy decision-making following LT.
中文摘要:对接受肝移植的肝细胞癌患者,复发风险分层、复发监测和辅助治疗指导仍缺乏敏感生物标志物。本研究探讨循环肿瘤DNA检测在肝移植后肝细胞癌复发预测与预防中的潜力。前瞻性纳入91例接受肝移植的肝细胞癌患者,采用下一代测序检测围术期血浆样本408份中的ctDNA,分析ctDNA状态与临床病理参数、肿瘤复发及辅助治疗效应的关联。术前ctDNA负荷较高与微血管侵犯相关(中位数45.0 vs 5.1 MTM/mL,P=0.003),也与复发相关(156.2 vs 7.7 MTM/mL,P<0.001)。肝移植后87.7%患者出现ctDNA清除,术后ctDNA持续阳性者复发风险更高(HR=8.86,P<0.001),尤其是1年内早期复发(75.0% vs 10.1%,P<0.001)。随访期间,纵向ctDNA阳性同样可预测复发(HR=36.50,P<0.001)。纵向ctDNA预测复发的AUC为0.930,显著高于甲胎蛋白的0.655(P<0.001)。与标准监测相比,纵向ctDNA较影像学证实的复发中位提前5.1个月检出。在接受辅助治疗的患者中,术后ctDNA阳性者可获益(HR=0.11,P=0.003),治疗后ctDNA负荷下降者从ctDNA阳性至复发的时间间隔更长(HR=0.17,P=0.006)。系列ctDNA分析具有较强预后价值,可在影像学复发前提示肿瘤复发并评估治疗疗效。将ctDNA整合入肝细胞癌临床实践,可为肝移植后辅助治疗决策提供独特机会。
The association between serrated polyp detection rates, including proximal serrated polyp detection rate (PSPDR), and postcolonoscopy colorectal cancer (PCCRC) remains unestablished. We investigated PCCRC incidence and characteristics, and explored associations of PSPDR and adenoma detection rate (ADR) with PCCRC in colonoscopy- and fecal immunochemical test (FIT)-based screening within the Screening of Swedish Colons (SCREESCO) trial. Data from participants who underwent colonoscopy in the colonoscopy and FIT arms were analyzed. PCCRC, defined as colorectal cancer (CRC) diagnosed >6 months after a colonoscopy that did not detect CRC, was identified through linkage with cancer registries. Associations between PSPDR and PCCRC incidence were assessed using Cox models. Of 9982 and 5875 individuals in the colonoscopy and FIT arms, PCCRC was identified in 20 and 17 individuals, with 3-year PCCRC rates of 5.9% (3/51) and 3.5% (4/115), respectively. Compared with screening-detected CRC, PCCRC more often involved right-sided location and advanced stage. The 5-year cumulative incidence of PCCRC was 0.16% (95%CI 0.10%-0.27%) and 0.06% (95%CI 0.02%-0.15%) when colonoscopies were performed by endoscopists with low vs. high PSPDR (<10% vs. ≥10%), respectively. Among endoscopists with high ADR, 5-year PCCRC incidence was 0.13% (95%CI 0.04%-0.32%) vs. 0.06% (95%CI 0.02%-0.16%) for those with low vs. high PSPDR, respectively. Within this group, PCCRC incidence over 8 years decreased as PSPDR increased (hazard ratio per percentage-point increase, 0.90; 95%CI 0.82-1.00; P = 0.04). Despite the limited number of PCCRC events, this study suggests that PSPDR provides complementary information beyond ADR for identifying colonoscopies with higher PCCRC incidence.
中文摘要:锯齿状息肉检出率,包括近端锯齿状息肉检出率(PSPDR),与结肠镜检查后结直肠癌(PCCRC)之间的关联尚未确立。本研究在瑞典结肠筛查(SCREESCO)试验中,分析结肠镜筛查组和粪便免疫化学检测(FIT)筛查组内接受结肠镜检查者的PCCRC发生率和特征,并探讨PSPDR与腺瘤检出率(ADR)同PCCRC的关联。PCCRC定义为结肠镜检查未检出结直肠癌(CRC)后超过6个月诊断的CRC,通过链接癌症登记识别。采用Cox模型评估PSPDR与PCCRC发生率之间的关联。结肠镜组9982人和FIT组5875人中,分别识别出20例和17例PCCRC,3年PCCRC率分别为5.9%(3/51)和3.5%(4/115)。与筛查检出的CRC相比,PCCRC更多位于右侧且分期更晚。结肠镜检查由PSPDR低与高的内镜医师完成时(<10%与≥10%),PCCRC的5年累积发生率分别为0.16%(95%CI 0.10%-0.27%)和0.06%(95%CI 0.02%-0.15%)。在ADR高的内镜医师中,PSPDR低与高者的5年PCCRC发生率分别为0.13%(95%CI 0.04%-0.32%)和0.06%(95%CI 0.02%-0.16%)。该组内,8年期间PCCRC发生率随PSPDR升高而下降(每增加1个百分点的风险比0.90,95%CI 0.82-1.00,P=0.04)。尽管PCCRC事件数量有限,本研究提示PSPDR在ADR之外提供补充信息,有助于识别PCCRC发生率较高的结肠镜检查。
The phase 3 TRANSFORM-1 study evaluated ruxolitinib (RUX) in combination with navitoclax (NAV) or placebo (PBO) in Janus kinase inhibitor-naïve adults with intermediate-2 or high-risk myelofibrosis and Eastern Cooperative Oncology Group performance status of ≤2. Patients were randomized 1:1 to NAV (200 mg/d starting dose, or 100 mg escalated to 200 mg/d) or PBO, with RUX dosed per label. The primary end point was ≥35% spleen volume reduction (SVR) at week 24 (SVR35W24). Secondary end points included change from baseline in total symptom score (TSS) at week 24 and SVR35 at any time. A total of 252 patients (NAV+RUX, n = 125; PBO+RUX, n = 127; median follow-up 20.3 months) were randomized; >80% had intermediate-2 risk, and ∼50% had high-molecular risk disease. SVR35W24 was achieved by 63.2% with NAV+RUX vs 31.5% with PBO+RUX (P< .0001). Mean change in TSS at week 24 was not significantly different between NAV+RUX and PBO+RUX (-10.2 vs -11.6; P = .2852). SVR35 at any time was achieved in 76.8% with NAV+RUX vs 44.1% with PBO+RUX (nominal P< .0001). A ≥20% variant allele frequency reduction (exploratory end point) occurred in 58.5% (95% confidence interval [CI], 49.0-67.5) with NAV+RUX and 45.5% (95% CI, 36.4-54.8) with PBO+RUX. NAV+RUX showed higher hematologic toxicity vs PBO+RUX (grade 3/4 thrombocytopenia, 54.0% vs 19.2%; grade 3/4 neutropenia, 40.3% vs 8.8%); diarrhea (any grade, 41.9% vs 16.8%) was also more common. Cytopenias were generally manageable and reversible with dose adjustments. This trial was registered at www.clinicaltrials.gov as NCT04472598.
中文摘要:3期TRANSFORM-1研究评估鲁索替尼(RUX)联合navitoclax(NAV)或安慰剂(PBO)用于未接受Janus激酶抑制剂治疗、中危-2或高危骨髓纤维化且东部肿瘤协作组体能状态评分≤2的成人患者。患者按1:1随机接受NAV(起始剂量200 mg/d,或100 mg递增至200 mg/d)或PBO,RUX按说明书剂量给药。主要终点为第24周脾体积缩小≥35%(SVR35W24)。次要终点包括第24周总症状评分(TSS)较基线变化及任意时间SVR35。共252例患者随机分组(NAV+RUX组125例;PBO+RUX组127例;中位随访20.3个月);>80%为中危-2风险,约50%具有高分子风险疾病。NAV+RUX组SVR35W24为63.2%,PBO+RUX组为31.5%(P<.0001)。第24周TSS平均变化在NAV+RUX与PBO+RUX间无显著差异(-10.2 vs -11.6;P=.2852)。任意时间SVR35在NAV+RUX组为76.8%,PBO+RUX组为44.1%(名义P<.0001)。探索性终点≥20%变异等位基因频率下降在NAV+RUX组为58.5%(95%置信区间[CI],49.0-67.5),PBO+RUX组为45.5%(95% CI,36.4-54.8)。NAV+RUX较PBO+RUX显示更高的血液学毒性(3/4级血小板减少54.0% vs 19.2%;3/4级中性粒细胞减少40.3% vs 8.8%);腹泻(任何级别,41.9% vs 16.8%)也更常见。血细胞减少总体可通过剂量调整管理且可逆。该试验在www.clinicaltrials.gov注册,注册号为NCT04472598。
The information regarding tumor cells, the immune environment and microorganisms can provide insights into the formation and progression of gastric cancer (GC) from various perspectives. However, there remains a need for a diagnostic strategy capable of integrating and analyzing these multiple dimensions to accurately assess the progression of GC. Extracellular vesicles (EVs), which carry multidimensional information, represent a promising non-invasive biomarker for the diagnosis and monitoring of GC. Despite their potential, the development of an efficient method for the enrichment and precise analysis of individual EVs remains a significant challenge. Herein, we present a versatile droplet digital assay, termed the Single-EV MagaDecoder, designed to enable both the enrichment of EVs and the decoding of individual EVs. This assay consisted of two main components: efficient reversible magnetic enrichment of EVs and single EV multidimensional biomarker decoding analysis. To evaluate the clinical utility of the single-EV MagaDecoder for GC diagnosis, screening (n = 64) and validation (n = 79) GC cohorts were utilized. This assay demonstrated exceptional performance in predicting gastric disease risk, achieving 100% accuracy, and distinguishing between benign and malignant conditions with an area under the curve (AUC) of 0.8875. These results were obtained through the detection of multidimensional signatures of GC-EVs in a validation cohort (n = 79). In summary, this study proposes a promising strategy for the precise analysis of multidimensional EV subpopulations at single EV level, thereby advancing the field of precision medicine for GC.
中文摘要:肿瘤细胞、免疫环境和微生物相关信息可从多个角度揭示胃癌(GC)的发生与进展。仍需要一种能够整合并分析这些多维信息的诊断策略,以准确评估GC进展。细胞外囊泡(EVs)携带多维信息,是用于GC诊断和监测的有前景的无创生物标志物。尽管具有潜力,开发高效富集并精确分析单个EV的方法仍是一项重大挑战。我们提出一种多功能液滴数字检测方法,称为Single-EV MagaDecoder,旨在实现EV富集和单个EV解码。该检测由两个主要部分组成:EV的高效可逆磁性富集和单EV多维生物标志物解码分析。为评估Single-EV MagaDecoder用于GC诊断的临床实用性,使用了GC筛查队列(n=64)和验证队列(n=79)。该检测在预测胃部疾病风险方面表现出卓越性能,达到100%准确率,并以0.8875的曲线下面积(AUC)区分良性与恶性病变。这些结果通过在验证队列(n=79)中检测GC-EVs的多维特征获得。该研究提出一种在单EV水平精确分析多维EV亚群的有前景策略,从而推动GC精准医学领域的发展。
Obesity is associated with elevated risks for multiple cancers. How bariatric surgery influences these risks across age and sex is insufficiently understood. To evaluate the association between bariatric surgery and obesity-related cancer (breast, endometrial, ovarian, esophageal adenocarcinoma, liver, pancreatic, colon, rectal, kidney, and multiple myeloma) and whether this association varies by age and sex. This population-based cohort study within the Nordic Obesity Surgery Cohort (NordOSCo) included individuals aged 18 to 59 years with an obesity record in Denmark, Finland, or Sweden from 1992 to 2023. Prospectively collected data on exposure, outcomes, and confounders were obtained from well-maintained national registries. Follow-up continued until cancer diagnosis, death, emigration, or December 31, 2023. These data were analyzed from December 2025 to April 2026. Bariatric surgery vs no surgery among individuals with obesity. The primary outcome was incidence of obesity-related cancers. Risks were compared using crude and multivariable-adjusted incidence rate ratios (aIRR) with 95% CIs derived from Poisson regression adjusted for age, sex, calendar year, country, and obesity- and lifestyle-related comorbidities. Effect modification by age group (18-39 vs 40-59 years) and sex (female vs male) was evaluated using interaction terms. Among 784 105 individuals with obesity (569 266 women [73%] and 214 839 men [27%]), 99 614 underwent bariatric surgery. Surgery was associated with a lower risk of obesity-related cancer overall (aIRR, 0.81; 95% CI, 0.77-0.85). The magnitude of risk reduction did not differ by age group (individuals aged 18 to 39 years: aIRR, 0.80; 95% CI, 0.72-0.88 and individuals aged 40 to 59 years: aIRR, 0.81; 95% CI, 0.78-0.86) (P for interaction = .88). Associations for non-sex-specific cancers were similar in men and women (P for interaction = .50). For individual cancers, the strongest inverse associations were observed for liver cancer (aIRR, 0.49; 95% CI, 0.34-0.70), endometrial cancer (aIRR, 0.51; 95% CI, 0.45-0.59), and ovarian cancer (aIRR, 0.73; 95% CI, 0.60-0.87). In contrast, pancreatic cancer risk was increased after surgery, particularly among younger adults (aIRR, 2.21; 95% CI, 1.44-3.39; P = .01). In this study, bariatric surgery was associated with a lower long-term risk of obesity-related cancers, with similar associations across age groups and sexes. These findings suggest that the long-term oncologic benefits of bariatric surgery apply broadly across age groups and sexes, supporting equitable access to bariatric surgery for patients with obesity.
中文摘要:肥胖与多种癌症风险升高相关。减重手术如何在不同年龄和性别中影响这些风险,尚缺乏充分认识。评估减重手术与肥胖相关癌症(乳腺癌、子宫内膜癌、卵巢癌、食管腺癌、肝癌、胰腺癌、结肠癌、直肠癌、肾癌和多发性骨髓瘤)之间的关联,以及该关联是否随年龄和性别变化。这项基于人群的队列研究属于北欧肥胖手术队列(NordOSCo),纳入1992年至2023年在丹麦、芬兰或瑞典有肥胖记录的18至59岁个体。暴露、结局和混杂因素数据来自保存良好的国家登记系统,为前瞻性收集。随访持续至癌症诊断、死亡、移居或2023年12月31日。数据分析时间为2025年12月至2026年4月。比较肥胖个体中接受减重手术与未接受手术。主要结局为肥胖相关癌症的发病率。使用粗发病率和多变量校正发病率比(aIRR)及95%CI比较风险,模型为泊松回归,校正年龄、性别、日历年、国家以及肥胖和生活方式相关合并症。通过交互项评估年龄组(18至39岁与40至59岁)和性别(女性与男性)的效应修饰。在784 105名肥胖个体(569 266名女性[73%]和214 839名男性[27%])中,99 614人接受减重手术。手术与肥胖相关癌症总体风险降低相关(aIRR,0.81;95%CI,0.77-0.85)。风险降低幅度未因年龄组不同而不同(18至39岁:aIRR,0.80;95%CI,0.72-0.88;40至59岁:aIRR,0.81;95%CI,0.78-0.86)(交互作用P=.88)。非性别特异性癌症的关联在男性和女性中相似(交互作用P=.50)。就单一癌症而言,最强的负相关见于肝癌(aIRR,0.49;95%CI,0.34-0.70)、子宫内膜癌(aIRR,0.51;95%CI,0.45-0.59)和卵巢癌(aIRR,0.73;95%CI,0.60-0.87)。相反,胰腺癌风险在手术后升高,尤其在较年轻成人中(aIRR,2.21;95%CI,1.44-3.39;P=.01)。在本研究中,减重手术与肥胖相关癌症的长期风险降低相关,且不同年龄组和性别间的关联相似。这些发现提示减重手术的长期肿瘤学获益可广泛适用于不同年龄组和性别,支持肥胖患者公平获得减重手术。
Artificial intelligence (AI) is reshaping the landscape of medical education, yet the widespread adoption of general-purpose AI tools in student learning raises substantial concerns about curricular alignment, information accuracy, and the absence of pedagogical scaffolding. This crossover pilot study evaluated a curriculum-aligned custom GPT that was developed to support AI-scaffolded self-directed learning (SDL), preparation that remains student-initiated but is supported by structured Socratic prompting, compared with fully unguided traditional preparation in second-year medical students at the University of South Carolina, Floyd School of Medicine (USC Floyd SoM). Forty-four second-year medical students voluntarily participated in the two faculty-led pathology small group discussions (Cushing's disease and prostate cancer), using the custom GPT for one case and conventional resources for the other. Faculty assessed SDL documentation forms and small group discussion performance using standardized rubrics. Students using the curriculum-aligned custom GPT achieved significantly higher SDL rubric scores (10.3 vs. 9.4 out of 12; mean difference 0.9, 95% CI 0.5-1.3; P<.001; Cohen d=0.71) and small group discussion scores (14.9 vs. 13.7 out of 16; mean difference 1.2, 95% CI 0.7-1.7; P<.001; Cohen d=0.78), with moderate to large effect sizes. Delayed retention (end-of-block examination items) did not differ significantly (Wilcoxon signed-rank P=.052). Students also reported significantly greater gains in understanding and pathophysiological reasoning. 34 out of 44 (77%) reported improved reasoning clarity, and 31 out of 44 (70%) improved conceptual understanding. Assessment of five prespecified AI-related concern domains did not identify major concerns. In this crossover pilot study, use of curriculum-aligned custom GPT was associated with higher faculty-assessed SDL documentation and small group discussion performance. Delayed knowledge retention did not differ significantly in the primary analysis. These findings support further investigation of curriculum-aligned AI tools in larger, multisite studies. This pilot study was not registered in a public trial registry. As a minimal-risk, exempt educational pilot study conducted within a single course block, formal registration was not pursued; the authors note this as a limitation and recommend prospective registration for future, larger-scale studies of this intervention.
中文摘要:人工智能正在重塑医学教育,通用型人工智能工具在学生学习中广泛使用,引发了对课程对齐、信息准确性以及缺少教学支架的担忧。这项交叉试点研究评估了一种与课程对齐的定制GPT,用于支持人工智能支架式自主学习(SDL),这种准备由学生自主发起,但由结构化苏格拉底式提问提供支持,并与完全无引导的传统准备方式进行比较,对象为南卡罗来纳大学Floyd医学院(USC Floyd SoM)二年级医学生。44名二年级医学生自愿参加两次由教师带领的病理学小组讨论(库欣病和前列腺癌),其中一个病例使用定制GPT,另一个病例使用常规资源。教师使用标准化量规评估SDL记录表和小 group discussion 表现。使用课程对齐定制GPT的学生获得显著更高的SDL量规评分(10.3 vs. 9.4,满分12;平均差0.9,95% CI 0.5-1.3;P<.001;Cohen d=0.71)和小组讨论评分(14.9 vs. 13.7,满分16;平均差1.2,95% CI 0.7-1.7;P<.001;Cohen d=0.78),效应量为中等至较大。延迟保持(区块末考试题目)无显著差异(Wilcoxon符号秩检验P=.052)。学生也报告在理解和病理生理推理方面有显著更大收获。44人中有34人(77%)报告推理清晰度改善,44人中有31人(70%)报告概念理解改善。对五个预设人工智能相关担忧领域的评估未发现重大担忧。在这项交叉试点研究中,使用课程对齐定制GPT与更高的教师评估SDL记录和小组讨论表现相关。主要分析中延迟知识保持无显著差异。这些发现支持在更大规模、多中心研究中进一步考察课程对齐的人工智能工具。该试点研究未在公共试验注册平台注册。作为在单一课程区块内开展的最小风险、豁免教育试点研究,未进行正式注册;作者将此列为局限性,并建议未来更大规模研究对该干预进行前瞻性注册。
The clinical efficacy of currently available third- and later-line treatment regimens for patients with metastatic colorectal cancer (mCRC) remains suboptimal. This study was designed to investigate fruquintinib plus TAS-102 regimen in this patient population. This study was a prospective, multi-center, single-arm phase II trial. A total of 50 patients with mCRC who had experienced treatment failure to at least two standard therapies were enrolled. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Survival outcomes were estimated using the Kaplan-Meier method. With a median follow-up duration of 25.1 months, the median PFS was 6.07 months (95% CI: 4.07-7.87) and the median OS was 14.10 months (95% CI: 9.84-23.28). The ORR was 10.0% (95% CI: 3.3-21.8), with a DCR of 66.0% (95% CI: 51.2-78.8). All the patients experienced treatment-related adverse events (TRAEs), with 68.0% reporting grade ≥ 3 TRAEs. No serious adverse events (AEs), deaths, or new safety concerns were reported. In conclusion, fruquintinib combined with TAS-102 showed preliminary anti-tumor activity with a manageable safety profile in patients with refractory mCRC, which highlights its potential as a viable later-line therapeutic option. Trial Registration: NCT05004831.
中文摘要:转移性结直肠癌(mCRC)现有三线及后线治疗方案的临床疗效仍不理想。本研究旨在评估呋喹替尼联合TAS-102在该患者人群中的表现。研究为前瞻性、多中心、单臂II期试验,共纳入50例至少两种标准治疗失败的mCRC患者。主要终点为无进展生存期(PFS),次要终点包括总生存期(OS)、客观缓解率(ORR)、疾病控制率(DCR)和安全性。生存结局采用Kaplan-Meier法估计。中位随访25.1个月时,中位PFS为6.07个月(95% CI:4.07-7.87),中位OS为14.10个月(95% CI:9.84-23.28)。ORR为10.0%(95% CI:3.3-21.8),DCR为66.0%(95% CI:51.2-78.8)。全部患者出现治疗相关不良事件(TRAE),68.0%报告≥3级TRAE。未报告严重不良事件(AE)、死亡或新的安全性问题。呋喹替尼联合TAS-102在难治性mCRC患者中显示出初步抗肿瘤活性,安全性可控,提示其作为后线治疗选择的潜力。试验注册号:NCT05004831。
Post-endoscopy upper gastrointestinal cancer (PEUGIC) is an emerging quality metric, but varying definitions complicate benchmarking. We characterized PEUGIC rates and outcomes by anatomic site and coded high-risk condition (HRC) status in a large US cohort. This was a retrospective cancer-first cohort study of 14 814 patients with upper gastrointestinal cancer (UGIC) from a multicenter database (2016-2024). Index endoscopy-detected UGIC was diagnosed within 6 months of esophagogastroduodenoscopy. PEUGIC was defined as UGIC diagnosed 6-36 months after a nondiagnostic esophagogastroduodenoscopy. The primary outcome was PEUGIC rate by cancer type and HRC status. Secondary outcomes included 3-year overall survival. The overall PEUGIC rate was 9.4% (esophageal cancer 9.6%, gastric cancer 8.6%, duodenal cancer 10.7%). Rates were higher with HRC (18.2%) than without HRC (5.0%; P < 0.001). PEUGIC rate without HRC plateaued (4.0%-5.1% in 2022-2024), while PEUGIC rate with HRC for esophageal cancer (16.8%) and gastric cancer (14.4%) decreased over time. In exploratory analysis, PEUGIC was associated with better survival vs. index endoscopy-detected UGIC for esophageal cancer (adjusted hazard ratio [aHR] 0.82, 95%CI 0.67-0.99) and gastric cancer (aHR 0.77, 0.62-0.96), and PEUGIC with HRC was associated with lower mortality vs. PEUGIC without HRC for esophageal cancer (aHR 0.51, 0.36-0.74) and gastric cancer (aHR 0.50, 0.34-0.73). 1 in 10 UGIC patients had a prior nondiagnostic endoscopy within 3 years. PEUGIC rates varied by anatomic site and HRC status, suggesting site- and HRC-stratified benchmarks may better capture endoscopic performance than aggregate metrics.
中文摘要:内镜后上消化道癌(PEUGIC)正成为一项新兴的质量指标,但定义不一致使横向基准比较变得困难。本研究在一个美国大型队列中,按解剖部位与编码高危状态(HRC)刻画了PEUGIC的发生率与结局。这是一项回顾性、以癌症为首发事件的队列研究,纳入多中心数据库(2016—2024年)中14 814例上消化道癌(UGIC)患者。内镜检出(index endoscopy-detected)UGIC指食管胃十二指肠镜检查后6个月内确诊的UGIC。PEUGIC定义为在未获诊断的食管胃十二指肠镜检查后6—36个月确诊的UGIC。主要结局为按癌种与HRC状态划分的PEUGIC发生率,次要结局包括3年总生存。总体PEUGIC发生率为9.4%(食管癌9.6%、胃癌8.6%、十二指肠癌10.7%)。合并HRC者发生率(18.2%)高于无HRC者(5.0%;P < 0.001)。无HRC者的PEUGIC发生率趋于平台(2022—2024年为4.0%—5.1%),而合并HRC的食管癌(16.8%)与胃癌(14.4%)PEUGIC发生率随时间下降。在探索性分析中,食管癌(校正风险比[aHR] 0.82,95%CI 0.67—0.99)与胃癌(aHR 0.77,0.62—0.96)的PEUGIC相比内镜检出UGIC与更好的生存相关;合并HRC的PEUGIC相比无HRC的PEUGIC与更低的死亡率相关,食管癌aHR 0.51(0.36—0.74),胃癌aHR 0.50(0.34—0.73)。约每10例UGIC患者中就有1例在3年内曾接受未获诊断的内镜检查。PEUGIC发生率随解剖部位与HRC状态而异,提示按部位与HRC分层的基准可能比汇总指标更好地反映内镜表现。
Imaging features play a central role in hepatocellular carcinoma (HCC) staging, but current systems remain limited in prognostic precision and treatment guidance. Pathological gross classification, which categorises HCC into four subtypes based on tumour margin morphology, represents a morphological surrogate of aggressive tumour behaviour encompassing histological and molecular features and has demonstrated value in predicting prognosis and guiding adjuvant locoregional therapy selection. Importantly, gross classification is assessable through imaging, but its evaluation utterly depends on postoperative pathology and remains subjective, time-consuming and poorly reproducible. We aimed to develop a three-dimensional (3D) Foundation Model-driven system to automatically perform non-invasive morphological phenotyping and to evaluate its prognostic utility. A cohort of 551 patients who underwent hepatectomy after gadoxetic acid-enhanced MRI from two medical centres was retrospectively analysed. Pathological gross classification served as the reference standard. The 3D MorphStratify Model was built to automatically phenotype 3D gross classification with a dedicated 3D Foundation Model encoder and a channel-aware fusion module. A combined model integrating 3D MorphStratify and Conventional Imaging Predictors (Morph-CIP) was constructed and validated for recurrence risk stratification. The biological rationale linking imaging morphological phenotyping to underlying biology was preliminarily explored. Eligible patients were divided into a development dataset (n=291), a validation dataset (n=192) and an external test set (n=68). The 3D MorphStratify Model achieved a micro-averaged area under the receiver operating characteristic curve (AUC) of 0.932, significantly outperforming senior radiologists (AUC 0.825) with about 40-fold improved efficiency. The imaging-based 3D morphological phenotyping (3D MorphStratify) independently predicted poor recurrence-free survival (RFS, HR 2.16, 95% CI 1.20 to 3.87, p=0.010). The Morph-CIP Model enables risk stratification through training set (AUC 0.836, 0.768, 0.765 for 1-year, 2-year, 3-year RFS), internal test set (AUC 0.816, 0.690, 0.711) and external test set (AUC 0.737, 0.709, 0.702). The high-risk group is characterised by the enrichment of glycolysis and hypoxia signalling pathways. 3D MorphStratify is the first automated 3D morphological phenotyping system for HCC, transforming subjective pathological gross classification into an objective, non-invasive imaging biomarker. The integration of 3D MorphStratify with conventional imaging predictors enables recurrence risk stratification, potentially providing complementary information for prognostic evaluation.
中文摘要:影像特征在肝细胞癌(HCC)分期中居于核心位置,现有分期体系在预后判断精度与治疗决策指导上仍显不足。病理大体分型依据肿瘤边缘形态将HCC分为四种亚型,是侵袭性肿瘤行为的形态学替代指标,涵盖组织学与分子层面的特征,在预测预后、指导辅助局部区域治疗选择方面已显示出价值。大体分型可通过影像评估,但其判定完全依赖术后病理,主观性强、耗时长、可重复性差。本研究拟构建由三维(3D)基础模型驱动的系统,自动完成无创形态学分型并评价其预后价值。回顾性分析来自两家医疗中心的551例接受钆塞酸二钠增强MRI后行肝切除术的患者,以病理大体分型为参考标准。构建3D MorphStratify模型,借助专用的3D基础模型编码器与通道感知融合模块,对3D大体分型进行自动分型。将3D MorphStratify与常规影像预测因子整合,建立Morph-CIP联合模型,用于复发风险分层并加以验证,同时对影像形态学分型与底层生物学之间的关联机制作初步探索。入组患者分为开发集(n=291)、验证集(n=192)与外部测试集(n=68)。3D MorphStratify模型的微平均受试者工作特征曲线下面积(AUC)为0.932,显著优于高年资放射科医师(AUC 0.825),效率提升约40倍。基于影像的3D形态学分型可独立预测较差的无复发生存(RFS,HR 2.16,95% CI 1.20~3.87,p=0.010)。Morph-CIP模型在训练集(1年、2年、3年RFS的AUC分别为0.836、0.768、0.765)、内部测试集(0.816、0.690、0.711)与外部测试集(0.737、0.709、0.702)中均可实现风险分层。高危组以糖酵解与缺氧信号通路富集为特征。3D MorphStratify是首个面向HCC的自动化3D形态学分型系统,将主观的病理大体分型转化为客观、无创的影像学生物标志物。该系统与常规影像预测因子结合可实现复发风险分层,有望为预后评估提供补充信息。
Biliary tract cancers (BTCs) are associated with poor outcomes, with many patients never receiving any cancer-directed treatment. Population-based registries from England, France, Italy and Spain share a similar picture: emergency presentation, rather than planned referral, accounts for roughly half of diagnoses, and >50% of patients with cholangiocarcinoma in England received neither surgery, systemic therapy nor stenting. This attrition is not exclusive to real-world settings: in PROOF-301 and FIGHT-302, a considerable proportion of eligible or randomly assigned patients never started their allocated treatment. BTC is also no longer a disease confined to older adults, with ∼7% of cases diagnosed in individuals <50 years of age. On top of this, access to reimbursed therapies, molecular profiling and expert multidisciplinary discussion remains markedly uneven across Europe. "Our patients deserve better" and closing these gaps in diagnosis, access to treatment and care delivery is as urgent as developing new drugs for this disease.
中文摘要:胆道癌(BTC)预后差,许多患者从未接受任何针对肿瘤的治疗。来自英格兰、法国、意大利和西班牙的基于人群的登记研究呈现相似情况:约半数诊断由急诊就诊而非计划转诊发现;英格兰胆管癌患者中超过50%既未接受手术,也未接受全身治疗或支架置入。这种治疗流失并非仅见于真实世界环境:在PROOF-301和FIGHT-302中,相当比例符合条件或已随机分组的患者从未开始其分配的治疗。BTC也不再局限于老年人,约7%的病例在50岁以下人群中诊断。除此之外,欧洲各地在报销治疗的可及性、分子谱检测和专家多学科讨论方面仍明显不均衡。「我们的患者理应得到更好的照护」,弥合诊断、治疗可及性和照护提供方面的差距,与开发针对该疾病的新药同样紧迫。
基础研究 (22篇)
Herein, a regenerable dielectrophoresis (DEP)-assisted microfluidic electrochemiluminescence (ECL) biosensor was developed for in situ detection of extracellular vesicles (EVs) in gastric cancer ascites. In the integrated microfluidic ECL sensor, a poly(vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP)/deep eutectic solvent (DES)/Au NP (PDES/Au NPs) self-supporting electrode was developed. The DES treatment increased the polar β-phase proportion in PVDF-HFP and improved its conductivity. Meanwhile, Au NPs deposited on the electrode surface amplified the ECL signal of Ru(bpy)32+/TPrA@SiO2 nanobeads through the localized surface plasmon resonance (LSPR) effect and generated an inhomogeneous electric field distribution for EV capture. Due to the DEP effect, the polarized EVs migrated and enriched on the PDES/Au NP electrode surface. As a result, the isolation time of EVs was reduced from 120 to 30 min. Consequently, the sensing platform effectively captured and detected EVs in gastric cancer ascites. The detection range was 1.0 × 101.6-1.0 × 105.3 particles μL-1, and the limit of detection was 9 particles μL-1. Moreover, a regenerative strategy was designed by controllably cleaving Au-S bonds on the self-supporting electrode. This developed microfluidic ECL biosensor achieved real-time quantification of low-concentration EVs in ascites, which established a promising analytical tool for gastric cancer diagnosis as well as the discrimination of peritoneal metastatic lesions.
中文摘要:在此,开发了一种可再生的介电泳(DEP)辅助微流控电化学发光(ECL)生物传感器,用于原位检测胃癌腹水中的细胞外囊泡(EVs)。在该集成微流控ECL传感器中,构建了聚偏氟乙烯-六氟丙烯共聚物(PVDF-HFP)/深共晶溶剂(DES)/Au NP(PDES/Au NPs)自支撑电极。DES处理提高了PVDF-HFP中极性β相比例并改善了其导电性。同时,沉积在电极表面的Au NPs通过局域表面等离子体共振(LSPR)效应放大Ru(bpy)3^2+/TPrA@SiO2纳米珠的ECL信号,并产生不均匀电场分布用于EV捕获。受DEP效应影响,极化的EVs迁移并富集在PDES/Au NP电极表面。结果,EVs分离时间从120 min缩短至30 min。因此,该传感平台有效捕获并检测胃癌腹水中的EVs。检测范围为1.0 × 10^1.6–1.0 × 10^5.3 particles μL^-1,检出限为9 particles μL^-1。此外,通过可控裂解自支撑电极上的Au-S键设计了再生策略。所开发的微流控ECL生物传感器实现了腹水中低浓度EVs的实时定量,为胃癌诊断及腹膜转移病灶判别建立了有前景的分析工具。
Chiral nanozymes are biomimetic materials that combine nanomaterials' unique physicochemical properties with enzyme-like catalytic functions. Their chiral microenvironments enable selective recognition and catalysis of substrate enantiomers, with demonstrated applications in biosensing, disease diagnosis/treatment, and antibacterial/anti-inflammatory therapies. This article provides a systematic review of the design and synthesis strategies, catalytic types, mechanisms of action, and biomedical application research progress of chiral nanozymes. In terms of design and synthesis, four strategies are emphasized, namely chiral ligand modification, the chiral template method, chiral self-assembly, and chiral defect engineering. In catalytic performance and mechanism, the redox activities such as peroxidase, oxidase, catalase, and superoxide dismutase, as well as esterase-/protease-like hydrolysis activity, were summarized. An in-depth exploration was conducted of the molecular mechanism by which chiral microenvironments synergistically regulate substrate binding and electron transfer through steric hindrance effects and multiple weak interactions. In addition, the latest research progress of chiral nanozymes in enantiomer recognition and detection, tumor chemodynamic/photodynamic/sonodynamic combination therapy, neurodegenerative disease protein aggregation intervention, and selective antibacterial and inflammatory regulation is also reviewed. Finally, the challenges and future development directions faced by chiral nanozymes in precise regulation of catalytic selectivity, long-term biological safety in vivo, and clinical translation are discussed. STATEMENT OF SIGNIFICANCE: 1. Four strategies for constructing chiral nanozymes: ligand modification, template induction, self-assembly, and defect engineering. 2. Mechanistic insights into how chiral microenvironments regulate oxidoreductase-like and hydrolase-like catalysis. 3. Biomedical applications, including chiral biosensing, tumor therapy, neurodegenerative disease intervention, and antibacterial treatment. 4. Critical evaluation of chiral-induced spin selectivity (CISS), the hurdles to clinical translation, and future directions for the intelligent design of chiral nanozymes.
中文摘要:手性纳米酶是一类仿生材料,将纳米材料独特的物理化学性质与类酶催化功能相结合。其手性微环境能够选择性识别和催化底物对映异构体,已在生物传感、疾病诊断与治疗以及抗菌抗炎治疗中展示应用。该文系统综述手性纳米酶的设计与合成策略、催化类型、作用机制及生物医学应用研究进展。设计与合成方面,重点阐述四种策略,即手性配体修饰、手性模板法、手性自组装和手性缺陷工程。催化性能与机制方面,总结过氧化物酶、氧化酶、过氧化氢酶和超氧化物歧化酶等氧化还原活性,以及酯酶/蛋白酶样水解活性。深入探讨手性微环境通过空间位阻效应和多重弱相互作用协同调控底物结合与电子传递的分子机制。综述还覆盖手性纳米酶在对映体识别与检测、肿瘤化学动力学/光动力学/声动力学联合治疗、神经退行性疾病蛋白聚集干预以及选择性抗菌和炎症调控方面的最新研究进展。最后讨论手性纳米酶在催化选择性精准调控、体内长期生物安全性和临床转化方面面临的挑战与未来发展方向。意义陈述:1. 构建手性纳米酶的四种策略:配体修饰、模板诱导、自组装和缺陷工程。2. 揭示手性微环境如何调控类氧化还原酶和类水解酶催化的机制。3. 生物医学应用,包括手性生物传感、肿瘤治疗、神经退行性疾病干预和抗菌治疗。4. 对手性诱导自旋选择性(CISS)、临床转化障碍以及手性纳米酶智能设计未来方向的批判性评价。
Bacteria are increasingly recognized as contributors to cancer, yet the underlying mechanisms remain unclear for most species. Here, we find that Gemella morbillorum (Gm) is enriched in feces and tumor tissues from patients with colorectal cancer (CRC) and reveal a multi-step host-pathogen mechanism that promotes colorectal tumorigenesis. In mouse models of CRC, Gm suppresses IL-22 production by type 3 innate lymphoid cells (ILC3s), impairing intestinal barrier function and facilitating bacterial translocation to early neoplastic lesions. At the tumor site, Gm utilizes an ANXA2-dependent, clathrin-mediated pathway to invade CRC cells. Gm induces profound lipid remodeling, characterized by the accumulation of oxidation-prone fatty acids and enhanced lipid peroxidation, which contributes to invasion-dependent DNA damage. Inhibition of lipid peroxidation attenuates Gm-induced DNA damage, functionally linking lipid oxidative stress to genotoxicity. Together, these findings identify Gm as a candidate onco-pathogen in CRC that uses multiple mechanisms to disarm the intestinal barrier and trigger genotoxicity.
中文摘要:细菌日益被认为参与癌症发生,但大多数菌种的具体机制仍不清楚。麻疹孪生球菌(Gm)在结直肠癌患者的粪便和肿瘤组织中富集,并揭示了一种多步骤的宿主-病原体机制促进结直肠肿瘤发生。在结直肠癌小鼠模型中,Gm抑制3型先天淋巴样细胞(ILC3s)产生IL-22,损害肠道屏障功能,并促使细菌易位至早期肿瘤性病变。在肿瘤部位,Gm利用ANXA2依赖、网格蛋白介导的途径侵入结直肠癌细胞。Gm诱导显著的脂质重塑,特征为易氧化脂肪酸积累和脂质过氧化增强,这促进了侵入依赖的DNA损伤。抑制脂质过氧化可减弱Gm诱导的DNA损伤,从功能上把脂质氧化应激与基因毒性联系起来。这些发现表明Gm是结直肠癌的候选致癌病原体,通过多种机制破坏肠道屏障并触发基因毒性。
Chemotherapeutic agents are often limited by poor tumor-specific accumulation, leading to off-target toxicity, while monochemotherapy frequently results in multidrug resistance and suboptimal treatment outcomes. To address these challenges, we have developed a carbon dot-based nanogel drug delivery system that integrates both glutathione (GSH) and photothermal dual-responsiveness, enabling controlled drug release, active tumor targeting, and synergistic photothermal-chemotherapy. Specifically, phenylboronic acid functionalized on the nanogel surface confers tumor-targeting capability. Upon internalization into tumor cells with elevated GSH levels, the nanogel disintegrates, releasing carbon dots conjugated with the chemotherapeutic drug doxorubicin (DOX). Under near-infrared (NIR) irradiation, the carbon dots generate heat, which not only directly damages cancer cells but also triggers on-demand DOX release, achieving a synergistic photothermal-chemotherapeutic effect. Notably, both in vitro and in vivo studies reveal that this system effectively induces cancer cell necrosis through a multimodal mechanism: disruption of lysosomes, induction of DNA damage, and simultaneous suppression of heat shock protein (HSP) expression. This integrated strategy results in significantly enhanced therapeutic outcomes, overcoming key limitations of conventional chemotherapy.
中文摘要:化疗药物常因在肿瘤部位蓄积不足而受限,造成脱靶毒性;单一化疗还常导致多药耐药与治疗结局欠佳。针对这些问题,我们构建了一种基于碳点的纳米凝胶递药系统,同时整合谷胱甘肽(GSH)与光热双重响应性,实现药物可控释放、主动肿瘤靶向与光热-化疗协同。纳米凝胶表面修饰的苯硼酸赋予其肿瘤靶向能力。进入GSH水平升高的肿瘤细胞后,纳米凝胶解体,释放与化疗药多柔比星(DOX)偶联的碳点。在近红外(NIR)照射下,碳点产热,既直接损伤癌细胞,也触发DOX的按需释放,形成光热-化疗协同效应。体外与体内研究均显示,该系统经多重机制有效诱导癌细胞坏死:破坏溶酶体、引发DNA损伤、同时抑制热休克蛋白(HSP)表达。该整合策略显著提升了治疗效果,克服了传统化疗的关键局限。
Adoptive cell transfer (ACT) has achieved durable clinical responses in hematological malignancies, yet remains limited in solid tumors owing to poor T cell infiltration, inadequate persistence, and tumor-driven immunosuppression. Here, we report a bio-orthogonally engineered probiotic-T cell chimera (T-FOLactis) that creates a mutually reinforcing cellular-microbial system, in which FOLactis, an engineered Lactococcus lactis expressing a Flt3L-OX40L fusion protein, provides localized immunostimulatory cues to enhance T cell activation and effector function, while adoptively transferred T cells serve as cytotoxic effectors and mobile carriers that facilitate delivery of the bacterial payload to the tumor microenvironment. Using strain-promoted azide-alkyne cycloaddition chemistry, FOLactis bacteria were covalently anchored onto the surface of T cells, generating a cell-bound platform for spatially restricted immune modulation. In syngeneic colorectal cancer models, T-FOLactis reduced tumor burden by 78.1% compared with saline-treated controls and by 65.0% relative to conventional ACT, while prolonging median survival from 22 to 46 d without overt systemic toxicity. Mechanistically, T-FOLactis promoted dendritic cell (DC)-T cell proximity and established a spatially organized immune-licensing niche that amplified the functional impact of FOLactis-induced inflammatory cues, including IL-18. This spatial configuration was associated with enhanced coupling of cytokine availability, DC maturation, local co-stimulation and cytotoxic CD8+ T cell effector programming. IL-18 blockade impaired this licensing program and reduced therapeutic benefit, supporting IL-18 as a key functional mediator within the DC-T cell licensing niche. Together, these findings establish a modular cell-surface engineering strategy for augmenting ACT in colorectal cancer through coordinated immune network engagement.
中文摘要:过继细胞转移(ACT)在血液肿瘤中已取得持久临床缓解,但在实体瘤中受限于T细胞浸润不足、持久性不够以及肿瘤驱动的免疫抑制。我们报道一种生物正交工程化的益生菌-T细胞嵌合体(T-FOLactis),它构建了相互增强的细胞-微生物系统:FOLactis是表达Flt3L-OX40L融合蛋白的工程化乳酸乳球菌,可提供局部免疫刺激信号以增强T细胞活化和效应功能;过继转移的T细胞则作为细胞毒性效应细胞和移动载体,促进细菌载荷递送至肿瘤微环境。利用应变促进的叠氮-炔环加成化学,将FOLactis细菌共价锚定于T细胞表面,形成可进行空间限定免疫调节的细胞结合平台。在同基因结直肠癌模型中,T-FOLactis较生理盐水对照组使肿瘤负荷降低78.1%,较传统ACT降低65.0%,并将中位生存期从22天延长至46天,且无明显的全身毒性。机制上,T-FOLactis促进树突状细胞(DC)与T细胞邻近,建立空间有序的免疫许可龛,放大FOLactis诱导的炎症信号(包括IL-18)的功能影响。该空间构型与细胞因子可利用性、DC成熟、局部共刺激和细胞毒性CD8+ T细胞效应程序之间的增强耦合相关。阻断IL-18会损害该许可程序并降低治疗获益,支持IL-18是DC-T细胞免疫许可龛中的关键功能介质。这些结果确立了一种模块化细胞表面工程策略,通过协调免疫网络参与来增强结直肠癌中的ACT。
Increased matrix stiffness is a biomechanical feature of hepatocellular carcinoma (HCC) that functions as an important promoting factor driving tumor progression. Characterization of the mechanosensors and the underlying downstream mechanisms driving HCC could help identify potential treatment strategies. In this study, we developed a standard procedure for screening and identifying mechanosensors, revealing two HCC mechanosensors, SDC4 and PKD2. These two mechanosensory pathways collaboratively mediated matrix stiffness-promoted DNA damage repair (DDR). Specifically, SDC4 and PKD2 modulated matrix stiffness-increased BANF1 nuclear translocation by increasing protein phosphatase 2A assembly and activity. Subsequently, nuclear BANF1 boosted the formation of the MRE11-RAD50-NBS1 complex and phosphorylation of its downstream effectors to enhance DDR. These findings not only expand the theoretical understanding of matrix stiffness-regulated DDR but also offer a screening/identification approach for mechanosensors in cancer. Matrix stiffness enhances DNA repair via dual pathways in hepatocellular carcinoma, suggesting that targeting mechanosensory cross-talk could be a potential strategy to overcome cytotoxic drug resistance.
中文摘要:基质硬度升高是肝细胞癌的生物力学特征,也是推动肿瘤进展的重要促进因素。明确机械感受器及其下游机制有助于发现潜在治疗策略。本研究建立了筛查和鉴定机械感受器的标准流程,发现肝细胞癌的两个机械感受器SDC4和PKD2。这两条机械感受通路协同介导基质硬度促进的DNA损伤修复。具体而言,SDC4和PKD2通过提高蛋白磷酸酶2A的组装和活性,调控基质硬度诱导的BANF1核转位增加。随后,核内BANF1促进MRE11-RAD50-NBS1复合物形成及其下游效应分子的磷酸化,从而增强DNA损伤修复。这些发现拓展了对基质硬度调控DNA损伤修复的理论认识,也为肿瘤机械感受器的筛查和鉴定提供了方法。基质硬度通过双通路增强肝细胞癌的DNA修复,提示靶向机械感受通路之间的交互作用可能成为克服细胞毒性药物耐药的潜在策略。
Microsatellite instability-high (MSI-H) colorectal cancer cells depend on the Werner syndrome helicase (WRN) to resolve cruciform DNA structures that arise from expanded TA-dinucleotide repeats. Loss of WRN induces replication stress and double-strand breaks, a vulnerability that can be recapitulated with the selective WRN inhibitor (WRNi) HRO761 in MSI-H cancer cells. To uncover the mechanisms governing sensitivity to WRN inhibition, we conducted genome-wide CRISPR/Cas9 screens in colorectal cancer cell lines treated with or without HRO761. These screens identified SMARCAL1 as a key modulator of WRN dependency. Depletion of SMARCAL1 rendered cells resistant to WRN inhibition, and rescue of this effect required the ATPase/translocase activity of SMARCAL1. Mechanistically, SMARCAL1 antagonized WRN and supported cruciform DNA structures, thereby enhancing cellular reliance on WRN. In addition, the MRE11-RAD50-NBS1 (MRN) complex, rather than MUS81 or ERCC1/XPF, was the principal mediator of cruciform DNA processing following WRN inhibition. Acute disruption of the MRN complex conferred profound resistance to WRN inhibition, whereas ataxia-telangiectasia mutated (ATM) deficiency produced a more modest resistant phenotype. Further genetic and pharmacologic epistasis analyses demonstrated that the MRN complex regulates WRNi sensitivity through both ATM-dependent signaling and MRE11 nuclease-dependent functions. Importantly, the key resistance mechanisms identified in this study were independently validated using a structurally distinct clinical-stage WRNi, VVD-214. Collectively, these findings identify the SMARCAL1-MRN-ATM axis as a critical regulator of WRN dependency and provide mechanistic insights into resistance to WRN-targeted therapy. SMARCAL1 and the MRN-ATM pathway determine sensitivity to WRN inhibition in microsatellite instability-high colorectal cancer, revealing key mechanisms of WRN dependency and potential drivers of resistance to WRN inhibitors.
中文摘要:微卫星高度不稳定(MSI-H)结直肠癌细胞依赖Werner综合征解旋酶(WRN)来解开由扩增的TA二核苷酸重复序列形成的十字形DNA结构。WRN缺失会诱发复制压力和双链断裂,这一脆弱性可在MSI-H癌细胞中通过选择性WRN抑制剂(WRNi)HRO761重现。为揭示WRN抑制敏感性的调控机制,我们在接受或不接受HRO761处理的结直肠癌细胞系中开展了全基因组CRISPR/Cas9筛选。筛选将SMARCAL1确定为WRN依赖性的关键调节因子。SMARCAL1耗竭使细胞对WRN抑制产生抗性,而逆转这一效应需要SMARCAL1的ATP酶/转位酶活性。机制上,SMARCAL1拮抗WRN并支持十字形DNA结构,从而增强细胞对WRN的依赖。WRN抑制后处理十字形DNA的主要介导者是MRE11-RAD50-NBS1(MRN)复合物,而非MUS81或ERCC1/XPF。急性破坏MRN复合物使细胞对WRN抑制产生显著抗性,而共济失调毛细血管扩张突变(ATM)缺陷导致的抗性表型较弱。进一步的遗传学和药理学上位性分析表明,MRN复合物通过ATM依赖的信号传导和MRE11核酸酶依赖的功能调控WRNi敏感性。本研究发现的关键抗性机制用一种结构不同的临床阶段WRNi VVD-214得到了独立验证。这些发现将SMARCAL1-MRN-ATM轴确定为WRN依赖性的关键调控因素,并为WRN靶向治疗的抗性提供了机制见解。SMARCAL1和MRN-ATM通路决定微卫星高度不稳定结直肠癌对WRN抑制的敏感性,揭示了WRN依赖性的关键机制以及WRN抑制剂抗性的潜在驱动因素。
Intrahepatic cholangiocarcinoma (ICC) is a lethal hepatic malignancy characterized by a prominent desmoplastic stroma. In this study, we demonstrated that AT-rich interactive domain-containing protein 1A (ARID1A), a core component of the Switch/Sucrose (SWI/SNF) protein complex, is upregulated in ICC and plays an oncogenic role. Mechanistically, ARID1A stabilized NICD1 protein by inhibiting AMPK-dependent autophagy and lysosomal degradation, thereby sustaining Notch signaling. Tolloid-like 1 (TLL1), a metalloproteinase that promotes collagen maturation, was found to be a downstream effector of ARID1A/Notch signaling. Specifically, TLL1 derived from ICC cells activated hepatic stellate cells (HSC) and thus promoted tumor progression. Accordingly, ablation of TLL1 attenuated cancer-associated fibroblast infiltration, collagen accumulation, and tumor progression. Moreover, virtual screening of a bioactive compound library identified acarbose, an effective medicine for glycemic control, as a potent inhibitor of TLL1. Pharmacologic inhibition of TLL1 with acarbose suppressed HSC activation, collagen deposition, and tumor development. Collectively, these results establish a tumor-promoting ARID1A-Notch-TLL1 axis in ICC and reveal acarbose as a potential precision therapy for patients with ARID1A-high ICC. The ARID1A-Notch-TLL1 axis promotes hepatic stellate cell activation and intrahepatic cholangiocarcinoma development, which can be targeted with acarbose as a TLL1 inhibitor to suppress tumor progression.
中文摘要:肝内胆管癌(ICC)是一种致死性肝脏恶性肿瘤,以显著的促纤维增生间质为特征。本工作显示,SWI/SNF蛋白复合物核心组分ARID1A在ICC中表达上调并发挥致癌作用。机制上,ARID1A通过抑制AMPK依赖的自噬与溶酶体降解稳定NICD1蛋白,从而维持Notch信号。促进胶原成熟的金属蛋白酶TLL1是ARID1A/Notch信号的下游效应分子。ICC细胞来源的TLL1可激活肝星状细胞(HSC),推动肿瘤进展。敲除TLL1可减轻癌相关成纤维细胞浸润、胶原沉积与肿瘤进展。对生物活性化合物库进行虚拟筛选,识别出降糖药阿卡波糖为TLL1的有效抑制剂。以阿卡波糖药理抑制TLL1,可抑制HSC活化、胶原沉积与肿瘤发展。这些结果确立了ICC中促进肿瘤的ARID1A-Notch-TLL1轴,并提示阿卡波糖可作为ARID1A高表达ICC患者的潜在精准治疗。ARID1A-Notch-TLL1轴推动肝星状细胞活化与肝内胆管癌发生发展,以阿卡波糖抑制TLL1可遏制肿瘤进展。
Colorectal cancer (CRC) represents a major cause of cancer-associated morbidity and mortality worldwide, with significantly higher incidence and lethality in elderly individuals. Growing evidence implicates immunosenescence, the age-dependent functional decline of the immune system, as a key contributor to CRC initiation, progression, and therapeutic resistance. In this review, telomere attrition, impaired DNA repair, mitochondrial dysfunction, oxidative stress, and epigenetic remodeling are discussed as interconnected molecular processes that contribute to immunosenescence. These processes disrupt immune homeostasis and promote chronic inflammation. Moreover, functional alterations in macrophages, natural killer cells, neutrophils, and T lymphocytes further enable immune evasion and immunosuppressive niche formation. Furthermore, the senescence-associated secretory phenotype (SASP) orchestrates inflammaging and reprograms the CRC microenvironment via pro-inflammatory cytokines, chemokines, and growth factors. Gut-specific factors, including microbiota dysbiosis, intestinal barrier dysfunction, and microbial metabolites, further accelerate immune aging and tumorigenesis. In addition, metabolic reprogramming interacts bidirectionally with immunosenescence. By integrating molecular, cellular, microbial, and metabolic insights, this review offers a comprehensive understanding of immunosenescence in CRC.
中文摘要:结直肠癌是全球癌症相关发病和死亡的重要原因,老年人群的发病率和致死率明显更高。越来越多证据表明,免疫衰老即免疫系统随年龄增长出现的功能下降,是结直肠癌发生、进展和治疗抵抗的关键因素。该综述将端粒磨损、DNA修复受损、线粒体功能障碍、氧化应激和表观遗传重塑作为相互关联的分子过程进行讨论,这些过程参与免疫衰老,破坏免疫稳态并促进慢性炎症。巨噬细胞、自然杀伤细胞、中性粒细胞和T淋巴细胞的功能改变进一步促成免疫逃逸和免疫抑制微环境形成。衰老相关分泌表型通过促炎细胞因子、趋化因子和生长因子协调炎性衰老并重编程结直肠癌微环境。肠道特异性因素包括菌群失调、肠道屏障功能障碍和微生物代谢物,进一步加速免疫衰老和肿瘤发生。代谢重编程与免疫衰老存在双向作用。该综述整合分子、细胞、微生物和代谢层面的认识,提供对结直肠癌免疫衰老的全面理解。
Perturbation of microbial-derived bile acid (BA) metabolism is strongly linked to the pathogenesis of intestinal diseases, including inflammatory bowel disease, enteric infections, and colorectal cancer. Recent advances in artificial intelligence-assisted pipelines have enabled the identification of BA modification reactions, which have uncovered novel targets and the mechanisms contributing to intestinal diseases. In this review, we summarize recent studies on microbial enzymatic pathways and modifications of BAs, and their roles in promoting or preventing intestinal diseases. The mechanisms altering gut microbiota populations and microbial BA metabolic landscapes that influence intestinal diseases are further examined along with how microbial-derived BAs modulate intestinal immune responses. Based on these advances, we suggest different dietary patterns that reshape the gut microbiota community and BAs to prevent intestinal diseases. We further discuss current challenges in basic and translational research on microbial BA modifications in intestinal homeostasis and propose future directions to drive progress in this field.
中文摘要:微生物来源胆汁酸(BA)代谢的紊乱与肠道疾病发病密切相关,包括炎症性肠病、肠道感染和结直肠癌。人工智能辅助流程的最新进展使胆汁酸修饰反应得以识别,由此发现了新的靶点及参与肠道疾病的机制。本综述总结近年来关于微生物酶途径与胆汁酸修饰及其促进或阻止肠道疾病作用的研究,进一步讨论改变肠道菌群组成和微生物胆汁酸代谢格局并影响肠道疾病的机制,以及微生物来源胆汁酸如何调节肠道免疫反应。基于这些进展,我们提出可通过不同饮食模式重塑肠道菌群和胆汁酸以预防肠道疾病。文章还讨论微生物胆汁酸修饰在肠道稳态中基础与转化研究面临的挑战,并提出推动该领域发展的未来方向。
Tumor genetics and the microbiome both shape colorectal cancer, but their reciprocal interplay remains poorly defined. In this issue of Cell Host & Microbe, Jiao et al. show that mutant KRAS favors Bacteroides acidifaciens, which signals back through a SusF-ARHGEF2 axis to reinforce RAS-MAPK signaling.
中文摘要:肿瘤遗传学与微生物组共同塑造结直肠癌,但两者的相互作用仍不清楚。在本期 Cell Host & Microbe 中,Jiao 等发现突变 KRAS 促进 Bacteroides acidifaciens,该菌通过 SusF-ARHGEF2 轴反向传递信号,强化 RAS-MAPK 信号。
The role of gut microbiota and their metabolites in the progression of hepatocellular carcinoma (HCC) has garnered increasing attention. Although Alistipes, a genus frequently reported as a beneficial bacterium, has been associated with antitumor effects and enhanced efficacy of cancer therapies, its specific functions and underlying mechanisms in HCC remain poorly defined. In this study, 16S rDNA sequencing revealed a marked decrease in the abundance of Alistipes in fecal samples from HCC patients compared to healthy controls, a finding that was also observed in HCC mouse models. Additionally, iso-15:0, an important fatty acid metabolite derived from Alistipes, was found to be significantly reduced in the feces of both HCC patients and HCC mouse models. Functional experiments demonstrated that iso-15:0 effectively suppresses the proliferation and migration of HCC cells in vitro and in vivo. Mechanistically, iso-15:0 inhibits the activation of the PI3K/AKT signaling pathway by interfering with G protein-coupled receptor (GPCR) downstream signaling, specifically through the Gβγ subunits. To further explore the potential for the clinical application of iso-15:0, we have developed a biomimetic nanodelivery system (3R/RGD/M1@iso-15:0 LNP) that markedly improves the delivery efficiency and therapeutic efficacy of iso-15:0 in vivo. Our findings elucidate for the first time that iso-15:0, derived from Alistipes, suppresses HCC progression by restricting the Gβγ-PI3K/AKT signaling axis, highlighting its potential as a novel therapeutic strategy for HCC.
中文摘要:肠道菌群及其代谢物在肝细胞癌(HCC)进展中的作用日益受到关注。Alistipes 常被报道为有益菌属,与抗肿瘤效应及提高癌症治疗疗效相关,但其在 HCC 中的具体功能和潜在机制仍不清楚。本研究通过 16S rDNA 测序发现,与健康对照相比,HCC 患者粪便样本中 Alistipes 丰度明显下降,HCC 小鼠模型中也观察到同样现象。此外,Alistipes 来源的重要脂肪酸代谢物 iso-15:0 在 HCC 患者和 HCC 小鼠模型粪便中均显著减少。功能实验表明,iso-15:0 在体外和体内均能有效抑制 HCC 细胞增殖和迁移。机制上,iso-15:0 通过干扰 G 蛋白偶联受体(GPCR)下游信号,具体经由 Gβγ 亚基,抑制 PI3K/AKT 信号通路激活。为进一步探索 iso-15:0 的临床应用潜力,我们构建了仿生纳米递送系统(3R/RGD/M1@iso-15:0 LNP),其在体内显著提高了 iso-15:0 的递送效率和治疗效果。研究首次阐明,Alistipes 来源的 iso-15:0 通过限制 Gβγ-PI3K/AKT 信号轴抑制 HCC 进展,提示其可作为 HCC 的新型治疗策略。
Colorectal cancer (CRC) is a multifactorial disease impacted by the tumor microbiome and host genetics, notably mutations that activate KRAS to stimulate a RAF-MEK-extracellular signal-regulated kinase (ERK) proliferative cascade. However, whether host genetics interplays with the tumor microbiome remains unclear. Here, we profiled intratumoral microbiomes from KRAS-mutant CRC patients and intestine-specific oncogenic KRASG12D mice, revealing that KRAS reshapes the microbial community, enriching Bacteroides acidifaciens that predicts poor prognosis in KRAS-mutant CRC patients. Employing isogenic CRC cells and mice with or without mutant KRAS, we demonstrate that B. acidifaciens promotes malignant phenotypes in KRAS-mutant CRC cells and intestine-specific KRASG12D mice but not in wild-type counterparts. B. acidifaciens SusF binds and stabilizes ARHGEF2, which promotes active KRAS and RAF-MEK-ERK signaling. SusF ablation or ARHGEF2 knockout in KRAS-mutant CRC cells abrogates the pro-tumorigenic effects of B. acidifaciens. These observations offer strategies for targeting mutant KRAS-driven B. acidifaciens to mitigate feedforward signaling leading to tumorigenesis.
中文摘要:结直肠癌是一种受肿瘤微生物组和宿主遗传共同影响的多因素疾病,其中激活KRAS的突变可驱动RAF-MEK-细胞外信号调节激酶(ERK)增殖级联。宿主遗传与肿瘤微生物组之间是否存在相互作用仍不清楚。我们对KRAS突变型结直肠癌患者的瘤内微生物组及肠道特异性致癌KRASG12D小鼠进行分析,发现KRAS重塑微生物群落,富集Bacteroides acidifaciens,而该菌可预测KRAS突变型结直肠癌患者的不良预后。利用携带或不携带突变KRAS的同基因结直肠癌细胞和小鼠,我们证明B. acidifaciens促进KRAS突变型结直肠癌细胞和肠道特异性KRASG12D小鼠的恶性表型,但对野生型对应细胞和小鼠无此作用。B. acidifaciens的SusF结合并稳定ARHGEF2,后者促进活化KRAS及RAF-MEK-ERK信号。在KRAS突变型结直肠癌细胞中敲除SusF或ARHGEF2可消除B. acidifaciens的促瘤效应。这些观察为靶向突变KRAS驱动的B. acidifaciens、削弱导致肿瘤发生的前馈信号提供了策略。
Ferroptosis is a unique form of regulated cell death characterized by iron-dependent lipid peroxidation. Although the molecular details of ferroptosis regulation have been widely explored, the contributions of short non-coding RNAs (ncRNAs) to ferroptosis regulation, other than miRNAs, remain poorly understood. Here, we identified vault RNA1-1 (vtRNA1-1) as a previously unrecognized short ncRNA regulator of ferroptosis in hepatocellular carcinoma (HCC) cells. vtRNA1-1 expression was upregulated by ferroptosis inducers and exhibited strong negative correlation with ferroptosis sensitivity, thus protecting cells from ferroptosis. vtRNA1-1 levels were elevated in selected ferroptosis-resistant cells, while its depletion reversed the phenotype thus resensitizing these cells to ferroptosis. These findings suggested a contribution of vtRNA1-1 to both intrinsic and acquired ferroptosis resistance. Mechanistically, we uncovered that increased oxidative stress, which potentiates lipid peroxidation, specifically induced expression of the vtRNA1-1 paralog in an NF-κB dependent manner. Elevated vtRNA1-1 levels suppressed NF-κB-mediated pro-oxidant gene expression, thereby limiting reactive oxygen species (ROS) accumulation and alleviating oxidative stress. Taken together, oxidative stress-inducible vtRNA1-1 governs redox balance by forming a reciprocal regulatory loop with NF-κB and this loop determines ferroptosis susceptibility by adjusting basal ROS levels. Our findings provide unprecedented insights into the regulation of redox homeostasis in HCC cells mediated by a short ncRNA and uncovered vtRNA1-1 as a potential therapeutic target for overcoming ferroptosis resistance in liver cancer.
中文摘要:铁死亡是一种独特的调节性细胞死亡形式,以铁依赖性脂质过氧化为特征。尽管铁死亡调控的分子细节已被广泛探索,除miRNA外,短链非编码RNA(ncRNA)对铁死亡的调控作用仍知之甚少。研究在肝细胞癌(HCC)细胞中鉴定出vault RNA1-1(vtRNA1-1)是此前未被认识的铁死亡短链ncRNA调控因子。铁死亡诱导剂上调vtRNA1-1表达,其表达与铁死亡敏感性呈强负相关,从而保护细胞免于铁死亡。vtRNA1-1水平在部分铁死亡抵抗细胞中升高,敲低后可逆转该表型,使这些细胞重新对铁死亡敏感。这些结果提示vtRNA1-1参与固有性和获得性铁死亡抵抗。机制上,增强脂质过氧化的氧化应激通过NF-κB依赖方式特异性诱导vtRNA1-1旁系同源物表达。vtRNA1-1水平升高抑制NF-κB介导的促氧化基因表达,限制活性氧(ROS)积累并减轻氧化应激。氧化应激可诱导的vtRNA1-1与NF-κB形成相互调控环路,维持氧化还原平衡,该环路通过调节基础ROS水平决定铁死亡敏感性。研究为短链ncRNA介导的HCC细胞氧化还原稳态调控提供了新见解,并表明vtRNA1-1是克服肝癌铁死亡抵抗的潜在治疗靶点。
Hepatocellular Carcinoma Targeted Thermosensitive Cu2+ Liposomes Based on the Cuproptosis Mechanism.
Cuproptosis is characterized by elevated intracellular copper concentrations that disrupt copper homeostasis and impair the tricarboxylic acid cycle, ultimately causing cell death. However, the lack of targeted intervention for intracellular copper may induce systemic side effects, hindering the application of cuproptosis in tumor therapy. Herein, we constructed a targeted copper ion delivery system (Cu-Lip-Gal(H)) based on galactose-modified thermosensitive liposomes, combined with local tumor hyperthermia targeted copper delivery into hepatocellular carcinoma (HCC) cells. Cu-Lip-Gal showed excellent physicochemical properties and 42°C thermosensitive release, with 64.67% ± 2.52% cumulative release within 0.5 h. The Cu-Lip-Gal(H) group reduced HepG2 and Huh7 cell viability to 24.48% ± 3.31% and 18.00% ± 3.18%, respectively; it exhibited 5.8-fold higher intracellular copper concentration in HepG2 cells and 5.2-fold higher in Huh7 cells. In nude mouse xenografts, Cu-Lip-Gal(H) achieved a tumor inhibition rate of 86.7% ± 1.9% without obvious histopathological changes in major organs but significantly increased necrotic cells in tumors along with the highest FDX1 expression levels observed in this study. These findings provide new insights into cuproptosis-based copper ion delivery systems for HCC treatment.
中文摘要:铜死亡的特征是细胞内铜浓度升高,破坏铜稳态并损害三羧酸循环,最终导致细胞死亡。然而,对细胞内铜缺乏靶向干预可能引起全身性副作用,阻碍铜死亡在肿瘤治疗中的应用。我们构建了基于半乳糖修饰热敏脂质体的靶向铜离子递送系统(Cu-Lip-Gal(H)),结合肿瘤局部热疗将铜靶向递送入肝细胞癌(HCC)细胞。Cu-Lip-Gal表现出优异的理化性质和42°C热敏释放,0.5 h内累积释放率为64.67% ± 2.52%。Cu-Lip-Gal(H)组使HepG2和Huh7细胞活力分别降至24.48% ± 3.31%和18.00% ± 3.18%;其使HepG2细胞内铜浓度提高5.8倍,Huh7细胞提高5.2倍。在裸鼠移植瘤中,Cu-Lip-Gal(H)实现86.7% ± 1.9%的肿瘤抑制率,主要器官未见明显组织病理学改变,但肿瘤内坏死细胞显著增加,同时观察到本研究中最高水平的FDX1表达。这些发现为基于铜死亡的铜离子递送系统用于HCC治疗提供了新见解。
Rising incidence of colorectal cancer (CRC) and limited therapeutic options highlight the urgent need to define the drivers of its progression. The SPP1+ tumor-associated macrophage (TAM) subset identified by single-cell transcriptomics is a functionally dominant population that extends beyond the classical M1/M2 paradigm. Here, we dissected the molecular mechanisms by which SPP1+ TAMs reprogram tumor progression and determined whether the gut microbiota regulates this process in colorectal cancer. Using a multi-platform strategy integrating clinical specimens, murine models and CRC cell lines, we found that SPP1+ TAMs increase progressively during CRC evolution and exhibit crosstalk with malignant epithelial cells, and their abundance is associated with adverse clinical outcome. Integrative analysis reveals a significant positive correlation between SPP1 and ARG2 expression. Further, TAM-derived SPP1 engages CD44 on CRC cells to induce ARG2 expression. Mechanistically, ARG2 facilitates the interaction between USP10 and c-Myc to deubiquitinate and stabilize c-Myc, which transactivates the glycolytic enzyme HK2, driving Warburg metabolism that fuels CRC cell proliferation. Moreover, ARG2 secreted by CRC cells is internalized by TAMs, which reciprocally upregulates SPP1, creating a feed-forward loop that drives a pro-tumorigenic microenvironment. Notably, Bifidobacterium longum downregulates CD44 expression on tumor cells, thereby disrupting the SPP1-ARG2 axis and attenuating CRC progression. These findings identify the SPP1-ARG2 circuit as a therapeutic target and propose B. longum as a microbiome-derived precision adjuvant therapy for CRC suppression.
中文摘要:结直肠癌发病率上升且治疗选择有限,亟需明确其进展驱动因素。单细胞转录组鉴定的SPP1+肿瘤相关巨噬细胞(TAM)亚群是功能上占优势的群体,超出经典M1/M2范式。本研究解析SPP1+ TAM重编程肿瘤进展的分子机制,并判断肠道菌群是否调控该过程。通过整合临床标本、小鼠模型和结直肠癌细胞系的多平台策略,发现SPP1+ TAM在结直肠癌演进中逐步增多,与恶性上皮细胞发生交互,其丰度与不良临床结局相关。整合分析显示SPP1与ARG2表达呈显著正相关。TAM来源的SPP1与结直肠癌细胞CD44结合,诱导ARG2表达。机制上,ARG2促进USP10与c-Myc相互作用,对c-Myc去泛素化并稳定其蛋白,c-Myc反式激活糖酵解酶HK2,驱动Warburg代谢并为结直肠癌细胞增殖供能。结直肠癌细胞分泌的ARG2被TAM内化,反过来上调SPP1,形成前馈环路,推动促肿瘤微环境。长双歧杆菌下调肿瘤细胞CD44表达,破坏SPP1-ARG2轴并减缓结直肠癌进展。这些发现将SPP1-ARG2环路确定为治疗靶点,并提出长双歧杆菌作为微生物组来源的精准辅助治疗以抑制结直肠癌。
Antiapoptotic buffering in solid tumors is generally mediated by both BCLXL and MCL1, so that BH3 mimetic drugs targeting only one have limited efficacy. To identify agents that may sensitize tumors to BH3 mimetics targeting BCLXL, we screened prostate cancer cells against a panel of mitochondria-targeted drugs in combination with navitoclax, a BH3 mimetic targeting BCL2 and BCLXL. Homoharringtonine (HHT) in combination with navitoclax and as a single agent emerged as a potent inducer of apoptosis. HHT has been identified as an inhibitor of protein translation, and proteomic analysis showed broad suppression of translation-related pathways, while immunoblotting demonstrated rapid decreases in short-lived proteins, including MCL1. HHT dose response and time course studies showed marked declines in MCL1 within 2 hours that were associated with apoptosis in response to BCLXL inhibition with navitoclax or A1331852. Further cell viability assays showed synergy between HHT and BCLXL inhibitors in multiple prostate, lung, and colorectal cancer cell lines. HHT monotherapy in vivo caused tumor regression in two prostate cancer xenograft models. Analysis of tumor tissue taken at 4 hours after dosing showed decreases in MCL1 and MYC, indicating that HHT levels obtainable in vivo are adequate to deplete short-lived proteins and potentially sensitize to BH3 mimetics targeting BCLXL. These findings support further exploration of HHT as a single agent in solid tumors and establish a rationale for investigating safer, tumor-selective approaches to combine HHT-mediated translational inhibition with BCLXL targeting.
中文摘要:实体瘤的抗凋亡缓冲通常由BCLXL和MCL1共同介导,因此仅靶向其中之一的BH3模拟药物疗效有限。为寻找可使肿瘤对靶向BCLXL的BH3模拟药物敏感的化合物,我们在前列腺癌细胞中筛选了一组线粒体靶向药物,并与navitoclax(靶向BCL2和BCLXL的BH3模拟药物)联合。高三尖杉酯碱(HHT)与navitoclax联用以及单药均显示出强效促凋亡作用。HHT已被鉴定为蛋白质翻译抑制剂,蛋白质组学分析显示翻译相关通路受到广泛抑制,免疫印迹显示包括MCL1在内的短寿命蛋白快速减少。HHT的剂量反应和时间进程研究显示,MCL1在2小时内明显下降,并与navitoclax或A1331852抑制BCLXL后的凋亡相关。进一步的细胞活力实验显示,HHT与BCLXL抑制剂在前列腺癌、肺癌和结直肠癌的多种细胞系中具有协同作用。HHT单药治疗在两种前列腺癌异种移植模型中引起肿瘤消退。给药后4小时取肿瘤组织分析显示MCL1和MYC下降,表明体内可达到的HHT水平足以耗竭短寿命蛋白,并可能使肿瘤对靶向BCLXL的BH3模拟药物敏感。这些发现支持进一步探索HHT作为实体瘤单药治疗,并为研究更安全、肿瘤选择性的策略以联合HHT介导的翻译抑制与BCLXL靶向提供了依据。
The current paradigm of N6-methyladenosine (m6A) homeostasis is implemented by a "writer/eraser/reader" system. Whether or not signaling pathways may regulate m6A homeostasis remains unclear. Here, we identify a negative feedback mechanism between m6A reader IGF2BPs and writer METTL3/METTL14 in human cell lines, which is orchestrated by poly(ADP-ribose) polymerase 1 (PARP1)-catalyzed ADP ribosylation. Specifically, IGF2BPs recruit PARP1 to m6A-modified RNAs and stimulate PARP1 activity; the m6A writer METTL3/14 is then ADP ribosylated, which impairs its RNA-binding capability and reduces m6A deposition. Based on the "read-orchestrate-write" mechanism, we combined PARP inhibitor (PARPi) therapy and m6A-targeting strategies (by inhibiting IGF2BP2 or METTL3) and observed synergistic anti-tumor effects. Taken together, this work expands our understanding of the regulatory paradigm of m6A methylation and provides an opportunity to exploit these findings for cancer therapy.
中文摘要:N6-甲基腺苷(m6A)稳态的现有范式由「写入器/擦除器/读取器」系统实现。信号通路是否调控m6A稳态仍不清楚。我们在人类细胞系中鉴定出m6A读取蛋白IGF2BPs与写入蛋白METTL3/METTL14之间的负反馈机制,该机制由聚(ADP-核糖)聚合酶1(PARP1)催化的ADP核糖基化所协调。具体而言,IGF2BPs将PARP1招募至m6A修饰的RNA并增强PARP1活性;随后m6A写入蛋白METTL3/14发生ADP核糖基化,损害其RNA结合能力并减少m6A沉积。基于「读取-协调-写入」机制,我们将PARP抑制剂(PARPi)治疗与m6A靶向策略(通过抑制IGF2BP2或METTL3)联合,观察到协同抗肿瘤效应。该工作拓展了对m6A甲基化调控范式的认识,并为利用这些发现开展肿瘤治疗提供了机会。
Transposable elements (TEs) are broadly reactivated in tumors, but their repetitive nature has limited transcript-level characterization. Here, we systematically investigate the TE-derived splicing landscape across pan-cancer samples and define a splice-resolved subset of TE-derived transcripts, termed TEtrans, with tumor enrichment and gene independence. TEtrans initiate within TEs, spliced within or between TE loci, and are composed predominantly of TE sequences. Their expression was associated with stemness and inflammation regulators in a context-dependent manner. Functional analyses identify an endogenous retrovirus-derived TEtrans that promotes colorectal cancer growth by enhancing topoisomerase I-mediated DNA relaxation. A subset of TEtrans encodes shared tumor antigens that elicit antigen-specific cytotoxic T cell responses, while a murine TEtrans-like transcript mediates antigen-dependent tumor control in vivo. Collectively, TEtrans represent a splice-resolved source of TE-derived oncogenic drivers and actionable tumor antigens, broadening the scope of TE reactivation in cancer.
中文摘要:转座元件(TE)在肿瘤中广泛再激活,但其重复性限制了转录本层面的表征。本研究系统考察泛癌样本中TE来源的剪接图谱,并界定出一个经剪接解析的TE来源转录本子集,称为TEtrans,具有肿瘤富集和基因独立性。TEtrans起始于TE内部,在TE位点内或位点间发生剪接,主要由TE序列组成。其表达以背景依赖的方式与干性及炎症调控因子相关。功能分析鉴定出一个内源性逆转录病毒来源的TEtrans,通过增强拓扑异构酶I介导的DNA松弛促进结直肠癌生长。一部分TEtrans编码共享肿瘤抗原,可引发抗原特异性细胞毒性T细胞应答;小鼠TEtrans样转录本在体内介导抗原依赖性肿瘤控制。总体而言,TEtrans构成一个经剪接解析的来源,可提供TE来源的致癌驱动因素和可靶向的肿瘤抗原,拓展了TE在癌症中再激活的范围。
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major risk factor for hepatocellular carcinoma (HCC), yet the molecular mechanisms linking metabolic stress to tumor progression remain poorly defined. RNA surveillance pathways, including nonsense-mediated decay (NMD), may represent a relevant but unexplored regulatory layer in this context. In this study, we analyzed the expression of NMD components across multiple human HCC and MASLD cohorts, identifying suppressor with morphogenetic effect on genitalia 7 (SMG7) as a key regulator of NMD associated with HCC progression. In vitro functional assays, NMD target expression, transcriptomic profiling, and weighted gene co-expression network analysis (WGCNA) were used to identify downstream pathways and mediators. More than 40% of NMD components were dysregulated in HCC. Among them, SMG7 was consistently upregulated across HCC and MASLD cohorts, induced by lipotoxic stress, and identified as a hub gene in HCC transcriptional networks. SMG7 overexpression promoted proliferation, migration, and clonogenicity, whereas its silencing reduced tumor aggressiveness in a context-dependent manner inversely associated with UPF1 levels. Combined depletion of SMG7 and UPF1 suppressed aggressive traits in vitro and limited tumor growth in vivo. Transcriptomic and network analyses identified Z-DNA-binding protein 1 (ZBP1) as a downstream mediator of SMG7 dysregulation in SNU-387 HCC cells, a finding further supported by functional rescue experiments. These results identify the SMG7-ZBP1 axis as a metabolic stress-responsive pathway linking NMD dysfunction to liver tumor progression and highlight NMD modulation as a therapeutic strategy to restrain tumor aggressiveness while enhancing tumor immunogenicity.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)是肝细胞癌(HCC)的重要危险因素,但代谢应激连接肿瘤进展的分子机制仍不清楚。RNA监控通路,包括无义介导的mRNA降解(NMD),可能是该背景下相关但尚未被探索的调控层。本研究分析了多个HCC和MASLD人群队列中NMD组分的表达,发现生殖器形态发生效应抑制因子7(SMG7)是与HCC进展相关的NMD关键调控因子。利用体外功能实验、NMD靶标表达、转录组分析和加权基因共表达网络分析(WGCNA)识别下游通路和介导因子。超过40%的NMD组分在HCC中失调。SMG7在HCC和MASLD队列中持续上调,可被脂毒性应激诱导,并被鉴定为HCC转录网络中的枢纽基因。SMG7过表达促进增殖、迁移和克隆形成,而其沉默以与UPF1水平呈负相关的背景依赖方式降低肿瘤侵袭性。联合敲低SMG7和UPF1在体外抑制侵袭性表型,并在体内限制肿瘤生长。转录组和网络分析在SNU-387 HCC细胞中鉴定Z-DNA结合蛋白1(ZBP1)为SMG7失调的下游介导因子,功能回补实验进一步支持这一发现。这些结果确定SMG7-ZBP1轴为连接NMD功能障碍与肝脏肿瘤进展的代谢应激响应通路,并提示调节NMD可作为限制肿瘤侵袭性并增强肿瘤免疫原性的治疗策略。
Intestinal T-cell migration links mucosal immunity with systemic immune homeostasis and contributes to immune surveillance, barrier defense, and peripheral tissue inflammation. Advances in single-cell omics, spatial analysis, and intravital imaging are reshaping our understanding of its subset specificity and tissue selectivity. This review summarizes the molecular mechanisms, microenvironmental regulation, pathological significance along the gut-organ axes, and related therapeutic strategies of intestinal T-cell migration, with a particular focus on how migratory imbalance contributes to intestinal and extraintestinal immune-mediated diseases. Intestinal T-cell migration is jointly driven by gut imprinting, S1P-S1PR-mediated egress, chemokine-guided trafficking, integrin-dependent adhesion, and cytoskeletal remodeling, and is further regulated by metabolic, epigenetic, and microbial signals. This process is highly dependent on T-cell subset and tissue context: it promotes effector T-cell recruitment and inflammatory amplification in inflammatory bowel disease, manifests as restricted antitumor T-cell infiltration in colorectal cancer, and may contribute to distant tissue injury through the gut-organ axes. Existing S1PR modulators, integrin antagonists, and chemokine-targeted strategies have demonstrated the therapeutic tractability of migratory pathways; however, pathway redundancy, tissue heterogeneity, and impairment of protective immunity continue to limit their application. Future strategies should move beyond broad suppression of migration toward subset-, tissue-, and disease stage-specific precision modulation, combined with microbiota-based interventions and biomarker-guided stratification to improve therapeutic efficacy.
中文摘要:肠道T细胞迁移连接黏膜免疫与全身免疫稳态,参与免疫监视、屏障防御和外周组织炎症。单细胞组学、空间分析和活体成像的进展正在重塑对其亚群特异性和组织选择性的认识。围绕肠道T细胞迁移的分子机制、微环境调控、沿肠-器官轴的病理意义及相关治疗策略进行总结,重点关注迁移失衡如何促成肠道及肠外免疫介导疾病。肠道T细胞迁移由肠道归巢印记、S1P-S1PR介导的流出、趋化因子引导的转运、整合素依赖性黏附和细胞骨架重塑共同驱动,并进一步受代谢、表观遗传和微生物信号调控。该过程高度依赖T细胞亚群和组织背景:在炎症性肠病中促进效应T细胞募集和炎症放大,在结直肠癌中表现为抗肿瘤T细胞浸润受限,并可能通过肠-器官轴参与远处组织损伤。现有S1PR调节剂、整合素拮抗剂和趋化因子靶向策略已证明迁移通路具有治疗可操作性;通路冗余、组织异质性和保护性免疫受损仍限制其应用。未来策略应从广泛抑制迁移转向针对亚群、组织和疾病阶段的精准调控,并结合微生物群干预和生物标志物指导的分层以提高疗效。
Pancreatic ductal adenocarcinoma (PDA) is among the deadliest malignancies, driven by metastatic progression and profound cellular heterogeneity. We previously identified glutathione S-transferase theta 1 (GSTT1) as a regulator of a slow-cycling, highly metastatic tumor cell population, suggesting that GSTT1High cells may possess stem-like properties. Here, we define the functional and molecular features of this subpopulation in metastatic PDA. Using a mCherry-tagged Gstt1 reporter system in metastatic murine PDAC cells, we enriched for Gstt1High cells and observed increased tumor sphere formation, accompanied by upregulation of stemness-associated genes including PROM1 (CD133) and activation of Wnt and FGF signaling pathways. In human PDA models, CD133HighGSTT1High cells exhibited enhanced tumor sphere initiation and expansion compared to other populations, defining a maximal stem-like state. Notably, sensitivity to FGFR inhibitors was observed only under tumor sphere conditions, highlighting a context-dependent therapeutic vulnerability. Mechanistically, FGFR3 expression correlated with GSTT1 and CD133 levels, and FGF signaling was required to sustain this state. GSTT1 knockdown reduced CD133 protein levels, impaired tumor sphere formation, and altered sensitivity to FGFR inhibition. These findings were largely recapitulated in patient-derived PDA organoids, where GSTT1 and PROM1 co-expression predicted increased tumor sphere formation and enhanced response to the multi-kinase inhibitor Nintedanib. Together, these results identify a GSTT1HighCD133High stem-like subpopulation in metastatic PDA and identify an FGFR-dependent signaling axis that sustains this state, representing a potential therapeutic vulnerability.
中文摘要:胰腺导管腺癌(PDA)是最致命的恶性肿瘤之一,其进展由转移和显著的细胞异质性驱动。我们此前发现谷胱甘肽S-转移酶theta 1(GSTT1)调控一个慢周期、高转移的肿瘤细胞群体,提示GSTT1高表达细胞可能具有干样特性。在此,我们界定转移性PDA中该亚群的功能和分子特征。利用在转移性小鼠PDAC细胞中构建的mCherry标签Gstt1报告系统,我们富集Gstt1高表达细胞,观察到肿瘤球形成增加,并伴随PROM1(CD133)等干性相关基因上调以及Wnt和FGF信号通路激活。在人PDA模型中,CD133高表达GSTT1高表达细胞相较其他群体表现出更强的肿瘤球起始和扩增能力,定义了最强的干样状态。对FGFR抑制剂的敏感性仅在肿瘤球条件下观察到,提示一种情境依赖的治疗易感性。机制上,FGFR3表达与GSTT1和CD133水平相关,FGF信号是维持该状态所必需的。敲低GSTT1降低CD133蛋白水平,损害肿瘤球形成,并改变对FGFR抑制的敏感性。这些发现在患者来源PDA类器官中基本得到重现,其中GSTT1与PROM1共表达预测肿瘤球形成增加以及对多激酶抑制剂Nintedanib的应答增强。这些结果共同识别了转移性PDA中GSTT1高表达CD133高表达干样亚群,并确定维持该状态的FGFR依赖信号轴,代表潜在的治疗易感性。
4临床/流行病学 (20篇)
临床研究 (12篇)
rVSVΔG-ZEBOV-GP vaccine is recommended for prevention of Ebola virus (EBOV) infection and disease (EVD). However, breakthrough EBOV infections have been observed in vaccinees. Currently available diagnostic and research assays cannot reliably distinguish individuals vaccinated against Ebola virus from those previously infected with the virus. This limitation complicates interpretation of vaccine-effectiveness studies, seroepidemiologic investigations, and estimates of infection or attack rates. The ability to differentiate vaccine-induced immune responses from those resulting from natural infection remains an important unmet public health and research need. We developed a multiplex sero-diagnostic assay simultaneously detecting IgA, IgG, and IgM antibodies against vesicular stomatitis Indiana virus nucleoprotein (VSV-N), a vaccine-specific marker absent in natural infection, and EBOV-GP, the vaccine's target antigen. We evaluated longitudinal samples from 30 individuals after vaccination and 30 placebo (saline) recipients, as well as 8 participants from a long-term vaccination follow-up study. We detected increase in all antibodies against both protein antigens in vaccinated individuals. Critically, the assay reveals that anti-VSV-N IgA responses emerge earlier and more robustly than anti-GP responses in vaccinees, establishing anti-N IgA as a definitive, early, and durable biomarker of rVSVΔG-ZEBOV-GP vaccination with high sensitivity and specificity. The assay enables rapid, accurate identification of vaccine recipients and supports real-time assessment of vaccine effectiveness during outbreaks. Furthermore, the assay's adaptability to the expanding pipeline of VSV-vectored vaccines positions it as a transformative diagnostic platform for accelerating preparedness for future infectious disease threats and outbreak response strategies. Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA). The National Cancer Institute (NCI) and the Divisions of Intramural Research (DIR) and Clinical Research (DCR) of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH).
中文摘要:rVSVΔG-ZEBOV-GP疫苗被推荐用于预防埃博拉病毒(EBOV)感染和埃博拉病毒病(EVD)。但在接种者中已观察到突破性EBOV感染。现有诊断和研究检测方法无法可靠区分接种过埃博拉疫苗的个体与既往感染过该病毒者。这一局限使疫苗有效性研究、血清流行病学调查以及感染率或发病率的估计难以解读。区分疫苗诱导免疫应答与自然感染所致应答仍是公共卫生和研究领域尚未满足的重要需求。我们开发了一种多重血清诊断检测,可同时检测针对水疱性口炎印第安纳病毒核蛋白(VSV-N)和EBOV-GP的IgA、IgG和IgM抗体;VSV-N是疫苗特异性标志物,自然感染中不存在,EBOV-GP是疫苗靶抗原。我们评估了30名个体接种后和30名安慰剂(生理盐水)受者的纵向样本,以及一项长期疫苗接种随访研究中的8名参与者。在接种者中检测到针对两种蛋白抗原的所有抗体均升高。该检测显示接种者中抗VSV-N IgA应答出现早于抗GP应答且更强,确立抗N IgA作为rVSVΔG-ZEBOV-GP接种的明确、早期且持久生物标志物,具有高敏感性和特异性。该检测可快速、准确识别疫苗受者,并支持疫情期间疫苗有效性的实时评估。该检测可适配不断扩展的VSV载体疫苗管线,使其成为变革性诊断平台,有助于加快对未来传染病威胁的防范准备和疫情应对策略。美国食品药品监督管理局(FDA)生物制品评价与研究中心(CBER)支持本研究。美国国立卫生研究院(NIH)下属国家癌症研究所(NCI)以及国家过敏和传染病研究所(NIAID)院内研究部(DIR)和临床研究部(DCR)也参与支持。
Hippocampal avoidance whole-brain radiotherapy (HA-WBRT) with memantine reduces, but does not eliminate, cognitive decline. Left hippocampal dose may be more closely associated with cognitive outcomes. We investigated whether unilateral (left) HA-WBRT is equivalent to bilateral HA-WBRT for neurocognitive function. In this randomized, single-blind, phase 2 equivalence trial, patients with brain metastases were assigned 1:1 to unilateral (left) or bilateral HA-WBRT (30 Gy in 10 fractions) with concurrent memantine. The primary endpoint was relative decline in Hopkins Verbal Learning Test-Revised (HVLT-R) memory score from baseline to 6 months; equivalence required the 90% CI for the between-arm difference to fall within ±15 percentage points. Among 73 patients (unilateral, n = 36; bilateral, n = 37; median follow-up, 13.2 months), mean 6-month relative HVLT-R decline was 4.75% versus 5.05% (difference, -0.31%; 90% CI, -12.02% to 11.40%; TOST P = .02), meeting the equivalence criterion. Brain progression-free survival (10.3 vs 10.8 months; P = .96), overall survival (17.8 vs 12.8 months; P = .94), acute toxicity (≥ grade 2, 44.4% vs 35.1%; P = .43), and 6-month neurocognitive failure (61.1% vs 56.8%; Gray test P = .78) were similar. Global health status appeared more stable with unilateral HA-WBRT (interaction, P < .001). Exploratory plasma BDNF trajectories varied by neurocognitive failure status (FDR q = .09). Unilateral (left) HA-WBRT with memantine met the prespecified equivalence criterion for verbal memory, with comparable oncologic outcomes and safety; non-verbal memory was not assessed. These findings warrant validation, particularly when bilateral avoidance is challenging.
中文摘要:海马保护全脑放疗(HA-WBRT)联合美金刚可减轻但并不能消除认知功能下降。左侧海马剂量可能与认知结局关系更密切。研究探讨单侧(左侧)HA-WBRT在神经认知功能方面是否等效于双侧HA-WBRT。在这项随机、单盲、2期等效性试验中,脑转移患者按1:1分配接受单侧(左侧)或双侧HA-WBRT(30 Gy分10次)并同步美金刚。主要终点为从基线至6个月时霍普金斯词语学习测验修订版(HVLT-R)记忆评分的相对下降;等效性要求两臂差异的90% CI落在±15个百分点以内。73例患者中(单侧组36例,双侧组37例;中位随访13.2个月),6个月HVLT-R平均相对下降分别为4.75%与5.05%(差异-0.31%;90% CI -12.02%至11.40%;TOST P=0.02),达到等效性标准。颅内无进展生存(10.3个月与10.8个月;P=0.96)、总生存(17.8个月与12.8个月;P=0.94)、急性毒性(≥2级,44.4%与35.1%;P=0.43)及6个月神经认知失败(61.1%与56.8%;Gray检验P=0.78)相近。单侧HA-WBRT的全局健康状况似乎更稳定(交互作用P<0.001)。探索性血浆BDNF轨迹随神经认知失败状态不同而变化(FDR q=0.09)。单侧(左侧)HA-WBRT联合美金刚在言语记忆方面达到预设等效性标准,肿瘤学结局与安全性相当;非言语记忆未评估。这些发现需要验证,尤其在双侧保护难以实施时。
Renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus is associated with substantial perioperative risk and frequent recurrence despite nephrectomy and thrombectomy. No established neoadjuvant local therapy exists for this high-risk population. To evaluate the feasibility, safety, clinical outcomes, and exploratory biomarker effects of neoadjuvant stereotactic ablative radiotherapy (SABR) targeting IVC tumor thrombus before nephrectomy and thrombectomy. This single-center prospective phase 2 nonrandomized clinical trial enrolled patients with newly diagnosed RCC and Mayo level II to IV IVC tumor thrombus eligible for neoadjuvant SABR and definitive surgery from July 2015 to January 2024. Data were analyzed from August 2025 to August 2026. Neoadjuvant SABR to the radiographically defined IVC tumor thrombus, delivered as 40 Gy in 5 fractions or 36 Gy in 3 fractions, followed by radical nephrectomy and IVC thrombectomy. The primary end point was 1-year recurrence-free survival (RFS) compared with a prespecified historical surgery-alone benchmark of 55.7%. Secondary outcomes included 90-day perioperative morbidity and mortality, adverse events, pulmonary embolism, overall survival, and cancer-specific survival. Exploratory analyses included Ki-67 immunohistochemistry and tumor-informed circulating tumor DNA. Of 23 patients who received neoadjuvant SABR, 22 completed surgery, and 21 were included in the primary RFS analysis. Of 21 included patients, 12 (57%) were male, and the median (IQR) age was 62.5 (54.0-73.2) years. A total of 19 patients had clear-cell RCC; all tumors were grade 3 or 4, and 3 patients had metastatic disease at enrollment. At a median (range) follow-up of 108.6 (2.0-127.2) months, 1-year RFS was 71.4% (80% CI, 56.6-82.0; 95% CI, 47.2-86.0), meeting the prespecified phase 2 screening criterion based on comparison with the historical surgery-alone benchmark of 55.7% (P = .09). One-year overall survival was 95.2% (80% CI, 83.9-98.7; 95% CI, 70.7-99.3) and cancer-specific survival was 95.2% (80% CI, 83.9-98.7; 95% CI, 70.7-99.3). No 90-day perioperative mortality occurred; 4 grade 4 treatment-attributed events occurred, but no grade 4/5 radiation-attributed toxic effects occurred. Ki-67 expression was reduced in patients with irradiated tumor thrombus compared with nonirradiated controls. Tumor-informed circulating tumor DNA was detected in all patients with available plasma and declined after treatment. In this nonrandomized clinical trial, neoadjuvant SABR before nephrectomy and IVC thrombectomy appeared feasible with an acceptable safety profile. RFS met the prespecified phase 2 screening criterion but remains exploratory and warrants further evaluation. ClinicalTrials.gov Identifier: NCT02473536.
中文摘要:伴下腔静脉瘤栓的肾细胞癌围手术期风险高,即使行肾切除和瘤栓取出术仍常见复发。这一高危人群尚无既定的新辅助局部治疗。研究评估肾切除和瘤栓取出术前针对下腔静脉瘤栓的新辅助立体定向消融放疗(SABR)的可行性、安全性、临床结局及探索性生物标志物效应。这项单中心前瞻性2期非随机临床试验于2015年7月至2024年1月入组新诊断肾细胞癌、Mayo II至IV级下腔静脉瘤栓、适合新辅助SABR和根治性手术的患者,数据分析时间为2025年8月至2026年8月。新辅助SABR照射影像学定义的下腔静脉瘤栓,方案为40 Gy分5次或36 Gy分3次,随后行根治性肾切除和下腔静脉瘤栓取出术。主要终点为1年无复发生存(RFS),与预设历史单纯手术基准55.7%比较。次要结局包括90天围手术期并发症和死亡、不良事件、肺栓塞、总生存和癌症特异性生存。探索性分析包括Ki-67免疫组化和肿瘤信息循环肿瘤DNA。23例接受新辅助SABR的患者中,22例完成手术,21例纳入主要RFS分析。21例纳入患者中12例(57%)为男性,中位(IQR)年龄62.5(54.0-73.2)岁。19例为透明细胞肾细胞癌;所有肿瘤均为3级或4级,3例入组时已有转移。中位(范围)随访108.6(2.0-127.2)个月时,1年RFS为71.4%(80% CI,56.6-82.0;95% CI,47.2-86.0),达到基于与历史单纯手术基准55.7%比较的预设2期筛选标准(P=.09)。1年总生存为95.2%(80% CI,83.9-98.7;95% CI,70.7-99.3),癌症特异性生存为95.2%(80% CI,83.9-98.7;95% CI,70.7-99.3)。未发生90天围手术期死亡;发生4例4级治疗归因事件,但未发生4/5级放疗归因毒性效应。与未照射对照相比,照射瘤栓患者的Ki-67表达降低。所有有可用血浆的患者均检出肿瘤信息循环肿瘤DNA,治疗后下降。在这项非随机临床试验中,肾切除和下腔静脉瘤栓取出术前的新辅助SABR表现可行,安全性可接受。RFS达到预设2期筛选标准,但仍属探索性,需要进一步评估。临床试验注册号 NCT02473536。
Transcutaneous auricular vagus nerve stimulation is effective for rosacea. However, its neuroimmunomodulatory effects lack sham-controlled serum biochemical evidence, and specialized device reliance limits its clinical popularization. To evaluate the clinical efficacy of device-free auricular acupressure for rosacea and verify its neuroimmunomodulatory effects using serum biomarkers and immediate vascular imaging in a sham-controlled trial. This single-center, randomized, sham-controlled, assessor-masked trial was conducted in the Dermatology Outpatient Department of the Second Affiliated Hospital of Xi'an Jiaotong University from October 2025 to May 2026 and included 204 patients with rosacea who were receiving standard first-line treatment. Participants were assigned in a 1:1 ratio using block randomization. Data analysis was initiated in May 2026. The active acupressure group received a Vaccaria segetalis seed on the bilateral cavum conchae (innervated by the auricular vagus branch), while the sham group received a seed on the auricular tubercle superior margin (pure somatosensory innervation). Participants performed acupressure 3 times daily for 30 seconds, with extra pressing allowed during acute flare-ups. The intervention lasted 8 weeks. Serum levels of cathelicidin antimicrobial peptide (LL-37), calcitonin gene-related peptide (CGRP), tumor necrosis factor α (TNF-α), and interleukin (IL) 6 were measured at baseline and week 8. Multispectral imaging was performed at baseline and week 4 to assess immediate vascular responses. The primary outcome was treatment success, defined as an Investigator Global Assessment (IGA) score of 0 or 1 at week 8. The number needed to treat was calculated from absolute risk difference. The 204 participants were equally divided into 2 groups (102 each; active acupressure: mean [SD] age, 32.51 [10.60] years, 86 female individuals [84.3%]; sham acupressure: mean [SD] age, 30.82 [9.32] years, 86 female individuals [84.3%]). At week 8, the active acupressure group had a higher IGA success rate (58 [56.9%] vs 36 [35.3%]; relative risk, 1.61; 95% CI, 1.18-2.20; P = .003; number needed to treat, 5). Serum LL-37, CGRP, TNF-α, and IL-6 levels decreased more significantly in the active acupressure group. The immediate vascular improvement rate was 59.3% vs 7.4% (P < .001). At week 20, the active acupressure group maintained significantly lower IGA and Clinical Erythema Assessment scores. No serious adverse events occurred. This randomized clinical trial found that device-free, on-demand intervention yielded substantial additional clinical benefits when combined with standard first-line therapy and established early sham-controlled, serum-based evidence for its neuroimmunomodulatory mechanism, potentially offering a strategy for self-management of rosacea. Chinese Clinical Trial Registry Identifier: ChiCTR2500110787.
中文摘要:经皮耳迷走神经刺激对玫瑰痤疮有效,但其神经免疫调节作用缺乏假刺激对照下的血清生化证据,且对专用设备的依赖限制临床推广。为在假刺激对照试验中评估无器械耳穴按压治疗玫瑰痤疮的临床疗效,并用血清生物标志物和即刻血管成像验证其神经免疫调节作用,这项单中心、随机、假刺激对照、评估者设盲试验于2025年10月至2026年5月在西安交通大学第二附属医院皮肤科门诊开展,纳入204例正在接受标准一线治疗的玫瑰痤疮患者。参与者采用区组随机化按1:1分配。数据分析于2026年5月启动。真耳穴按压组在双侧耳甲腔(耳迷走神经支支配区)贴敷王不留行籽,假组在耳廓结节上缘(纯躯体感觉支配区)贴敷王不留行籽。参与者每日按压3次,每次30秒,急性发作期可额外按压。干预持续8周。基线及第8周检测血清cathelicidin抗菌肽(LL-37)、降钙素基因相关肽(CGRP)、肿瘤坏死因子α(TNF-α)和白细胞介素6(IL-6)水平。基线及第4周进行多光谱成像以评估即刻血管反应。主要结局为治疗成功,定义为第8周研究者整体评估(IGA)评分为0或1。根据绝对风险差计算需治疗人数。204名参与者均分为2组(每组102例;真耳穴按压组平均[SD]年龄32.51[10.60]岁,女性86例[84.3%];假耳穴按压组平均[SD]年龄30.82[9.32]岁,女性86例[84.3%])。第8周,真耳穴按压组IGA成功率更高(58例[56.9%] vs 36例[35.3%];相对风险1.61;95% CI 1.18-2.20;P=.003;需治疗人数5)。真耳穴按压组血清LL-37、CGRP、TNF-α和IL-6水平下降更明显。即刻血管改善率为59.3% vs 7.4%(P<.001)。第20周,真耳穴按压组维持显著更低的IGA和临床红斑评估评分。未发生严重不良事件。这项随机临床试验发现,无器械、按需干预与标准一线治疗联合时带来显著的额外临床获益,并为其神经免疫调节机制提供了早期假刺激对照的血清学证据,可能为玫瑰痤疮自我管理提供一种策略。中国临床试验注册中心注册号:ChiCTR2500110787。
The optimal perioperative regimen for resectable hepatocellular carcinoma (HCC) remains undefined. This study evaluated the efficacy and safety of perioperative camrelizumab combined with apatinib in patients with resectable high-risk HCC. In this single-arm, phase II study, 31 patients with resectable HCC and high recurrence risk factors (e.g., large tumor size, multinodularity, and vascular invasion) received neoadjuvant camrelizumab (200 mg every 2 weeks) and apatinib (250 mg daily) for four cycles, followed by surgical resection and adjuvant therapy with the same regimen for up to 1 year. The primary endpoint was major pathological response (MPR), defined as ≤ 50% viable tumor cells in resected specimens. A total of 31 patients were enrolled in the study. Among 26 patients who underwent surgery, the MPR rate was 46.2%. The median disease-free survival (DFS) in patients who underwent surgery was 24.1 months (95% confidence interval [CI]: 14.4-not estimable [NE]). The median progression-free survival (PFS) in all patients was 18.3 months (95% CI: 11.6-NE). In the neoadjuvant setting, Grade 3 or higher adverse events were observed in 12.9% of patients. Perioperative camrelizumab combined with apatinib demonstrated promising efficacy and manageable safety in high-risk resectable HCC.
中文摘要:可切除肝细胞癌的最佳围手术期方案尚未确定。本研究评估围手术期卡瑞利珠单抗联合阿帕替尼用于可切除高危肝细胞癌患者的疗效与安全性。这项单臂Ⅱ期研究纳入31例具有高复发风险因素的可切除肝细胞癌患者,风险因素包括肿瘤体积大、多结节和血管侵犯;患者接受4个周期新辅助卡瑞利珠单抗(200 mg,每2周1次)联合阿帕替尼(250 mg,每日1次),随后行手术切除,并接受同一方案辅助治疗,最长1年。主要终点为主要病理缓解(MPR),定义为切除标本中存活肿瘤细胞≤50%。共31例患者入组。26例接受手术的患者中,MPR率为46.2%。接受手术患者的中位无病生存期(DFS)为24.1个月(95%置信区间[CI]:14.4至无法估计[NE])。全部患者的中位无进展生存期(PFS)为18.3个月(95%CI:11.6至NE)。新辅助治疗阶段,12.9%的患者发生3级及以上不良事件。围手术期卡瑞利珠单抗联合阿帕替尼在高危可切除肝细胞癌中显示出有希望的疗效和可控的安全性。
Pulmonary nodules are increasingly detected by thoracic imaging and low-dose computed tomography-based lung cancer screening, but most are benign, transient, or indolent. Clinically, the key task is to distinguish nodules that require timely cancer-directed evaluation from those that can be safely observed. This review summarizes the classification, disease spectrum, risk assessment, early diagnosis, biomarkers, signaling mechanisms, translational models, and management of pulmonary nodules. We first distinguish imaging phenotypes and disease entities, then differentiate the individual-level models used to select candidates for lung cancer screening from the nodule-level models and structured reporting systems used after nodule detection. Low-dose computed tomography remains the foundation of screening and surveillance approaches, whereas magnetic resonance imaging (MRI), positron emission tomography combined with computed tomography, contrast-enhanced computed tomography, nonsurgical biopsy, surgical diagnosis, and local therapies play more selective roles depending on the probability of malignancy and patient fitness. Noninvasive biomarkers, including circulating cellular, nucleic acid, methylation, protein, autoantibody, extracellular vesicle, and metabolic analytes, are most likely to serve as adjuncts to imaging and clinical risk assessment rather than as stand-alone diagnostic tests. Artificial intelligence may support detection, workflow efficiency, malignancy risk reclassification, invasiveness assessment, and multimodal integration, but its value depends on external validation, calibration, implementation, and prospective evidence of management benefit. Mechanistic studies of adenocarcinoma spectrum subsolid nodules have implicated the involvement of early oncogenic signaling, genomic instability, immune escape, stromal and vascular remodeling, and adaptive survival pathways. Translational models can support mechanistic and procedural research, but do not replicate real-world nodule management in patients. Overall, care for pulmonary nodules should be risk-adapted, longitudinal, multidisciplinary, and patient-centered.
中文摘要:肺部结节在胸部影像学和低剂量计算机断层扫描肺癌筛查中越来越多被发现,但大多数为良性、短暂或惰性。临床上关键任务是区分需要及时进行癌症相关评估的结节与可以安全观察的结节。本综述总结肺结节的分类、疾病谱、风险评估、早期诊断、生物标志物、信号机制、转化模型和管理。我们首先区分影像表型和疾病实体,再区分用于筛选肺癌筛查候选者的个体水平模型与结节发现后所用的结节水平模型和结构化报告系统。低剂量计算机断层扫描仍是筛查和监测方法的基础,而磁共振成像、正电子发射断层扫描联合计算机断层扫描、增强计算机断层扫描、非手术活检、手术诊断和局部治疗根据恶性概率和患者体能状况发挥更具选择性的作用。无创生物标志物,包括循环细胞、核酸、甲基化、蛋白质、自身抗体、细胞外囊泡和代谢分析物,最可能作为影像和临床风险评估的辅助手段,而不是独立的诊断试验。人工智能可支持检测、流程效率、恶性风险重分类、侵袭性评估和多模态整合,但其价值取决于外部验证、校准、实施以及管理获益的前瞻性证据。对腺癌谱系亚实性结节的机制研究提示早期致癌信号、基因组不稳定、免疫逃逸、基质和血管重塑以及适应性生存通路参与其中。转化模型可支持机制和操作研究,但不能复制真实世界中的患者结节管理。总体而言,肺结节诊疗应风险适应、纵向、多学科并以患者为中心。
Although neoadjuvant immunochemotherapy (NICT) has improved survival in locally advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC), lymph node metastasis (LNM) patterns following NICT remain undefined. We aimed to characterize topographical LNM patterns after NICT and evaluate the association between lymphadenectomy extent, surgical approach, and survival outcomes. Data were pooled from 4 prospective clinical trials (NEOSUMMIT-01 - 04), comprising 126 patients with GC (n = 61) or GEJC (n = 65) undergoing curative gastrectomy following NICT. ypN0 was achieved in 71 patients (56%). In GEJC, station No. 3, 7 were high risk; No. 1, 2, 9, and 11 were intermediate risk; and No. 4, 5, 6, 8, 12 were low risk. In GC, station No. 12 was low-risk; D1 stations (No. 1, 3, 4, 5, 6, 7) were high-risk, D1+ stations (No. 8, 9) and No. 11 were intermediate-risk. At a median follow-up of 36.2 months, 24-month EFS and OS rates were 76.4% and 90.5%. Nodal yield (≥ 30 vs. < 30) was not significantly associated with EFS (P = .611) or OS (P = .911). In exploratory comparisons within the GEJC cohort, EFS (P = .219) and OS (P = .290) did not differ significantly between proximal and total gastrectomy. In GEJC, distal perigastric lymph node stations (No. 4, 5, 6, and 12) exhibited low metastasis rates, while exploratory survival outcomes support prospective clinical trials of proximal gastrectomy in appropriately selected patients. Conversely, the broader residual nodal involvement in GC reinforces the continued role of standard D2 lymphadenectomy.
中文摘要:新辅助免疫化疗(NICT)虽改善了局部进展期胃癌(GC)与胃食管结合部癌(GEJC)的生存,但NICT后的淋巴结转移(LNM)模式仍不明确。本研究旨在刻画NICT后的拓扑性LNM模式,并评估淋巴结清扫范围、手术方式与生存结局的关联。数据 pooled 自4项前瞻性临床试验(NEOSUMMIT-01至04),共126例接受NICT后根治性胃切除术的GC(n=61)或GEJC(n=65)患者。71例(56%)达到ypN0。在GEJC中,第3、7站为高风险,第1、2、9、11站为中风险,第4、5、6、8、12站为低风险。在GC中,第12站为低风险;D1各站(第1、3、4、5、6、7站)为高风险,D1+各站(第8、9站)及第11站为中风险。中位随访36.2个月时,24个月EFS率和OS率分别为76.4%和90.5%。淋巴结获取数(≥30比<30)与EFS(P=.611)或OS(P=.911)无显著关联。在GEJC队列的探索性比较中,近端胃切除术与全胃切除术之间的EFS(P=.219)和OS(P=.290)无显著差异。在GEJC中,远端胃周淋巴结站(第4、5、6、12站)转移率低,探索性生存结局支持在适当选择的患者中开展近端胃切除术的前瞻性临床试验。相反,GC中更广泛的残留淋巴结受累支持标准D2淋巴结清扫继续发挥作用。
Ritlecitinib (Litfulo®) is an oral dual inhibitor of Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases. It is approved in several countries worldwide for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In the pivotal, randomized, double-blind, placebo-controlled, phase 2b/3 ALLEGRO trial in adults and adolescents with alopecia areata with ≥ 50% scalp hair loss, ritlecitinib 50 mg once daily significantly increased the proportion of patients achieving ≤ 20% scalp hair loss at week 24 compared with placebo. Ritlecitinib also improved patient-reported outcomes, including Patient's Global Impression of Change responses. Response rates for key efficacy outcomes in the pivotal trial continued to increase through 48 weeks and were sustained for up to 3 years in the open-label phase 3 ALLEGRO-LT trial. Longer-term treatment was also associated with improvements in health-related quality of life. Ritlecitinib was generally well tolerated, with most adverse events being of mild or moderate severity. While further data are needed to fully characterize long-term safety, currently available data suggest that ritlecitinib is a valuable new option for the treatment of severe alopecia areata, including in adolescents for whom approved treatment options are limited.
中文摘要:Ritlecitinib(Litfulo®)是Janus激酶3与肝细胞癌中表达酪氨酸激酶(TEC)家族激酶的口服双重抑制剂。该药已在多个国家获批用于治疗成人和12岁及以上青少年的重度斑秃。在针对头皮脱发≥50%的成人和青少年斑秃患者开展的关键性随机、双盲、安慰剂对照2b/3期ALLEGRO试验中,Ritlecitinib 50 mg每日一次较安慰剂显著提高第24周达到头皮脱发≤20%的患者比例。Ritlecitinib还改善了患者报告结局,包括患者总体印象变化应答。关键疗效结局的应答率在关键试验中持续升高至第48周,并在开放标签3期ALLEGRO-LT试验中维持长达3年。更长疗程治疗还与健康相关生活质量的改善相关。Ritlecitinib总体耐受性良好,多数不良事件为轻度或中度。全面描述长期安全性仍需更多数据,现有数据提示Ritlecitinib是治疗重度斑秃的有价值新选择,包括获批治疗选择有限的青少年。
Cervical cancer is the third most common gynecologic cancer, with more than 13 000 new cases diagnosed in 2025. The incidence of and mortality from cervical cancer vary across racial and ethnic groups and in persons living in medically underserved or geographically isolated areas, with half of all cervical cancers occurring in women who are underscreened or have never been screened. Persistent infection with high-risk types of human papillomavirus (HPV) is the most important risk factor for cervical cancer and is associated with nearly all cases. Although genital tract HPV infection is common, most HPV infections are transient, and cervical cancer occurs in only a small portion of patients with HPV. For decades, cervical cancer screening relied on annual cytologic assessment. A growing understanding of the role of HPV infection in the natural progression of cervical cancer has led to updated screening recommendations from the American Cancer Society and the Women's Preventive Services Initiative, as well as a draft update from the U.S. Preventive Services Task Force. These recommendations include primary HPV testing as a preferred screening strategy and include an option for self-collected specimens for HPV testing. Here, 2 experts in this field, a primary care physician and an obstetrics and gynecology physician, debate how to apply these guidelines when screening a patient for cervical cancer. They discuss a range of screening options and consider the challenges of applying these guidelines across different age groups and in patients at increased risk.
中文摘要:宫颈癌是第三常见妇科癌症,2025年诊断的新发病例超过13000例。宫颈癌的发病率和死亡率在不同种族和族裔群体以及居住在医疗资源不足或地理偏远地区的人群中存在差异,约一半宫颈癌发生在筛查不足或从未接受筛查的女性中。持续感染高危型人乳头瘤病毒(HPV)是宫颈癌最重要的危险因素,与几乎所有宫颈癌病例相关。生殖道HPV感染较常见,但多数HPV感染为一过性,仅小部分HPV感染者发生宫颈癌。数十年来,宫颈癌筛查依赖年度细胞学评估。对HPV感染在宫颈癌自然进展中作用的认识不断加深,促使美国癌症协会和女性预防服务倡议更新筛查建议,美国预防服务工作组也发布了草案更新。这些建议包括将HPV初筛作为首选筛查策略,并提供自采集标本用于HPV检测的选项。两位该领域专家,一名初级保健医生和一名妇产科医生,讨论在筛查患者时如何应用这些指南。他们讨论一系列筛查选择,并考虑在不同年龄组和风险增加患者中应用这些指南的挑战。
The phase 2 randomized LUNAR trial previously demonstrated that neoadjuvant 177Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved progression-free survival (PFS) in patients with oligorecurrent hormone-sensitive prostate cancer (orHSPC). We report updated efficacy and safety outcomes with extended follow-up. Patients with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-detected orHSPC and one to five metastatic lesions amenable to SBRT were randomized 1:1 to SBRT alone or two cycles of neoadjuvant 177Lu-PNT2002 followed by SBRT. The primary end point was PFS, defined as new lesions on PSMA PET/CT, initiation of salvage hormonal therapy, or death. Secondary end points included hormonal therapy-free survival (HT-FS) and 24-mo progression-free status. Exploratory end points included polymetastatic PFS (poly-PFS), castration-resistant disease-free survival (CRFS), and conventional imaging progression-free survival (CT-PFS). Between September 2022 and November 2023, 92 patients were randomized to SBRT alone (n = 47) or 177Lu-PNT2002 plus SBRT (n = 45). At a median follow-up of 31.9 mo, 177Lu-PNT2002 significantly improved PFS (median 17.6 vs 7.4 mo; hazard ratio [HR] 0.38, 95% confidence interval [CI] = 0.23-0.61; p < 0.001) and HT-FS (HR 0.57, 95% CI = 0.34-0.95; p = 0.03). Exploratory analyses demonstrated improved poly-PFS (HR 0.28, 95% CI = 0.08-1.03; p = 0.04), CRFS (HR 0.13, 95% CI = 0.02-1.10; p = 0.03), and CT-PFS (HR 0.46, 95% CI = 0.19-1.09; p = 0.07). No new safety signals were observed. With extended follow-up, neoadjuvant 177Lu-PNT2002 before SBRT produced durable improvements in PFS and HT-FS. While poly-PFS, CRFS, and CT-PFS were exploratory end points, their improvement provides hypothesis-generating evidence that the addition of radioligand therapy to SBRT may alter disease trajectory beyond delaying PSMA PET/CT-detected recurrence.
中文摘要:2期随机LUNAR试验此前显示,在立体定向体部放疗(SBRT)前给予新辅助177Lu-PNT2002可显著改善寡复发激素敏感前列腺癌(orHSPC)患者的无进展生存期(PFS)。研究报告延长随访后的更新疗效和安全性结果。经前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)检出orHSPC且具有1至5个适合SBRT的转移灶的患者,按1:1随机分配至单纯SBRT或两周期新辅助177Lu-PNT2002后SBRT。主要终点为PFS,定义为PSMA PET/CT出现新病灶、开始挽救性激素治疗或死亡。次要终点包括无激素治疗生存期(HT-FS)和24个月无进展状态。探索性终点包括多转移PFS(poly-PFS)、无去势抵抗生存期(CRFS)和传统影像学无进展生存期(CT-PFS)。2022年9月至2023年11月,92例患者随机分配至单纯SBRT组(n=47)或177Lu-PNT2002联合SBRT组(n=45)。中位随访31.9个月时,177Lu-PNT2002显著改善PFS(中位17.6个月 vs 7.4个月;风险比[HR] 0.38,95%置信区间[CI] 0.23-0.61;p<0.001)和HT-FS(HR 0.57,95% CI 0.34-0.95;p=0.03)。探索性分析显示poly-PFS(HR 0.28,95% CI 0.08-1.03;p=0.04)、CRFS(HR 0.13,95% CI 0.02-1.10;p=0.03)和CT-PFS(HR 0.46,95% CI 0.19-1.09;p=0.07)改善。未观察到新的安全性信号。延长随访后,SBRT前新辅助177Lu-PNT2002对PFS和HT-FS产生持久改善。尽管poly-PFS、CRFS和CT-PFS为探索性终点,其改善提供了产生假设的证据,即SBRT联合放射配体治疗可能改变疾病轨迹,而不只是延迟PSMA PET/CT检出的复发。
Cancer drugs are frequently approved based on uncertain benefits and risks that are not communicated to patients. To evaluate the effect of communicating uncertainties about the benefits and risks of new cancer drugs on changes in individuals' hypothetical decisions to take the drug. Two randomized clinical trials recruited online a demographically diverse sample of US adults (census matched for age, sex, education, income, and race and ethnicity) from May 9 to July 26, 2025. Plain-language statements describing uncertainties about drug benefits and risks. Trial 1 randomized participants to 1 of 5 uncertainties: (1) single-arm trial design, (2) unrepresentative population in terms of race and ethnicity, (3) short study duration, (4) surrogate end point, or (5) no noticeable improvement. Trial 2 randomized participants to 1, 2, 3, or 4 uncertainties or to a control group. The primary outcome in trial 1 was changes in hypothetical decisions to take a new cancer drug (within-group difference), while in trial 2 the primary outcome was the change in between-group differences in hypothetical decisions (control vs intervention groups). Secondary outcomes included perceived treatment effectiveness, worry associated with taking the drug, and trust in the information and the US Food and Drug Administration. A total of 6272 adults were included in the primary analysis (3102 [49.5%] women). In trial 1, learning about uncertainties reduced hypothetical decisions to take the drug by a mean of 10.1 percentage points (pp; 95% CI, -11.7 to -8.5 pp; P < .001). The reduction in hypothetical decisions to take the drug was observed for all uncertainties, including among those in the group that learned that it was unknown whether patients would notice an improvement with the drug (-14.1 pp; 95% CI, -17.9 to -10.4 pp; P < .001) and those who learned that the drug was not studied in patients of similar race or ethnicity (-12.8 pp; 95% CI, -16.4 to -9.2; P < .001). In trial 2, hypothetical decisions to take the drug decreased with each additional uncertainty, demonstrating a dose-dependent effect. Learning about uncertainties reduced perceived effectiveness and trust but did not affect worry. In 2 randomized clinical trials including a demographically diverse sample of US adults, learning about common uncertainties with a new cancer drug's benefits and risks reduced hypothetical decisions to take the drug. ClinicalTrials.gov Identifiers: NCT06997185 and NCT07110597.
中文摘要:癌症药物常基于不确定的获益和风险获批,而这些不确定性未向患者传达。评估传达新癌症药物获益和风险的不确定性对个体假设性用药决定变化的影响。两项随机临床试验于2025年5月9日至7月26日在线招募了具有人口学多样性的美国成年人样本(按年龄、性别、教育、收入以及种族和族裔与人口普查匹配)。干预为描述药物获益和风险不确定性的通俗语言陈述。试验1将参与者随机分配至5类不确定性之一:(1)单臂试验设计,(2)种族和族裔方面不具代表性的人群,(3)研究持续时间短,(4)替代终点,或(5)无明显改善。试验2将参与者随机分配至1、2、3或4类不确定性或对照组。试验1的主要结局为假设性服用新癌症药物决定的变化(组内差异),试验2的主要结局为假设性决定组间差异的变化(对照组与干预组)。次要结局包括感知的治疗有效性、服用药物相关的担忧,以及对信息和美国食品药品监督管理局的信任。主要分析共纳入6272名成年人(3102名[49.5%]女性)。在试验1中,了解不确定性使假设性服药决定平均降低10.1个百分点(pp;95% CI,-11.7至-8.5 pp;P < .001)。所有不确定性均观察到假设性服药决定的降低,包括了解到患者是否会注意到药物改善尚不清楚的组(-14.1 pp;95% CI,-17.9至-10.4 pp;P < .001),以及了解到该药物未在相似种族或族裔患者中研究的组(-12.8 pp;95% CI,-16.4至-9.2;P < .001)。在试验2中,每增加一类不确定性,假设性服药决定均下降,显示出剂量依赖性效应。了解不确定性降低了感知有效性和信任,但未影响担忧。在纳入人口学多样性美国成年人样本的2项随机临床试验中,了解新癌症药物获益和风险的常见不确定性降低了假设性服药决定。ClinicalTrials.gov标识符:NCT06997185和NCT07110597。
To evaluate the clinical applicability of previously established transcriptomic signatures (molecular subtypes, components and GemPred status) in metastatic pancreatic cancer, we conducted a retrospective pooled analysis of 178 patients from three phase 2 trials (PRODIGE35/37, AFUGEM; 2013-2016) testing first-line regimens (FOLFIRINOX, GemNab, FuNab, FOLFIRI3). RNA sequencing was performed on primary/metastatic tumors across French centers, with blinded assessment of subtypes (immune classical, pure basal-like, stroma-activated), quantitative components, and GemPred status. Primary endpoint: progression-free survival (PFS). Immune classical subtype showed superior median PFS (9.03 months) and OS (11.27 months) versus basal-like and stroma-activated subtypes (PFS: p = 0.015; OS: p = 0.010). Higher classical component correlated with improved OS (HR = 0.737, p = 0.005) but not PFS (HR = 0.90, p = 0.339). Inactive stroma predicted better PFS (HR = 0.66, p = 0.003) and OS (HR = 0.697, p = 0.013). GemPred-negative patients treated with FOLFIRINOX versus GemNab had higher ORR (46.9% vs. 19.1%, p = 0.046), longer PFS (8.2 vs. 2.3 months; HR = 2.28, p = 0.008), and OS (11.6 vs. 5.0 months; HR = 2.04, p = 0.021). No differences occurred in GemPred-positive patients. In a formal treatment-by-GemPred interaction analysis (FOLFIRINOX vs. GemNab), the interaction was significant for OS (adjusted p-interaction = 0.050) but not for PFS (adjusted p-interaction = 0.51). Transcriptomic signatures retain prognostic and predictive utility in metastatic pancreatic cancer, with GemPred representing a hypothesis-generating predictive signal for OS (e.g., a FOLFIRINOX OS benefit in GemPred-negative). Prospective validation is warranted for clinical implementation.
中文摘要:为评估既往建立的转录组特征(分子亚型、组分及GemPred状态)在转移性胰腺癌中的临床适用性,对三项2期试验(PRODIGE35/37、AFUGEM;2013—2016年)中178例患者进行回顾性汇总分析,这些试验考察一线方案FOLFIRINOX、GemNab、FuNab、FOLFIRI3。法国多个中心对原发/转移肿瘤行RNA测序,盲法判定亚型(免疫经典型、纯基底样型、基质活化型)、定量组分及GemPred状态。主要终点为无进展生存期(PFS)。免疫经典型的中位PFS(9.03个月)和OS(11.27个月)优于基底样型和基质活化型(PFS:p=0.015;OS:p=0.010)。经典型组分较高与OS改善相关(HR=0.737,p=0.005),与PFS无关(HR=0.90,p=0.339)。基质未活化预示更好的PFS(HR=0.66,p=0.003)和OS(HR=0.697,p=0.013)。GemPred阴性患者接受FOLFIRINOX相比GemNab有更高ORR(46.9% vs 19.1%,p=0.046)、更长PFS(8.2 vs 2.3个月;HR=2.28,p=0.008)和OS(11.6 vs 5.0个月;HR=2.04,p=0.021)。GemPred阳性患者未见差异。在正式的治疗与GemPred交互作用分析中(FOLFIRINOX vs GemNab),OS的交互作用显著(校正p交互=0.050),PFS不显著(校正p交互=0.51)。转录组特征在转移性胰腺癌中保留预后和预测价值,GemPred代表针对OS的假说生成性预测信号(例如GemPred阴性者从FOLFIRINOX获得OS获益)。临床落地仍需前瞻性验证。
基础研究 (8篇)
Chronic colitis is a major risk factor for colorectal cancer (CRC), particularly for colitis-associated colorectal cancer (CAC), where persistent inflammation drives the transition from mucosal injury to malignant transformation. Accumulating evidence indicates that gut microbiota dysbiosis, epithelial barrier disruption, microbial translocation, chronic immune activation, and aberrant inflammatory signaling collectively contribute to CAC initiation and progression. Sustained inflammation promotes oxidative stress, DNA damage, genetic/epigenetic alterations, and tumor microenvironment remodeling, ultimately facilitating tumor development and immune evasion. These processes form an interconnected pathogenic network linking microbial, inflammatory, genetic, immune, and stromal alterations. This review comprehensively summarizes the key drivers and molecular mechanisms of CAC, covering microbiota and barrier dysfunction, inflammatory signaling, oxidative stress and DNA damage, genetic and epigenetic alterations, and tumor microenvironment remodeling and immune dysregulation. We further review recent advances in diagnostic biomarkers, disease monitoring, chemoprevention, targeted therapies, and emerging interventions, including the potential utility of specific chemokine axes as biomarkers and therapeutic targets. Particular emphasis is placed on the translational challenges of linking mechanistic insights to diagnostic and therapeutic advances, including biomarker validation, stage-specific interventions, and patient stratification across disease progression. By integrating these interconnected mechanisms and therapeutic strategies, this review provides a comprehensive framework for understanding CAC pathogenesis and identifies opportunities for precision prevention, early detection, and multimodal treatment.
中文摘要:慢性结肠炎是结直肠癌(CRC)的重要危险因素,对结肠炎相关结直肠癌(CAC)尤其如此,持续炎症推动黏膜损伤向恶性转化。越来越多证据表明,肠道菌群失调、上皮屏障破坏、微生物易位、慢性免疫激活和异常炎症信号共同促进CAC发生与进展。持续炎症促进氧化应激、DNA损伤、遗传与表观遗传改变及肿瘤微环境重塑,最终推动肿瘤发展并帮助免疫逃逸。这些过程构成连接微生物、炎症、遗传、免疫和基质改变的相互关联致病网络。本综述系统总结CAC的关键驱动因素和分子机制,涵盖菌群与屏障功能障碍、炎症信号、氧化应激与DNA损伤、遗传和表观遗传改变,以及肿瘤微环境重塑和免疫失调。文中进一步回顾诊断生物标志物、疾病监测、化学预防、靶向治疗和新兴干预措施的最新进展,包括特定趋化因子轴作为生物标志物和治疗靶点的潜在用途。重点讨论将机制认识转化为诊断和治疗进展所面临的转化挑战,包括生物标志物验证、分期特异性干预和跨疾病进展的患者分层。通过整合这些相互关联的机制和治疗策略,本综述为理解CAC发病机制提供综合框架,并指出精准预防、早期发现和多模式治疗的机会。
Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk. Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the onset and reduces the incidence of postpartum mammary cancer in K14-Cre; Brca1F/F, Trp53F/F mice. In these mice, cabergoline treatment remodels the mammary gland by potentiating involution, reducing ductal area and proliferation, and reversing T cell exhaustion, potentially through modulation of ion channel expression. Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate 69% reduction in risk. Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.
中文摘要:产后发生的乳腺癌常预后较差,迫切需要化学预防策略,尤其是高风险女性。研究报告,在K14-Cre; Brca1F/F, Trp53F/F小鼠中,哺乳结束后单次给予卡麦角林(一种阻断催乳素分泌的多巴胺能激动剂)可延迟产后乳腺肿瘤发生并降低其发生率。在这些小鼠中,卡麦角林通过促进乳腺复旧重塑乳腺,减少导管面积和增殖,并逆转T细胞耗竭,其作用可能涉及离子通道表达的调控。两项针对欧洲女性大型队列的独立回顾性研究显示,卡麦角林治疗与产后乳腺癌发生率较低相关,荟萃分析提示风险约降低69%。这项工作强调以哺乳后乳腺复旧为靶点是预防产后乳腺癌的策略,并将卡麦角林定位为一种新型、低风险的化学预防方案。
Glioblastoma (GBM) is a highly aggressive malignancy, with chemoresistance acting as a major hurdle that severely limits clinical efficacy and long-term prognosis. Mitophagy, a core mechanism of mitochondrial quality control, enables tumor cells to adapt to chemotherapy-induced stress and maintain survival. However, its regulatory mechanism in GBM chemoresistance remains poorly understood. Here, we identify SLMO2 as a key factor mediating chemoresistance in GBM. Low-dose TMZ induces protective mitophagy, whereas SLMO2 knockdown abrogates this autophagic defense, thereby sensitizing GBM cells to TMZ-induced apoptosis. Mechanistically, TMZ treatment upregulates SLMO2, which potently activates HIF-1α signaling to transcriptionally drive BNIP3-mediated mitophagy, a process dependent on ROS-NF-κB signaling. Notably, this SLMO2-mediated cascade is also engaged under cisplatin-induced stress, indicating a broader role in chemoresistance. Collectively, our findings reveal that SLMO2 promotes chemoresistance in GBM by regulating BNIP3-mediated mitophagy. Targeting SLMO2 disrupts mitochondrial homeostasis by this process, offering a novel therapeutic strategy for enhancing chemosensitivity in GBM.
中文摘要:胶质母细胞瘤(GBM)是一种侵袭性极强的恶性肿瘤,化疗耐药是限制其临床疗效与长期预后的主要障碍。线粒体自噬作为线粒体质量控制的核心机制,使肿瘤细胞得以适应化疗压力并维持存活,但其在GBM化疗耐药中的调控机制仍不清楚。本研究确认SLMO2是介导GBM化疗耐药的关键因子。低剂量替莫唑胺(TMZ)可诱导保护性线粒体自噬,而敲低SLMO2会消除这一自噬防御,使GBM细胞对TMZ诱导的凋亡更敏感。机制上,TMZ处理上调SLMO2,后者有效激活HIF-1α信号,在转录水平驱动BNIP3介导的线粒体自噬,这一过程依赖ROS-NF-κB信号。该SLMO2介导的级联反应在顺铂诱导的压力下同样被激活,提示其在化疗耐药中作用更广。上述结果揭示SLMO2通过调控BNIP3介导的线粒体自噬促进GBM化疗耐药;靶向SLMO2可经此途径破坏线粒体稳态,为提高GBM化疗敏感性提供了新的治疗策略。
Lung adenocarcinoma (LUAD) is a multi-kinase hyperactivation-driven malignancy. Targeted therapies are effective but have limited application, primarily due to a small eligible patient population and the development of drug resistance. Analysis of TCGA and tissue microarray show that Dystonia 8 (DYT8) is specially highly expressed in more than 70% of LUAD patients. Furthermore, increased DYT8 expression is positively associated with tumor malignancy and negatively associated with survival. Using the Dyt8 knock-in (cKrasLSL-G12D/+p53R172H/+-Dyt8-KI) and knockout (cKrasLSL-G12D/+p53R172H/+-Dyt8-KO) transgenic mice, we identify DYT8 as key activator that accelerates the initiation and progression of LUAD. Mechanistically, EGFR-mediated phosphorylation of DYT8 at Y120 reinforces its stability by increasing its interaction with PSMC6, a protein that is highly expressed in LUAD and associated with an unfavorable prognosis. DYT8 drives LUAD malignant transformation by activating Src. Although Y419 phosphorylation is a recognized key event in Src-driven LUAD, our study identifies novel phosphorylation sties at S306 and S525 that are activated by DYT8, which these novel sites being more critical for DYT8-driven malignant transformation than Y419 phosphorylation. Furthermore, the knockdown of Dyt8 rescues EGFR-triggered carcinogenesis and resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). These findings reveal that DYT8 drives LUAD via a previously unreported Src activation mechanism and identify EGFR-DYT8-PSMC6 axis as the key determinant of high DYT8 level, thereby conferring a novel therapeutic strategy for wider LUAD patients, including those with EGFR-TKIs resistant.
中文摘要:肺腺癌(LUAD)是一种多激酶过度激活驱动的恶性肿瘤。靶向治疗有效,但适用范围有限,主要受限于可获益患者群体较小以及耐药性的产生。对TCGA和组织芯片的分析显示,Dystonia 8(DYT8)在超过70%的LUAD患者中特异性高表达。DYT8表达升高与肿瘤恶性程度呈正相关,与生存期呈负相关。利用Dyt8敲入(cKrasLSL-G12D/+p53R172H/+-Dyt8-KI)和敲除(cKrasLSL-G12D/+p53R172H/+-Dyt8-KO)转基因小鼠,研究确认DYT8是加速LUAD发生和进展的关键激活因子。机制上,EGFR介导的DYT8 Y120磷酸化通过增强DYT8与PSMC6的相互作用提高其稳定性;PSMC6在LUAD中高表达并与不良预后相关。DYT8通过激活Src驱动LUAD恶性转化。Y419磷酸化是Src驱动LUAD的公认关键事件,本研究还发现由DYT8激活的S306和S525两个新磷酸化位点,且这些新位点对DYT8驱动的恶性转化比Y419磷酸化更关键。敲低Dyt8可逆转EGFR触发的癌变及对EGFR酪氨酸激酶抑制剂(EGFR-TKIs)的耐药。这些发现揭示DYT8通过一种此前未报道的Src激活机制驱动LUAD,并确定EGFR-DYT8-PSMC6轴是高DYT8水平的关键决定因素,从而为更广泛的LUAD患者(包括EGFR-TKIs耐药患者)提供新的治疗策略。
Salt stress causes concurrent sodium (Na+) and chloride (Cl-) toxicity that severely inhibits plant growth and reduces crop yield. Although Na+ homeostasis has been studied extensively, the molecular mechanisms that underlie Cl- homeostasis during salt stress remain to be fully characterized. Root-to-shoot Cl- translocation is tightly regulated to prevent excessive Cl- accumulation in the shoots. Here, we show that the zinc finger protein ZAT7 directly binds to the promoter of the Cl- transporter gene NRT1/PTR FAMILY 2.4 (NPF2.4) and represses its expression, thus inhibiting the upward transport of Cl- mediated by NPF2.4. Through yeast two-hybrid screening and functional validation, we identified three upstream regulators of ZAT7: DUF295 ORGANELLAR A 9 (DOA9), the deubiquitinase OVARIAN TUMOR 11 (OTU11), and CYSTATIN 13 (CYS13). Under normal growth conditions, OTU11 stabilizes DOA9 to promote the degradation of ZAT7, thereby maintaining NPF2.4 expression and basal Cl- translocation to the shoots. Upon Cl- stress, CYS13 is rapidly induced and inactivates the OTU11-DOA9 module, leading to ZAT7 accumulation, NPF2.4 suppression, and reduced Cl- translocation. These findings reveal that plants fine-tune the abundance of the core chloride-resistance regulator ZAT7 via CYS13 under salt stress to precisely control root-to-shoot Cl- delivery.
中文摘要:盐胁迫会同时造成钠离子和氯离子毒害,严重抑制植物生长并降低作物产量。钠离子稳态已被广泛研究,但盐胁迫下氯离子稳态的分子机制仍未完全阐明。根系向地上部的氯离子转运受到严格调控,以防止地上部过度积累氯离子。本研究发现,锌指蛋白ZAT7可直接结合氯离子转运基因NRT1/PTR FAMILY 2.4(NPF2.4)的启动子并抑制其表达,从而抑制NPF2.4介导的氯离子向上运输。通过酵母双杂交筛选和功能验证,鉴定出ZAT7的三个上游调控因子:DUF295 ORGANELLAR A 9(DOA9)、去泛素化酶OVARIAN TUMOR 11(OTU11)和CYSTATIN 13(CYS13)。正常生长条件下,OTU11稳定DOA9,促进ZAT7降解,维持NPF2.4表达和基础的氯离子向地上部转运。氯胁迫下,CYS13被快速诱导并失活OTU11-DOA9模块,导致ZAT7积累、NPF2.4受抑制以及氯离子转运减少。这些结果揭示,植物在盐胁迫下通过CYS13精细调节核心耐氯调控因子ZAT7的丰度,从而精确控制根系向地上部的氯离子输送。
Cancer cachexia is a multifactorial and progressive syndrome characterized by the not fully reversible loss of skeletal muscle and adipose tissue, which significantly impairs treatment tolerance, quality of life, and patient survival. Despite its high clinical burden, cachexia remains underdiagnosed and undertreated, largely because current diagnostic criteria rely on late-stage clinical manifestations, such as weight loss, and reliable biomarkers for early detection are still lacking. In addition, available therapeutic strategies are mostly palliative and fail to target the underlying mechanisms of the syndrome. A deeper understanding of the molecular and systemic drivers of cachexia is therefore essential for the development of effective interventions. In this context, preclinical models have become indispensable tools for investigating disease mechanisms, identifying therapeutic targets, and validating biomarkers under controlled conditions. Herein, we review the main preclinical platforms used to study cancer cachexia, including in vivo, in vitro, and emerging microphysiological systems, highlighting their respective strengths and limitations in recapitulating tumor-host interactions and tissue wasting. Further, we highlight the need for advanced biosensing technologies as promising tools for the sensitive detection of predictive cachectic biomarkers, with potential applications in early detection, disease monitoring, and translational research. Together, these approaches may accelerate the future development of mechanism-based strategies for cancer cachexia.
中文摘要:癌性恶病质是一种多因素、进行性综合征,特征为骨骼肌与脂肪组织丢失且不能完全逆转,显著损害治疗耐受性、生活质量与患者生存。尽管临床负担高,恶病质仍诊断不足、治疗不足,主要因为现行诊断标准依赖体重下降等晚期临床表现,早期检测的可靠生物标志物仍缺乏。现有治疗策略多为姑息性,未能针对该综合征的潜在机制。深入理解恶病质的分子与全身驱动因素,对开发有效干预至关重要。在此背景下,临床前模型已成为在受控条件下研究疾病机制、识别治疗靶点与验证生物标志物不可缺少的工具。综述梳理了用于研究癌性恶病质的主要临床前平台,包括体内、体外及新兴微生理系统,强调其在再现肿瘤-宿主相互作用与组织消耗方面各自的优势与局限。进一步指出先进生物传感技术作为有前景工具的必要性,用于灵敏检测预测性恶病质生物标志物,可能在早期发现、疾病监测与转化研究中应用。这些方法有望加速未来基于机制的癌性恶病质策略开发。
Prognostic assessment via whole-slide images (WSIs) is a key task in computational pathology. However, the development of robust predictive models is often bottlenecked by the scarcity of survival-annotated data, given the longitudinal nature of clinical follow-up. Despite its potential, semi-supervised learning (SSL) remains underexplored in this field. Existing SSL methods, primarily designed for natural image classification, rely on the assumption of marginally independent categories, which makes them difficult to adapt to the high-dimensional complexity of WSIs and the temporal continuity inherent in survival outcomes. To bridge this gap, we propose a novel semi-supervised multiple instance learning (MIL) framework tailored for WSI-based prognosis. Specifically, we first introduce a morphology-perceived MIL network (Morph-MIL) that jointly models tissue composition and global semantic representations. To maintain a stable reference, a dynamic memory bank is employed to encapsulate the multi-level representations of labeled samples (censored & uncensored). Furthermore, we develop a pseudo-labeling strategy that assigns discrete labels containing temporal relationships to annotation-free data by aligning their features with the memory bank through bin-wise aggregation. Comprehensive evaluation establishes the superiority of the proposed framework, while extensive ablation analyses and visualizations confirm its efficacy in prognostic prediction and biological interpretation. Consequently, this study offers a scalable solution for WSI survival modeling in scenarios with limited annotations. The code is available at: https://github.com/yihuangswust-alt/SSL-Morph_MIL.
中文摘要:基于全切片图像(WSIs)的预后评估是计算病理学的一项关键任务。临床随访具有纵向性质,带生存标注的数据稀缺,常使稳健预测模型的开发受到瓶颈限制。半监督学习(SSL)在该领域仍未被充分探索,尽管其具有潜力。现有SSL方法主要面向自然图像分类设计,依赖类别边缘独立的假设,难以适配WSIs的高维复杂性以及生存结局固有的时间连续性。为弥补这一差距,我们提出一种面向WSI预后的新型半监督多实例学习(MIL)框架。具体而言,我们引入形态感知MIL网络(Morph-MIL),联合建模组织组成与全局语义表征。为保持稳定参考,采用动态记忆库封装有标注样本(删失与未删失)的多层次表征。我们开发一种伪标签策略,通过分箱聚合将无标注数据的特征与记忆库对齐,从而为其分配包含时间关系的离散标签。综合评估表明所提框架具有优越性,广泛的消融分析与可视化验证了其在预后预测和生物学解释方面的有效性。本研究为标注有限场景下的WSI生存建模提供了一种可扩展方案。代码见:https://github.com/yihuangswust-alt/SSL-Morph_MIL。
Pancreatic ductal adenocarcinoma (PDAC) is characterized by high malignancy and poor prognosis. However, chemotherapy remains the cornerstone of its treatment. Through transcriptomic analysis of gemcitabine-treated PDAC cells, we identified TRDMT1, rather than other known 5-methylcytosine (m5C) methyltransferases, as a principal regulator of mRNA m5C methylation. TRDMT1 deficiency attenuated the malignant phenotype of PDAC cells and increased their sensitivity to gemcitabine, 5-fluorouracil, oxaliplatin, and irinotecan. Furthermore, deletion of TRDMT1 impaired the recruitment of homologous recombination-related proteins, including BRCA1, RAD51, and RAD52. Analysis of mRNA m5C modification sequencing in TRDMT1-deficient PDAC cells demonstrated that IRS2 exhibited significantly reduced m5C methylation levels and decreased expression. The IRS2/PI3K/AKT axis was identified as the potential downstream signaling pathway through which TRDMT1 mediated the chemotherapeutic response. Survival data from patients with PDAC, and findings from TRDMT1-deficient mouse models, further supported the role of TRDMT1 in reducing chemosensitivity. Collectively, these findings indicate that TRDMT1-mediated mRNA m5C methylation is essential for homologous recombination repair in PDAC and suggest that TRDMT1 may represent a potential therapeutic target for overcoming chemoresistance.
中文摘要:胰腺导管腺癌(PDAC)恶性程度高、预后差,化疗仍是其治疗基石。通过对吉西他滨处理的PDAC细胞进行转录组分析,我们发现TRDMT1而非其他已知的5-甲基胞嘧啶(m5C)甲基转移酶,是mRNA m5C甲基化的主要调控因子。TRDMT1缺失削弱PDAC细胞的恶性表型,并提高其对吉西他滨、5-氟尿嘧啶、奥沙利铂和伊立替康的敏感性。TRDMT1缺失还损害同源重组相关蛋白BRCA1、RAD51和RAD52的招募。对TRDMT1缺陷PDAC细胞的mRNA m5C修饰测序分析显示,IRS2的m5C甲基化水平显著降低,表达下降。IRS2/PI3K/AKT轴被确定为TRDMT1介导化疗反应的潜在下游信号通路。PDAC患者的生存数据和TRDMT1缺陷小鼠模型的结果进一步支持TRDMT1降低化疗敏感性的作用。这些发现表明TRDMT1介导的mRNA m5C甲基化对PDAC同源重组修复至关重要,并提示TRDMT1可能成为克服化疗耐药的潜在治疗靶点。
5肺癌 (17篇)
临床研究 (9篇)
P-loop and αC-helix compressing (PACC) mutations comprise a structurally distinct subgroup of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) with limited treatment options. Firmonertinib is a once-daily oral, brain-penetrant, mutant-selective EGFR tyrosine kinase inhibitor with a unique trifluoroethoxy side chain. Firmonertinib had high anti-proliferative efficacy in EGFR PACC-mutant cells and xenografts. In the phase 1b FURTHER study (NCT05364073), patients with metastatic EGFR PACC-mutant NSCLC randomized to receive first-line firmonertinib 160 mg (n = 25) or 240 mg (n = 22) had confirmed objective response rates (ORRs) of 43% and 68%, median duration of response not reached and 14.6 months, and median progression-free survival of 11.1 and 16.0 months, respectively; treatment-related adverse events led to dose reductions (19% and 24%) and discontinuation (3% and 0%). Intracranial ORR among patients with brain metastases at baseline was 47% (8/17). Results support further study of first-line firmonertinib in patients with EGFR PACC-mutant NSCLC.
中文摘要:P环和αC螺旋压缩(PACC)突变是非小细胞肺癌(NSCLC)中表皮生长因子受体(EGFR)突变的一个结构上独特的亚组,治疗选择有限。firmonertinib是一种每日一次口服、可穿透血脑屏障、突变选择性EGFR酪氨酸激酶抑制剂,具有独特的三氟乙氧基侧链。firmonertinib在EGFR PACC突变细胞和异种移植模型中表现出高抗增殖活性。在1b期FURTHER研究(NCT05364073)中,转移性EGFR PACC突变NSCLC患者随机接受一线firmonertinib 160 mg(n=25)或240 mg(n=22)治疗,确认的客观缓解率(ORR)分别为43%和68%,中位缓解持续时间分别为未达到和14.6个月,中位无进展生存期分别为11.1和16.0个月;治疗相关不良事件导致剂量降低(19%和24%)和停药(3%和0%)。基线有脑转移的患者颅内ORR为47%(8/17)。结果支持进一步研究一线firmonertinib用于EGFR PACC突变NSCLC患者。
EGFR PACC-mutant non-small cell lung cancer (NSCLC) has limited treatment options. In this issue of Cancer Cell, Le et al. report preclinical profiles and promising systemic and intracranial efficacy of the broad-spectrum CNS-penetrant tyrosine kinase inhibitor firmonertinib in PACC-mutant NSCLC, supporting its further clinical development in this challenging mutation class.
中文摘要:EGFR PACC突变非小细胞肺癌(NSCLC)的治疗选择有限。在本期 Cancer Cell 中,Le 等报告了广谱、可透过血脑屏障的酪氨酸激酶抑制剂 firmonertinib 的临床前特征,以及其在 PACC 突变 NSCLC 中令人鼓舞的全身和颅内疗效,支持在这一具有挑战性的突变类别中进一步开展临床开发。
The association between lichen planus (LP) and subsequent cancer risk, particularly by anatomical site, is not well established. To assess the association between any LP, and site-specific LP, and the subsequent risk of cancer compared to the general population. This was a retrospective cohort study using nationwide Danish register-based data of individuals with an incident LP diagnosis (1978-2020), with no prior cancer, identified through the National Patient Register (any LP) and the Danish Pathology Register (any LP and site-specific LP). Data were analyzed from August 20 to December 20, 2025. Any diagnosis of LP independent of site, and LP at specific anatomical sites (oral, cutaneous, and genital). Participants were followed up for incident cancer outcomes until death, emigration, or December 31, 2023. Cancers were identified through the Danish Cancer Register. Standardized incidence ratios (SIRs) with 95% CIs were calculated separately for females and males, comparing cancer incidence in patients with LP to the general Danish female or male population. A total of 35 845 patients with LP (21 650 females and 14 195 males) were included in the analysis. Compared to the general population, females with any LP had increased risk of oral cancers (lip, SIR = 6.0; 95% CI, 3.3-10.0; oral cavity, SIR = 7.5; 95% CI, 6.4-8.9; tongue, SIR = 6.8; 95% CI, 5.4-8.4) and vulvar cancer (SIR = 2.6; 95% CI, 2.0-3.4), while the risk of squamous cell carcinoma was slightly elevated (SIR = 1.4; 95% CI, 1.3-1.6). In contrast, lung cancer risk was decreased (SIR = 0.7; 95% CI, 0.6-0.8). Results were consistent across follow-up. The cancer risk pattern was similar in male patients with LP. Site-specific analyses showed the highest risk of oral cancers in patients with oral LP, and of genital cancer in patients with genital LP. The 20-year absolute risks in female and male patients were 0.8% (95% CI, 0.7%-1.0%) and 1.0% (95% CI, 0.8-1.2) for oral cavity cancers, 0.5% (95% CI, 0.4%-0.6%) and 0.6% (95% CI, 0.5%-0.8%) for tongue cancers, 0.1% (95% CI, 0%-0.1%) and 0.2% (95% CI, 0.1%-0.3%) for lip cancers, and 0.4% (95% CI, 0.2%-0.5%) and 0.2% (95% CI, 0.1%-0.2%) for genital cancers, respectively. In this cohort study, LP was associated with markedly increased risks of oral and genital cancers, as well as a slightly increased risk of skin cancer, particularly at sites corresponding to the anatomical LP location. While the absolute risk is low, site-specific cancer should be considered a possible long-term complication of LP.
中文摘要:扁平苔藓(LP)与后续癌症风险的关联,尤其是按解剖部位区分的风险,尚未充分明确。研究比较任何LP及部位特异性LP患者与普通人群的后续癌症风险。这是一项回顾性队列研究,使用丹麦全国登记资料,纳入1978至2020年间新诊断LP且此前无癌症的个体,经国家患者登记(任何LP)与丹麦病理登记(任何LP及部位特异性LP)识别。数据分析时间为2025年8月20日至12月20日。暴露为不区分部位的LP诊断,以及特定解剖部位(口腔、皮肤、生殖器)的LP。随访至死亡、移居或2023年12月31日,观察癌症发生。癌症经丹麦癌症登记识别。按女性与男性分别计算标准化发病比(SIR)及95% CI,将LP患者的癌症发病率与丹麦普通女性或男性人群比较。共纳入35 845例LP患者(女性21 650例,男性14 195例)。与普通人群相比,任何LP的女性唇癌风险升高(SIR=6.0;95% CI 3.3-10.0),口腔癌SIR=7.5(95% CI 6.4-8.9),舌癌SIR=6.8(95% CI 5.4-8.4),外阴癌SIR=2.6(95% CI 2.0-3.4),鳞状细胞癌风险轻度升高(SIR=1.4;95% CI 1.3-1.6)。肺癌风险则降低(SIR=0.7;95% CI 0.6-0.8)。各随访阶段结果一致。男性LP患者的癌症风险模式相似。部位特异性分析显示,口腔LP患者口腔癌风险最高,生殖器LP患者生殖器癌风险最高。女性和男性患者20年绝对风险分别为:口腔癌0.8%(95% CI 0.7%-1.0%)与1.0%(95% CI 0.8-1.2),舌癌0.5%(95% CI 0.4%-0.6%)与0.6%(95% CI 0.5%-0.8),唇癌0.1%(95% CI 0%-0.1%)与0.2%(95% CI 0.1%-0.3%),生殖器癌0.4%(95% CI 0.2%-0.5%)与0.2%(95% CI 0.1%-0.2)。该队列研究中,LP与口腔癌和生殖器癌风险明显升高相关,皮肤癌风险轻度升高,且主要见于与LP解剖部位相对应的部位。绝对风险虽低,部位特异性癌症应视为LP可能的长期并发症。
Definitive chemoradiotherapy followed by immunotherapy consolidation is the current standard of care for limited-stage small cell lung cancer (LS-SCLC). We conducted a randomized phase II trial (ChiCTR2000032275) to evaluate a camrelizumab-based induction-consolidation strategy in previously untreated patients with LS-SCLC. Patients were randomly assigned (1:1) to receive induction camrelizumab plus etoposide-platinum followed by concurrent chemoradiotherapy (CRT) and camrelizumab consolidation (camrelizumab group), or induction chemotherapy followed by concurrent CRT alone (cCRT group). The primary endpoint was the 1‑year progression‑free survival (PFS) rate. Secondary endpoints included objective response rate (ORR), PFS, overall survival (OS), and safety. Between November 2020 and April 2024, 41 patients were enrolled. At a median follow‑up of 32.1 months (interquartile range [IQR]: 26.4-38.7), ORR was 100% in the camrelizumab group and 83.3% in the cCRT group. The 1‑year PFS rates were 65.5% with camrelizumab versus 47.4% with cCRT (P = 0.029). Median PFS was 24.0 months versus 11.8 months, and median OS was not reached versus 23.9 months (P = 0.042). Exploratory biomarker analyses indicated that patients with lower baseline systemic inflammatory indices, including neutrophil-to-lymphocyte ratio <2.8 and platelet-to-lymphocyte ratio <207.0, and those with a decline in lactate dehydrogenase at week 12 after CRT, derived greater benefit from camrelizumab. The OS benefit was also more evident in patients with Ki-67 ≤80%. Toxicities in the camrelizumab group were manageable, with a low incidence of severe immune-related adverse events (4.8%), and radiation pneumonitis rates were comparable between groups. Taken together, induction camrelizumab combined with chemotherapy, followed by CRT and camrelizumab consolidation, significantly improved survival outcomes in LS-SCLC, with a manageable safety profile, warranting further validation for this aggressive malignancy.
中文摘要:局限期小细胞肺癌(LS-SCLC)现行标准治疗为根治性放化疗后行免疫巩固治疗。本研究开展一项随机II期试验(ChiCTR2000032275),评估以卡瑞利珠单抗为基础的诱导-巩固策略在初治LS-SCLC患者中的疗效。患者按1:1随机分配,接受卡瑞利珠单抗联合依托泊苷-铂类诱导治疗,随后行同步放化疗(CRT)及卡瑞利珠单抗巩固治疗(卡瑞利珠单抗组),或接受诱导化疗后行单纯同步CRT(cCRT组)。主要终点为1年无进展生存(PFS)率。次要终点包括客观缓解率(ORR)、PFS、总生存(OS)及安全性。2020年11月至2024年4月共入组41例患者。中位随访32.1个月(四分位距[IQR]:26.4-38.7),卡瑞利珠单抗组ORR为100%,cCRT组为83.3%。1年PFS率卡瑞利珠单抗组为65.5%,cCRT组为47.4%(P=0.029)。中位PFS分别为24.0个月与11.8个月,中位OS卡瑞利珠单抗组未达到,cCRT组为23.9个月(P=0.042)。探索性生物标志物分析提示,基线全身炎症指标较低者,包括中性粒细胞与淋巴细胞比值<2.8和血小板与淋巴细胞比值<207.0,以及CRT后第12周乳酸脱氢酶下降者,从卡瑞利珠单抗治疗中获益更多。Ki-67≤80%患者的OS获益也更明显。卡瑞利珠单抗组毒性可管理,严重免疫相关不良事件发生率低(4.8%),两组放射性肺炎发生率相当。卡瑞利珠单抗联合化疗诱导,继以CRT及卡瑞利珠单抗巩固治疗,可显著改善LS-SCLC患者的生存结局,安全性可控,这一侵袭性恶性肿瘤的治疗方案值得进一步验证。
Lung cancer is a heterogeneous disease, and while targeted therapies and immunotherapies have improved patient outcomes, 5-year overall survival remains poor at approximately 20%. Antibody-drug conjugates (ADCs) target tumors using a targeted antibody that delivers a cytotoxic payload with clinically proven antitumor activity, and over a dozen ADCs are under consideration for solid tumors. Recent clinical trial data in metastatic non-small cell lung cancer have led to FDA approval of three ADCs: trastuzumab deruxtecan for patients with human epidermal growth factor receptor 2-mutated disease, telisotuzumab vedotin for MET-overexpressing tumors, and datopotamab deruxtecan for patients with epidermal growth factor receptor-mutated disease. In this article, we review the trajectory of individual ADC targets in lung cancer, describe the latest clinical trial results, and discuss future innovations in ADC therapies and potential mechanisms of resistance.
中文摘要:肺癌异质性强,靶向治疗与免疫治疗虽已改善患者预后,5年总生存率仍仅约20%。抗体偶联药物(ADC)以靶向抗体为载体,将细胞毒性载荷递送至肿瘤,其抗肿瘤活性已有临床证据支持,目前十余种ADC正在实体瘤中接受评估。近期转移性非小细胞肺癌的临床试验数据促成三款ADC获FDA批准:德曲妥珠单抗用于人表皮生长因子受体2突变患者,telisotuzumab vedotin用于MET过表达肿瘤,datopotamab deruxtecan用于表皮生长因子受体突变患者。文章梳理各ADC靶点在肺癌中的演进过程,介绍最新临床试验结果,并讨论ADC治疗的未来创新与潜在耐药机制。
Small cell lung cancer (SCLC) has a poor prognosis despite standard first-line chemoimmunotherapy. Reliable, non-invasive biomarkers for risk stratification are urgently needed. Three-dimensional (3D) body composition (BC) analysis from chest CT scans offers a promising approach to assess systemic metabolic status. In this multicenter study, we analyzed patients treated with first-line chemoimmunotherapy across five institutions. Using a deep learning model, 3D BC parameters were automatically extracted from baseline chest CTs. We evaluated their associations with overall survival (OS) and progression-free survival using Kaplan-Meier and Cox regression analyses. A total of 101 machine learning model configurations were evaluated to develop predictive models, and the SHapley Additive exPlanations method was applied to enhance model interpretability. Additionally, we investigated the association between BC parameters and CD8+ T-cell infiltration in the tumor microenvironment. Among 575 patients (training: 161; internal validation: 69; external validation: 345), all four 3D BC indices significantly stratified OS. Multivariable Cox analysis showed that higher skeletal muscle volume index was independently associated with better OS (HR=0.956, 95% CI 0.928 to 0.985, p=0.003), whereas higher visceral fat volume index was associated with worse OS (HR=1.017, 95% CI 1.002 to 1.032, p=0.026). 3D BC provided more pronounced prognostic stratification than conventional two-dimensional measures and body mass index. The selected linear discriminant analysis model achieved area under the curves of 0.756, 0.781, and 0.783 in the training, internal validation, and external validation cohorts, respectively. In an exploratory subset of 35 patients, higher skeletal muscle volume index was associated with increased intratumoral CD8+T cell density. Higher skeletal muscle volume index was associated with better OS, whereas higher visceral fat volume index was associated with worse OS. Automated 3D BC may provide complementary non-invasive prognostic information in patients with SCLC receiving first-line chemoimmunotherapy.
中文摘要:小细胞肺癌(SCLC)即使接受标准一线化疗联合免疫治疗,预后仍差。临床迫切需要可靠、无创的风险分层生物标志物。基于胸部CT的三维(3D)身体成分分析为评估全身代谢状态提供了有前景的方法。这项多中心研究分析了五家机构接受一线化疗联合免疫治疗的患者。采用深度学习模型从基线胸部CT自动提取3D身体成分参数。通过Kaplan-Meier和Cox回归分析评估这些参数与总生存期(OS)和无进展生存期的关联。共评估101种机器学习模型配置以构建预测模型,并应用SHAP方法提高模型可解释性。还考察了身体成分参数与肿瘤微环境中CD8+ T细胞浸润的关联。575例患者(训练集161例,内部验证69例,外部验证345例)中,四项3D身体成分指标均能显著对OS进行分层。多变量Cox分析显示,较高的骨骼肌体积指数与更好的OS独立相关(HR=0.956,95% CI 0.928~0.985,p=0.003),较高的内脏脂肪体积指数与更差的OS相关(HR=1.017,95% CI 1.002~1.032,p=0.026)。3D身体成分的预后分层效果比传统二维指标和体重指数更明显。所选线性判别分析模型在训练集、内部验证集和外部验证集的曲线下面积分别为0.756、0.781和0.783。在35例患者的探索性亚组中,较高的骨骼肌体积指数与更高的瘤内CD8+ T细胞密度相关。较高的骨骼肌体积指数与更好的OS相关,较高的内脏脂肪体积指数与更差的OS相关。自动3D身体成分分析可为接受一线化疗联合免疫治疗的SCLC患者提供补充性无创预后信息。
Radiation therapy (RT) is highly efficacious in treating thoracic malignancies. However, RT has been linked to potential cardiotoxicity. Yet, the long-term incidence, severity, and implications of HTN-development post-RT are unknown. Leveraging a large US-based Comprehensive-Cancer-Center-cohort of patients treated with thoracic-RT from 2007 to 2019, we included patients ≥18 years old with histologically confirmed esophageal or lung cancers. The primary outcome was incidence of incident/new or worsened HTN [systolic-blood-pressure-(SBP) ≥130 mmHg] after RT-initiation. The secondary outcomes were major-adverse-cardiac-events (MACE- heart-failure, myocardial-infarction, arrhythmia, stroke, and sudden-death), disease-progression, and overall-survival, by HTN-status. Differences in outcomes by HTN-status were also evaluated via landmark-analysis, excluding those with undiagnosed HTN. Observed new HTN rates were compared to Framingham-predicted-rates, and absolute-excess-risks were estimated. Multivariate regression was used to define the relation between clinical and RT measures and both new or worsened HTN-development and survival-outcomes. Overall, 439 RT-treated patients (238 esophageal; 201 lung; 66.7% male; mean age 63.6 years; 65% baseline HTN) were identified. Over a median follow-up of 23 months, 255 (58.1%) developed new or worsened HTN; median SBP increase of 7 mmHg. In landmark-analysis, the cumulative incidence of new or worsened HTN by 1-year was 48.0% and 63.4%, respectively. Using the JNC-8 cutoff of ≥140/90 mmHg, the new HTN rate was 21.6% at 1-year, translating to a 3.4-fold higher rate than the Framingham-predicted-rate (RR 3.37, P < 0.001). In multivariate regression, RT-dose was consistently associated with new or worsened HTN-development (P < 0.05); those with RT-induced-HTN saw improved progression-free-survival and overall-survival (HR 0.67 and 0.54, P < 0.01, respectively). Beyond traditional factors, only RT-dose is consistently associated with MACE (P < 0.05). No specific antihypertensive class prevented RT-related HTN. These data suggest that thoracic-RT increases early HTN risk.
中文摘要:放疗对胸部恶性肿瘤具有较高疗效,但可能与心脏毒性相关。胸部放疗后发生高血压的长期发生率、严重程度及影响仍不清楚。研究利用美国一家大型综合癌症中心2007年至2019年接受胸部放疗的患者队列,纳入年龄≥18岁、经组织学确诊的食管癌或肺癌患者。主要结局为放疗开始后新发或加重高血压(收缩压≥130 mmHg)的发生率。次要结局按高血压状态评价主要不良心脏事件(心力衰竭、心肌梗死、心律失常、卒中及猝死)、疾病进展和总生存。还通过landmark分析排除未确诊高血压者,评估不同高血压状态下的结局差异。将观察到的新发高血压率与Framingham预测率比较,并估计绝对超额风险。多因素回归用于分析临床因素和放疗指标与新发或加重高血压及生存结局的关系。共纳入439例接受放疗的患者(食管癌238例,肺癌201例;男性66.7%;平均年龄63.6岁;基线高血压65%)。中位随访23个月期间,255例(58.1%)出现新发或加重高血压;收缩压中位升高7 mmHg。landmark分析中,新发和加重高血压的1年累积发生率分别为48.0%和63.4%。按JNC-8的≥140/90 mmHg界值,1年新发高血压率为21.6%,为Framingham预测率的3.4倍(RR 3.37,P < 0.001)。多因素回归中,放疗剂量与新发或加重高血压持续相关(P < 0.05);出现放疗相关高血压者无进展生存和总生存更好(HR 0.67和0.54,P < 0.01)。在传统因素之外,仅放疗剂量与主要不良心脏事件持续相关(P < 0.05)。未发现特定降压药类别可预防放疗相关高血压。这些数据提示胸部放疗增加早期高血压风险。
Patients with non-small cell lung cancer (NSCLC) and brain metastases whose tumors lack EGFR, ALK, or ROS1 alterations have heterogeneous outcomes and limited evidence to guide treatment intensity. We assessed whether Lung-molGPA could stratify prognosis and inform treatment selection in this population. This retrospective two-center cohort included 811 patients with EGFR/ALK/ROS1-wild-type NSCLC treated between September 2013 and August 2022. Overall survival (OS) was evaluated using Kaplan-Meier methods and center-stratified multivariable Cox regression across three Lung-molGPA strata and treatment modalities. Median OS was 6.9 months (95% confidence interval [CI], 6.4-7.4) overall and 4.81 (4.20-5.30), 7.65 (6.73-8.40), and 16.00 (13.40-22.90) months in the Lung-molGPA 0-1.0, 1.5-2.0, and 2.5-3.0 groups, respectively (p < 0.001). Compared with the 0-1.0 group, adjusted mortality was lower in the 1.5-2.0 (hazard ratio [HR], 0.68; 95% CI, 0.58-0.80) and 2.5-3.0 groups (HR, 0.39; 95% CI, 0.30-0.50). Chemotherapy, immunotherapy, antiangiogenic therapy, and brain- and chest-directed local therapy were independently associated with lower mortality, although their associations varied across prognostic strata and treatment contexts. Lung-molGPA provides clinically meaningful prognostic separation and may help tailor treatment intensity for EGFR/ALK/ROS1-wild-type NSCLC with brain metastases.
中文摘要:在非小细胞肺癌(NSCLC)脑转移患者中,肿瘤缺乏EGFR、ALK或ROS1变异的群体结局差异较大,治疗强度的选择缺乏证据支持。本研究评估Lung-molGPA能否在该人群中区分预后并指导治疗选择。这项回顾性双中心队列纳入2013年9月至2022年8月治疗的811例EGFR/ALK/ROS1野生型NSCLC患者。采用Kaplan-Meier法及按中心分层的多因素Cox回归,在三个Lung-molGPA分层及不同治疗方式间评估总生存(OS)。全组中位OS为6.9个月(95%置信区间[CI] 6.4-7.4),Lung-molGPA 0-1.0、1.5-2.0与2.5-3.0组分别为4.81个月(4.20-5.30)、7.65个月(6.73-8.40)和16.00个月(13.40-22.90)(p < 0.001)。与0-1.0组相比,1.5-2.0组(风险比[HR] 0.68;95% CI 0.58-0.80)与2.5-3.0组(HR 0.39;95% CI 0.30-0.50)的校正后死亡风险更低。化疗、免疫治疗、抗血管生成治疗以及针对脑和胸部的局部治疗均与较低死亡风险独立相关,但其相关性在不同预后分层和治疗情境中存在差异。Lung-molGPA可提供有临床意义的预后区分,并可能有助于为EGFR/ALK/ROS1野生型NSCLC脑转移患者调整治疗强度。
Leaky blood vessels are a hallmark of solid tumors. However, the molecular mechanisms and clinical implications of vascular leakage in human cancer remain unexplored. Here, we identified fibrinopeptide-A (FpA) as a robust in-situ marker of vascular leakage, analyzing diagnostic specimens from two non-small cell lung cancer (NSCLC) cohorts (N = 327 and N = 200). Mechanistically, FpA+ staining localized to discrete stromal niches characterized by increased endothelial VEGF receptor-2 phosphorylation, elevated VEGFA production by tumor cells and loss of the endothelial tyrosine phosphatase PTPRB. Immune profiling revealed reduced density of mature dendritic cells and granzyme B-expressing cytotoxic T cells in tumors with high-leakage. This leakage-associated immunosuppression was linked to the presence of tertiary lymphoid structures (TLS) in lung adenocarcinoma (LUAD). However, compared to low-leakage, TLS in high-leakage tumors were enriched in regulatory T cells and conferred no survival advantage. Patients with high vascular leakage exhibited a reduced overall survival. Moreover, in a separate immunotherapy cohort (N = 64), high-leakage was associated with poor response to anti-PD-1/PD-L1 treatment. This study establishes vascular leakage as an important prognostic factor in NSCLC, and provides mechanistic understanding and a methodological framework to stratify NSCLC patients with regard to responsiveness to immunotherapy.
中文摘要:渗漏血管是实体瘤的标志,但人类癌症中血管渗漏的分子机制和临床意义仍未得到探索。本研究将纤维蛋白肽A(FpA)鉴定为血管渗漏的可靠原位标志物,并分析了两组非小细胞肺癌(NSCLC)队列的诊断标本(N=327和N=200)。机制上,FpA+染色定位于离散的间质微环境,其特征为内皮VEGF受体-2磷酸化增加、肿瘤细胞VEGFA产生升高以及内皮酪氨酸磷酸酶PTPRB缺失。免疫分析显示,高渗漏肿瘤中成熟树突状细胞和表达颗粒酶B的细胞毒性T细胞密度降低。这种与渗漏相关的免疫抑制与肺腺癌(LUAD)中三级淋巴结构(TLS)的存在相关。然而,与低渗漏相比,高渗漏肿瘤中的TLS富含调节性T细胞,并未带来生存优势。高血管渗漏患者的总生存期缩短。在另一组免疫治疗队列(N=64)中,高渗漏与抗PD-1/PD-L1治疗反应差相关。本研究确立血管渗漏是NSCLC的重要预后因素,并为按免疫治疗反应性对NSCLC患者分层提供了机制理解和方法学框架。
基础研究 (8篇)
Mitophagy, the selective degradation of mitochondria by lysosomes, is a major mitochondrial quality-control pathway, yet its role in lung cancer initiation and therapeutic response remains poorly understood. We investigated PINK1-dependent mitophagy in human lung adenocarcinoma and directly monitored mitophagy in vivo using mito-QC reporter mice during lung tumor development. We found that PINK1 activity and mitophagy are increased in human tumors and are activated from the earliest stages of tumorigenesis. Genetic inhibition of PINK1 impaired oncogenic transformation but had little impact once tumor cells were established, identifying mitophagy as a critical early adaptation during lung cancer initiation. PINK1 deficiency markedly enhanced the efficacy of KRAS-targeted therapy in vitro and in vivo. Together, our findings identify PINK1-dependent mitophagy as an early vulnerability in KRAS-driven lung cancer and provide a rationale for targeting mitophagy to improve the efficacy of KRAS-targeted therapies.
中文摘要:线粒体自噬是线粒体经溶酶体选择性降解的过程,是线粒体质量控制的主要途径,但其在肺癌发生和治疗反应中的作用仍不清楚。我们研究了人肺腺癌中PINK1依赖的线粒体自噬,并使用mito-QC报告小鼠在肺肿瘤发生过程中直接监测体内线粒体自噬。发现PINK1活性和线粒体自噬在人肿瘤中升高,并在肿瘤发生最早阶段被激活。遗传抑制PINK1可削弱致癌转化,但肿瘤细胞形成后影响很小,表明线粒体自噬是肺癌发生中的关键早期适应。PINK1缺失在体外和体内显著增强KRAS靶向治疗的疗效。这些发现将PINK1依赖的线粒体自噬确定为KRAS驱动肺癌的早期弱点,并为靶向线粒体自噬以提高KRAS靶向治疗疗效提供依据。
Small cell lung cancer (SCLC) remains one of the most lethal malignancies, with a 5-year survival of <10% despite advances in treatment. Seizure-related gene 6 (SEZ6), a type I transmembrane protein preferentially expressed in neuroendocrine tumors, has recently emerged as a promising therapeutic target, supported by clinical activity of SEZ6-targeted antibody-drug conjugates in relapsed SCLC. In this study, we developed and evaluated a humanized anti-SEZ6 monoclonal antibody for SEZ6-targeted positron emission tomography imaging and α-particle radioimmunotherapy. Immunohistochemistry of patient tissues confirmed strong, stage-independent SEZ6 expression. Cell-based studies demonstrated high SEZ6 receptor densities, supporting high-affinity antibody binding and rapid receptor-mediated internalization. [89Zr]Zr-DFO-SEZ6-Ab administered at low antibody mass exhibited rapid hepatosplenic clearance with minimal tumor uptake despite high intratumoral levels. This pattern was consistent with active ectodomain shedding and local accumulation of soluble antigen within the tumor microenvironment, creating an extracellular antigen sink and limiting effective target engagement. Increasing the antibody mass overcame this barrier, dramatically increasing tumor uptake in xenografts. Treatment with [225Ac]Ac-Macropa-SEZ6-Ab induced complete tumor regression, whereas coadministration of the ATR inhibitor berzosertib enhanced efficacy at lower radioactivity doses without added toxicity. Together, these findings identify tumor-localized SEZ6 shedding as a biological barrier to SEZ6-targeted therapy, define dosing strategies to overcome it, and demonstrate potent antitumor activity of SEZ6-directed α-particle radioimmunotherapy in SCLC. Dosing strategies that overcome antigen sink effects induced by a tumor-localized ectodomain shedding enable SEZ6-based imaging and theranostics in small cell lung cancer.
中文摘要:小细胞肺癌仍是最致命的恶性肿瘤之一,尽管治疗已有进展,5年生存率仍低于10%。癫痫相关基因6(SEZ6)是一种优先在神经内分泌肿瘤中表达的I型跨膜蛋白,近期因SEZ6靶向抗体偶联药物在复发小细胞肺癌中显示临床活性而成为有前景的治疗靶点。本研究开发并评估了一种人源化抗SEZ6单克隆抗体,用于SEZ6靶向正电子发射断层成像和α粒子放射免疫治疗。患者组织免疫组化证实SEZ6强表达,且表达与分期无关。细胞研究显示SEZ6受体密度高,支持高亲和力抗体结合和快速的受体介导内化。低抗体质量给药的[89Zr]Zr-DFO-SEZ6-Ab表现为肝脾清除迅速,尽管瘤内水平较高,肿瘤摄取却很低。这一模式与活跃的胞外域脱落及可溶性抗原在肿瘤微环境中的局部蓄积一致,形成细胞外抗原池并限制有效的靶点结合。提高抗体质量可克服这一屏障,使异种移植瘤中的肿瘤摄取显著增加。[225Ac]Ac-Macropa-SEZ6-Ab治疗诱导肿瘤完全消退,在较低放射性剂量下联合ATR抑制剂berzosertib可增强疗效,且未增加毒性。这些结果将肿瘤局部SEZ6脱落确定为SEZ6靶向治疗的生物学屏障,明确了克服该屏障的给药策略,并证明SEZ6导向的α粒子放射免疫治疗在小细胞肺癌中具有强效抗肿瘤活性。克服肿瘤局部胞外域脱落所致抗原池效应的给药策略,使基于SEZ6的成像和诊疗一体化在小细胞肺癌中成为可能。
Limited intratumoral persistence and insufficient proliferative capacity severely restrict the efficacy of chimeric antigen receptor (CAR) T-cell therapies in solid tumors. In this study, we demonstrated that DLL3-targeting CAR T cells co-expressing a CD56 chimeric switch receptor and incorporating parallel 4-1BB costimulatory signaling (DBBζ.CBB) effectively address these limitations. In preclinical small cell lung cancer models, DBBζ.CBB exhibited sustained tumor infiltration, prolonged persistence, and superior antitumor activity. Mechanistically, parallel 4-1BB signaling dynamically programmed CAR T-cell fate by promoting early expansion and memory maintenance, driving a highly proliferative effector state at the intermediate stage, and delaying terminal exhaustion at the later stage, thereby sustaining in vivo persistence and enabling durable antitumor responses. Building upon the intratumoral T-cell pool established by DBBζ.CBB, subsequent DLL3 trispecific T-cell engager administration synergistically enhanced tumor eradication by further boosting CD8+ T-cell infiltration and overall activation while mitigating exhaustion and terminal differentiation. Collectively, these findings establish a clinically translatable combinatorial framework to enhance the efficacy and durability of CAR T therapy in solid tumors. Incorporation of parallel 4-1BB signaling enhances the persistence and proliferation of DLL3/CD56 CAR T cells and enables effective synergy with DLL3 trispecific T-cell engager for eradication in small cell lung cancer.
中文摘要:瘤内持久性不足和增殖能力有限严重制约嵌合抗原受体(CAR)T细胞疗法在实体瘤中的疗效。本研究报告,靶向DLL3的CAR T细胞共表达CD56嵌合转换受体并整合平行4-1BB共刺激信号(DBBζ.CBB),可有效克服上述限制。在临床前小细胞肺癌模型中,DBBζ.CBB表现出持续的肿瘤浸润、延长的持久性和更优的抗肿瘤活性。机制上,平行4-1BB信号动态编程CAR T细胞命运,促进早期扩增和记忆维持,在中间阶段驱动高增殖效应状态,在后期延迟终末耗竭,从而维持体内持久性并实现持久的抗肿瘤应答。在DBBζ.CBB建立的瘤内T细胞池基础上,后续给予DLL3三特异性T细胞衔接器可协同增强肿瘤清除,进一步增加CD8+ T细胞浸润和整体活化,同时减轻耗竭和终末分化。这些结果建立了一个可临床转化的联合框架,用于提高CAR T疗法在实体瘤中的疗效和持久性。整合平行4-1BB信号可增强DLL3/CD56 CAR T细胞的持久性和增殖能力,并使其与DLL3三特异性T细胞衔接器有效协同,以清除小细胞肺癌。
Diet rich in fat, such as high-fat diet (HFD) and ketogenic diet (KD), has complex impacts on immunity. Neutrophils adapt to tissue-specific signals and exert innate defense functions against infections and malignancies. However, whether and how dietary fat shapes tissue-specific neutrophil functions remains unclear. This study aims at determining the effect of dietary fat on tissue-specific pulmonary antitumor responses mediated by neutrophils. Mouse models of HFD or KD feeding, in combination with a lung metastatic B16 melanoma or a primary Lewis lung carcinoma lung cancer model, were used to determine the impact of dietary fat on pulmonary tissue-specific reprogramming of antitumor functions in neutrophils. A multitude of experimental approaches were used to address the mechanisms through which HFD/KD boosts antitumor functions of intrapulmonary neutrophils. We also performed correlation analysis between immune activation signatures in human lung cancer-infiltrating neutrophils and serum lipids, and analyzed published single-cell transcription data in human lungs, to determine the potential correlation between serum lipid contents or endothelial cell-derived signals and antitumor functions of lung neutrophils. Both HFD-fed and KD-fed mice demonstrated enhanced neutrophil-mediated pulmonary tumor resistance compared with chow diet-fed mice, in either a prophylactic or a therapeutic setting. Intrapulmonary, but not systemic, neutrophils in HFD/KD-fed mice exhibited enhanced potential for reactive oxygen species (ROS) production and ROS-dependent tumor cytotoxicity. Mechanistically, HFD/KD-induced increased serum palmitic acid (PA) and cholesterol stimulate lung vascular endothelial cells (LVECs), which reprogram neutrophils via contact-dependent and intercellular adhesion molecule-1-dependent mechanisms. In humans, increased serum cholesterol levels are associated with increased myeloperoxidase contents in lung cancer-infiltrating neutrophils, and intensified adhesion and priming signals from human LVECs are potentially associated with immune activation in intrapulmonary neutrophils. These data suggest that dietary fat boosts lung tissue-specific antitumor immunity mediated by neutrophils with an enhanced potential for ROS production, which are primed by LVECs stimulated by elevated serum PA and cholesterol. Our findings highlight the roles of dietary fats in shaping neutrophil functions in a tissue-specific manner. Dietary intervention targeting tissue-specific reprogramming of neutrophils, therefore, represents a potential strategy against malignancies in the lungs.
中文摘要:富含脂肪的饮食如高脂饮食(HFD)和生酮饮食(KD)对免疫具有复杂影响。中性粒细胞适应组织特异性信号,并对感染和恶性肿瘤发挥固有防御功能。膳食脂肪是否以及如何塑造组织特异性中性粒细胞功能仍不清楚。本研究旨在确定膳食脂肪对中性粒细胞介导的肺组织特异性抗肿瘤反应的影响。研究采用HFD或KD喂养小鼠,并结合B16黑色素瘤肺转移模型或Lewis肺癌原发模型,以确定膳食脂肪对中性粒细胞抗肿瘤功能的肺组织特异性重编程的影响。研究使用多种实验方法探讨HFD/KD增强肺内中性粒细胞抗肿瘤功能的机制。研究还分析了人肺癌浸润中性粒细胞中的免疫激活特征与血清脂质之间的相关性,并分析已发表的人肺单细胞转录数据,以确定血清脂质含量或内皮细胞来源信号与肺中性粒细胞抗肿瘤功能之间的潜在相关性。与普通饲料喂养小鼠相比,HFD喂养和KD喂养小鼠在预防性或治疗性设置中均表现出增强的中性粒细胞介导的肺部肿瘤抵抗。HFD/KD喂养小鼠的肺内而非全身中性粒细胞表现出增强的活性氧(ROS)产生潜力和ROS依赖性肿瘤细胞毒性。机制上,HFD/KD诱导的血清棕榈酸(PA)和胆固醇升高刺激肺血管内皮细胞(LVEC),后者通过接触依赖性和细胞间黏附分子-1依赖性机制重编程中性粒细胞。在人类中,血清胆固醇水平升高与肺癌浸润中性粒细胞中髓过氧化物酶含量增加相关,人LVEC增强的黏附和致敏信号可能与肺内中性粒细胞的免疫激活相关。这些数据提示,膳食脂肪增强由中性粒细胞介导的肺组织特异性抗肿瘤免疫,其ROS产生潜力增强,并由血清PA和胆固醇升高所刺激的LVEC致敏。研究结果强调膳食脂肪以组织特异性方式塑造中性粒细胞功能的作用。因此,靶向中性粒细胞组织特异性重编程的饮食干预是应对肺部恶性肿瘤的潜在策略。
In this issue of Cancer Cell, Ng et al. characterize and leverage cytotoxic γδ T cells in small cell lung cancer to overcome unsuccessful checkpoint blockade immunotherapy. Engaging Vδ2+ cells with a bispecific T cell engager (BiTE) bypasses the challenge of low MHC-I expression and ineffective CD8+ T cells.
中文摘要:在本期Cancer Cell中,Ng等人对小细胞肺癌中的细胞毒性γδ T细胞进行了表征并加以利用,以应对检查点阻断免疫治疗未能奏效的问题。用双特异性T细胞衔接器(BiTE)招募Vδ2+细胞,可绕开MHC-I表达低和CD8+ T细胞无效这两项难题。
RAS proteins (HRAS, KRAS, NRAS) contribute to many physiological signal transduction pathways involving cell growth, cell division, and survival. RAS proteins possess GTPase activity. These proteins toggle between inactive and active forms; the conversion of inactive RAS-GDP to active RAS-GTP is facilitated by guanine nucleotide exchange factors (GEFs) turning the switch on and the intrinsic RAS-GTPase activity accelerated by the GTPase activating proteins (GAPs) turning the switch off. RAS is the upstream component of the RAS-RAF-MEK-ERK and the PI3-kinase-AKT signaling cascades. One-fifth of all cancers bear RAS mutations and about 75% of them involve KRAS. Except for the GTP/GDP binding site, RAS proteins lack deep surface pockets able to bind high-affinity inhibitors, which impeded the development of specific antagonists. KRAS mutations occur frequently in pancreatic, lung, and colorectal cancers, which are among the deadliest cancers worldwide. RAS mutations include those of codon 12 G12D/V/C/R, codon 13 G13D, and codon 61 Q61R/K/L. Studies conducted over the last 15 years led to the discovery of the so-called RAS switch II pocket. Sotorasib and adagrasib, which interact with this pocket and directly block the action of KRAS following the covalent modification of KRAS C12, are FDA-approved for the second-line treatment of KRASG12C-mutant non-small cell lung cancer. Daraxonrasib, which is an indirect inhibitor of wildtype and mutant H/K/NRAS isoforms, is FDA approved for the second-line treatment of all RAS-mutant pancreatic cancers. Daraxonrasib first forms a complex with cyclophilin A (a chaperone protein), which then interacts with active RAS to block RAS signaling.
中文摘要:RAS蛋白(HRAS、KRAS、NRAS)参与涉及细胞生长、分裂和存活的多种生理信号转导通路。RAS蛋白具有GTP酶活性。这些蛋白在失活与激活形式之间切换;失活型RAS-GDP向激活型RAS-GTP的转化由鸟苷酸交换因子(GEF)促进,使开关开启,而GTP酶激活蛋白(GAP)加速RAS内在的GTP酶活性,使开关关闭。RAS是RAS-RAF-MEK-ERK和PI3激酶-AKT信号级联的上游组分。全部癌症中五分之一携带RAS突变,其中约75%涉及KRAS。除GTP/GDP结合位点外,RAS蛋白缺乏能够结合高亲和力抑制剂的深表面口袋,这阻碍了特异性拮抗剂的开发。KRAS突变常见于胰腺癌、肺癌和结直肠癌,这些癌症属于全球最致命的癌症。RAS突变包括第12位密码子G12D/V/C/R、第13位密码子G13D和第61位密码子Q61R/K/L。过去15年的研究发现了所谓的RAS开关II口袋。Sotorasib和adagrasib与该口袋相互作用,并在KRAS C12共价修饰后直接阻断KRAS作用,已获FDA批准用于KRASG12C突变非小细胞肺癌的二线治疗。Daraxonrasib是野生型和突变型H/K/NRAS亚型的间接抑制剂,已获FDA批准用于所有RAS突变胰腺癌的二线治疗。Daraxonrasib先与亲环素A(一种伴侣蛋白)形成复合物,该复合物随后与活性RAS相互作用,阻断RAS信号传导。
Non-small cell lung cancer (NSCLC) continues to pose a significant global health challenge, as conventional therapies often exhibit limited effectiveness. Ferroptosis has emerged as a critical vulnerability across diverse malignancies, including NSCLC, offering a promising opportunity for therapeutic intervention. Nevertheless, molecular mediators dictating ferroptosis sensitivity and exploitable vulnerabilities remain largely elusive in NSCLC. In this study, pyruvate carboxylase (PC) is identified as a pivotal ferroptosis regulator that is highly expressed in NSCLC tissues and associated with aggressive progression and poor prognosis. Functionally, PC promotes NSCLC cell proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, PC confers resistance to ferroptosis by suppressing AMPK activation in an ATP-dependent manner, thereby activating the AKT-mTOR signaling pathway, upregulating fatty acid synthase (FASN) and malonyl-CoA-acyl carrier protein transacylase (MCAT), and ultimately inhibiting the PPARα-ACSL4 axis. Further analyses revealed that PC is targeted by Deltex E3 ubiquitin ligase 1 (DTX1) and ubiquitin-specific peptidase 51 (USP51), which modulate NSCLC progression by altering ferroptosis susceptibility. Therapeutically, the combination of the USP51 inhibitor dihydromyricetin (DHM) and anti-PD-1 treatment enhances antitumor efficacy with increased ferroptosis in vivo. Collectively, these results demonstrate that blocking PC facilitates ferroptosis, highlighting PC as a potential therapeutic target for NSCLC.
中文摘要:非小细胞肺癌(NSCLC)仍是全球重要的健康挑战,常规治疗的效果常有限。铁死亡已成为包括NSCLC在内的多种恶性肿瘤的关键脆弱点,为治疗干预提供了机会,但决定NSCLC铁死亡敏感性的分子介质和可利用的脆弱环节仍大多不明确。研究将丙酮酸羧化酶(PC)鉴定为关键的铁死亡调控因子,其在NSCLC组织中高表达,并与侵袭性进展和不良预后相关。功能上,PC在体外和体内均促进NSCLC细胞增殖、迁移和侵袭。机制上,PC以ATP依赖的方式抑制AMPK活化,从而激活AKT-mTOR信号通路,上调脂肪酸合酶(FASN)和丙二酰辅酶A-酰基载体蛋白转酰基酶(MCAT),最终抑制PPARα-ACSL4轴,赋予铁死亡抵抗。进一步分析显示,PC受Deltex E3泛素连接酶1(DTX1)和泛素特异性肽酶51(USP51)靶向调控,二者通过改变铁死亡易感性影响NSCLC进展。治疗上,USP51抑制剂二氢杨梅素(DHM)与抗PD-1治疗联合可增强体内抗肿瘤疗效并增加铁死亡。这些结果共同表明,阻断PC可促进铁死亡,提示PC是NSCLC的潜在治疗靶点。
Despite the success in infectious diseases, mRNA vaccines have inherent limitations in stability and immunogenicity. Non-small cell lung cancer remains the leading cause of cancer-related death worldwide, with poor prognosis in advanced stages, underscoring the urgent need for novel therapeutic strategies. Previously, we have developed a scarless circular RNA synthesis platform (NeoAna) that exhibited enhanced stability and long-lasting antigen expression with minimal cytotoxicity compared to mRNA. In this study, we construct a circRNA vaccine using NY-ESO-1 as the antigen and deliver circRNA vaccine with lipid nanoparticles. The circRNA vaccine elicited robust innate and adaptive immune responses both in vitro and in vivo. It demonstrated superior antitumor efficacy relative to mRNA vaccine, achieving 93.1% tumor inhibition when combined with immune checkpoint blockade. Prophylactic vaccination prevented tumor establishment, while adjuvant therapy conferred protection against tumor re-challenge, highlighting durable immune memory. Mechanistically, circRNA vaccine promoted dendritic cell maturation and enhanced tumor infiltration of T cells, and mediated antitumor immunity in a CD8+ T cell-dependent manner. Additionally, single-nucleus RNA sequencing revealed that it remodeled the tumor microenvironment toward a pro-inflammatory and antitumor phenotype. Following circRNA vaccination, the proportions of cytotoxic T cells, pro-inflammatory macrophages, and antigen-presenting cancer-associated fibroblasts were all increased within the tumor microenvironment, accompanied by activation of immunity-related signaling pathways. In conclusion, our findings demonstrate the immunogenicity and therapeutic potential of the NeoAna circRNA-based therapeutic vaccine, supporting its further evaluation in clinical trials.
中文摘要:尽管mRNA疫苗在传染病中取得成功,其在稳定性和免疫原性方面仍存在固有局限。非小细胞肺癌仍是全球癌症相关死亡的主要原因,晚期患者预后较差,迫切需要新的治疗策略。此前,我们开发了无瘢痕环状RNA合成平台(NeoAna),与mRNA相比,该平台具有更高的稳定性和持久抗原表达,细胞毒性较低。本研究以NY-ESO-1为抗原构建circRNA疫苗,并用脂质纳米颗粒递送。该circRNA疫苗在体外和体内均激发强烈的固有免疫和适应性免疫应答。与mRNA疫苗相比,其抗肿瘤疗效更优,与免疫检查点阻断联合时肿瘤抑制率达93.1%。预防性接种可阻止肿瘤形成,辅助治疗则对肿瘤再挑战提供保护,显示持久的免疫记忆。机制上,circRNA疫苗促进树突状细胞成熟,增强T细胞向肿瘤浸润,并以CD8+ T细胞依赖方式介导抗肿瘤免疫。单核RNA测序显示,该疫苗使肿瘤微环境向促炎和抗肿瘤表型重塑。circRNA疫苗接种后,肿瘤微环境中细胞毒性T细胞、促炎巨噬细胞和抗原提呈癌相关成纤维细胞比例均升高,免疫相关信号通路同步激活。这些结果证明NeoAna circRNA治疗性疫苗具有免疫原性和治疗潜力,支持其进一步开展临床试验评估。
6肿瘤基础/转化 (11篇)
基础研究 (11篇)
Post-translational modifications (PTMs) of histone H3 at lysine 9 (H3K9) contribute to chromatin homeostasis and transcriptional regulation and have been implicated in cancer progression. However, how distinct H3K9 modification states differ in function, compete for the same lysine residue, and dynamically respond to cellular context remains incompletely understood. This review summarizes the biochemical characteristics and enzymatic regulation of H3K9 methylation, acetylation, and non-acetyl acylations, including lactylation, β-hydroxybutyrylation, butyrylation, and crotonylation. We examine their roles in DNA replication, transcription, and DNA damage repair, as well as their interplay with other epigenetic regulatory mechanisms. We further discuss how H3K9-associated regulatory networks contribute to tumor proliferation, stemness maintenance, metabolic reprogramming, invasion and metastasis, immune microenvironment remodeling, therapeutic resistance, and programmed cell death, emphasizing their context-dependent and, in some settings, opposing biological effects. Finally, we evaluate preclinical and clinical advances in pharmacologically targeting H3K9-associated regulatory enzymes, distinguishing residue-specific mechanistic evidence from broader enzyme-level effects, and outline future directions for biomarker-guided epigenetic therapies in cancer.
中文摘要:组蛋白H3第9位赖氨酸(H3K9)的翻译后修饰参与染色质稳态与转录调控,并与癌症进展相关。不同H3K9修饰状态在功能上的差异、对同一赖氨酸残基的竞争以及随细胞环境作出的动态响应,仍未完全阐明。该文总结H3K9甲基化、乙酰化及非乙酰化酰基化(包括乳酸化、β-羟基丁酰化、丁酰化、巴豆酰化)的生化特征与酶学调控,考察其在DNA复制、转录和DNA损伤修复中的作用,以及其与其他表观遗传调控机制的相互作用。进一步讨论H3K9相关调控网络如何参与肿瘤增殖、干性维持、代谢重编程、侵袭转移、免疫微环境重塑、治疗耐药和程序性细胞死亡,强调其依赖环境、在某些情形下相反的生物学效应。最后评估药理学靶向H3K9相关调控酶的临床前与临床进展,区分残基特异性机制证据与较宽泛的酶水平效应,并展望生物标志物指导的癌症表观遗传治疗方向。
Here we present AmpliconSuite, a toolkit for focal amplification analysis from cancer whole-genome sequencing that identifies extrachromosomal DNA (ecDNA), breakage-fusion-bridges and other amplification modes. Its ecContext module categorizes ecDNA structures to understand formation mechanisms. Validation across 175 metaphase fluorescence in situ hybridization-probed genes in 72 models demonstrated accurate predictions. Analysis of 6,506 patient pan-cancer samples revealed ecDNA-mediated oncogene co-amplification preferences. To democratize data sharing, we created AmpliconRepository, a community-contributable platform, enabling investigation of results across >15,000 publicly hosted samples.
中文摘要:这里介绍 AmpliconSuite,一个用于癌症全基因组测序中局灶性扩增分析的工具包,可识别染色体外DNA(ecDNA)、断裂-融合-桥及其他扩增模式。其 ecContext 模块对 ecDNA 结构进行分类,以理解形成机制。在72个模型中对175个经中期荧光原位杂交探针检测的基因进行验证,显示出准确预测。对6,506份泛癌患者样本的分析揭示了 ecDNA 介导的癌基因共扩增偏好。为促进数据共享,我们建立了 AmpliconRepository,一个可由社区贡献的平台,可对超过15,000份公开托管样本的结果进行研究。
Prostate cancer is a common malignancy with a heterogeneous disease course. Prior studies have identified a paucity of point mutations in protein-coding genes and only a few clinically relevant driver alterations. Here, using the Pan Prostate Cancer Group whole genome sequencing dataset from 1001 men, we perform an integrative analysis of cancer driver genes by quantifying recurrent genomic alterations among small mutations, structural variants, and copy number alterations in 961 primary prostate tumour samples. We identify at least one recurrent somatic or germline alteration in 97% of tumours and identify putative driver genes and mechanisms of dysregulation including frequently altered regulatory elements. A prominent example is the activation of oncogenes by structural variation-mediated hijacking of onco-enhancers of the solute carrier gene family including SLC30A4. Other recurrent alterations including FOXA1, MDM4, COL5A1, TP53, and BRCA1 stratify with metastatic disease, with additional drivers enriched in African-ancestry tumours. One quarter of tumours have acquired genome-informed therapeutic targets. Unsupervised analysis of alterations reveals four oncotypes with distinct genetic and clinical characteristics, including two clinically unfavourable oncotypes with shorter metastasis-free survival. Our study uncovers the full spectrum and recurrence patterns of genomic driver alterations in primary prostate cancers and delivers targets for biomarker development, mechanistic studies, and potential therapeutic interventions.
中文摘要:前列腺癌是常见恶性肿瘤,病程异质性强。既往研究显示蛋白编码基因点突变较少,临床相关驱动改变也有限。利用泛前列腺癌协作组1001例男性的全基因组测序数据,在961份原发前列腺肿瘤样本中整合分析癌驱动基因,量化小突变、结构变异和拷贝数改变中的复发性基因组改变。97%的肿瘤至少存在一种复发性体细胞或胚系改变,研究识别出推定驱动基因及失调机制,包括频繁改变的调控元件。一个突出例子是结构变异介导的溶质载体基因家族癌增强子劫持激活癌基因,涉及SLC30A4。FOXA1、MDM4、COL5A1、TP53和BRCA1等其他复发性改变与转移性疾病分层相关,非洲血统肿瘤中富集额外驱动因素。四分之一肿瘤获得基于基因组的治疗靶点。对改变的无监督分析揭示四种具有不同遗传和临床特征的癌型,其中两种临床不利癌型无转移生存期较短。该研究揭示原发前列腺癌基因组驱动改变的全谱和复发模式,为生物标志物开发、机制研究和潜在治疗干预提供靶点。
Dysregulated cell death signaling profoundly influences oncogenesis, making the targeted elimination of malignant cells a cornerstone of modern oncological interventions. Insights into programmed cell death kinetics have revealed cross-talk among apoptosis, pyroptosis, and necroptosis, establishing the conceptual framework of PANoptosis. As an inflammatory death modality, PANoptosis is orchestrated by a multi-subunit protein platform termed the PANoptosome, which integrates and executes these distinct death programs. This review outlines the fundamental molecular cascades governing PANoptosis, alongside its multifaceted involvement in tumorigenesis, immune microenvironment remodeling, and metastatic dissemination. Although PANoptosis potentiates host antitumor defense mechanisms, its impact on malignant progression remains context-dependent. Pharmacological intervention directed at central node molecules or combined with radiation and immune checkpoint blockade represents a compelling strategy. Notably, suppressing ZBP1 attenuates chemotherapy-induced systemic toxicities, whereas multimodal therapies synergistically augment therapeutic efficacy. Nevertheless, precise regulatory networks demand further elucidation, and clinical translation requires rigorous validation. Ultimately, PANoptosis offers novel insights into cancer biology and paves the way for personalized therapeutic paradigms.
中文摘要:细胞死亡信号失调深刻影响肿瘤发生,靶向清除恶性细胞因此成为现代肿瘤干预的基石。对程序性细胞死亡动力学的认识揭示了凋亡、焦亡与坏死性凋亡之间的交叉对话,由此形成PANoptosis的概念框架。作为一种炎症性死亡方式,PANoptosis由多亚基蛋白平台PANoptosome编排,该平台整合并执行上述不同的死亡程序。该综述梳理了调控PANoptosis的基本分子级联,并概述其在肿瘤发生、免疫微环境重塑和转移播散中的多维作用。PANoptosis可增强宿主抗肿瘤防御,但其对恶性进展的影响仍取决于具体情境。针对核心节点分子的药物干预,或与放疗及免疫检查点阻断联合,是有吸引力的策略。抑制ZBP1可减轻化疗引起的全身毒性,多模式治疗则协同提高疗效。精确的调控网络仍需进一步阐明,临床转化也需严格验证。PANoptosis为肿瘤生物学提供了新见解,并为个体化治疗范式开辟了道路。
Extrachromosomal DNA (ecDNA) is a key element driving the malignant progression of tumors. Since ecDNA lacks canonical high-order chromatin compaction, how it maintains structural and functional stability in highly oxidizing tumor environments remains unclear. Using metabolomics, biochemistry, and imaging assays in human cancer cells and mouse models, we herein show that ecDNA hub establishes an active electrochemical environment, which drives the reduction of oxidized glutathione (GSSG) to reduced glutathione (GSH) through a non-enzymatic mechanism. GSH forms a protective "cloud" around ecDNA hubs, shielding ecDNA from damage and sustaining oncogene expression. Lastly, using spermidine, which disrupts the interfacial environment of ecDNA hubs, we found that affecting the redox balance of ecDNA hubs drives tumor death. This study uncovers a non-enzymatic function of ecDNA hubs that establishes a self-reinforcing maintenance loop to regulate spatial redox environments, revealing an electrochemical environment-dependent redox-regulation strategy in cancer biology.
中文摘要:染色体外DNA(ecDNA)是驱动肿瘤恶性进展的关键元件。ecDNA缺乏经典的高阶染色质压缩,其如何在高度氧化的肿瘤环境中维持结构与功能稳定性仍不清楚。我们在人癌细胞和小鼠模型中运用代谢组学、生物化学和成像分析,发现ecDNA枢纽建立活跃的电化学环境,通过非酶机制驱动氧化型谷胱甘肽(GSSG)还原为还原型谷胱甘肽(GSH)。GSH在ecDNA枢纽周围形成保护性「云」,使ecDNA免受损伤并维持癌基因表达。使用可破坏ecDNA枢纽界面环境的亚精胺,我们发现影响ecDNA枢纽的氧化还原平衡可驱动肿瘤死亡。本研究揭示ecDNA枢纽的一种非酶功能,该功能建立自我强化的维持环路以调控空间氧化还原环境,为癌症生物学提供了一种依赖电化学环境的氧化还原调控策略。
Pancreatic ductal adenocarcinoma (PDAC), an aggressive cancer with a poor prognosis, contains resident tissue macrophages (RTMs) present before tumor onset and monocyte-derived macrophages recruited during tumor development, but their distinct roles in supporting tumor progression remain unclear. Combining single-cell profiling, spatial analysis, lineage tracing, RTM depletion, and selenium tracing, we found that RTMs preferentially localize at the tumor border, where they promote epithelial-mesenchymal transition (EMT), tumor growth, and metastasis. Mechanistically, RTMs transfer the selenium transporter Selenop to EMThi tumor cells through LRP8-dependent uptake, increasing tumor-cell selenium availability, limiting lipid peroxidation, and shielding EMThi tumor cells from ferroptosis. RTM-specific Selenop deletion or tumor-cell Lrp8 disruption reduced EMT and tumor progression, whereas ferroptosis inhibition reversed the effect of RTM depletion. Human PDAC showed border-enriched SEPP1+ RTMs near EMThi tumor cells, suggesting a conserved macrophage-derived selenium niche that supports invasive tumor states and highlighting the potential for targeting RTMs or their secretory factors in PDAC.
中文摘要:胰腺导管腺癌(PDAC)侵袭性强、预后差,肿瘤发生前即存在组织驻留巨噬细胞(RTM),肿瘤发展过程中又招募单核细胞来源巨噬细胞,但二者支持肿瘤进展的不同作用仍不清楚。结合单细胞图谱、空间分析、谱系追踪、RTM清除和硒示踪,我们发现RTM优先定位在肿瘤边界,促进上皮-间质转化(EMT)、肿瘤生长和转移。机制上,RTM通过LRP8依赖的摄取将硒转运蛋白Selenop转移给EMThi肿瘤细胞,提高肿瘤细胞硒可利用性,限制脂质过氧化,使EMThi肿瘤细胞免受铁死亡。RTM特异性敲除Selenop或破坏肿瘤细胞Lrp8可减少EMT和肿瘤进展,而抑制铁死亡可逆转RTM清除的效应。人PDAC中可见边界富集的SEPP1+ RTM靠近EMThi肿瘤细胞,提示存在保守的巨噬细胞来源硒微环境,支持侵袭性肿瘤状态,并突出靶向RTM或其分泌因子在PDAC中的潜力。
Serine is a critical nutrient for cancer cell proliferation due to its numerous downstream biosynthetic functions. Given the ongoing clinical efforts to utilize dietary serine starvation as a potential therapy for serine auxotrophic tumors, it is important to understand how cancer cells respond to serine starvation. In this study, we demonstrated that serine starvation induces dramatic changes in mRNA splicing. These effects are due, in part, to reduced translation of serine-rich proteins, including the serine/arginine-rich splicing factor (SRSF) proteins that are known regulators of mRNA splicing. Indeed, translation of SRSF6 was reduced upon serine starvation in serine auxotrophic cancer cells and contributes to the RNA splicing changes seen upon serine deprivation. Furthermore, reduced SRSF6 affected DNA damage response and cell survival in the absence of exogenous serine, and modulators of RNA splicing combined with dietary serine starvation to inhibit tumor growth. Collectively, this work describes a fundamental role for serine in supporting mRNA splicing, which may have implications in the clinical efforts to bring dietary serine starvation to the clinic. Serine starvation induces changes in mRNA splicing by inhibiting translation of serine-rich proteins like SRSF6, which impacts the DNA damage response and could affect how cancer cells respond to chemotherapy.
中文摘要:丝氨酸因具有多种下游生物合成功能,是癌细胞增殖所需的关键营养物。鉴于目前正尝试将饮食丝氨酸饥饿作为丝氨酸依赖型肿瘤的潜在治疗策略,理解癌细胞如何响应丝氨酸饥饿十分重要。该研究显示,丝氨酸饥饿会显著改变mRNA剪接。这些效应部分源于富含丝氨酸蛋白的翻译减少,其中包括已知的mRNA剪接调节因子——富含丝氨酸/精氨酸的剪接因子(SRSF)蛋白。在丝氨酸依赖型癌细胞中,丝氨酸饥饿确实降低了SRSF6的翻译,并促成了丝氨酸剥夺后观察到的RNA剪接变化。SRSF6减少还会在外源丝氨酸缺乏时影响DNA损伤应答和细胞存活;RNA剪接调节剂与饮食丝氨酸饥饿联合可抑制肿瘤生长。总体而言,这项工作揭示了丝氨酸在支持mRNA剪接中的基础作用,这可能对将饮食丝氨酸饥饿推向临床的努力具有意义。丝氨酸饥饿通过抑制SRSF6等富含丝氨酸蛋白的翻译来改变mRNA剪接,进而影响DNA损伤应答,并可能影响癌细胞对化疗的响应。
Epigenetic dysregulation plays a vital role in the progression of endometrial cancer (EC), yet targeted treatment options remain limited. Here, we identified the histone acetyltransferase KAT5 as a therapeutic target in EC. KAT5 was significantly overexpressed in EC and correlated with poor patient outcome. Silencing KAT5 inhibited EC cell proliferation and tumor growth. KAT5-deficient EC cells exhibited impaired cytoskeletal dynamics, leading to heightened DNA damage and increased micronuclei formation. The release of micronuclear DNA into the cytoplasm activated the cGAS-STING pathway, thereby amplifying proinflammatory immune responses. Mechanistically, KAT5 acetylated H2A.Z to transcriptionally activate Arp2/3 complex genes, promoting actin polymerization and chromosomal stability. Inhibition of Arp2/3 or depletion of its subunit ARPC5 replicated the effects of KAT5 loss, whereas restoring ARPC5 mitigated chromosomal instability and cGAS activation. In transplantation models of EC cell lines and syngeneic murine Trp53-/-;Pten-/- EC organoids, pharmacological inhibition of KAT5 with NU9056 suppressed tumor progression and enhanced immune cell infiltration. NU9056 also induced Arp2/3 disruption, genomic instability, and cGAS-STING activation in patient-derived organoids from clinical endometrial cancer samples. Together, these findings highlight KAT5 as a promising therapeutic target in EC that influences chromatin remodeling, cytoskeletal dynamics, and immune modulation.
中文摘要:表观遗传失调在子宫内膜癌(EC)进展中起重要作用,靶向治疗选择仍有限。研究将组蛋白乙酰转移酶KAT5确定为EC治疗靶点。KAT5在EC中显著高表达,并与患者不良结局相关。沉默KAT5可抑制EC细胞增殖和肿瘤生长。KAT5缺失的EC细胞出现细胞骨架动态受损,导致DNA损伤加重和微核形成增加。微核DNA释放至胞质后激活cGAS-STING通路,增强促炎免疫反应。机制上,KAT5乙酰化H2A.Z以转录激活Arp2/3复合体基因,促进肌动蛋白聚合和染色体稳定性。抑制Arp2/3或敲低其亚基ARPC5可重现KAT5缺失效应,而恢复ARPC5可减轻染色体不稳定性和cGAS激活。在EC细胞系移植模型和同基因小鼠Trp53-/-;Pten-/- EC类器官模型中,NU9056药理学抑制KAT5可抑制肿瘤进展并增强免疫细胞浸润。NU9056还在临床子宫内膜癌样本来源的类器官中诱导Arp2/3破坏、基因组不稳定和cGAS-STING激活。这些结果提示KAT5是EC有前景的治疗靶点,影响染色质重塑、细胞骨架动态和免疫调节。
Overcoming premature activation of aggregation-induced emission photosensitizers (AIE-PSs) before they reach the tumor is critical for the broad clinical application of photodynamic therapy (PDT). Here, we report a bowl-shaped nanoplatform as a universal AIE delivery vessel, together with a new endoplasmic reticulum (ER)-targeting AIE PS (TSQE), for precision PDT. A hollow polydopamine (PDA) nanobowl was fabricated to confine oleic acid (OA) molecules within its cavity, forming a localized hydrophobic phase that attracts and disperses TSQE molecules into dynamic aggregates, thereby enabling efficient delivery while avoiding premature activation. The TSQE-OA mixture responds to pH stimuli in the tumor microenvironment, resulting in specific TSQE accumulation in the ER of tumor cells. Additionally, upconversion nanoparticles (UCNPs) co-loaded in the nanobowl enable deep-tissue activation of the TSQE molecules using 980 nm light, triggering potent apoptosis and ferroptosis via ER stress and lipid peroxidation (LPO). The therapeutic effect is further amplified by manganese deposited on the PDA shell, which catalyzes reactive oxygen species (ROS) generation in combination with the PDA's photothermal effect under 808 nm irradiation. In vitro and in vivo studies demonstrate superior and specific anti-tumor efficacy. Our nanobowl-based delivery platform and the TSQE represent a dual-level strategy for improving PDT precision.
中文摘要:聚集诱导发光光敏剂(AIE-PSs)在到达肿瘤前发生过早激活,是光动力疗法(PDT)广泛临床应用需要解决的关键问题。我们报道了一种碗状纳米平台作为通用AIE递送载体,并结合一种新的内质网(ER)靶向AIE光敏剂(TSQE),用于精准PDT。制备中空聚多巴胺(PDA)纳米碗,将油酸(OA)分子限制在其腔内,形成局部疏水相,吸引并分散TSQE分子成为动态聚集体,从而在避免过早激活的同时实现高效递送。TSQE-OA混合物响应肿瘤微环境中的pH刺激,导致TSQE在肿瘤细胞ER中特异性蓄积。纳米碗中共载的上转换纳米颗粒(UCNPs)可利用980 nm光实现TSQE分子的深层组织激活,通过ER应激和脂质过氧化(LPO)触发强烈的凋亡和铁死亡。沉积在PDA壳上的锰与PDA在808 nm照射下的光热效应协同催化活性氧(ROS)生成,进一步放大治疗效果。体外和体内研究证明其具有优越且特异的抗肿瘤疗效。我们的纳米碗递送平台和TSQE代表了一种提高PDT精准度的双重策略。
Extrachromosomal DNA (ecDNA) contributes to cancer genome instability by enabling high-copy oncogene amplification and genetic intratumoral heterogeneity. Micronuclei (MNs) are common in chromosomally unstable cancers, yet their role in ecDNA-driven tumors remains unclear. Here we investigate how ecDNA damage, mitotic segregation and MN formation are linked. We find that ecDNAs are a major source of MNs following their damage, particularly under replication stress. Replication stress promotes mitotic ecDNA clustering, asymmetric inheritance, mis-segregation into MNs and reduced transcriptional output. Single-MN sequencing reveals that multiple distinct ecDNA species coalesce within individual MNs. Cells inheriting ecDNA+ MNs display impaired proliferative capacity and are more likely to undergo cell death. In patients with MYCN-amplified neuroblastoma, higher frequencies of ecDNA+ MNs at diagnosis are associated with improved overall survival. Together, these findings identify ecDNA mis-segregation as a mechanism that limits tumor fitness, highlighting mitotic ecDNA retention as a potential therapeutic vulnerability.
中文摘要:染色体外DNA(ecDNA)通过介导癌基因高拷贝扩增和瘤内遗传异质性,促进癌症基因组不稳定。微核在染色体不稳定的癌症中常见,但其在ecDNA驱动肿瘤中的作用仍不清楚。我们探讨ecDNA损伤、有丝分裂分离与微核形成之间的联系。我们发现,ecDNA受损后是微核的主要来源,在复制压力下尤其明显。复制压力促进有丝分裂期ecDNA聚集、不对称继承、错误分离进入微核以及转录输出下降。单微核测序显示,多种不同的ecDNA种类会在单个微核内汇聚。继承ecDNA阳性微核的细胞增殖能力受损,更易发生细胞死亡。在MYCN扩增的神经母细胞瘤患者中,诊断时ecDNA阳性微核频率较高与总生存改善相关。这些结果将ecDNA错误分离确定为限制肿瘤适合度的机制,并提示有丝分裂期ecDNA保留可能成为治疗脆弱点。
Neutrophils are dynamic regulators of cancer progression rather than short-lived bystanders. Within the tumor microenvironment (TME), tumor-associated neutrophils (TANs) adopt heterogeneous, context-dependent states that extend far beyond the conventional N1/N2 dichotomy. Recent single-cell and spatial transcriptomic insights reveal that cytokine, stromal, metabolic, and epigenetic cues orchestrate this remarkable TAN plasticity. Once activated, TAN-derived proteases, reactive oxygen species, and neutrophil extracellular traps (NETs) drive angiogenesis, immune evasion, metastasis, and therapy resistance. Conversely, specific TAN subpopulations can directly kill tumor cells, present antigens, and synergize with adaptive immunity. This review synthesizes recent breakthroughs in TAN recruitment, heterogeneity, metabolic and epigenetic reprogramming, and cellular crosstalk. Furthermore, we evaluate therapeutic strategies targeting molecular signaling and NET formation, alongside emerging approaches to reprogram or engineer neutrophils, such as chimeric antigen receptor-engineered neutrophils (CAR-Ns). Finally, we address current barriers to clinical translation and outline how to achieve context-dependent modulation of neutrophil states to preserve essential host defenses during TAN-targeted oncology therapies.
中文摘要:中性粒细胞是癌症进展的动态调控者,而非存活短暂的旁观者。在肿瘤微环境(TME)中,肿瘤相关中性粒细胞(TAN)呈现异质的、依赖情境的状态,远超传统的N1/N2二分法。近期单细胞与空间转录组学的发现显示,细胞因子、基质、代谢与表观遗传信号共同编排了TAN这种显著的可塑性。活化之后,TAN来源的蛋白酶、活性氧与中性粒细胞胞外诱捕网(NET)推动血管生成、免疫逃逸、转移与治疗耐药。相反,特定的TAN亚群能够直接杀伤肿瘤细胞、递呈抗原并与适应性免疫协同。本综述整合了TAN募集、异质性、代谢与表观遗传重编程及细胞间交互方面的近期突破,并评估了靶向分子信号与NET形成的治疗策略,以及重编程或工程化中性粒细胞的新兴途径,例如嵌合抗原受体工程化中性粒细胞(CAR-N)。文章还讨论了当前临床转化面临的障碍,并勾勒了在靶向TAN的肿瘤治疗中如何实现依赖情境的中性粒细胞状态调控,以保留宿主必需的防御功能。
7神经系统肿瘤 (7篇)
临床研究 (1篇)
D2C7-ATC is a recombinant antibody-toxin conjugate (ATC) targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII). We conducted a single-arm, single-site, open-label phase 1 trial evaluating a single infusion of D2C7-ATC via convection-enhanced delivery in the enhancing disease of 81 patients with biopsy-confirmed recurrent malignant glioma. The primary objective was to determine toxicity and the recommended phase 2 dose (RP2D) of D2C7-ATC. Secondary objectives included describing overall survival (OS) and assessing the association between EGFR expression and OS. The median overall survival (mOS) was 7.9 months among 72 patients with isocitrate dehydrogenase wild-type recurrent glioblastoma (IDHwt rGBM), including 35 patients in the dose-escalation stage (40 to 35,032 ng ml-1) and 37 patients in the dose-expansion stage (RP2D of 6,920 ng ml-1). D2C7-ATC was generally well tolerated, with mainly grade 1-2 treatment-related adverse events (67%). The maximum tolerated dose was exceeded at 35,032 ng ml-1, where four patients experienced dose-limiting toxicities, including grade 4 (N = 2) and grade 3 (N = 2) events. Eight patients died on trial; all deaths were unrelated to D2C7-ATC. Univariate analyses identified survival-associated biomarkers, including tumor D2C7 antibody reactivity, circulating cytokines, a tumor inflammatory gene signature and neutrophils, monocytes and lymphocytes in blood. Notably, patients with IDHwt rGBM with a D2C7 antibody reactivity score of <1.5+ in pre-treatment tumor had an mOS of 17.38 months, whereas those with low IL-8 in post-treatment plasma had an mOS of 16.6 months. These findings indicate that EGFR-targeted D2C7-ATC therapy prolongs survival in a subset of patients with IDHwt rGBM via intratumoral and systemic immune activation. ClinicalTrials.gov identifier: NCT02303678 .
中文摘要:D2C7-ATC是一种重组抗体-毒素偶联物,靶向野生型表皮生长因子受体(EGFR)和突变型EGFR变体III(EGFRvIII)。我们开展了一项单臂、单中心、开放标签1期试验,评估通过对流增强递送将单次D2C7-ATC输注给予81例活检证实的复发性恶性胶质瘤患者的强化病灶。主要目标是确定D2C7-ATC的毒性和推荐2期剂量(RP2D)。次要目标包括描述总生存期(OS)以及评估EGFR表达与OS之间的关联。72例异柠檬酸脱氢酶野生型复发性胶质母细胞瘤(IDHwt rGBM)患者的中位总生存期(mOS)为7.9个月,其中35例处于剂量递增阶段(40至35,032 ng/ml),37例处于剂量扩展阶段(RP2D为6,920 ng/ml)。D2C7-ATC总体耐受良好,治疗相关不良事件主要为1-2级(67%)。在35,032 ng/ml时超过最大耐受剂量,4例患者出现剂量限制性毒性,包括4级(N=2)和3级(N=2)事件。8例患者在试验期间死亡;所有死亡均与D2C7-ATC无关。单因素分析识别出与生存相关的生物标志物,包括肿瘤D2C7抗体反应性、循环细胞因子、肿瘤炎症基因特征以及血液中的中性粒细胞、单核细胞和淋巴细胞。治疗前肿瘤D2C7抗体反应性评分<1.5+的IDHwt rGBM患者mOS为17.38个月,治疗后血浆IL-8水平较低者mOS为16.6个月。这些结果表明,靶向EGFR的D2C7-ATC治疗通过瘤内和全身免疫激活延长部分IDHwt rGBM患者的生存期。ClinicalTrials.gov标识符:NCT02303678。
基础研究 (6篇)
Pediatric brain tumors (PBTs) remain a leading cause of cancer-related mortality in children, underscoring the need for more effective therapeutic strategies. These tumors arise from disrupted neurodevelopmental programs and evolve within a developmentally constrained immune landscape that is tolerogenic, epigenetically plastic, and susceptible to tumor-mediated co-option. Increasing evidence indicates that, besides molecular heterogeneity, the tumor immune microenvironment critically influences clinical outcomes. Despite its therapeutic promise, immunotherapy has yet to demonstrate consistent clinical benefit in most PBTs, highlighting the need for rational multimodal strategies guided by deeper understanding of tumor-immune interactions in the developing brain. To provide a comprehensive perspective on fetal immune ontogeny and its tumor-driven dysregulation we used medulloblastoma, pediatric gliomas, atypical teratoid/rhabdoid tumors, and ependymoma as representative entities. Drawing on insights from developmental neurobiology, tumor immunology, and emerging multi-omic studies, we outline how PBTs exploit physiological immune maturation programs to establish immune evasion, sustain chronic inflammation, and promote therapy resistance. We further discuss emerging multimodal immunotherapeutic strategies and next-generation CAR T-cell approaches currently under clinical investigation. In addition, we highlight therapeutic avenues such as targeting tumor-associated myeloid populations and key inflammatory regulators that may offer promising opportunities for future clinical translation. We believe this Review will help address current limitations in preclinical models, improve patient stratification and guide rational design of therapeutic strategies.
中文摘要:儿童脑肿瘤仍是儿童癌症相关死亡的主要原因之一,迫切需要更有效的治疗策略。这类肿瘤源于神经发育程序紊乱,并在发育受限的免疫环境中演化;该环境具有免疫耐受性、表观遗传可塑性,并易被肿瘤利用。越来越多证据表明,除分子异质性外,肿瘤免疫微环境对临床结局有重要影响。免疫治疗虽有治疗潜力,但在多数儿童脑肿瘤中尚未显示一致的临床获益,这提示需要基于对发育中大脑内肿瘤与免疫相互作用的更深理解,制定合理的多模式策略。为全面审视胎儿免疫个体发生及其受肿瘤驱动的失调,文章以髓母细胞瘤、儿童胶质瘤、非典型畸胎样/横纹肌样瘤和室管膜瘤为代表实体。结合发育神经生物学、肿瘤免疫学及新兴多组学研究,文章概述儿童脑肿瘤如何利用生理性免疫成熟程序建立免疫逃逸、维持慢性炎症并促进治疗抵抗。文章进一步讨论正在临床研究中的新兴多模式免疫治疗策略和下一代CAR T细胞方法。文章还强调靶向肿瘤相关髓系细胞群和关键炎症调节因子等治疗途径,这些途径可能为未来临床转化提供机会。该综述有望帮助解决当前临床前模型的局限,改善患者分层,并指导治疗策略的合理设计。
Human centromeres are highly variable but remain among the least characterized regions of the genome because their repetitive structure has hindered conventional analysis of population diversity and disease relevance. Here, we show that rare k-mers in centromeric regions capture lineage-specific variation, defining discrete haplogroups with distinct structural features. We developed ascairn to infer these haplogroups from short-read whole-genome sequencing (WGS) data. Applying this framework to >3,300 genomes reveals extensive global diversity in centromere haplogroups and signatures of population history. Analyzing short-read WGS data from 142 oligodendroglioma cases with 1p/19q co-deletion, we mapped breakpoints to the centromere regions of chromosomes 1 and 19, revealing a clear positional relationship to kinetochore attachment sites and a link between centromere haplotype structure and rearrangement susceptibility. Rare k-mers thus open centromeres to population-scale analysis, linking centromere structural diversity to human evolutionary history and disease-associated genomic instability.
中文摘要:人类着丝粒高度可变,但因重复结构阻碍了群体多样性和疾病相关性的常规分析,仍是基因组中特征最不清楚的区域之一。稀有k-mer可捕获着丝粒区域的谱系特异性变异,定义出具有不同结构特征的离散单倍群。我们开发了ascairn,从短读长全基因组测序数据中推断这些单倍群。将该框架应用于超过3300个基因组,揭示了着丝粒单倍群广泛的全球多样性及群体历史特征。分析142例伴1p/19q共缺失的少突胶质细胞瘤病例的短读长全基因组测序数据,将断裂点定位到1号和19号染色体着丝粒区域,显示其与动粒附着位点有明确位置关系,并揭示着丝粒单倍型结构与重排易感性之间的联系。稀有k-mer因此使着丝粒可用于群体规模分析,将着丝粒结构多样性与人类进化史及疾病相关基因组不稳定性联系起来。
Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults, characterized by diffuse infiltrative lesions, distinct oncogenic alterations, and a suppressive tumor immune microenvironment (TIME). These traits, however, are not fully recapitulated in current syngeneic murine glioma models, thereby limiting the pre-clinical development of novel therapies. Here we developed murine GBM models with patient-specific mutations that shared striking resemblance with human disease. Mosaic analysis with dual-recombinase mediated cassette exchange (MADR) and CRISPR-Cas9 were leveraged to generate autochthonous tumor models with single-copy somatic transgenesis of murine epidermal growth factor receptor variant III (mEGFRvIII) and loss-of-function mutations commonly observed in GBM. Characterization of a model lacking Pten and Cdkn2a (mEGFRvIII-PC) via histopathologic analyses, functional assays, and single-cell RNA sequencing showed these tumors developed as diffuse, infiltrative lesions with ill-defined margins and a necrotic core. The TIME was primarily comprised of microglia with minimal lymphocyte infiltration, recapitulating patient tumors. Furthermore, these tumors displayed intrinsic resistance to immune checkpoint blockade, potentially due to poor myeloid cell antigen presentation and T cell priming. Additionally, mEGFRvIII-PC cells were the most resistant to antigen-specific T cell-induced cytotoxicity and simultaneously promoted T cell exhaustion, while murine interferon-γ (mIFN-γ) stimulation induced a greater response in vitro with enhanced upregulation of PD-L1 relative to MHC-I. In sum, these findings demonstrate the improved fidelity of the mEGFRvIII-PC model to patient tumors and support its use in developing and refining novel therapeutic paradigms for GBM.
中文摘要:胶质母细胞瘤(GBM)是成人最常见且致死性最高的原发性脑肿瘤,特征为弥漫浸润性病变、独特的致癌改变以及抑制性肿瘤免疫微环境(TIME)。现有同系小鼠胶质瘤模型未完全重现这些特征,限制了新疗法的临床前开发。我们构建了携带患者特异性突变的小鼠GBM模型,与人疾病高度相似。利用双重组酶介导的盒式交换嵌合分析(MADR)和CRISPR-Cas9,生成具有鼠表皮生长因子受体变异III(mEGFRvIII)单拷贝体细胞转基因及GBM常见功能缺失突变的原位肿瘤模型。通过组织病理学分析、功能实验和单细胞RNA测序表征缺乏Pten和Cdkn2a的模型(mEGFRvIII-PC),显示这些肿瘤呈弥漫浸润性病变,边界不清并伴坏死核心。TIME主要由小胶质细胞组成,淋巴细胞浸润极少,重现了患者肿瘤。这些肿瘤对免疫检查点阻断具有内在抵抗性,可能与髓系细胞抗原提呈和T细胞启动不佳有关。mEGFRvIII-PC细胞对抗原特异性T细胞诱导的细胞毒性最具抵抗性,同时促进T细胞耗竭;鼠干扰素-γ(mIFN-γ)刺激在体外引起更强反应,PD-L1上调相对MHC-I增强。这些发现表明mEGFRvIII-PC模型对患者肿瘤具有更高保真度,支持其用于开发和优化GBM的新型治疗范式。
Selenium is essential for the synthesis of redox-active selenoproteins, including glutathione peroxidase 4 (GPX4), a central suppressor of ferroptosis. However, how malignant cells coordinate selenium acquisition and reutilization to maintain redox homeostasis remains poorly understood. Here, we identify a tumor-associated selenoprotein P (SELENOP) cycle in glioblastoma (GBM) that is coordinated by the long non-coding RNA (lncRNA) CCDC152. Highly proliferative GBM cells secrete SELENOP, recapture it through LRP8, and reutilize selenium to maintain intracellular selenoprotein abundance and cell proliferation. Disruption of SELENOP or LRP8 suppressed GBM cell proliferation, while LRP8 depletion reduced GPX1 and GPX4 abundance and its intracellular domain was required for growth-promoting activity. Unexpectedly, although CCDC152 suppresses SELENOP translation in hepatocyte-derived cells, it positively regulated SELENOP production, LRP8 expression, and intracellular GPX1 and GPX4 abundance in GBM cells. CCDC152 depletion also increased ferroptosis susceptibility. Clinical analyses further showed that elevated expression of SELENOP and CCDC152 was associated with poor prognosis in astrocytoma, IDH-mutant. Together, these findings identify the CCDC152- SELENOP-LRP8 axis as a tumor-adapted selenium utilization system that couples extracellular selenium transport to intracellular redox homeostasis, revealing selenium utilization as a redox vulnerability that may be exploited by ferroptosis-inducing therapies.
中文摘要:硒是合成具有氧化还原活性的硒蛋白所必需,其中包括谷胱甘肽过氧化物酶4(GPX4),后者是铁死亡的核心抑制因子。恶性肿瘤细胞如何协调硒的获取与再利用以维持氧化还原稳态,仍不清楚。我们在胶质母细胞瘤(GBM)中鉴定出一个与肿瘤相关的硒蛋白P(SELENOP)循环,该循环由长链非编码RNA(lncRNA)CCDC152协调。高增殖的GBM细胞分泌SELENOP,通过LRP8将其重新捕获,并再利用硒以维持细胞内硒蛋白丰度和细胞增殖。破坏SELENOP或LRP8可抑制GBM细胞增殖,而LRP8缺失降低GPX1和GPX4丰度,并且其胞内结构域是促生长活性所必需的。与预期不同,尽管CCDC152在肝细胞来源细胞中抑制SELENOP翻译,但它在GBM细胞中正向调控SELENOP生成、LRP8表达以及细胞内GPX1和GPX4丰度。CCDC152缺失还增加铁死亡易感性。临床分析进一步显示,SELENOP和CCDC152表达升高与IDH突变型星形细胞瘤的不良预后相关。这些发现将CCDC152-SELENOP-LRP8轴鉴定为一个肿瘤适应的硒利用系统,将细胞外硒转运与细胞内氧化还原稳态偶联,并揭示硒利用是一种可被铁死亡诱导疗法利用的氧化还原脆弱性。
A Multi-Omic Phenobank Reveals Axes of Glioblastoma Growth, Invasion, and Therapeutic Vulnerability.
Glioblastoma (GBM) invasion is clinically decisive but difficult to model systematically. Existing patient-derived xenograft (PDX) resources rarely couple reproducible in vivo invasion phenotypes with matched multi-omic profiles at scale, limiting mechanistic insight and phenotype-informed therapeutic hypotheses. We established the HGCC Phenobank, comprising 65 patient-derived GBM stem-like cultures with matched multi-omic profiling and orthotopic engraftment in 449 mice. Blinded histopathology quantified ten invasion traits per case. These phenotypes were integrated with RNA sequencing, DNA methylation, and mass-spectrometry-based proteomics. Multi-Omic Factor Analysis (MOFA) identified latent molecular programs. Phenotype-specific RNA signatures were matched to LINCS drug-perturbation profiles and validated in 3D gliomasphere and ex vivo brain-slice assays. Two dominant, reproducible invasion modes emerged across models: diffuse parenchymal infiltration and perivascular/condensed growth. Proneural cultures formed more aggressive tumors in immunodeficient mice, and mouse survival showed a modest correlation with patient survival in matched cases (Pearson r=0.1832, p=0.045). MOFA identified 15 latent factors; Factor 1, marked by ASCL1/OLIG1/OLIG2 programs across multiple molecular layers, was associated with increased tumor formation and diffuse invasion in mice. Higher Factor 1 scores were associated with significantly longer postoperative survival in both the matched patient cohort (p = 0.00018) and TCGA (p = 0.017), although Factor 1 was not associated with survival of the xenografted mice. Drug-signature matching separated mechanisms targeting diffuse versus perivascular invasion. Experimental validation confirmed phenotype-selective sensitivities, and inhibitors PIK-75 and buparlisib suppressed invasion dynamics across representative models in 3D and brain-slice assays. The HGCC Phenobank provides the first openly available PDX resource that systematically links GBM invasion phenotypes to multi-omic programs and therapeutic predictions. This framework enables reproducible model selection, mechanistic dissection of invasion modes, and phenotype-guided therapeutic discovery.
中文摘要:胶质母细胞瘤(GBM)的侵袭具有临床决定性,但难以系统建模。现有患者来源异种移植(PDX)资源很少在大规模上把可重复的体内侵袭表型与匹配的多组学图谱结合起来,限制了机制认识与基于表型的治疗假设。我们建立了HGCC表型库,包含65例患者来源的GBM干细胞样培养物,配有匹配的多组学分析和449只小鼠的原位移植。盲法组织病理学对每例量化十项侵袭特征。这些表型与RNA测序、DNA甲基化和基于质谱的蛋白质组学整合。多组学因子分析(MOFA)识别潜在分子程序。表型特异性RNA特征与LINCS药物扰动图谱匹配,并在三维胶质瘤球和离体脑片实验中验证。模型中出现两种主要且可重复的侵袭模式:弥漫性实质浸润和血管周围/致密生长。前神经型培养物在免疫缺陷小鼠中形成更具侵袭性的肿瘤,匹配病例中小鼠生存与患者生存呈弱相关(Pearson r=0.1832,p=0.045)。MOFA识别出15个潜在因子;因子1以跨多个分子层的ASCL1/OLIG1/OLIG2程序为标志,与小鼠中肿瘤形成增加和弥漫性侵袭相关。较高的因子1评分与匹配患者队列(p=0.00018)和TCGA(p=0.017)中显著更长的术后生存相关,但因子1与异种移植小鼠的生存无关。药物特征匹配区分了靶向弥漫性与血管周围侵袭的机制。实验验证确认了表型选择性敏感性,抑制剂PIK-75和buparlisib在三维和脑片实验中抑制了代表性模型的侵袭动态。HGCC表型库提供了首个公开可用的PDX资源,系统地将GBM侵袭表型与多组学程序及治疗预测联系起来。该框架支持可重复的模型选择、侵袭模式的机制解析和表型指导的治疗发现。
Therapeutic options for progressive glioblastoma remain limited, with chlorethyl-cyclohexyl-nitrosourea (CCNU, lomustine) among the approved treatments. Beyond MGMT gene promoter methylation, molecular determinants of CCNU sensitivity or resistance are ill- defined. We employed genome-wide functional knockout screening using the CRISPR-Cas9 technology to identify and subsequently validate modulators of response to CCNU in experimental glioma. We established an immunocompetent glioma mouse model to enable functional interrogation of Fanconi anemia pathway (FA) genes in tumor growth and synthetic lethal interactions in vivo using the RCAS/tv-a somatic gene delivery system. Multiple FA pathway members recurrently emerged as potent synthetic lethal interactors of CCNU treatment. In vivo knockdown of Fancm accelerated tumor onset and significantly increased CCNU sensitivity. Consistently, FA pathway inhibition enhanced CCNU efficacy across in vitro, ex vivo and in vivo models. Together, these findings identify FA pathway components as key synthetic lethal interactors of CCNU response and reveal a therapeutically actionable vulnerability in glioblastoma.
中文摘要:进展性胶质母细胞瘤的治疗选择仍然有限,氯乙基环己亚硝基脲(CCNU,洛莫司汀)是获批治疗之一。除MGMT基因启动子甲基化外,CCNU敏感或耐药的分子决定因素尚未充分明确。我们采用CRISPR-Cas9技术进行全基因组功能敲除筛选,在实验性胶质瘤中鉴定并随后验证CCNU反应的调控因子。建立免疫健全胶质瘤小鼠模型,借助RCAS/tv-a体细胞基因递送系统,在体内对范可尼贫血通路(FA)基因在肿瘤生长及合成致死相互作用中的功能进行探究。多个FA通路成员反复作为CCNU治疗的有力合成致死相互作用因子出现。体内敲低Fancm加速肿瘤发生并显著提高CCNU敏感性。与之一致,抑制FA通路在体外、离体和体内模型中均增强CCNU疗效。这些发现将FA通路组分确定为CCNU反应的关键合成致死相互作用因子,并揭示胶质母细胞瘤中一个具有治疗可操作性的脆弱点。
8其他实体瘤 (6篇)
临床研究 (2篇)
Despite a 43% higher age-adjusted mortality rate among rural working-age adults and a 29.1% decline in general surgeon supply between 2001 and 2019, the public health impact of the family medicine-general surgery (FM-GS) specialty dyad remains understudied. To examine longitudinal changes in access to FM-GS dyads and their association with health outcomes in rural US counties. This longitudinal, repeated cross-sectional analysis used linked county-level data to conduct a population-based study of rural US counties. Rural US counties with available workforce and mortality data were eligible for inclusion. Duration of access to an FM-GS dyad, derived from annual county physician counts and classified as no dyad, continuous access, newly gained, lost, or intermittent. Primary outcomes included age-adjusted annual mortality rates for cancer and ischemic heart disease (IHD) per 100 000 population and years of potential life lost (YPLL; age-adjusted rate per 100 000 population under age 75 years). A total of 1871 counties were linked to outcome and covariate data, and 1428 to 1644 counties contributed to each outcome model. Among 1871 rural counties, dyad access declined from 997 counties (53.3%) in 2010 to 914 counties (48.9%) in 2021, with 176 counties losing and 93 gaining access. Formation and loss of dyads was almost entirely attributable to general surgery: of counties gaining a dyad, 66 gained a general surgeon and 1 gained a family physician. After adjusting for baseline county population, no exposure category was significantly associated with any outcome. This conclusion was robust to 2 sensitivity analyses that tested inverse probability of treatment weighting and different regression link functions. Per the results of this cross-sectional study, rural FM-GS dyads experienced a net decline between 2010 and 2021, driven primarily by the loss of general surgeons, and after adjusting for confounding, dyad availability was not independently associated with population-level mortality outcomes. Because dyad presence alone did not directly alter short-term mortality outcomes independent of structural factors, such as county population and health system infrastructure, policy efforts-including Rural Health Transformation funding-should target hospital viability and structural equity alongside workforce recruitment.
中文摘要:美国农村劳动年龄成年人年龄调整死亡率高出43%,2001年至2019年普通外科医生供给下降29.1%,家庭医学-普通外科(FM-GS)专科组合的公共卫生影响仍缺乏研究。研究旨在考察美国农村县获得FM-GS组合的纵向变化及其与健康结局的关联。该纵向重复横断面分析使用关联的县级数据,对美国农村县开展基于人群的研究。纳入具备劳动力和死亡率数据的美国农村县。FM-GS组合可及持续时间由年度县级医生计数得出,分为无组合、持续可获得、新获得、失去和间断可获得。主要结局包括每10万人口癌症和缺血性心脏病(IHD)的年龄调整年死亡率,以及75岁以下每10万人口的年龄调整潜在寿命损失年(YPLL)。共有1871个县与结局和协变量数据关联,每个结局模型纳入1428至1644个县。在1871个农村县中,组合可及性从2010年的997个县(53.3%)降至2021年的914个县(48.9%),176个县失去组合,93个县获得组合。组合的形成和失去几乎全部归因于普通外科:获得组合的县中,66个县获得普通外科医生,1个县获得家庭医生。调整县基线人口后,任何暴露类别均与任何结局无显著关联。该结论在两项敏感性分析中保持稳健,分别检验了逆概率治疗加权和不同回归链接函数。根据这项横断面研究结果,农村FM-GS组合在2010年至2021年间净减少,主要由普通外科医生流失驱动;调整混杂因素后,组合可得性与人群水平死亡率结局无独立关联。由于组合存在本身不能独立于县人口和卫生系统基础设施等结构性因素直接改变短期死亡率结局,政策努力(包括农村健康转型资金)应在招募劳动力的同时关注医院存续能力和结构公平。
Surgery is the primary curative treatment for early-stage lung adenocarcinoma (LUAD), with accurate identification of tumor invasiveness critical for determining pulmonary resection extent. Due to significant variability in postoperative recurrence among early-stage LUAD patients with aggressive tumors, a more effective risk stratification system is urgently needed to improve prognosis. This study developed the T1LUT system, a transformer-based tool for T1N0M0 LUAD management, covering preoperative tumor invasiveness identification and postoperative recurrence risk stratification. Preoperatively, a 3D Vision Transformer (ViT) with extra learnable tokens analyzes CT images. It outperforms 3D ViT with only CLS tokens, 2D ViT, and 3D ResNet across three independent test centers (Center D: 0.896 vs. 0.892, 0.879, 0.836; Center E: 0.906 vs. 0.837, 0.837, 0.835; Center F: 0.884 vs. 0.884, 0.881, 0.861), achieving higher mean AUROC to accurately assess invasiveness and guide surgical resection extent. Postoperatively, the multimodal IAC-PR model integrates CT images, reports, pathological data, and clinical/demographic information. It stratifies invasive adenocarcinoma (IAC) patients into low-, medium-, or high-risk groups with an AUROC of 0.807 in testing-significantly better than single/partial-modal models. Validated via large-scale multicenter research, this system overcomes traditional assessment limitations, offering a robust tool for precise early LUAD treatment and improved prognosis.
中文摘要:手术是早期肺腺癌(LUAD)的主要根治性治疗,准确识别肿瘤浸润性对确定肺切除范围至关重要。早期LUAD中侵袭性肿瘤患者术后复发差异显著,亟需更有效的风险分层系统以改善预后。研究开发了T1LUT系统,这是一种基于Transformer的T1N0M0 LUAD管理工具,涵盖术前肿瘤浸润性识别和术后复发风险分层。术前,带有额外可学习token的3D视觉Transformer(ViT)分析CT图像。在三个独立测试中心,其表现优于仅含CLS token的3D ViT、2D ViT和3D ResNet(中心D:0.896 vs. 0.892、0.879、0.836;中心E:0.906 vs. 0.837、0.837、0.835;中心F:0.884 vs. 0.884、0.881、0.861),平均AUROC更高,可准确评估浸润性并指导手术切除范围。术后,多模态IAC-PR模型整合CT图像、报告、病理数据及临床/人口学信息。该模型将浸润性腺癌(IAC)患者分为低、中、高风险组,测试中AUROC为0.807,显著优于单模态/部分模态模型。经大规模多中心研究验证,该系统克服了传统评估的局限,为早期LUAD的精准治疗和预后改善提供了稳健工具。
基础研究 (4篇)
In this study, we sought to comprehensively map ubiquitin signaling networks at the crossroads of cellular proliferation and proteostasis, both crucial in cancer. Genome-wide CRISPR knockout screening in the presence of the ubiquitin E1 inhibitor TAK-243 identified 239 genes whose ablation sensitizes cells to ubiquitination blockade. Follow-up studies reveal a role for the nuclear protein, C16orf72/HECT, UBA, and WWE domain containing E3 ubiquitin protein ligase 1 (HUWE1)-Associated Protein modifying Stress Responses (HAPSTR1), in chromatin proteostasis and DNA replication. We show that HAPSTR1 recruits the E3 ligase HUWE1 to the chromatin, keeping the chromatin-associated proteome in check, and is itself turned over by HUWE1 during cell cycle progression. Structural modeling of the HAPSTR1/HUWE1 complex, supported by mutational analysis, demonstrates that loss of HUWE1 binding renders HAPSTR1 unable to support cellular proliferation when ubiquitin signaling is suppressed. Consequently, HAPSTR1 ablation impairs clearance of chromatin-associated proteins, triggering global transcriptional and proteostatic adaptations. Under diminished ubiquitin signaling, these adaptive mechanisms give way to replication stress and premature S phase entry, culminating in cell cycle collapse and DNA damage. Our findings uncover protein networks exhibiting synthetic lethality with ubiquitin signaling blockade and highlight vulnerabilities of actively proliferating cells to proteostatic imbalance at the chromatin.
中文摘要:研究旨在全面绘制细胞增殖与蛋白质稳态交叉处的泛素信号网络,二者在癌症中均至关重要。在泛素E1抑制剂TAK-243存在下进行全基因组CRISPR敲除筛选,鉴定出239个基因,其缺失使细胞对泛素化阻断敏感。后续研究揭示核蛋白C16orf72(含HECT、UBA和WWE结构域的E3泛素蛋白连接酶1 HUWE1相关蛋白,即调节应激反应的HAPSTR1)在染色质蛋白质稳态和DNA复制中的作用。研究显示HAPSTR1将E3连接酶HUWE1招募至染色质,控制染色质相关蛋白质组,而其自身在细胞周期进程中由HUWE1周转。HAPSTR1/HUWE1复合物的结构建模结合突变分析表明,当泛素信号受抑制时,失去HUWE1结合使HAPSTR1无法支持细胞增殖。因此,HAPSTR1缺失损害染色质相关蛋白的清除,引发全局转录和蛋白质稳态适应。在泛素信号减弱时,这些适应机制让位于复制应激和过早进入S期,最终导致细胞周期崩溃和DNA损伤。研究结果揭示了与泛素信号阻断表现合成致死的蛋白网络,并突出活跃增殖细胞在染色质处对蛋白质稳态失衡的脆弱性。
Cancer genomes harbor extensive somatic genetic and epigenetic variation, yet large portions of the genome remain inaccessible to conventional reference-based analyses. Here, we demonstrate that pairing a near-telomere-to-telomere (near-T2T) diploid assembly of a donor with deep short- and long-read sequencing of their melanoma reveals that 16% of somatic variants localize to sequences absent from GRCh38, with satellite repeats acting as hotspots for UV-associated mutagenesis. Centromere kinetochore binding domains emerge as focal sites of chromosome arm aneuploidy breakpoints and somatic genetic variation, features we further demonstrate are also present in non-cancerous tissues. By contrast, extensive epigenetic remodeling of kinetochore binding domains appears specific to oncogenesis. Single-molecule telomere analyses reconstruct the cycle of telomere erosion and telomerase-mediated extension during tumor evolution, while haplotype-resolved chromatin maps reveal widespread somatic epimutations impacting regulatory elements. Together, these findings define previously inaccessible dimensions of somatic variation and establish a framework for telomere-to-telomere studies of human mosaicism.
中文摘要:癌症基因组携带广泛的体细胞遗传与表观遗传变异,但其中很大一部分序列无法通过常规的参考基因组分析获得。将供者的近端粒到端粒(near-T2T)二倍体组装与其黑色素瘤的深度短读长和长读长测序结合,发现16%的体细胞变异位于GRCh38中不存在的序列,卫星重复序列充当紫外线相关诱变的热点。着丝粒动粒结合域成为染色体臂非整倍体断裂点和体细胞遗传变异的局灶位点,这些特征在非癌组织中也存在。相比之下,动粒结合域广泛的表观遗传重塑似乎为肿瘤发生所特有。单分子端粒分析重建了肿瘤演化过程中端粒侵蚀与端粒酶介导延长的循环,单倍型分辨的染色质图谱揭示影响调控元件的广泛体细胞表观突变。这些发现界定了此前无法获得的体细胞变异维度,并为人类嵌合现象的端粒到端粒研究建立了框架。
Targeted kinase inhibitors induce marked tumor regressions but are limited by the emergence of drug-tolerant residual disease and resistance. Although tumor-intrinsic and adaptive immune mechanisms have been extensively studied, a better understanding of the contribution of innate immunity to targeted therapy durability is needed to devise optimal treatment strategies. In this study, we showed that natural killer (NK) cells constrain targeted therapy resistance and identified a regression-associated macrophage program that promotes NK cell recruitment. In immunocompetent melanoma models that recapitulate patient treatment trajectories, tumor regression was characterized by robust NK infiltration, which transitioned to an NK-excluded residual state preceding resistance. A regression-associated macrophage subset (F4/80high CCL5+ MHC class II+ CD63+) contributed to NK cell recruitment via CCR2/5 signaling. Genetic depletion of macrophages using LysM-cre;iDTR mice impaired NK cell infiltration. Pharmacologic inhibition of protein tyrosine phosphatase nonreceptor type 22 (Ptpn22), a negative regulator of immune activation, reprogrammed the residual tumor microenvironment, restored NK cell recruitment, and delayed resistance onset. An analysis of data from patients with melanoma and lung cancer revealed concordant NK dynamics during therapy, linking this innate immune program to clinical outcomes. These findings identify innate immune remodeling as a key contributor to targeted therapy durability and identify NK cell recruitment, promoted in part by regression-associated macrophages, as a therapeutically actionable node for extending the durability of response across oncogene-driven cancers. Natural killer cells recruited by regression-associated macrophages delay resistance to targeted therapies, highlighting the role of innate immune remodeling in targeted therapy durability and providing a strategy to prolong treatment efficacy.
中文摘要:靶向激酶抑制剂可诱导明显的肿瘤消退,但耐药耐受性残留病灶和耐药性的出现限制了其疗效。肿瘤内在机制和适应性免疫机制已得到广泛研究,但仍需更好理解先天免疫对靶向治疗持久性的贡献,以制定最佳治疗策略。本研究发现自然杀伤细胞可限制靶向治疗耐药,并识别出一个促进自然杀伤细胞招募的消退相关巨噬细胞程序。在可重现患者治疗轨迹的免疫健全黑色素瘤模型中,肿瘤消退以强烈的自然杀伤细胞浸润为特征,随后在耐药出现前转变为自然杀伤细胞被排斥的残留状态。一个消退相关巨噬细胞亚群(F4/80高表达 CCL5+ MHC II类+ CD63+)通过CCR2/5信号促进自然杀伤细胞招募。使用LysM-cre;iDTR小鼠进行巨噬细胞基因敲除会削弱自然杀伤细胞浸润。药理学抑制蛋白酪氨酸磷酸酶非受体22型(Ptpn22,免疫激活的负调控因子)可重编程残留肿瘤微环境,恢复自然杀伤细胞招募并延迟耐药发生。对黑色素瘤和肺癌患者数据的分析显示治疗期间自然杀伤细胞动态一致,将该先天免疫程序与临床结局联系起来。这些发现表明先天免疫重塑是靶向治疗持久性的关键贡献因素,并提示自然杀伤细胞招募部分由消退相关巨噬细胞促进,可作为延长致癌基因驱动癌症缓解持久性的治疗可操作节点。由消退相关巨噬细胞招募的自然杀伤细胞可延迟靶向治疗耐药,突出先天免疫重塑在靶向治疗持久性中的作用,并提供延长治疗疗效的策略。
Erythropoietin-producing hepatocellular (EPH) receptors, the largest receptor tyrosine kinase family, have been shown to play a crucial role in normal physiological processes and pathologies. EPHA2, encoded by EPHA2 gene, a member of the EPH receptor family, has been implicated in cataracts and various bone tumors, including osteosarcoma, chondrosarcoma, and bone metastases of breast cancer. However, no association between the EPHA2 gene and genetic skeletal disorders has been reported to date. Here, we identified a Chinese family with a diagnosis of dysosteosclerosis, presenting with significant increase in lumbar spine bone mineral density, multifocal sclerotic lesions throughout the body, sclerotic skull, platyspondyly and sandwich vertebrae, and demonstrated compound heterozygous mutations in EPHA2 gene (c.890 C > T, p.Thr297Met; c.988dupT, p.Ser330PhefsX51). We observed a reduction in numerous sclerotic lesions in patients during the five-year follow-up. To systematically investigate the molecular mechanisms of pathogenesis, we employed a range of methodologies, including in vitro cellular assays, genome-wide association studies analysis, induced pluripotent stem cells models and Epha2 knockout mice models. We have determined that loss-of-function mutations in EPHA2 gene lead to dysosteosclerosis through enhancing mesenchymal stem cells osteogenic differentiation and downregulating the p38-MAPK pathway, leading to decreased osteoclast differentiation. Consequently, we proposed and validated EPHA2 as a viable therapeutic target for osteoporosis by constructing femoral fracture mice models and ovariectomized mice models. In summary, this study identifies bi-allelic loss-of-function mutations in EPHA2 gene lead to dysosteosclerosis and its underlying mechanisms, and suggests EPHA2 as a potential therapeutic target for osteoporosis.
中文摘要:促红细胞生成素产生肝细胞(EPH)受体是最大的受体酪氨酸激酶家族,参与正常生理过程和病理过程。EPHA2由EPHA2基因编码,属于EPH受体家族,已发现与白内障及多种骨肿瘤相关,包括骨肉瘤、软骨肉瘤和乳腺癌骨转移。迄今未见EPHA2基因与遗传性骨骼疾病相关的报道。我们识别了一个诊断为骨硬化性发育不良的中国家系,患者表现为腰椎骨密度显著升高、全身多灶性硬化性病变、颅骨硬化、扁平椎和三明治椎体,并证实其携带EPHA2基因复合杂合突变(c.890 C > T,p.Thr297Met;c.988dupT,p.Ser330PhefsX51)。五年随访中观察到患者多处硬化性病变减少。为系统研究发病的分子机制,我们采用体外细胞实验、全基因组关联分析、诱导多能干细胞模型和Epha2敲除小鼠模型。结果确定EPHA2基因功能缺失突变通过增强间充质干细胞成骨分化并下调p38-MAPK通路导致破骨细胞分化减少,从而引起骨硬化性发育不良。通过构建股骨骨折小鼠模型和卵巢切除小鼠模型,我们提出并验证EPHA2可作为骨质疏松的可行治疗靶点。该工作识别了EPHA2基因双等位基因功能缺失突变导致骨硬化性发育不良及其机制,并提示EPHA2是骨质疏松的潜在治疗靶点。
9乳腺癌 (5篇)
临床研究 (2篇)
Tumor-derived exosomes carry multi-scale molecular signatures (e.g., surface proteins and nucleic acids) that reflect tumor heterogeneity, yet simultaneously profiling these biomarkers in single intact vesicles remains technically challenging. Herein, we developed a digital droplet microfluidic platform that integrates a DNA walker and a CRISPR/Cas13a system for the simultaneous detection of surface proteins (EpCAM, HER2) and miRNA (miR-21) at the single exosome level. This platform employed engineered liposome nanoprobes (eLipo-NPs) with EpCAM aptamers and hairpin probes (HPs) functionalized on their outer membranes, and encapsulated a CRISPR/Cas13a system within their lumen. Upon co-encapsulation with single exosomes into droplets, EpCAM-mediated membrane fusion redistributed HPs across the hybrid membrane and delivered CRISPR/Cas13a into the exosomes. The membrane-anchored DNA walker then bound HER2 and drove cyclic DNAzyme cleavage of HPs to restore red fluorescence. At the same time, crRNA-guided Cas13a recognized miR-21 and triggered trans-cleavage of reporters to generate green fluorescence. Digital counting of dual-positive droplets enabled quantitative single-exosome analysis with a limit of detection (LOD) of 10 particles/μL and a detection time of 60 min. Clinical validation using plasma-derived exosomes from 24 breast cancer patients and 14 healthy donors demonstrated distinct distributions among HER2-positive, HER2-negative, and healthy control groups, with the percentage of dual-positive droplets significantly correlated with clinical HER2 status, highlighting the platform's potential for liquid biopsy and precision oncology.
中文摘要:肿瘤来源的外泌体携带可反映肿瘤异质性的多尺度分子特征(如表面蛋白和核酸),但在单个完整囊泡中同时分析这些生物标志物仍存在技术挑战。为此,我们构建了一个数字液滴微流控平台,整合DNA步行器与CRISPR/Cas13a系统,在单外泌体水平同时检测表面蛋白(EpCAM、HER2)和miRNA(miR-21)。该平台采用工程化脂质体纳米探针(eLipo-NPs),其外膜修饰EpCAM适配体和发夹探针(HPs),腔内包裹CRISPR/Cas13a系统。当与单个外泌体共包裹进入液滴后,EpCAM介导的膜融合使HPs在杂合膜上重新分布,并将CRISPR/Cas13a递送入外泌体。膜锚定的DNA步行器随后结合HER2,驱动循环DNA酶切割HPs,恢复红色荧光。同时,crRNA引导的Cas13a识别miR-21,触发报告探针的反式切割,产生绿色荧光。对双阳性液滴进行数字计数,可实现单外泌体定量分析,检测限为10个颗粒/μL,检测时间为60分钟。利用24例乳腺癌患者和14例健康供者的血浆外泌体进行临床验证,结果显示HER2阳性、HER2阴性和健康对照组之间分布存在明显差异,双阳性液滴百分比与临床HER2状态显著相关,提示该平台在液体活检和精准肿瘤学中的应用潜力。
Antibody-drug conjugates (ADCs) are one of the most significant advancements in modern cancer therapeutics. Combining the target selectivity of monoclonal antibodies with the cytotoxic potential of payloads, ADCs effectively kill cancer cells and offer hope to patients with even refractory cancer types. Beyond simply increasing the number of therapeutic options available for cancer patients, ADCs have become a powerful frontline agent in overcoming multidrug resistance (MDR). As one of the most challenging obstacles to effective cancer care, MDR is mediated by ATP-binding cassette (ABC) transporter-mediated drug efflux, target-based mutations, and dysregulated apoptosis. The clinical success of ADCs specifically engineered to overcome MDR, including in heterogeneous tumors and cancer cells that exhibit bypass signaling, is well established. This is especially evident with trastuzumab deruxtecan (T-DXd) in HER2-low, HER2-positive, and HER2-mutant cancers; sacituzumab govitecan (SG) in TROP2-expressing triple-negative breast cancer (TNBC) and urothelial carcinoma; and enfortumab vedotin in Nectin-4-positive bladder cancer. By overcoming MDR, ADCs have enabled more effective treatment algorithms across multiple malignancies. Most importantly, the clinical application of ADCs has become inextricably linked to cancer genomics. HER2 testing has evolved from a two-tiered system to a continuous spectrum including HER2-ultralow, HER2-low, HER2-positive, and ERBB2-mutant categories. Each of these categories exhibits different eligibility guidelines for ADC patient selection. As cancer cells continue to evolve and develop resistance to even ADCs through mutations and variants, researchers and clinicians have used pharmacogenomics to predict ADC response and resistance. To define the genomic architecture of ADC-resistant tumor subpopulations, single-cell transcriptomic studies and liquid biopsy approaches are being used to enable real-time examination of the tumor genome during ADC therapy, thereby optimizing treatment and circumventing resistance driven by emerging mutations and variants. This review provides a comprehensive analysis of the molecular structure of ADCs, the pharmacological principles underlying their potent cytotoxic activity against MDR cancer cells, the genomic and transcriptomic biomarkers that guide ADC patient selection, and the emerging resistance mechanisms that will shape the next generation of promising ADC development.
中文摘要:抗体药物偶联物(ADC)是现代肿瘤治疗领域最重要的进展之一。ADC将单克隆抗体的靶向选择性与载荷的细胞毒性潜力结合,可有效杀伤癌细胞,也为难治性癌种患者带来希望。ADC不仅增加了癌症患者的治疗选择,还已成为克服多药耐药(MDR)的有力一线药物。MDR是有效肿瘤治疗中最具挑战性的障碍之一,由ATP结合盒(ABC)转运体介导的药物外排、靶点相关突变和凋亡失调等机制造成。专门设计用于克服MDR的ADC已在异质性肿瘤和具有旁路信号传导的癌细胞中确立临床成功,曲妥珠单抗德鲁替康(T-DXd)在HER2低表达、HER2阳性和HER2突变癌症中的表现,戈沙妥珠单抗(SG)在TROP2表达的三阴性乳腺癌(TNBC)和尿路上皮癌中的表现,以及恩诺单抗维多汀在Nectin-4阳性膀胱癌中的表现尤为明显。通过克服MDR,ADC使多种恶性肿瘤的治疗方案更为有效。ADC的临床应用与肿瘤基因组学已密不可分。HER2检测从两级系统发展为连续谱,包括HER2超低表达、HER2低表达、HER2阳性和ERBB2突变类别。各类别对ADC患者选择的准入指南不同。癌细胞通过突变和变异不断演化并对ADC产生耐药,研究人员和临床医生利用药物基因组学预测ADC反应和耐药。为界定ADC耐药肿瘤亚群的基因组结构,单细胞转录组研究和液体活检正用于在ADC治疗期间实时检查肿瘤基因组,从而优化治疗并规避新出现的突变和变异驱动的耐药。该综述全面分析ADC的分子结构、其对MDR癌细胞强效细胞毒性作用的药理学原理、指导ADC患者选择的基因组和转录组生物标志物,以及将影响下一代有前景ADC开发的新兴耐药机制。
基础研究 (3篇)
To evaluate the functional relevance of mutations newly detected in breast cancer metastases, we analyzed genomic data from 662 paired and ~6,000 unpaired primary and metastatic tumors. These analyses indicate that metastasis-specific mutations are frequently acquired post-dissemination, with a disproportionate contribution from APOBEC-mediated mutagenesis. Metastasis-specific mutations converged on a set of pathways that were highly recurrent, distinct from those altered in primary tumors, and dependent on metastatic site. 95% of patients harbored metastasis-specific mutations within a minimum set of 10 pathways. Remarkably, more than half the variation in metastatic latency across patients was explained by the relative timing of mutation acquisition within implicated pathways before versus after dissemination. These findings support a "mutability-dependent" model of metastasis in which functionally consequential mutations accumulate after primary tumor dissemination and contribute to metastatic outgrowth, with latency reflecting the time required for DTCs to acquire the remaining driver mutations needed to achieve metastatic competence.
中文摘要:为评估乳腺癌转移灶中新检出突变的功能相关性,分析了662对配对肿瘤及约6000例未配对的原发与转移肿瘤的基因组数据。分析显示,转移特异性突变多在播散之后获得,其中APOBEC介导的诱变贡献比例偏高。转移特异性突变集中于一组高度反复出现的通路,这些通路与原发肿瘤中改变的 Pathway 不同,并随转移部位而异。95%的患者在最少10条通路的集合内带有转移特异性突变。患者间转移潜伏期的差异有一半以上可由相关通路中突变获得时间相对于播散前或播散后的差异来解释。这些结果支持一种「可变变性依赖」的转移模型:有功能后果的突变在原发肿瘤播散后累积,并促进转移灶生长,潜伏期则反映播散肿瘤细胞获得达到转移能力所需其余驱动突变所需的时间。
The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is a central regulator of cancer progression, with frequent activation of the PI3Kα catalytic subunit (p110α) in breast cancer. Here, an integrated in silico to experimental workflow was applied to systematically identify dietary phytochemicals capable of inhibiting PI3Kα and suppressing cancer cell proliferation. A curated PhytoHub library comprising 1966 food-derived compounds was screened by molecular docking against the PI3Kα catalytic domain, followed by isoform-specific enzymatic validation and cellular evaluation. Several flavonoids demonstrated strong PI3Kα inhibition at 30 μM, with jaceosidin and luteolin exhibiting the highest potency (IC₅₀ ≤ 0.1 and 0.76 μM, respectively), whereas anthocyanidins delphinidin and petunidin showed weaker activity. In MCF-7 breast cancer cells, myricetin, delphinidin, apigenin, and kaempferol produced the strongest antiproliferative effects (~55-65% inhibition; p < 0.05). These findings identify flavone-type scaffolds as potent PI3Kα inhibitors and highlight dietary flavonoids as promising functional food bioactives targeting oncogenic signaling.
中文摘要:磷酸肌醇3-激酶(PI3K)/AKT/mTOR通路是癌症进展的核心调控通路,乳腺癌中PI3Kα催化亚基(p110α)频繁激活。本研究采用从计算机模拟到实验验证的整合流程,系统识别能够抑制PI3Kα并抑制癌细胞增殖的膳食植物化学物。对包含1966种食物来源化合物的整理版PhytoHub库,通过分子对接针对PI3Kα催化结构域进行筛选,随后开展亚型特异性酶学验证和细胞评价。多种黄酮类化合物在30 μM下表现出较强的PI3Kα抑制作用,其中jaceosidin和木犀草素(luteolin)效力最高,IC₅₀分别≤0.1和0.76 μM;花青素类飞燕草素(delphinidin)和矮牵牛素(petunidin)活性较弱。在MCF-7乳腺癌细胞中,杨梅素(myricetin)、飞燕草素、芹菜素(apigenin)和山奈酚(kaempferol)产生最强的抗增殖效应,抑制率约55-65%(p<0.05)。这些发现确定黄酮型骨架为强效PI3Kα抑制剂,并提示膳食黄酮类可作为靶向致癌信号的有前景的功能性食品生物活性物。
Tumor-associated macrophages (TAMs) drive the immunosuppressive tumor microenvironment (TME), promoting oncogenic progression, metastasis and treatment resistance. While we previously established that intratumoral administration of poly(I:C) and R848 (TLR3 and TLR7/8 agonists) has strong therapeutic efficacy and triggers STAT1-mediated TAM reprogramming superior to monotherapies, this study evaluates the translational potential, systemic tolerability and immunological impact of their combined systemic (intravenous) delivery. Across diverse syngeneic murine models of solid tumors, including lung adenocarcinoma, triple-negative breast cancer (TNBC), fibrosarcoma and glioblastoma, systemic poly(I:C) + R848 administration significantly inhibited primary tumor growth and spontaneous lung metastasis. The treatment exhibited good tolerability under the conditions tested, with no body weight loss or histopathological damage to major organs. Treatment triggered a transient trend toward elevation of pro-inflammatory cytokines (TNF-α, IFN-γ, CXCL10, CCL5), while anti-inflammatory markers (IL-10, IL-4) remained unchanged. In primary tumors, treatment-induced TAM reprogramming was evidenced by upregulated M1-like markers (Irf7, Ccl5) and decreased M2-like markers (Arg1), accompanied by enhanced Cd8 and Cd4 T cell markers and cytotoxic effectors (Prf-1 and Gzmb). Multispectral immunophenotyping confirmed this shift toward an antitumor macrophage phenotype, characterized by increased CD86 and decreased ARG1 across all primary tumors. Furthermore, treatment significantly prevented lung metastasis and tumor-induced splenomegaly, shifting splenic macrophages toward an elevated M1/M2 ratio in both fibrosarcoma and TNBC models. These findings demonstrate that intravenous administration of the poly(I:C) + R848 combination effectively reprograms TAMs, suppressing tumor progression and preventing metastasis across a variety of preclinical models of difficult-to-treat solid tumors.
中文摘要:肿瘤相关巨噬细胞(TAMs)驱动免疫抑制性肿瘤微环境(TME),促进肿瘤进展、转移和治疗耐药。此前已证实,瘤内给予poly(I:C)和R848(TLR3与TLR7/8激动剂)具有较强治疗效力,并可触发STAT1介导的TAM重编程,效果优于单药治疗;本研究评估二者联合全身(静脉)给药的转化潜力、全身耐受性和免疫学影响。在多种同种小鼠实体瘤模型中,包括肺腺癌、三阴性乳腺癌(TNBC)、纤维肉瘤和胶质母细胞瘤,全身给予poly(I:C) + R848显著抑制原发肿瘤生长和自发肺转移。在所测试条件下,治疗表现出良好耐受性,未出现体重下降,主要器官也无组织病理学损伤。治疗引起促炎细胞因子(TNF-α、IFN-γ、CXCL10、CCL5)短暂升高的趋势,抗炎标志物(IL-10、IL-4)保持不变。在原发肿瘤中,治疗诱导的TAM重编程表现为M1样标志物(Irf7、Ccl5)上调、M2样标志物(Arg1)下降,同时Cd8和Cd4 T细胞标志物及细胞毒效应分子(Prf-1、Gzmb)增强。多重免疫表型分析证实,所有原发肿瘤均向抗肿瘤巨噬细胞表型转变,特征为CD86升高、ARG1降低。治疗还显著阻止肺转移和肿瘤诱导的脾肿大,在纤维肉瘤和TNBC模型中使脾脏巨噬细胞向M1/M2比值升高方向转变。这些发现表明,静脉给予poly(I:C) + R848组合可有效重编程TAMs,在多种难治性实体瘤临床前模型中抑制肿瘤进展并阻止转移。
10泌尿生殖肿瘤 (2篇)
临床研究 (1篇)
Immune checkpoint therapies have shown limited efficacy in metastatic castration-resistant prostate cancer (mCRPC). The AMADEUS prostate expansion cohort (NCT03651271) evaluated the efficacy, safety, and biomarkers of escalating ipilimumab doses combined with nivolumab. Patients received ipilimumab 1 milligram per kilogram (mg/kg) + nivolumab 360 mg (I1+N360), ipilimumab 3 mg/kg + nivolumab 1 mg/kg (I3+N1), or ipilimumab 5 mg/kg + nivolumab 1 mg/kg (I5+N1). Coprimary endpoints were 6-month disease control rate (DCR) and changes in tumoral CD8 percentage. Thirty-two patients were enrolled. DCRs were 33% (4 of 12) for I1+N360, 20% (1 of 5) for I3+N1, and 20% (3 of 15) for I5+N1. Across cohorts, tumoral CD8 percentage increased by a median of 5.0%. Although higher ipilimumab doses were tolerable, I1+N360 achieved similar disease control and immune activation with a more favorable safety profile. Early disease progression was associated with increased expression of a TREM2-associated myeloid gene signature, which was also significantly enriched in two independent prostate cancer datasets.
中文摘要:免疫检查点治疗在转移性去势抵抗性前列腺癌(mCRPC)中的疗效有限。AMADEUS前列腺扩展队列(NCT03651271)评估了递增剂量伊匹木单抗联合纳武利尤单抗的疗效、安全性及生物标志物。患者接受伊匹木单抗1毫克/千克联合纳武利尤单抗360毫克(I1+N360)、伊匹木单抗3毫克/千克联合纳武利尤单抗1毫克/千克(I3+N1)或伊匹木单抗5毫克/千克联合纳武利尤单抗1毫克/千克(I5+N1)。共同主要终点为6个月疾病控制率(DCR)和肿瘤内CD8百分比变化。共入组32例患者。DCR分别为I1+N360组33%(12例中4例)、I3+N1组20%(5例中1例)、I5+N1组20%(15例中3例)。各队列肿瘤内CD8百分比中位增加5.0%。较高伊匹木单抗剂量可耐受,I1+N360达到相似的疾病控制和免疫激活,且安全性更好。早期疾病进展与TREM2相关髓系基因特征表达升高有关,该特征在两个独立前列腺癌数据集中也显著富集。
基础研究 (1篇)
Patient-derived tumor organoids (PDOs) closely preserve the cellular heterogeneity, histopathology, and molecular features of the original tumors, making them powerful preclinical models. Antisense oligonucleotides (ASOs) are an emerging class of precision medicines that modulate gene expression at the RNA level with high target specificity, yet their application in organoid systems remains underexplored. Here, we adapted previously described protocols to establish a biobank of prostate cancer (PC) PDOs, achieving a high initial growth success rate (>90%). Histological and molecular analyses confirmed the preservation of key tumor features. Using these models, we assessed several ASOs, with particular emphasis on OGX-427 (Apatorsen), an ASO targeting heat shock protein 27 (HSP27) that has been evaluated in phase I/II clinical trials. While OGX-427 effectively suppressed HSP27 expression and inhibited cell growth in 2D cultures, its efficacy was markedly limited in 3D organoids, likely due to extracellular matrix and structural barriers. Removing Matrigel and applying single-cell transfection overcame these barriers, achieving efficient ASO uptake, significant target protein downregulation, and robust, dose-dependent inhibition of organoid growth. These findings underscore the utility of PDOs for evaluating ASO-based therapies and their potential to accelerate precision oncology strategies for PC and other malignancies.
中文摘要:患者来源肿瘤类器官(PDOs)能较好保留原发肿瘤的细胞异质性、组织病理学和分子特征,是强有力的临床前模型。反义寡核苷酸(ASOs)是一类新兴精准药物,可在RNA水平以高靶向特异性调节基因表达,但其在类器官系统中的应用仍待探索。本研究采用既往描述方案建立前列腺癌(PC)PDO生物样本库,初始培养成功率高(>90%)。组织学和分子分析证实关键肿瘤特征得以保留。利用这些模型评估多种ASO,重点为靶向热休克蛋白27(HSP27)的OGX-427(Apatorsen),该ASO已在I/II期临床试验中评价。OGX-427在2D培养中有效抑制HSP27表达和细胞生长,但在3D类器官中效果明显受限,可能与细胞外基质和结构屏障有关。去除Matrigel并采用单细胞转染可克服这些屏障,实现高效ASO摄取、显著下调靶蛋白以及稳健的剂量依赖性类器官生长抑制。这些结果说明PDOs可用于评估ASO治疗,并有望加速前列腺癌及其他恶性肿瘤的精准肿瘤学策略。
11其他 (9篇)
基础研究 (9篇)
The RAS/MAPK pathway is among the most frequently dysregulated in human cancer, predominantly driven by activating mutations across RAS and BRAF in a broad spectrum of tumor types. The recent clinical validation of direct inhibitors of RAS, long considered undruggable, has reenergized the field and renewed focus on targeting the full RAS/MAPK axis. MEK, a central node in MAPK signaling, remains an attractive mutation-agnostic target, yet the efficacy of first-generation MEK inhibitors has been limited by pathway reactivation in tumors and by on-target, off-tissue toxicity. In this issue of Cancer Research, Kolitz and colleagues describe atebimetinib, a novel MEK inhibitor that also prevents feedback-induced MEK phosphorylation by RAF. The uniquely short plasma half-life of atebimetinib enables deep cyclic inhibition (DCI): transient but profound MEK/ERK output suppression with full recovery between doses. At each drug's tolerability limit, atebimetinib outperformed the MEK inhibitor binimetinib across multiple RAS- and BRAF-mutant tumor models. Whether DCI or suppression of MEK phosphorylation is the primary driver of the improved therapeutic window and how atebimetinib compares with the clinical standard and other MEK-targeting agents remain important open questions, but the work makes a compelling case that novel pharmacology can unlock therapeutic spaces at targets long considered exhausted. See related article by Kolitz et al., p. 5223.
中文摘要:RAS/MAPK通路是人类癌症中最常失调的通路之一,主要由RAS和BRAF的激活突变驱动,见于多种肿瘤类型。曾长期被认为不可成药的RAS直接抑制剂近期获得临床验证,使该领域重新活跃,并重新聚焦于靶向整个RAS/MAPK轴。MEK是MAPK信号的中枢节点,仍是具吸引力的突变不可知靶点,但第一代MEK抑制剂的疗效受肿瘤内通路再激活和靶向、脱组织毒性限制。在本期Cancer Research中,Kolitz及其同事描述了atebimetinib,这是一种新型MEK抑制剂,还能阻止RAF引起的反馈诱导MEK磷酸化。atebimetinib独特地短血浆半衰期使深度循环抑制成为可能:短暂但深度的MEK/ERK输出抑制,并在给药间期完全恢复。在各药物的耐受性极限下,atebimetinib在多种RAS和BRAF突变肿瘤模型中优于MEK抑制剂binimetinib。深度循环抑制或抑制MEK磷酸化是否是改善治疗窗的主要驱动因素,以及atebimetinib与临床标准及其他MEK靶向药物如何比较,仍是重要未解问题,但这项工作有力表明,新药理学可在长期被认为已耗尽的靶点上开辟治疗空间。参见Kolitz等第5223页相关文章。
Buckwheat polysaccharides (BWPs), key bioactive constituents broadly distributed across tissues of Fagopyrum Mill, have received growing attention for their nutritional value and health-promoting functions in functional food research. This review consolidates recent progress in BWP extraction and purification strategies, structural elucidation, bioactivities, and prospective applications. Current preparation approaches include hot-water extraction, enzyme-assisted extraction, ultrasound and microwave-assisted techniques, as well as emerging green processes. BWPs are mainly complex heteropolysaccharides composed of monosaccharides, including glucose, arabinose, xylose, galactose, mannose, and galacturonic acid, with arabinoxylan and pectin-like polysaccharides as representative types. BWPs exert diverse bioactivities, notably antioxidant effects, modulation of glucose and lipid metabolism, immunomodulatory and anti-inflammatory actions, anti-tumor potential, and improvements in gut microbiota composition. BWPs hold strong promise for applications in functional foods, nutritional interventions, and biomedical materials. Future studies should prioritize elucidating their mechanism of action, establishing clearer structure-activity relationships, and standardizing extraction processes to support scalable and high-value applications.
中文摘要:荞麦多糖(BWPs)是广泛分布于荞麦属(Fagopyrum Mill)各组织中的关键生物活性成分,因其营养价值和健康促进作用在功能食品研究中受到越来越多关注。本综述汇总了荞麦多糖提取纯化策略、结构解析、生物活性及潜在应用的最新进展。现有制备方法包括热水提取、酶辅助提取、超声和微波辅助技术以及新兴绿色工艺。荞麦多糖主要为由葡萄糖、阿拉伯糖、木糖、半乳糖、甘露糖和半乳糖醛酸等单糖组成的复杂杂多糖,阿拉伯木聚糖和类果胶多糖是代表性类型。荞麦多糖具有多种生物活性,包括抗氧化作用、调节糖脂代谢、免疫调节与抗炎作用、抗肿瘤潜力以及改善肠道菌群组成。荞麦多糖在功能食品、营养干预和生物医学材料方面具有较大应用前景。未来研究应优先阐明其作用机制、建立更清晰的结构-活性关系并规范提取工艺,以支持可规模化及高值化应用。
Pyruvate dehydrogenase (PDH) complex is a key regulator of metabolism, controlling flux from glycolysis into the tricarboxylic acid (TCA) cycle. PDH is often dysregulated in metabolic diseases and cancer. We discover here that in addition to its well characterized regulation by phosphorylation, PDH activity is also regulated via inhibitory oxidation of three cysteines of the DLAT subunit - Cys488, Cys586 and Cys618. Oxidation of these cysteines increases under oxidative stress, and is highly prevalent in mouse and human tissues. This mechanism enables cells to efficiently fight oxidative stress. Under oxidative stress, cells execute a metabolic shift, blocking glycolytic flux into the TCA cycle to shunt glycolytic carbons toward the pentose phosphate pathway. This generates NADPH which cells use to detoxify H2O2 and to reduce oxidized cysteines. We find that DLAT oxidation is required for cells to mount an effective antioxidant response. Mutations preventing DLAT oxidation render PDH resistant to oxidative inhibition, impair NADPH generation, reduce peroxide detoxification, and sensitize cells to oxidative damage and death. DLAT oxidation also drives a Warburg-like metabolic phenotype of increased glucose uptake, elevated lactate secretion, and reduced TCA cycle activity. Thus DLAT oxidation is a redox-sensing mechanism that regulates PDH activity and central carbon metabolism.
中文摘要:丙酮酸脱氢酶(PDH)复合体是代谢的关键调控因子,控制糖酵解进入三羧酸(TCA)循环的通量。PDH在代谢性疾病和癌症中常发生失调。本研究发现,除了已被充分表征的磷酸化调控外,PDH活性还通过DLAT亚基三个半胱氨酸Cys488、Cys586和Cys618的抑制性氧化受到调控。这些半胱氨酸的氧化在氧化应激下增加,并在小鼠和人类组织中广泛存在。该机制使细胞能够有效应对氧化应激。在氧化应激下,细胞发生代谢转变,阻断糖酵解通量进入TCA循环,使糖酵解碳流向磷酸戊糖途径。这一过程生成NADPH,细胞利用NADPH解毒H2O2并还原被氧化的半胱氨酸。DLAT氧化是细胞建立有效抗氧化应答所必需的。阻止DLAT氧化的突变使PDH对氧化抑制产生抵抗,损害NADPH生成,降低过氧化物解毒能力,并使细胞对氧化损伤和死亡更敏感。DLAT氧化还驱动一种Warburg样代谢表型,表现为葡萄糖摄取增加、乳酸分泌升高和TCA循环活性降低。因此,DLAT氧化是一种氧化还原感应机制,调控PDH活性和中心碳代谢。
Loss of skeletal muscle mass is a major driver of frailty and disability, yet how systemic metabolic cues protect muscle integrity remains unclear. We identify Serpina3n, an adipose-derived adipokine, as a key mediator of the protective effects of nicotinamide adenine dinucleotide (NAD+) supplementation against muscle atrophy. Elevation of NAD+ in adipose tissue activates signal transducer and activator of transcription (STAT)1-dependent transcription of Serpina3n, leading to its systemic release and muscle protection across models of aging, disuse, and cancer cachexia. In muscle, Serpina3n preserves pyruvate carboxylase protein level, promoting anaplerosis, oxidative metabolism, and protein synthesis. These findings define an NAD+-responsive adipose-to-muscle signaling axis that links metabolic status to tissue preservation, defining a systemic mechanism by which inter-organ communication maintains muscle integrity and suggesting potential strategies to counteract muscle degeneration.
中文摘要:骨骼肌质量丢失是衰弱和残疾的主要驱动因素,但系统性代谢信号如何保护肌肉完整性仍不清楚。研究确定 Serpina3n 是一种脂肪来源脂肪因子,是烟酰胺腺嘌呤二核苷酸(NAD+)补充对抗肌肉萎缩保护效应的关键介质。脂肪组织中 NAD+ 升高激活信号转导与转录激活因子(STAT)1 依赖的 Serpina3n 转录,促使其系统性释放,并在衰老、废用和癌症恶病质模型中保护肌肉。在肌肉中,Serpina3n 维持丙酮酸羧化酶蛋白水平,促进回补反应、氧化代谢和蛋白质合成。这些发现界定了一条 NAD+ 响应性的脂肪到肌肉信号轴,将代谢状态与组织保存联系起来,明确了器官间通讯维持肌肉完整性的系统性机制,并提示对抗肌肉退化的潜在策略。
Fibroblast activation protein-α (FAP-α) is an important biomarker for the diagnosis of malignant tumors. However, conventional positron emission tomography/computed tomography techniques for FAP-α imaging suffer from either persistent radioactive background signals or incapability of real-time imaging. Taking the advantage of photoacoustic (PA) imaging, we developed an FAP-α-triggered "turn-on" PA probe Cbz-Gly-Pro-Cys(StBu)-Lys(IR780)-Gly-CBT (GP-IR-CBT) for real-time PA imaging of pancreatic tumor. Upon entering cancer cells, GP-IR-CBT undergoes FAP-α-triggered CBT-Cys click reaction to form cyclic dimer which self-assembles into nanoparticle, turning the PA signal "on". Under the activation of FAP-α, GP-IR-CBT-treated group showed 2.9-, 2.6-, or 3.1-fold higher PA intensity than that in the FAP-α-inhibited control group in solution, Mia Paca-2 cells, or tumor-bearing mice, respectively. These findings indicate that GP-IR-CBT enables sensitive visualization of FAP-α activity in vivo and holds potential for the early diagnosis of malignant tumors.
中文摘要:成纤维细胞活化蛋白-α(FAP-α)是恶性肿瘤诊断的重要生物标志物。常规正电子发射断层扫描/计算机断层扫描用于FAP-α成像时,存在持续性放射性背景信号或无法实时成像的问题。利用光声成像优势,我们开发了一种FAP-α触发的「开启」型光声探针Cbz-Gly-Pro-Cys(StBu)-Lys(IR780)-Gly-CBT(GP-IR-CBT),用于胰腺肿瘤的实时光声成像。进入癌细胞后,GP-IR-CBT发生FAP-α触发的CBT-Cys点击反应,形成环状二聚体并自组装为纳米颗粒,使光声信号「开启」。在FAP-α激活下,GP-IR-CBT处理组在溶液、Mia Paca-2细胞和荷瘤小鼠中的光声强度分别比FAP-α抑制对照组高2.9倍、2.6倍和3.1倍。这些结果表明,GP-IR-CBT能够灵敏地可视化体内FAP-α活性,并具有恶性肿瘤早期诊断的潜力。
In this issue of Cancer Cell, Luo et al. report an ensemble approach that integrates five pretrained pathology foundation models into a slide-level representation to exploit their complementary information, yielding improvements in tumor subtyping, biomarker, and therapy-response prediction. This shows the potential of ensemble and multimodal approaches in computational pathology.
中文摘要:在本期 Cancer Cell 中,Luo 等人报告了一种集成方法,将五个预训练的病理基础模型整合为切片级表示,以利用其互补信息,在肿瘤亚型分型、生物标志物和治疗反应预测方面取得改进。这显示了集成与多模态方法在计算病理学中的潜力。
Cancer genomes harbor hundreds of mutated genes, but their exact roles in tumorigenesis often remain incompletely understood. Here, by integrating protein structures with mutation data from 139,818 patients, we generate detailed, functional maps of mutations for 173 cancer genes in 18+ tumor types. In most cancer genes, oncogenic mutations accumulate in "significantly mutated regions" aligned with key functions, including DNA-binding domains in transcription factors (e.g., FOXA1), ligand-binding sites in receptors (e.g., ERBB2), catalytic domains in chromatin remodelers (e.g., EP300), substrate-recognition sites in ubiquitin-proteasome regulators (e.g., SPOP), and degradation signals in cell-cycle proteins (e.g., CCND1). In other cancer genes, mutations align more closely with constraints in three-dimensional protein structures, such as targeting the interior core (e.g., TP53) or a specific secondary structure (e.g., PTEN). Broadly, our study provides a proteo-genomic framework to characterize the effects of mutations in tumorigenesis and integrate them into workflows for clinical interpretation in precision medicine.
中文摘要:癌症基因组携带数百个突变基因,但其在肿瘤发生中的确切作用常未完全明确。该研究将蛋白结构与139,818例患者的突变数据整合,为18种以上肿瘤类型中的173个癌症基因构建了详细的功能性突变图谱。在多数癌症基因中,致癌突变聚集于与关键功能一致的「显著突变区域」,包括转录因子的DNA结合结构域(如FOXA1)、受体的配体结合位点(如ERBB2)、染色质重塑因子的催化结构域(如EP300)、泛素-蛋白酶体调控因子的底物识别位点(如SPOP)以及细胞周期蛋白的降解信号(如CCND1)。在另一些癌症基因中,突变更符合三维蛋白结构中的约束,例如作用于内部核心(如TP53)或特定二级结构(如PTEN)。该研究提供了一个蛋白基因组学框架,用于刻画突变在肿瘤发生中的效应,并将其整合到精准医学的临床解读流程中。
Black phosphorus (BP) holds significant potential in biomedicine, biosensing, and phototherapy; however, its instability and the poor understanding of its in vivo fate have limited its applications. Here, we developed an integrated label-free mass spectrometry imaging (MSI) platform to investigate BP's in vivo distribution, transformation, clearance, and metabolism in tumor-bearing mice. We detected BPs and related nitrogen/oxygen-containing phosphorus (P) clusters in six organs and tumor tissues, revealing distinctive tissue distributions. BP and its degradation products primarily accumulated in the liver and spleen, with the liver showing a radial distribution pattern around hepatic lobules. Notably, BP and related clusters can cross the blood-brain barrier into brain parenchyma. We further establish the in vivo transformation and metabolic pathways of BPs. Cellular experiments confirmed that nitric oxide synthase (NOS)-mediated nitric oxide (NO) generation drives BP nitridation during its transformation and metabolism under physiological conditions. This work not only provides vital information for biomedical applications of BP, but also establishes a platform for understanding in vivo translocation and transformation of nanomaterials, aiding their biosafety and health impact assessments.
中文摘要:黑磷(BP)在生物医学、生物传感和光疗中具有重要潜力,但其不稳定性及体内命运认识不足限制了应用。我们开发了无标记质谱成像(MSI)集成平台,研究荷瘤小鼠体内BP的分布、转化、清除和代谢。在六个器官和肿瘤组织中检测到BP及相关含氮/氧磷簇,显示出不同的组织分布。BP及其降解产物主要蓄积于肝和脾,肝内呈围绕肝小叶的放射状分布。BP及相关簇可穿越血脑屏障进入脑实质。进一步建立了BP体内转化和代谢通路。细胞实验证实,生理条件下一氧化氮合酶(NOS)介导生成的一氧化氮(NO)驱动BP转化代谢过程中的氮化。该工作为BP生物医学应用提供重要信息,也建立了理解纳米材料体内转运与转化的平台,有助于其生物安全与健康影响评估。
The stroma architects early cancer by building a precancerous niche that supports the expansion of nascent tumors. Disrupting the niche limits tumor growth, and the niche alone may be sufficient to confer tumor-like behavior on otherwise normal epithelial cells. Could mapping the stromal niche transform premalignant risk management?
中文摘要:间质通过构建癌前微环境来塑造早期癌症,该微环境支持新生肿瘤的扩增。破坏这一微环境可限制肿瘤生长,而微环境本身可能足以使原本正常的上皮细胞获得类似肿瘤的行为。绘制间质微环境图谱能否改变癌前风险管理?